UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 20-F

(Mark One)

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31 2015, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report . .. . . . . . . . . . . . . . . . . .

For the transition period from                   to

Commission file number: 000-55135001-41319

POET TECHNOLOGIES INC.

POET TECHNOLOGIES INC.

(Exact name of Registrant as specified in its charter)
Ontario, Canada
(Jurisdiction of incorporation or organization)
121 Richmond Street West, Suite 501
Toronto, Ontario, M5H 2K1, Canada
(Address of principal executive offices)

(Exact name of Registrant as specified in its charter)

Ontario, Canada

(Jurisdiction of incorporation or organization)

1107 – 120 Eglinton Avenue East

Toronto, Ontario, M4P 1E2, Canada

(Address of principal executive offices)

Suresh Venkatesan, CEO

2550 Zanker Road1107 – 120 Eglinton Avenue East

Toronto, Ontario, M4P 1E2, Canada

San Jose, California 95131Telephone No.: 416368 9411

Tel: (408)435-2665Email: svv@poet-technologies.com

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Email: svv@poet-technologies.com
(Name, Telephone, Email and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:None.

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Shares, no par valuePTKTSX Venture Exchange
Common Shares, no par valuePOETNasdaq Capital Market

Securities registered or to be registered pursuant to Section 12(g) of the Act:Common Stock, no par value. None.

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:Not Applicable. None.

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

42,488,045 Common Shares, no par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

☐ Yes     ☒ No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes ☐ No

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes     ☐ No

Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Not Applicable.

☐ Yes     ☐ No

Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Emerging growth company

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S GAAP ☐

International Financial Reporting Standards as issued
by the
International Accounting Standards Board ☒

Other ☐

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

☐ Item 17     ☐ Item 18

☐ Item 17 ☐ Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes No

 

POET TECHNOLOGIES INC.
FORM 20-F ANNUAL REPORT
TABLE OF CONTENTS

Page
Introduction1
   
PART I

POET TECHNOLOGIES INC.

FORM 20-F ANNUAL REPORT

TABLE OF CONTENTS

Page
ITEM 1.Introduction1
PART I
Item 1.Identity of Directors, Senior Management and AdvisorsAdvisers24
ITEMItem 2.Offer Statistics and Expected Timetable24
ITEMItem 3.Key Information24
ITEMItem 4.Information on the Company1520
ITEM 4a.Item 4A.Unresolved Staff Comments2029
ITEMItem 5.Operating and Financial Review and Prospects2029
ITEMItem 6.Directors, Senior Management and Employees2941
ITEMItem 7.Major Shareholders and Related Party Transactions4160
ITEMItem 8.Financial Information4261
ITEMItem 9.The Offer and Listing4362
ITEMItem 10.Additional Information4463
ITEMItem 11.Quantitative and Qualitative Disclosures About Market Risk5473
ITEMItem 12.Description of Securities Other Thanthan Equity Securities5575
PARTPart II
ITEMItem 13.Defaults, Dividend Arrearages and Delinquencies5575
ITEMItem 14.Material Modifications to the Rights of Security Holders and Use of Proceeds5575
ITEMItem 15.Controls and Procedures5675
ITEMItem 16.Reserved5677
ITEM 16a.Item 16A.Audit Committee Financial Expertcommittee financial expert5677
ITEM 16b.Item 16B.Code Ofof Ethics5677
ITEM 16c.Item 16C.Principal Accounting Fees and Services5678
ITEM 16d.Item 16D.Exemptions from the Listing Standards for Audit Committees5778
ITEM 16e.Item 16E.Purchases of Equity Securities by the Issuer and Affiliated Purchasers5778
Item 16F.Change in Registrant’s Certifying Accountant78
Item 16G.Corporate Governance78
Item 16H.Mine Safety Disclosure78
Item 16I.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections79
Item 16J.Insider Trading Policies79
Item 16K.Cybersecurity79
PART III
Item 17.Financial Statements80
Item 18.Financial Statements80
Item 19.Exhibits80

   
PART III
 
ITEM 17.Financial Statements57
ITEM 18.Financial Statements57
ITEM 19.Exhibits57

INTRODUCTION

INTRODUCTION

POET Technologies Inc. is organized under the Business Corporations Act (Ontario). In this Annual Report, the “Company”, “we”, “our”, “POET” and “us” refer to POET Technologies Inc. and its subsidiaries (unless the context otherwise requires). We refer you to the documents attached as exhibits hereto for more complete information than may be contained in this Annual Report. Our principal Canadian corporate offices are located at Suite 501, 121 Richmond Street West,1107, 120 Eglinton Avenue East, Toronto, Ontario M5H 2K1,M4P 1E2, Canada. Our principal operationsU.S office is located in the U.S. at 2550 Zanker Road, San Jose, CA, 95131.1605 N. Cedar Crest Boulevard, Allentown, PA, 18104. Our telephone number in Toronto is (416) 368-9411. Our telephone number in San Jose is (408) 435-2665.

We file reports and other information with the Securities and Exchange Commission (“SEC”) located at 100 F Street NE, Washington,

D.C. 20549. You may obtain copies of our filings with the SEC by accessing their website located at www.sec.gov. We also file reports under Canadian regulatory requirements on SEDAR; you may access our reports filed on SEDAR by accessing the website www.sedar.com.

This Annual Report (including the consolidated audited financial statements for the years ended December 31, 2023, 2022 and 2021 attached thereto, together with the auditors’ report thereon), and the exhibits thereto shall be deemed to be incorporated by reference as exhibits to the Registration Statement of the Company on Form F- 10, as amended (File No. 333-227873), and to be a part thereof from the date on which this report was filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Page 1

Business of POET Technologies Inc.

POET designs, develops, manufactures and sells integrated opto-electronic solutions for data communications, telecommunications and artificial intelligence markets. POET has developed and is marketing its proprietary POET Optical InterposerTM, a novel platform that allows the seamless integration of electronic and photonic devices onto a single chip using advanced wafer-level semiconductor manufacturing techniques. The semiconductor industry has adopted the term “Wafer-Level Chip-Scale Packaging” (or “WLCSP”) to describe similar approaches within the semiconductor industry. POET’s Optical Interposer eliminates costly components and labor-intensive assembly, alignment, and testing methods employed in conventional photonics. The cost-efficient integration scheme and scalability of the POET Optical Interposer brings value to devices or systems that integrate electronics and photonics, including high-growth areas of communications and computing, such as high-speed networking for cloud service providers and data centers, 5G networks, machine-to-machine communication, sometimes referred to as the “Internet of Things” (IoT), self-contained “edge” computing applications, such as accelerators for Artificial Intelligence – Machine Learning (AI-ML) systems and sensing applications, such as LIDAR systems for autonomous vehicles and point-of-use health care products.

On October 21, 2020, the Company signed a Joint Venture Agreement (“JVA”) establishing a joint venture company (the “JV”), Super Photonics Integrated Circuit Xiamen Co., Ltd (“SPX”) with Xiamen Sanan Integrated Circuit Co. Ltd. (“Sanan IC”) whose purpose is to assemble, test, package and sell cost-effective, high-performance optical engines based on POET’s proprietary Optical Interposer platform technology.

SPX’S capitalization will consist of a combination of committed cash, capital equipment and intellectual property from Sanan IC and intellectual property and know-how from POET, with a combined estimated value of approximately $50M. Capitalization is on-going and has not yet been completed. POET’s contribution of certain intellectual property and know-how was valued by an independent appraiser at $22.5M. Sanan IC will contribute cash of approximately $25M for capital equipment and operating expenses, with the expectation that the eventual ownership of the JV will be approximately 52% Sanan IC and 48% POET. SPX is an independent company and is operated as a true joint venture, so its financial results are not consolidated into POET’s but are reported as a gain in the value of the contribution to the JV and a gain or loss in the Company’s percentage ownership of the JV.

Sanan IC is a developerworld-class wafer foundry service company with an advanced compound semiconductor technology platform, serving the optical, RF microelectronics and power electronics markets. Sanan IC is a wholly owned subsidiary of opto-electronicSanan Optoelectronics Co., Ltd. (Shanghai Stock Exchange, SSE: 600703), the leading manufacturer of advanced ultra-high brightness LED epitaxial wafers and photonic fabrication processes and products. Photonics integration is fundamental to increasing functional scaling and lowering the cost of current photonic solutions.  POET believes that its advanced opto-electronics process platform enables substantial improvements in energy efficiency, component cost and sizechips in the productionworld.

Significant progress on SPX included the registration of smart optical components,SPX, appointment of the engines driving applications rangingboard of directors and key personnel, hiring of 36 employees, completion of 5,000 square feet of temporary facilities, ordering of key capital equipment for installation and qualification and outflow of approximately $7 million from data centersSanan IC to consumer productscover initial operating and capital expenditures to military applications. Silicon Valley-based POET’s patented module-on-a-chip process, which integrates digital, high-speed analogbe contributed to the JV.

While each joint venturer has appointed one member to the Board of Directors of SPX, the company has its own governance and optical devicesmanagement structure and is operated under the laws of the Peoples Republic of China.

The Company has recognized a gain of $5,366,294 related to its contribution of intellectual property to SPX in accordance with IAS 28. The Company only recognizes a gain on the same chip,contribution of the intellectual property equivalent to the Sanan IC’s interest in SPX, the unrecognized gain of $17,127,825 will be applied against the investment and periodically realized as the Company’s ownership interest in SPX is designed to serve as an industry standardreduced. As at December 31, 2023, Sanan IC’s and the Company’s ownership interests were approximately 23.9% and 76.1% respectively.

Net loss for smart optical components.

the year ended December 31, 2023 was $20,267,365. The Company currently operates at a loss. We have no revenues. Our expenses,net loss included $10,077,930 incurred for research and development activities directly or indirectly, relaterelated to the development and commercialization of the POET process or our status as a publicly traded Company. During the fiscal year ended December 31, 2015, researchOptical Interposer and POET Optical Engine products. Research and development expenses were $3,532,492 while generalincluded non-cash costs of $1,539,235 related to stock-based compensation. $10,795,155 was incurred for selling, marketing and administration expenses were $8,614,109. Included in generalwhich included non-cash costs of $2,662,209 related to stock-based compensation and administrative$1,922,140 related to depreciation and research and development are non-cash share based expensesamortization.

The Company incurred $70,182 of $4,265,704 and $552,416, respectively, relatinginterest expense, of which $53,614 was non-cash.

Page 2

The Company recorded a gain on contribution of intellectual property to the fair valuejoint venture of stock based compensation. We have yet to commercialize the POET technology. To date, proceeds from the issuance of its common shares have financed$1,031,807. Additionally, the Company’s continuing operations and research and development initiatives.share of loss in joint venture was limited to $1,031,807 as required by IFRS standards.

AsThe Company’s statement of financial position as of December 31, 2015, we had over $14.5 million2023 reflects assets with a book value of $8,777,417 compared to $15,390,453 as of December 31, 2022. Thirty six percent (36%) of the book value at December 31, 2023 was in current assets consisting primarily of cash and approximately $515,000cash equivalents of accounts payable$3,019,069 compared to sixty two percent (62%) of the book value as of December 31, 2022, which consisted primarily of cash and accrued liabilities. We are confident that the current levelcash equivalents of working capital is sufficient to support the Company beyond 2016  as we work toward the goal of monetizing the POET process.$9,229,845.

Financial and Other Information

In this Annual Report, unless otherwise specified, all dollar amounts are expressed in United States Dollars (“US$”, “USD” or “$”).

Cautionary Statements Regarding Forward-Looking Statements

This Annual Report on Form 20-F and other publicly available documents, including the documents incorporated herein and therein by reference contain forward-lookingforward- looking statements and information within the meaning of U.S. and Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-lookingforward- looking terminology or words, such as, “continues”, “with a view to”, “is designed to”, “pending”, “predict”, “potential”, “plans”, “expects”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, and similar expressions or variations thereon, or statements that events, conditions or results “can”, “might”, “will”, “shall”, “may”, “must”, “would”, “could”, or “should” occur or be achieved and similar expressions in connection with any discussion, expectation, or projection of future operating or financial performance, events or trends. Forward- looking statements and information are based on management’s current expectations and assumptions, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict.

TheOur actual results, performance and achievements may differ materially from those expressed in, or implied by, the forward-looking statements and information in this Annual Report are subject toas a result of various risks, uncertainties and uncertainties, including those described in ITEM 3.D. “Risk Factors”,other factors, many of which are difficult to predict and generally beyond the control of the Company, including without limitation:

·we have a limited operating history;
·
our need for additional financing, which may not be available on acceptable terms or at all;
·
the possibility that we will not be able to compete in the highly competitive semiconductor market;
·
the risk that our objectives will not be met within the time linestimelines we expect or at all;
·
research and development risks;
·
the risks associated with successfully protecting patents and trademarks and other intellectual property;

·
the need to control costs and the possibility of unanticipated expenses;

1
·manufacturing and development risks;
·
the risk that the price of our common stockshares will be volatile; and

 ·Page 3

the risk that geopolitical uncertainties may negatively impact our business venture in China;
the risk that shareholders’ interests will be diluted through future stock offerings, option and warrant exercises.exercises; and
other risks and uncertainties described in Item 3.D. “Risk Factors”.

For all of the reasons set forth above, investors should not place undue reliance on forward-looking statements. Other than any obligation to disclose material information under applicable securities laws or otherwise as maybe required by law, we undertake no obligation to revise or update any forward-looking statements after the date hereof.

Data relevant to estimated market sizes for our technologies under development are presented in this Annual Report. These data have been obtained from a variety of published resources including published scientific literature, websites and information generally available through publicized means. The Company attempts to source reference data from multiple sources whenever possible for confirmatory purposes. Although the Company believes the foregoing data is reliable,However, the Company has not independently verified the accuracy and completeness of this data.

PART I

ITEMItem 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORSIdentity of Directors, Senior Management and Advisers

A.A. Not Applicable.required.

ITEMItem 2. OFFER STATISTICS AND EXPECTED TIMETABLEOffer Statistics and Expected Timetable

Not Applicable.required.

ITEMItem 3. KEY INFORMATIONKey Information

A.A.Selected Financial Data[Reserved]

The selected financial data of the Company for the years ended December 31, 2015, 2014 and 2013 was derived from the audited annual consolidated financial statements of the Company, which have been audited by Marcum LLP, independent registered public accounting firm. Selected financial data of the Company for the years ended December 31, 2012 and 2011 was derived from the consolidated financial statements of the Company, which are not included in this Annual Report.

The information contained in the selected financial data for the 2015, 2014 and 2013 years is qualified in its entirety by reference to the Company’s consolidated financial statements and related notes included under the heading “ITEM 17. Financial Statements” and should be read in conjunction with such financial statements and with the information appearing under the heading “ITEM 5.

Operating and Financial Review and Prospects.” Except where otherwise indicated, all amounts are presented in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

Since its formation, the Company has financed its operations from public and private sales of equity securities, proceeds received upon the exercise of warrants and stock options, research and development contracts from U.S. government agencies and, prior to 2012, by sales of solar energy equipment products. The Company has never been profitable, so its ability to finance operations has been dependent on equity financings. The Company believes that it will continue to rely on the sale of its equity securities to provide funds for its activities. We believe the Company is well capitalized , nevertheless the Company may effect a future financing if an appropriate opportunity presents itself. See ITEM 3.D. “Risk Factors.”

The Company has not declared any dividends since incorporation and does not anticipate that it will do so in the foreseeable future.

2

The following consolidated financial information is separated between continuing and discontinued operations.

Consolidated Statements of Operations

Under International Financial Reporting Standards

(US$)

  Years Ended December 31,
  2015 2014 2013 2012 2011
Costs and Expenses                    
General and Administration $8,614,109  $9,677,705  $6,284,288  $3,023,471  $2,695,956 
Research and Development  3,532,492   2,277,927   1,925,974   1,093,998   1,327,057 
Investment Income, including interest  (76,431)     (18,371)     (21,915)
Total Expenses  12,070,170   11,955,632   8,191,891   4,117,469   4,001,098 
                     
Loss, before the following                    
Other income     169,832   342,874   238,806   755,422 
Net Loss for the Period                    
Loss from continuing operations  (12,070,170)  (11,785,800)  (7,849,017)  (3,878,663)  (3,245,676)
Loss from discontinued operations, net of taxes           (4,685,449)  (11,898,225)
Net Loss  (12,070,170)  (11,785,800)  (7,849,017)  (8,564,112)  (15,143,901)
Deficit, beginning of period  (78,780,502)  (66,994,702)  (59,145,685)  (50,442,457)  (35,298,556)
Divestiture of non-controlling interest           (139,116)   
Deficit, end of period $(90,850,672) $(78,780,502) $(66,994,702) $(59,145,685) $(50,442,457)
Basic and Diluted Loss Per Share: $(0.07) $(0.08) $(0.06) $(0.08) $(0.17)
Continuing Operations $(0.07) $(0.08) $(0.06) $(0.04) $(0.04)
Discontinued Operations          $(0.04) $(0.13)

Consolidated Statements of Discontinued Operations

Under International Financial Reporting Standards
(US$)

  Years Ended December 31,    
  2015 2014 2013 2012 2011
Revenue $  $  $  $617,728  $5,122,507 
Costs and Expenses                    
Cost of Goods Sold           1,117,282   8,916,603 
General and Administration           3,380,117   5,551,286 
Research and Development           611,644   2,561,217 
Investment Income, including interest           (3,044)  (8,374)
Total Expenses           5,105,999   17,020,732 
                     
Net Operating Income (Loss) from Discontinued Operations           (4,488,271)  (11,898,225)
Loss on Divestiture of Subsidiaries           (197,178)   
Net Income (Loss) from Discontinued Operations           (4,685,449)  (11,898,225)
Attributable to non-controlling interest              107,662 
Attributable to equity shareholders $  $  $  $(4,685,449) $(11,790,563)

3

Consolidated Statements of Financial Position

Under International Financial Reporting Standards

(US$)

  December 31,    
  2015 2014 2013 2012 2011
Assets                    
Cash $14,409,996  $11,287,864  $3,260,967  $1,435,762  $1,330,141 
Accounts and Other Receivable           96,749   526,229 
Prepaids and Other Current Assets  150,923   243,501   267,012   158,257   152,162 
Inventories              1,426,003 
Marketable Securities        397   426   415 
Assets Available for Sale           606,413    
Investment in Opel Solar Asia Company Limited              197,178 
Property and Equipment  947,107   1,058,860   903,792   26,670   1,798,779 
Patents and Licenses  426,813   260,721   125,676   75,550   198,249 
Total Assets $15,934,839  $12,850,946  $4,557,844  $2,399,827  $5,629,156 
Liabilities                    
Accounts Payable and Accrued Liabilities $515,421  $451,724  $256,027  $231,903  $1,705,876 
Product Warranty           25,899   25,899 
Disposal Group Liabilities           606,413    
Deferred Energy Credit              614,363 
Asset Retirement Obligation              74,277 
Total Liabilities  515,421   451,724   256,027   864,215   2,420,415 
Shareholders’ Equity                    
Share Capital  81,027,171   61,688,953   42,911,455   40,225,401   38,507,720 
Special Voting Share           100   100 
Special Warrants and Shares to be Issued              27,521 
Warrants  2,013,747   6,458,659   8,135,590   3,850,685   1,813,729 
Contributed Surplus  25,618,159   23,616,664   20,261,067   16,361,282   13,162,981 
Accumulated Other Comprehensive Income (loss)  (2,388,987)  (584,552)  (11,593)  243,829   278,263 
Deficit  (90,850,672)  (78,780,502)  (66,994,702)  (59,145,685)  (50,442,457)
Non-Controlling Interest              (139,116)
Total Shareholders’ Equity  15,419,418   12,399,222   4,301,817   1,535,612   3,208,741 
Total Liabilities and Shareholders’ Equity $15,934,839  $12,850,946  $4,557,844  $2,399,827  $5,629,156 

B.B.Capitalization and IndebtednessIndebtedness.

Not Applicable.required.

C.C.Reasons for the Offer and Use of ProceedsProceeds.

Not Applicable.required.

4
D.D.Risk Factors.

We are subject to various risks, including those described below, which could materially adversely affect our business, financial condition and results of operations and, in turn, the value of our securities. In addition, other risks not presently known to the other information presented in this Annual Report, the following shouldus or that we currently believe to be considered carefully in evaluating the Companyimmaterial may also adversely affect our business, financial condition and its business. This Annual Report containsresults of operations, perhaps materially. The risks discussed below also include forward-looking statements and information within the meaning of U.S. and Canadian securities laws that involve risks and uncertainties. The Company’s actual results may differ materially from the results discussed in the forward-looking statements and information.information Factors that might cause such differences include those discusseddiscussed. Before making an investment decision with respect to any of our securities, you should carefully consider the following risks and uncertainties described below and elsewhere in this Annual Report. See also “Cautionary Statement Regarding Forward-Looking Statements.”

Page 4

Risks Related to Our Business

As a result of our limited financial liquidity, we and our auditors have expressed substantial doubt regarding our ability to continue as a going concern.

 

As a result of our current limited financial liquidity, our auditors’ report for our 2023 financial statements, which is included as part of this report, contains a statement concerning our ability to continue as a going concern. Our limited liquidity could make it more difficult for us to secure additional financing or enter into strategic relationships on terms acceptable to us, if at all, and may materially and adversely affect the terms of any financing that we may obtain and our public stock price generally.

Our continuation as a going concern is dependent upon, among other things, achieving positive cash flow from operations and, if necessary, augmenting such cash flow using external resources to satisfy our cash needs. Our plans to achieve positive cash flow primarily include engaging in offerings of securities. Additional potential sources of funds include negotiating milestone payments for non-recurring engineering services or royalties from sales of our products. These cash sources could, potentially, be supplemented by financing or other strategic agreements. However, we may be unable to achieve these goals or obtain required funding on commercially reasonable terms, or at all, and therefore may be unable to continue as a going concern.

We have a limitedhistory of large operating history, and we do not expect to become profitable in the near future.

We are a fabless semiconductor technology development company with a limited operating history. We are not profitable and have incurred losses. We continuemay not be able to incur research and development and general and administrative expenses related to our operations. We expect to continue to incur losses for the foreseeable future, and these losses may increase as we move toward the commercialization of our technology currently under development. If our POET technology platform does not achieve market acceptance, we may never become profitable. Even if we achieveor sustain profitability in the future and as a result we may not be able to sustain profitability in subsequent periods.maintain sufficient levels of liquidity.

Accordingly, it is difficult

We have historically incurred losses and negative cash flows from operations since our inception. As of December 31, 2023, we had an accumulated deficit of $214,291,025. We expect that operating losses will continue into the near term. Our revenues are not considered sufficient to evaluate our business prospects. Moreover, our prospects mustcover operating expenses. We can give no assurance that we will be considered in light ofprofitable even if we successfully commercialize or products. Failure to become and remain profitable may adversely affect the risks and uncertainties encountered by an early-stage company and competitive markets, such as the semiconductor market where market acceptanceprice of our technology is uncertain.common stock and ability to raise capital and continue operations.

As of December 31, 2023, we held $3,019,069 in cash and cash equivalents. We dependhad working capital of $716,881.

We divested our major operating asset, adopted a new “fab-light” strategy, and we plan to focus on the implementationOptical Interposer as our main business. Any or all of these decisions if incorrect may have a material adverse effect on the results of our operations, financial position and cash flows, and pose further risks to the successful operation of our business plan,over the short and long-term.

There are substantial risks associated with our adoption of a “fab-light” strategy, including the loss of revenue associated with the divested operation, the loss of control over an internal development asset, and the loss of key technical knowledge available from personnel who will no longer be employed by the Company, many of whom we may have to replace.

We have some previous experience with managing development without an internal development resource under a similar “fab-light” strategy which was not successful, and there is no guarantee that our abilitynew approach to makeoperating a company with our chosen strategy will be successful. Further, our strategy will be solely dependent on the future progressmarket acceptance and sale of Optical Interposer-based solutions, which in some cases are neither fully developed nor in qualification stages. Customers are in the initial stages of committing to a production product.

We have taken substantial measures to protect POET’s intellectual property in the Optical Interposer, including development and production with a separate third-party company which engaged no engineering personnel from our former subsidiary company DenseLight. We conducted development of component devices with a segregated team at our DenseLight facility and took measures to protect POET’s intellectual property on those developments as well. However, we cannot guarantee that all our measures to protect our intellectual property on either the POET technology. Optical Interposer or its component devices have been totally effective. In addition, we cannot guarantee that DenseLight or any other third-party that we rely on to perform development, manufacturing, packaging or testing services will perform as expected and produce the devices we will need to grow our Optical Interposer business.

There can be no assurance that our efforts will ultimately result in profits.

We have not yet commercialized the POET technology and there is no certainty that we will be able to do so.

We have not yet commercialized our POET technology, andsuccessful in addressing these or any other significant risks we may neverencounter in the divestment of DenseLight, the adoption of a “fab-light” strategy or the focus of our business solely on the Optical Interposer.

We may not be able to obtain additional capital when desired, on favorable terms or at all.

We operate in a market that makes our prospects difficult to evaluate and, to remain competitive, we will be required to make continued investments in capital equipment, facilities and technology. We expect that substantial capital will be required to continue technology and product development, to expand our contract manufacturing capacity if we need to do so. Weso and to fund working capital for anticipated growth. If we do not know whengenerate sufficient cash flow from operations or ifotherwise have the capital resources to meet our future capital needs, we will completemay need additional financing to implement our development efforts or successfully license our technology. Even if we are successful in developing a commercially useful POET platform, we will not be successful unless POET gains market acceptance. The degree of market acceptance of these products may depend on a number of factors, including:business strategy.

·the adoption of our technology by semiconductor device designers, manufacturers and end market users;
·the competitive market environment;
·the establishment and demonstration in the technology community of the efficacy of our technology and its potential advantages over existing technology; and
 ·the adequacy and success of sales and marketing efforts regarding licensing our technology.Page 5

We have had a historyThe Company expects that it will need to raise additional capital in the future to fund more rapid expansion, respond to competitive pressures, acquire complementary businesses or technologies or take advantage of lossesunanticipated opportunities, and expectit may seek to continue to incur additional losses for the foreseeable future.

do so through public or private financing, strategic relationships or other arrangements. The Company’s primary focus is on the research and developmentability of a specific semiconductor technology, which requires the expenditure of significant amounts of cash over a relatively long time period. As at December 31, 2015, the Company’s total deficit was $90,850,672, with net losses in fiscal years 2015, 2014 and 2013 of $12,070,170, $11,785,800 and $7,849,017 respectively. There can be no assurance that the Company to secure any required financing will ever record any earnings.

We may need to obtain additional investmentdepend in part upon prevailing capital market conditions and therebusiness success. There can be no assurance that the Company will be successful in generating sufficientits efforts to secure any additional financing on terms satisfactory to Management or at all. Even if such funding is available, the Company cannot predict the size of future issues of common shares or securities convertible into common shares or the effect, if any, that future issues and sales of common shares will have on the price of the Company’s common shares.

If the Company raises additional capital through the issuance of equity securities, the percentage ownership of the Company’s existing shareholders may be reduced, and such existing shareholders may experience additional dilution in net book value per share. Any such newly-issued equity securities may also have rights, preferences or privileges senior to those of the holders of the common shares. If additional funds are raised through the incurrence of indebtedness, such indebtedness may involve restrictive covenants that impair the ability of the Company to pursue its growth strategy and other aspects of its business plan, expose the Company to greater interest rate risk and volatility, require the Company to dedicate a substantial portion of its cash flow from operations to payments on its indebtedness, thereby reducing the availability of its cash flow to continue its development.

As stated above,fund working capital and capital expenditures, increase the Company’s vulnerability to general adverse economic and industry conditions, place the Company expectsat a competitive disadvantage compared to incur losses for the foreseeable future. As of December 31, 2015, 2014 and 2013,its competitors that have less debt, limit the Company’s working capital was $14,045,498, $11,079,641ability to borrow additional funds, and $3,272,349 respectively.

The Company has no capital asset commitments. The increased working capital balance in 2015 over 2014 was due to the $12.1 million dollars raised through the exercise of stock options and warrants during the year ended December 31, 2015.

5

The Company’s balance sheet as at December 31, 2015 reflects assets with a book value of $15,934,839 (2014 - $12,850,946) of which 91% (2014 - 89%) or $14,560,919 (2014 - $11,531,365) is current and consists primarily of cash totaling $14,409,996 (2014 - $11,287,864). It is our intention that the Company’s liquidity and unencumbered balance sheet will allow for investments in research and development and valuable human capital which are necessary to enableotherwise subject the Company to achieve its technicalthe risks discussed under “Indebtedness” below and operational milestones

As of February 22, 2016, there were 1,116,051 warrants outstanding to purchase common shares at an average exercise price of CAD$0.23 expiring between June 22, 2016 and September 27, 2016. Should those warrants be exercised, there is a potential for an additional CAD $256,692 to be raised byheighten the Company. Whether the warrants will be exercised is dependent on a number of factors that are outsidepossible effects of the Company’s control.

Between January 1, 2016 and February 22, 2016, the Company raised $1,965,327 from the exercise of 2,686,947 warrants and 628,000 stock options.

Based on current plans and cash utilization, we believe we have sufficient liquidity to support our operations and technological programs beyond 2016, which include further development of the POET semiconductor process and increasing the POET intellectual property portfolio to enable us to exploit POET, through licenses and collaborative arrangements.

The Company has no external sources of financing such as bank lines of credit. The Company will likely require future additional financing to carry out its business plan. The current market for both debt and equity financings for companies such as the Company is challenging, and there can be no assurance that a financing, whether debt or equity, will be available on acceptable terms or at all. The failure to obtain financing on a timely basis may result in the Company having to reduce or delay one or more of its planned research, development and marketing programs and to reduce related overhead, any of which could impair the Company’s current and future value. Any additional equity financing, if obtained, may result in significant dilution to the existing shareholders at the time of such financing. The Company may also seek additional funding from other sources, including technology licensing, co-development collaborations and other strategic alliances, which, if obtained, may reduce the Company’s interest in our intellectual property. There can be no assurance, however, thatrisks discussed in these risk factors. In connection with any such alternative sourcesfuture capital raising transaction, whether involving the issuance of funding will be available.

Rapid technological change could render our technology non-competitive and obsolete.

The semiconductor industry is subject to rapid and substantial technological change. Developments by others may renderequity securities or the Company’s POET technology non-competitive, andincurrence of indebtedness, the Company may not be ablerequired to keep pace with technological developments. Competitors have developed technologiesaccept terms that compete with the functionality expectedrestrict its ability to raise additional capital for a period of the Company’s technology. Some of these technologies have an entirely different approachtime, which may limit or means of accomplishing the desired process and function than the POET process being developed byprevent the Company from raising capital at times when it would otherwise be opportunistic to do so.

The process of developing new, technologically advanced products in semiconductor manufacturing and may be more effectivephotonics products is highly complex and less costly to implement than the technologies developed by the Company.uncertain, and we cannot guarantee a positive result.

Currently, the industryThe development of new, technologically advanced products is dominated by silicon-based semiconductor technology that requires the fabrication of multiple chips for opticala complex and electrical functions. As such, manufacturers of electronic devices are accustomed to designing their products around multi-chip platforms. If more advanced silicon-based technology is developed, manufacturers may determine that maintenance of the silicon platform will be less costly to implement and utilize than alternative technologies. Also, competitors may develop other integrated circuit platforms that are easier for manufacturers to adopt.

Our researchuncertain process requiring frequent innovation, highly-skilled engineering and development efforts are focused on the POET platform,personnel and any delay in the development, or the abandonment of the POET technology, or the POET technology’s failure to achieve market acceptance, would compromise our competitive position.

We have devoted and expect to continue to devote a large amount of resources to develop new and emerging technologies and standards that can be developed into products or commercially licensed in the future. Our POET platform is a new technology which as of yet does not have an established base of application and may not be embraced for use by the semiconductor industry. Should we fail to develop commercially available products based on our POET platform, or should we fail to license POET to technology companies who in turn develop products on the platform, our research and development efforts with respect to these technologies and standards likely would have no appreciable value. In addition, if we do not correctly anticipate new technologies and standards, or if the products that we and our licensees, if any, develop based on these new technologies and standards fail to achieve market acceptance, our competitors may be better able to address market demand than we would. Furthermore, if markets for these new technologies and standards develop later than we anticipate, or do not develop at all, demand for our technologies or products that are currently in development would suffer, resulting in reduced product sales or licensing sales of these technologies, if any.

6

We are a relatively small company with limited resources compared to some of our current and potential competitors and we may not be able to compete effectively and increase market share.

Some of our current and potential competitors have longer operating histories, significantly greater resources, name recognition and a base ofcustomers. As a result, these competitors may have greater credibility with our potential customers. They also may be able to adoptmore aggressive pricing policies and devote greater resources to the development, promotion and licensing of their products and technologies thanwe would be able to. In addition, some of our potential competitors have likely already established sales, licensing or joint development relationships with the decision makers at our potential customers. In addition, many of what we perceive as potential customers have the capabilities to develop technology competitive to ours internally. These competitors may be able to leverage their existingrelationships to discourage their customers from buying POET products or licensing or otherwise utilizing our technology. These competitors may elect not to support our technology which could complicate and impede our sales efforts. These and other competitive pressures may prevent us from competing successfully against current or future competitors, and may materially harm our business.

We are party to an intellectual property license agreement granting a portion of certain future revenues.

The Company has a License Agreement, as amended in 2014, with the University of Connecticut (“UCONN”) whereby UCONNgranted the Company an exclusive license to the intellectual property developed by a consultant of the Company,

Dr. Geoffrey Taylor, who is also a member of the faculty at UCONN. Such a license may reduce the profitability of the Company ifand when our products reach market. The Company is obligated to pay up to $1,000,000 per year when revenues reach certainmilestonessignificant capital, as well as pay an additional 3%the accurate anticipation of certain revenue received in connection with the exploitation of the licensed intellectualproperty or sales of products to third parties other than engineering expenses received from third parties.

We will be dependent on both semiconductor manufacturers and major intellectual property licensees.

We will be dependent on semiconductor manufacturers, as licensees of our technology, to manufacturetechnological and market opto-electronic productsbased on our architecture in order to receive royalties in the future. We also depend on them to add value to our licensed technology byproviding complete POET-based solutions to meet the specific application needs of systems companies. However, the semiconductormanufacturers, if any, will not be contractually obliged to manufacture, distribute or sell devices based on our technology or to market our POET technology on an exclusive basis. Some potential semiconductor partners design, develop and/or manufacture and marketdevices based on different competing architectures, including their own, and others may do so in the future.

We anticipate that our revenue will depend in part on these major license customers, although the companies considered to be major customers and the percentage of revenue represented by each major customer may vary from period to period depending on the addition of new agreements, the timing of work performed by us and the number of products utilizing our platform technology. In addition, we cannot be certain that any of the opto-electronic manufacturers will produce products incorporating our intellectual property components or that, if production occurs, they will generate significant royalty revenue for us.

trends. We cannot assure you that we will be successful in developing relationships with semiconductor manufacturersable to identify, develop, manufacture, market or support new or enhanced products successfully or on a timely basis. Further, we cannot assure you that our new products will gain market acceptance or that we will be able to maintain relationships with semiconductor manufacturers once developed, that semiconductor device manufacturers will dedicaterespond effectively to product introductions by competitors, technological changes or emerging industry standards. We also may not be able to develop the resourcesunderlying core technologies necessary to promotecreate new products and developenhancements, license these technologies from third parties, or remain competitive in our markets.

Page 6

The optical data communications industry in which we have chosen to operate is subject to significant risks, including rapid growth and volatility, dependence on rapidly changing underling technologies, market and political risks and uncertainties and extreme competition. We cannot guarantee that we will be able to anticipate or overcome any or all of these risks and uncertainties, especially as a small company operating in an environment dominated by large, well-capitalized competitors with substantially more resources.

The optical data communications industry is subject to significant operational fluctuations. In order to remain competitive, we incur substantial costs associated with research and development, qualification, prototype production capacity and sales and marketing activities in connection with products based on our POET technology or that they will manufacture products based on our POET technology in quantities sufficient to meet demand.

Our revenues will depend in part on royalties that may be received on POET-based devices,purchased, if at all, long after we have incurred such costs. In addition, the rapidly changing industry in which will likely be generated based onwe operate, thevolumes length of time between developing and priceintroducing a product to market, frequent changing customer specifications for products, customer cancellations of devices manufacturedproducts and sold bygeneral down cycles in the industry, among other things, make our semiconductor manufacturer licensees, if any. Our royalties will betherefore influenced by many of the risks faced by the semiconductor market in general. These risks include reductions in demand and reduced average selling prices. The semiconductor market is intensely competitive. It is also generally characterized by decliningaverage selling prices over the life ofprospects difficult to evaluate. As a generation of devices. The effectresult of these price decreasesfactors, it is compoundedpossible that we may not (i) generate sufficient positive cash flow from operations; (ii) raise funds through the issuance of equity, equity-linked or convertible debt securities; or (iii) otherwise have sufficient capital resources to meet our future capital or liquidity needs. There are no guarantees we will be able to generate additional financial resources beyond our existing balances.

Investors may not be able to obtain enforcement of civil liabilities against the Company.

The enforcement by investors of civil liabilities under the U.S. federal or state securities laws may be adversely affected by the fact that royalty rates decreaseseveral of the Company’s officers and directors reside outside of the U.S. and that all, or a substantial portion, of their assets and a portion of our assets, are located outside the U.S. It may not be possible for an investor to effect service of process within the U.S. on, or enforce judgments obtained in the U.S. courts against, us, certain of our subsidiaries or certain of our directors and officers based upon the civil liability provisions of U.S. federal securities laws or the securities laws of any state of the U.S. In light of the above, there is doubt as to whether a judgment of a U.S. court based solely upon the civil liability provisions of U.S. federal or state securities laws would be enforceable against the Company, certain of its subsidiaries or the Company’s directors and officers.

We have contributed a portion of our intellectual property and exclusive assembly and sales rights for certain key initial products to a joint venture company that we formed in China. Although we believe that the joint venture offers significant opportunities for growth that we might not otherwise have and solves several major known challenges, we also recognize that there are substantial risks and uncertainties associated with executing a major portion of our strategy through a joint venture, regardless of the intentions and capabilities of the parties involved.

On October 21, 2020, the Company signed a Joint Venture Agreement (“JVA”) with Sanan IC to form a joint venture company, Super Photonics Xiamen Co., Ltd. (“SPX”), which will eventually be owned 48% by the Company once SAIC is fully invested. SPX will assemble, test, package and sell certain optical engines on an exclusive basis globally and certain others on an exclusive basis in the territory of Greater China. Optical engines based on the POET Optical Interposer are expected to be a primary component of several types of optical transceivers used in data centers. The joint venture is based on the contribution by the Company of certain assembly and test know-how and other intellectual property and cash to be contributed by Sanan IC in stages, subject to meeting certain milestones, to cover all capital and operating expenses of SPX until it is self-sustaining. We cannot guarantee that SPX will meet each milestone or that Sanan IC will or will not contribute capital on schedule when and if such milestones are met, nor can we guarantee that SPX will be successful in assembling and testing optical engines, nor in the marketing and sales once the optical engines are tested and qualified by potential customers.

Because no party to the joint venture, including the Company has a control position, we are not able to consolidate revenue and expenses directly into the Company’s financial statements. The earnings or loss from the joint venture operations are included as a functionsingle line item in the financial statements and the gain or loss on the intellectual property contributed to the joint venture is reported on another. Further, even though the joint venture may appreciate in market value if successful, the Company will not be able to reflect any increase in fair value, other than adding or subtracting on a periodic basis the income or loss experienced by the joint venture in relation to the Company’s percentage ownership at the time.

Page 7

The Company’s investment into “Super Photonics Xiamen” (“SPX”) is into an independent company operating as a true joint venture under the laws of volume.the Peoples Republic of China (“PRC”). There are significant governance and operational risks associated with joint ventures and with companies operating in the PRC, in general. We cannot assure youguarantee that we will be able to anticipate or overcome the risks and uncertainties of operating a joint venture company in China.

Although SPX has its own governance structure to which both parties contribute directors, most major decisions must be unanimous, which means that such decisions will require the support of the management of SPX and both of the JV partners. Although the Company has sought the support of well-known and competent legal and other professional advisors and has had a major role in the recruitment of the senior management team of SPX, the Company has no prior experience with either the operation of a joint venture or with the operation of a JV company under the laws of the PRC, so we cannot guarantee that the joint venture will be successfully managed without substantial investment in time and effort by the Company’s current management team or at all

If our customers do not qualify our products for use on a timely basis, our results of operations may suffer.

Prior to the sale of new products, our customers typically require us to “qualify” our products for use in their applications. At the successful completion of this qualification process, we refer to the resulting sales opportunity as a “design win.” Additionally, new customers often audit our manufacturing facilities and perform other evaluations during this qualification process. The qualification process involves product sampling and reliability testing and collaboration with our product management and engineering teams in the design and manufacturing stages. If we are unable to accurately predict the amount of time required to qualify our products with customers, or are unable to qualify our products with certain customers at all, then our ability to generate revenue could be delayed or our revenue would be lower than expected and we may not be able to recover the costs associated with the qualification process or with our product development efforts, which would have an adverse effect on our results of operations.

We have limited operating history in the data center market, and our business could be harmed if this market does not develop as we expect.

The initial target market for our Optical Interposer-based optical engine is the data center market for data communications within the data center and beyond. We have limited experience in selling products in this market. We may not be successful in developing a product for this market and even if we do, it may never gain widespread acceptance by large data center operators. If our expectations for the growth of the data center / datacom market are not realized, our financial condition or results of operations may be adversely affected.

Customer demand is difficult to forecast accurately and, as a result, we may be unable to match production with customer demand.

We make planning and spending decisions, including determining the levels of business that we will seek and accept, production schedules, component procurement commitments, personnel needs and other resource requirements, based on our estimates of product demand and customer requirements. Our products are typically sold pursuant to individual purchase orders. While our customers may provide us with their demand forecasts, they are typically not contractually committed to buy any quantity of products beyond firm purchase orders. Furthermore, many of our customers may increase, decrease, cancel or delay purchase orders already in place without significant penalty. The short-term nature of commitments by our expected customers and the possibility of unexpected changes in demand for their products reduce our ability to accurately estimate future customer requirements. If any of our customers decrease, stop or delay purchasing our products for any reason, we will likely have excess manufacturing capacity or inventory and our business and results of operations would be harmed.

The markets in which we operate are highly competitive, which could result in lost sales and lower revenues.

The market for optical components and modules is highly competitive and this competition could result in our existing customers moving their orders to our competitors. We are aware of a number of companies that have developed or are developing integrated optical products, including silicon photonics engines, remote light sources, pluggable components, modules and subsystems, photonic integrated circuits, among others, that compete (or may in the future compete) directly with our current and proposed product offerings.

Page 8

Some of our current competitors, as well as some of our potential competitors, have longer operating histories, greater name recognition, broader customer relationships and industry alliances and substantially greater financial, technical and marketing resources than we do. We may not be able to compete successfully with our competitors and aggressive competition in the market may result in lower prices for our products and/or decreased gross margins. Any such development could have a material adverse effect on our business, financial condition and results of operations.

We depend on a limited number of suppliers and key contract manufacturers who could disrupt our business and technology development activities if they stopped, decreased, delayed or were unable to meet our demand for shipments of their products or manufacturing of our products.

We depend on a limited number of suppliers of epitaxial wafers and contract manufacturers for our Indium Phosphide (“InP”) laser developments and optical interposer production activities. Some of these suppliers are sole source suppliers. We typically have not entered into long-term agreements with our suppliers. As a result, these suppliers generally may stop supplying us materials and other components at any time. Our reliance on a sole supplier or limited number of suppliers could result in delivery problems, reduced control over technology development, product development, pricing and quality, and an inability to identify and qualify another supplier in a timely manner. Some of our suppliers that may be small or under-capitalized may experience financial difficulties that could prevent them from supplying us materials and other components. In addition, our suppliers, including our sole source suppliers, may experience manufacturing delays or shutdowns due to circumstances beyond their control such as pandemics, earthquakes, floods, fires, labor unrest, political unrest or other natural disasters. A change in supplier could require technology transfer that could require multiple iterations of test wafers. This could result in significant delays in licensing, poor demand for servicesresumption of production.

Any supply deficiencies relating to the quality or decreases in pricesquantities of materials or inequipment we use to manufacture our royalty rates will notproducts could materially and adversely affect our ability to fulfill customer orders and our results of operations. Lead times for the purchase of certain materials and equipment from suppliers have increased and, in some cases, have limited our ability to rapidly respond to increased demand, and may continue to do so in the future. To the extent we introduce additional contract manufacturing partners, introduce new products with new partners and/or move existing internal or external production lines to new partners, we could experience supply disruptions during the transition process. In addition, due to our customers’ requirements relating to the qualification of our suppliers and contract manufacturing facilities and operations, we cannot quickly enter into alternative supplier relationships, which prevent us from being able to respond immediately to adverse events affecting our suppliers.

Our international business and operations expose us to additional risks.

We have significant tangible assets located outside Canada and the United States. Conducting business outside Canada and the United States subjects us to a number of additional risks and challenges, including:

periodic changes in a specific country’s or region’s economic conditions, such as recession;
licenses and other trade barriers;
the provision of services may require export licenses;
environmental regulations;
certification requirements;
fluctuations in foreign currency exchange rates;
inadequate protection of intellectual property rights in some countries;
preferences of certain customers for locally produced products;
potential political, legal and economic instability, foreign conflicts, and the impact of regional and global infectious illnesses in the countries in which we and our customers, suppliers and contract manufacturers are located;
Canadian and U. S. and foreign anticorruption laws;
seasonal reductions in business activities in certain countries or regions; and
fluctuations in freight rates and transportation disruptions.

Page 9

These factors, individually or in combination, could impair our ability to effectively operate one or more of our foreign facilities or deliver our products, result in unexpected and material expenses, or cause an unexpected decline in the demand for our products in certain countries or regions. Our failure to manage the risks and challenges associated with our international business and operations could have a material adverse effect on our business.

If we fail to attract and retain key personnel, our business could suffer.

Our future success depends, in part, on our ability to attract and retain key personnel, including executive management. Competition for highly skilled technical personnel is extremely intense and we may face difficulty identifying and hiring qualified engineers in many areas of our business. We may not be able to hire and retain such personnel at compensation levels consistent with our existing compensation and salary structure. Our future success also depends on the continued contributions of our executive management team and other key management and technical personnel, each of whom would be difficult to replace. The loss of services of these or other executive officers or key personnel or the inability to continue to attract qualified personnel could have a material adverse effect on our business.

If we fail to protect, or incur significant costs in defending, our intellectual property and other proprietary rights, our business and results of operations and financial condition.could be materially harmed.

The enforceability of the Company’s patents and the Company’sOur success depends on our ability to maintain trade secrets cannot be predictedprotect our intellectual property and suchpatents or trade secrets may not provide the Company with a competitive advantage against competitors with similar products ortechnologies.

other proprietary rights. We rely on a combination of patent, andtrademark, copyright, trade secret and unfair competition laws, as well as license agreements and restrictions on disclosureother contractual provisions, to establish and protect our intellectual property and other proprietary rights. We have applied for patent registrations in the U.S. and in foreign countries, some of which have been issued. We cannot guarantee that our pending applications will be approved by the applicable governmental authorities. Moreover, our existing and future patents and trademarks may not be sufficiently broad to protect our proprietary rights or may be held invalid or unenforceable in court. A failure to obtain patents or trademark registrations or a successful challenge to our registrations in the U.S. or foreign countries may limit our ability to protect the intellectual property rights that these applications and registrations intended to cover.

Policing unauthorized use of our technology is difficult and we cannot be certain that the steps we have taken will prevent the misappropriation, unauthorized use or other infringement of our intellectual property. Any failureproperty rights. Further, we may not be able to effectively protect our intellectual property rights from misappropriation or other infringement in foreign countries where we have not applied for patent protections, and where effective patent, trademark, trade secret and other intellectual property laws may be unavailable or may not protect our proprietary rights as fully as Canadian or U.S. law. We may seek to secure comparable intellectual property protections in other countries. However, the level of protection afforded by patent and other laws in other countries may not be comparable to that afforded in Canada and the U.S.

We also attempt to protect our intellectual property, rights would diminish or eliminateincluding our trade secrets and know-how, through the competitive advantages that we derive fromuse of trade secret and other intellectual property laws, and contractual provisions. We enter into confidentiality and invention assignment agreements with our employees and independent consultants. We also use non-disclosure agreements with other third parties who may have access to our proprietary technology. We cannot assure youtechnologies and information. Such measures, however, provide only limited protection, and there can be no assurance that our confidentiality and non-disclosure agreements will not be breached, especially after our employees end their employment, and that our trade secrets will not otherwise become known by competitors or that we will be ablehave adequate remedies in the event of unauthorized use or disclosure of proprietary information. Unauthorized third parties may try to adequately protectcopy or reverse engineer our technologyproducts or otherportions of our products, otherwise obtain and use our intellectual property, from third-party infringementor from misappropriation in the U.S. and abroad. Any patent licensed by usmay independently develop similar or issued to us could be challenged, invalidatedequivalent trade secrets orcircumvented or rights granted thereunder may not provide a competitive advantage to us. Furthermore, patent

7

applications that know-how. If we file may not result in issuance of a patent or, if a patent is issued, the patent may not be issued in a form that is advantageous to us. Despite our effortsfail to protect our intellectual property rights, others may independently develop similar products, duplicate our products or design around our patents and other rights. proprietary rights, or if such intellectual property and proprietary rights are infringed or misappropriated, our business, results of operations or financial condition could be materially harmed.

In addition, it is difficultthe future, we may need to monitor compliance with, and enforce,take legal actions to prevent third parties from infringing upon or misappropriating our intellectual property on a worldwide basis in a cost-effective manner. In jurisdictions where foreign laws provide lessor from otherwise gaining access to our technology. Protecting and enforcing our intellectual property protection than affordedrights and determining their validity and scope could result in significant litigation costs and require significant time and attention from our technical and management personnel, which could significantly harm our business. We may not prevail in such proceedings, and an adverse outcome may adversely impact our competitive advantage or otherwise harm our financial condition and our business.

Page 10

We may be involved in intellectual property disputes in the U.S.future, which could divert management’s attention, cause us to incur significant costs and abroad,prevent us from selling or using the challenged technology.

Participants in the markets in which we sell our technology orproducts have experienced frequent litigation regarding patent and other intellectual property mayrights. There can be compromised,no assurance that third parties will not assert infringement claims against us, and we cannot be certain that our businessproducts would not be materially adversely affected.

We may occasionally become involved in administrative proceedings, lawsuits or other proceedings if others allege that we infringefound infringing on their intellectual property rights. Some of these claims could subject us to significant liability for damages and invalidate our property rights. If successful, such claims could impair our ability to collect royalties or license fees or could force us or our customers to:

·stop using or exploiting the challenged intellectual property;
·obtain from the owner of the infringed intellectual property, at our expense, a license to sell the relevant technology at an additional cost, which license may not be available on reasonable terms, or at all; or
·redesign our technology to make it non-infringing.

Our failure to protect our proprietary rights, or the costs of protecting these rights, may harm our ability to compete.

Our success depends in part on our ability to obtain patents and licenses and to preserve other intellectual property rights covering our products and development and testing tools. To that end, we have obtained certain domestic and foreign patents and intendof others. Regardless of their merit, responding to continue to seek patents on our inventions when appropriate. The process of seeking patent protectionsuch claims can be time consuming, divert management’s attention and expensive.

We cannot ensure the following:

·that patents will be issued from currently pending or future applications;
·that our existing patents or any new patents will be sufficient in scope or strength to provide meaningful protection or any commercial advantage to us;
·that foreign intellectual property laws will protect our foreign intellectual property rights; and
·that others will not independently develop similar products, duplicate our products or design around any patents issued to us.

resources and may cause us to incur significant expenses. Intellectual property rights are uncertain and adjudication of such rights involves complex legal and factual questions. We may be unknowingly infringing on the proprietary rights of others and may be liable for that infringement, whichclaims against us could result in significant liability for us. We may receive correspondencea requirement to license technology from third parties alleging infringementothers, discontinue manufacturing or selling the infringing products, or pay substantial monetary damages, each of their intellectual property rights. could result in a substantial reduction in our revenue and could result in losses over an extended period of time.

If we are foundfail to infringeobtain the proprietary rights of others, we could be forcedright to either seek a license touse the intellectual property rights of others or alterthat are necessary to operate our technologies so that they no longer infringe the proprietary rights of others. A license could be very expensivebusiness, and to obtain or may not be available at all. Similarly, changing our processes to avoid infringing the rights of others may be costly or impractical.

We would be responsible for any patent litigation costs. Our License Agreement with UCONN does not provide for indemnification of the Company by UCONN. If we were to become involved in a dispute regardingprotect their intellectual property, whether ours or thatour business and results of another company, we may have to participate in legal proceedings in the United States Patent and Trademark Office or in the United States or Canadian courts to determine any or all of the following issues: patent validity, patent infringement, patent ownership or inventorship. These types of proceedings mayoperations will be costly and time consuming for us, even if we eventually prevail. If we do not prevail, we might be forced to pay significant damages, obtain a license, if available, or stop making a certain product. adversely affected.

From time to time, we may prosecute patentchoose to or be required to license technology or intellectual property from third parties in connection with the development of our products. We cannot assure you that third party licenses will be available to us on commercially reasonable terms, if at all. Generally, a license, if granted, would include payments of up-front fees, ongoing royalties or both. These payments or other terms could have a significant adverse impact on our results of operations. Our inability to obtain a necessary third-party license required for our product offerings or to develop new products and product enhancements could require us to substitute technology of lower quality or performance standards, or of greater cost, either of which could adversely affect our business. If we are not able to obtain licenses from third parties, if necessary, then we may also be subject to litigation to defend against othersinfringement claims from these third parties. Our competitors may be able to obtain licenses or cross-license their technology on better terms than we can, which could put us at a competitive disadvantage.

Failure to comply with requirements to design, implement and maintain effective internal control over financial reporting could have a materially adverse impact on our financial reporting and our business. We are required to have our internal controls over financial reporting audited under Section 404(b) of the Sarbanes-Oxley Act.

Preparing our consolidated financial statements involves a number of complex manual and automated processes, which are dependent upon individual data input or review and require significant management judgment. One or more of these elements may result in errors that may not be detected and could result in a material misstatement of our consolidated financial statements. The Sarbanes-Oxley Act in the U.S. requires, among other things, that as a publicly traded company we disclose whether our internal control over financial reporting and disclosure controls and procedures are effective. Until December 31, 2021 we qualified as an “emerging growth company” under the JOBS Act, and, as a result, were exempted from certain SEC reporting requirements, including those requiring registrants to include an auditor’s report regarding the Company’s internal controls as part of such litigation,registrant’s periodic reports. Our “emerging growth company” status expired on December 31, 2021. The report of our auditors regarding the effectiveness of our internal controls over disclosure and financial reporting as of December 31, 2023 is attached as an exhibit to this annual report.

Page 11

Our internal control over financial reporting cannot guarantee that no accounting errors exist or that all accounting errors, no matter how immaterial, will be detected because a control system, no matter how well designed and operated, can provide only reasonable, but not absolute assurance that the control system’s objectives will be met. If we are unable to implement and maintain effective internal control over financial reporting, our ability to accurately and timely report our financial results could be adversely impacted. This could result in late filings of our annual and quarterly reports under the Securities Act (Ontario) and the Securities Exchange Act of 1934 (the “Exchange Act”), restatements of our consolidated financial statements, a decline in our stock price, suspension or delisting of our common shares by the TSX Venture Exchange (“TSXV”), or other partiesmaterial adverse effects on our business, reputation, results of operations or financial condition.

The process of designing and implementing effective internal control over financial reporting is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a system of internal control that is adequate to satisfy our reporting obligations as a public company. In addition, we are required, pursuant to Section 404(a) of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment must include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. Testing and maintaining our internal control over financial reporting may allegedivert our management’s attention from other matters that are important to our patents are not infringed, are invalid and are unenforceable. We also rely on trade secrets, proprietary know-how and confidentiality provisions in agreements with employees and consultants to protect our intellectual property. Such parties may not complybusiness. In connection with the termsimplementation of their agreementsthe necessary procedures and practices related to our internal control over financial reporting, we and/or our independent registered accounting firm may identify material weaknesses and other deficiencies that may require significant effort and expense to remediate. We may encounter problems or delays in completing the remediation of any such weaknesses or other deficiencies.

If there is a change in conditions, or the degree of compliance with us,policies or procedure deteriorates, internal review of our internal control over financial reporting or the subsequent testing by our independent registered public accounting firm may reveal deficiencies in our internal control over financial reporting that are deemed material weaknesses. If this occurs, our consolidated financial statements or disclosures may contain material misstatements and we could be required to restate our financial results. Additionally, we may not be able to adequately enforceconclude on an ongoing basis that we have effective internal control over financial reporting or our rights against these parties.independent registered public accounting firm may not in future issue an unqualified opinion, each of which could lead to investors losing confidence in our reported financial information, which could have a material adverse effect on the trading price of our common shares, and we may be unable to maintain compliance with applicable stock exchange listing requirements.

Our management has identified a material weakness in the Company’s internal control over financial reporting and may identify additional material weaknesses in the future. If we fail to remediate the material weakness or if we otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results may be affected, and such failure may adversely affect investor confidence and business operations.

In connection with the audit of our financial statements for the fiscal years ended December 31, 2023, a material weakness in our internal control over financial reporting was identified related to Cybersecurity controls.

 

The identified material weakness, if not corrected, could result in a material misstatement to our consolidated financial statements that may not be prevented or detected. In addition, even if we remediate our material weakness, we may be required to expend significant time and resources to further improve our internal control over financial reporting. If we fail to remediate our material weakness or fail to maintain adequate internal control over financial reporting, any new or recurring material weaknesses could prevent us from concluding that our internal control over financial reporting is effective and impair our ability to prevent material misstatements in our consolidated financial statements, which could cause our business to suffer.

Our resultsability to use our net operating losses and certain other tax attributes may fluctuate significantlybe limited.

As of December 31, 2023, we had accumulated net operating losses (“NOLs”), of approximately $150 million. Varying jurisdictional tax codes have restrictions on the use of NOLs, if a corporation undergoes an “ownership change,” the Company’s ability to use its pre-change NOLs, R&D credits and other pre-change tax attributes to offset its post-change income may be unpredictable.limited. An ownership change is generally defined as a greater than 50% change in equity ownership. Based upon an analysis of our equity ownership, we do not believe that we have experienced such ownership changes and therefore our annual utilization of our NOLs is not limited. However, should we experience additional ownership changes, our NOL carry forwards may be limited.

Page 12

 

AssumingWe are subject to governmental export and import controls that could subject us to liability or impair our ability to compete in international markets. Such controls have recently increased for companies in China under the US government’s “control list”, and may further limit or impair our ability to use certain sub-contractors or to sell directly to companies on the list

We are subject to export and import control laws, trade regulations and other trade requirements that limit which raw materials and technology we can import or export and which products we sell and where and to whom we sell our products. Specifically, the Bureau of Industry and Security of the U.S. Department of Commerce is responsible for regulating the export of most commercial items that are so called dual-use goods that may have both commercial and military applications. A limited number of our products are exported by license under certain classifications. Export Control Classification requirements are dependent upon an item’s technical characteristics, the destination, the end-use, and the end-user, and other activities of the end-user. Should the regulations applicable to our products change, or the restrictions applicable to countries to which we ship our products change, then the export of our products to such countries could be restricted. As a result, our ability to export or sell our products to certain countries could be restricted, which could adversely affect our business, financial condition and results of operations. Changes in our products or any change in export or import regulations or related legislation, shift in approach to the enforcement or scope of existing regulations, or change in the countries, persons or technologies targeted by such regulations, could result in delayed or decreased sales of our products to existing or potential customers. In such event, our business and results of operations could be adversely affected.

Our manufacturing operations are subject to environmental regulation that could limit our growth or impose substantial costs, adversely affecting our financial condition and results of operations.

Our properties, operations and products are subject to the environmental laws and regulations of the jurisdictions in which we operate and sell products. These laws and regulations govern, among other things, air emissions, wastewater discharges, the management and disposal of hazardous materials, the contamination of soil and groundwater, employee health and safety and the content, performance, packaging and disposal of products. Our failure to comply with current and future environmental laws and regulations, or the identification of contamination for which we are liable, could subject us to substantial costs, including fines, cleanup costs, third-party property damages or personal injury claims, and make significant investments to upgrade our facilities or curtail our operations. Identification of presently unidentified environmental conditions, more vigorous enforcement by a governmental authority, enactment of more stringent legal requirements or other unanticipated events could give rise to adverse publicity, restrict our operations, affect the design or marketability of our products or otherwise cause us to incur material environmental costs, adversely affecting our financial condition and results of operations.

We are exposed to risks and increased expenses and business risk as a result of Restriction on Hazardous Substances, or RoHS directives, which have been amended but are still in effect.

Following the lead of the European Union, or EU, various governmental agencies have either already put into place or are planning to introduce regulations that regulate the permissible levels of hazardous substances in products sold in various regions of the world. For example, the RoHS directive for EU took effect on July 1, 2006. The labeling provisions of similar legislation in China went into effect on March 1, 2007 and is still in effect, as amended. Consequently, many suppliers of products sold into the EU have required their suppliers to be compliant with the new directive. We anticipate that our customers may adopt this approach and will require our full compliance, which will require a significant amount of resources and effort in planning and executing our RoHS program, it is possible that some of our products might be incompatible with such regulations. In such events, we could experience the following consequences: loss of revenue, damages reputation, diversion of resources, monetary penalties, and legal action.

Page 13

Failure to comply with the U.S. Foreign Corrupt Practices Act could subject us to penalties and other adverse consequences.

We are subject to the U.S. Foreign Corrupt Practices Act, which generally prohibits companies operating in the U.S. from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. In addition, we are required to maintain records that accurately and fairly represent our transactions and have an adequate system of internal accounting controls. Non-U.S. companies, including some that may compete with us, may not be subject to these prohibitions, and therefore may have a competitive advantage over us. If we are not successful in implementing and maintaining adequate preventative measures, we may be responsible for acts of our employees or other agents engaging in such conduct. We could suffer severe penalties and other consequences that may have a material adverse effect on our financial condition and results of operations.

Natural disasters or other catastrophic events could harm our operations.

Our operations in the U.S., Canada, Singapore and China could be subject to significant risk of natural disasters, including earthquakes, hurricanes, typhoons, flooding and tornadoes, as well as other catastrophic events, such as epidemics, terrorist attacks or wars. For example, our testing facility in Singapore is in an area that is susceptible to hurricanes. Any disruption in our facilities or those of our contractors and suppliers arising from these and other natural disasters or other catastrophic events could cause significant delays in the production or shipment of our products until we are able to finish development of the POET platform technology and commence its exploitation, we will likely experience in the future significant quarterly fluctuations inarrange for third parties to manufacture our results of operations. Our results may fluctuate because of a variety of factors. Such factors include:

·the timing of entering into agreements with customers and licensees;
·the financial terms and delivery schedules of our agreements with customers and licensees;
·the demand for products that incorporate our technology;
·the mixture of license fees, royalties, revenues from the sale of products and development systems and fees from services;
·the introduction of new technology by us, our licensees or our competition;

8
·the timing of orders from and shipments to systems companies of POET-based devices from us or other semiconductor manufacturers;
·the sudden technological or other changes in the semiconductor industry; and
·new litigation or developments in current litigation.

In future periods, our operating results may not meet the expectations of public market analysts or investors. In such an event the market price of our shares could be materially adversely affected.

products. We anticipate that sales of POET products and licenses of our POET platform to a relatively limited number of customers will account for a significant portion of our total net revenues.

Once our POET technology is fully developed, we expect that a relatively small number of customers will account for a significant portion of our future net revenues in any particular period. Due to this, some of the following may reduce our future revenues or adversely affect our business:

·reduction in scope, delay in completion or cancellation of product sales or licenses to one or more potentially significant customers;
·development by one or more of our potentially significant customers of other technologies for current or future products;
·loss of one or more of our potentially significant customers or a disruption in our sales and licensing activities;
·failure of one or more of our potentially significant customers to make timely payment of our invoices; and
·failure of one or more of our customers to implement our technology in products successfully, thus limiting any potential sales or royalty income.

We cannot be certain that any potential customer will purchase products or license technology from us, or, once established as a customer, that they will generate further income to us by means of further product sales, licenses or royalties.

Our success will depend substantially on systems companies.

Our future success will depend substantially on the acceptance of our technology by systems companies, particularly those which develop and market electronic products in the defense, wireless, consumer electronics and networking markets where demand may be highly cyclical. The reason for this dependence is that sales of POET-based devices by us and other semiconductor manufacturers to systems companies directly affect the amount of product sale revenue or royalties we might receive. We are subject to many risks beyond our control that may influence the success or failure of a particular systems company. These risks include:

·competition faced by the systems company in its particular industry:
·the engineering and marketing capabilities of the systems company;
·market acceptance of the systems company’s products;
·technical challenges unrelated to our technology or products faced by the systems company in developing its products; and
·the financial and other resources of the systems company.

It will likely take a long time to persuade systems companies to accept our POET technology and, even if accepted, we cannot assure you that our devices or technology will be used in a product that is ultimately brought to market. Furthermore, even if our devices or technology are used in a product brought to market, we cannot assure you that such product will be commercially accepted or result in significant sales by us or royalties to us. Demand for our products and intellectual property may also be affected by consolidation in the integrated circuit and related industries, which may reduce the aggregate level of purchases of our intellectual property components and services by the combined companies.

Competition — we may not be able to compete successfully in the future.

Our target markets are intensely competitive and characterized by rapid technological change and compliance to standards. We cannot assure you that we will have the financial resources, technical expertise or marketing or support capabilities to compete successfully in the future. Competition is basedobtain alternate capacity on a variety of factors including price, performance, features, software availability, marketing, customer support, name recognition and financial strength.

Our future capital needs may require us to seek debt financing or additional equity funding which, if not available, could cause our business to suffer.

From time to time, we may be required to raise additional funds for our future capital needs through public or private financing, strategic relationships or other arrangements. There can be no assurance that the funding, if needed, will be available on attractive

9

favorable terms or at all. Furthermore,Our property insurance coverage with respect to natural disaster is limited and is subject to deductible and coverage limits. Such coverage may not be adequate or continue to be available at commercially reasonable rates and terms. The occurrence of any additional financing arrangementsof these circumstances may adversely affect our financial condition and results of operation.

We may be dilutivesubject to shareholders,disruptions or failures in information technology systems and debt financing, if available, may involve restrictive covenants. Strategic arrangements, if necessary to raise additional funds, may require us to relinquish our rights to certain of our technologies or products. Our failure to raise capital when needednetwork infrastructures that could have a material adverse effect on our business.business and financial condition.

We are dependentrely on key personnelthe efficient and uninterrupted operation of complex information technology systems and network infrastructures to operate our business. A disruption, infiltration or failure of our information technology systems as a result of software or hardware malfunctions, system implementations or upgrades, computer viruses, third-party security breaches, employee error, theft or misuse, malfeasance, power disruptions, natural disasters or accidents could cause a breach of data security, loss of intellectual property and critical data and the release and misappropriation of sensitive competitive information and partner, customer, and employee personal data. Any of these events could harm our competitive position, result in a loss of customer confidence, cause us to incur significant costs to remedy any damages and ultimately materially adversely affect our business and financial condition.

A significant disruption in, or breach in security of, our information technology systems or violations of data protection laws could materially adversely affect our business and reputation.

In the ordinary course of business, we collect and store confidential information, including proprietary business information belonging to us, our customers, suppliers, business partners and other third parties and personally identifiable information of our employees. We rely on information technology systems to protect this information and to keep financial records, process orders, manage inventory, coordinate shipments to customers, and operate other critical functions. Our information technology systems may be susceptible to damage, disruptions or shutdowns due to power outages, hardware failures, telecommunication failures and user errors. If we experience a disruption in our information technology systems, it could result in the loss of any of these individualssales and customers and significant incremental costs, which could materially adversely affect our business. We may also be subject to security breaches caused by computer viruses, illegal break-ins or hacking, sabotage, or acts of vandalism by disgruntled employees or third parties. The risk of a security breach or disruption, particularly through cyberattack or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has increased as the Company.

The Company’s abilitynumber, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Our information technology network and systems have been and, we believe, continue to continue its developmentbe under constant attack. Accordingly, despite our security measures or those of potential products, and to developour third-party service providers, a competitive edge in the marketplace, depends, in large part, on its ability to attract and maintain qualified key management and technical personnel. Competition for such personnel is intense and the Companysecurity breach may occur, including breaches that we may not be able to attractdetect. Security breaches of our information technology systems could result in the misappropriation or unauthorized disclosure of confidential information. Such breaches could also result in legal action against us by third parties.

Page 14

Outbreaks of diseases and retain such personnel. public health crises could delay our development activities and adversely affect our results of operations.

The Company’s growthCompany faces risks related to health epidemics and other outbreaks of communicable diseases, which could significantly disrupt its operations and may materially and adversely affect its business and financial conditions.

The global outbreak of COVID-19 has resulted in Canada, the United States, Singapore, China and other countries halting or sharply curtailing the movement of people, goods and services. The curtailed activity has negatively affected many businesses, including the Company and other businesses that operate in our sector. The prolonged economic impact of COVID-19 remains uncertain. At this point, we believe the conditions may have a material adverse impact on our business, as our suppliers are experiencing major delays resulting from high backlogs of orders and an inability to operate at full capacity. Such delays have resulted in a four to six months delay or longer in the Company achieving certain development objectives. Given the rapidly changing developments we cannot accurately predict what effects these developments will have on our business going forward, which will depend on, among other factors, the efforts of its senior management, particularly its; CEO, Dr. Suresh Venkatesan; Executive Co-Chairman, Peter Copetti; Founder and Chief Scientist, Dr. Geoffrey Taylor, Chief Operating Officer, Dr. Subhash Deshmukh and other officers and membersultimate geographic spread of the team. virus, governmental limitations, the duration of the outbreak, travel restrictions and business closures.

The Company has entered into a consulting agreement with Dr. Taylor,continues to monitor the developments and employment agreements with Mr. Copetti, Dr. Venkatesanimpacts of any health crises and Dr. Deshmukh. Ifpandemic diseases as they may arise. The Company cannot estimate whether, or to what extent, any future outbreak of epidemics or pandemics or other health crises may have an impact on the business, operations and financial condition of the Company. The outbreak of epidemics, pandemics or other public health crises, such as COVID-19 pandemic, may result in volatility and disruptions global supply chains and financial markets, as well as declining trade and market sentiment and reduced mobility of people, all of which could affect prices, interest rates, credit ratings, credit risk, share prices and inflation. The risks to the Company loses the services of key personnel through loss of life, impairment or resignation, it may be unable to replace them, and its business could be negatively affected.

We will be dependent upon collaborative partners to develop and commercialize products using our POET Technology.

A key part of our strategy is to form collaborations with semiconductor, defense and electronics companies that will assist us in developing, testing, and commercializing the POET platform.

We expect to negotiate specific ownership rights with respect to the intellectual property developed as a result of the collaboration with each partner. While ownership rights will likely vary from program to program, in general we will seek to retain ownership rights to developments directly relating to POET and our partner will retain rights specific to the application under development.

Despite our existing development agreements we cannot ensure the following:

·we will be able to enter into additional collaborative arrangements to develop products utilizing our POET technology;
·any existing or future collaborative arrangements will be sustainable or successful;
·the applications contemplated in collaborative arrangements will be further developed by partners in a timely fashion;
·any collaborative partner will not infringe upon our intellectual property position in violation of the terms of the collaboration contract; or
·milestones in collaborative agreements will be met and milestone payments, if any, will be received.

If we are unable to obtain development assistance and funds from other companies to fund a portion of our development costs and to commercialize our technology, we may be required to delay, curtail, or stop development of our projects.

We face risks from failures in the device manufacturing processes of the POET Technology.

The fabrication of integrated circuits, particularly those made of gallium arsenide (“GaAs”), is a highly complex and precise process. Integrated circuits incorporating the POET platform are primarily manufactured on wafers made of GaAs. Compared to the manufacturing of silicon integrated circuits, GaAs technology is less mature and more difficult to design and manufacture within specifications in large volume. In addition, the more brittle nature of GaAs wafers can result in lower manufacturing yields than with silicon wafers. Further, during manufacturing, each wafer is processed to contain numerous integrated circuits or which may also result in lower manufacturing yields. As a result, we or our customers utilizing POET GaAs wafers may reject or be unable to sell a substantial percentage of wafers or the die on a given wafer because of, among other factors:

·minute impurities;
·difficulties in the fabrication process, such as failure of special equipment, operator error or power outages;

10
·defects in the masks used to print circuits on a wafer;
·electrical and/or optical performance; or
·wafer breakage.

Our future customers may experience similar difficulty in maintaining acceptable manufacturing yields, which in turn may hinder adoption of our POET platform for cost or yield reasons.

Our POET platform incorporates technology licensed from third parties.

We incorporate technology (including software) licensed from a limited number of third parties in the deployment of our POET platform, including from UCONN. We could be subjected to claims of infringement regardless of our lack of involvement in the development of the licensed technology. Although a third-party licensor may, in some cases, indemnify us if the licensed technology infringes on another party’s intellectual property rights, such indemnification is typically limited in amount and may be worthless if the licensor becomes insolvent. Our agreement with UCONN does not provide for indemnification of us for intellectual property infringement. Furthermore, any failure of third-party technology to perform properly would adversely affect the development or exploitation of POET.

Our intellectual property indemnification practices may adversely impact our business.

We expect to be required to indemnify our customers for certain costs and damages of intellectual property rights in circumstances where one of our products is the factor creating the customer’s infringement exposure. This practice may subject us to significant indemnification claims by our customers. In some instances, our technology may be utilized to manufacture devices by us or our customers that comply with international standards. These international standards are often covered by patent rights held by third parties, which may include our competitors. The costs of obtaining licenses from holders of patent rights essential to such international standards could be high. The cost of not obtaining such licenses could also be high if a holder of such patent rights bringspublic health crises also include risks to employee health and safety, a claim for patent infringement. We are not awareslowdown or temporary suspension of any claimed violations on our part. However, we cannot assure you that claims for indemnification will not be madeoperations in geographic locations impacted by an outbreak, increased labor costs, regulatory changes, political or that if made,economic instabilities or civil unrest as well as the Company’s ability to service its obligations as they arise. As such, claims would notthe impacts of such crises may have a material adverse effect on ourthe Company’s business, results of operations or financial condition.

We may be subject to information technology failures that could damage our reputation, business operations and financial condition.

We rely on information technology forcondition and the effective operation of our business. Our systems are subject to damage or interruption from a number of potential sources, including natural disasters, accidents, power disruptions, telecommunications failures, acts of terrorism or war, computer viruses, physical or electronic break-ins, cyber attacks, sabotage, vandalism, or similar events or disruptions. Our security measures may not detect or prevent such security breaches. Any such compromise of our information security could result in the unauthorized publication of our confidential business or proprietary information, result in the unauthorized release of customer, supplier or employee data, result in a violation of privacy or other laws, expose us to a risk of litigation or damage our reputation.

Although safeguards exist, third parties with which we currently conduct business may have access to certain portions of our sensitive data. In the event that these third parties do not properly safeguard our data that they hold, security breaches could result and negatively impact our business. In addition, our inability to use or access these information systems at critical points in time could unfavorably impact the timely and efficient operation of our business, which could negatively affect our business and operating results, operations and financial results.

The high cost of building advanced semiconductor manufacturing facilities may limit the number of foundries or manufacturing facilities and potential customers for our POET platform.

The cost of developing leading-edge manufacturing facilities and processes needed for building advanced chips is rising. Some of our potential foundry customers may delay or cancel plans for expanding current processes or developing new manufacturing processes, which, if done, may reduce our licensing opportunities. In addition, the bargaining powermarket price of the remaining foundries with advanced manufacturing facilities wouldCommon Shares. There can be increased. This could make it harder for us to win profitable licensingno assurance that the Company’s personnel or manufacturing deals withits contractors’ personnel will not be impacted by these foundries, further reducing both licensingpandemic diseases and royalty revenueultimately see its workforce productivity reduced or incur increased safety and medical costs / insurance premiums as well as adversely affecting product sales margins.a result of these health risks.

There are foreign exchange risks associated with our Company.

The Company is exposed to foreign currency risk with the Canadian dollar. The Company maintains bank accounts and cash reserves in both currencies with the majority of reserves currently in Canadian dollars which has exposure to currency fluctuations. Most of the company’s operations are transacted in US dollars. A 10% change in the Canadian dollar would increase or decrease other comprehensive loss by $1,135,639.

11

Risks Related to Our Common Stockshares

In order to qualify for listing on Nasdaq, we consolidated our common shares on a 10-for-1 basis, thereby reducing the total number of our common shares which are outstanding on a post-consolidation basis. We cannot guarantee that the reduction in the number of our outstanding common shares as a result of the consolidation will not adversely affect the liquidity of our common shares or decrease the overall value of the Company in the future.

On February 28, 2022, the Company completed a 10-for-1 consolidation of our outstanding common shares, resulting in a total of 36,496,456 common shares of the Company outstanding on a post-consolidation basis. The reduced number of outstanding shares may reduce market liquidity of our common shares and/or affect investor perception of the value of the Company, and as a result shareholders may not be able to sell their shares on a timely basis, or at all.

Our stock price has been and may continue to be volatile.

The trading price for our common stockshares on the TSX Venture Exchange (“TSXV”)TSXV has been and is likely to continue to be highly volatile. Although we have registered our stock with the U.S. Securities Exchange Commission (“SEC”),SEC, the U.S. market for our shares has been slow to develop, and if and as such a market develops, prices on that market are also likely to be highly volatile. The market prices for securities of early stageearly-stage technology companies have historically been highly volatile.

Page 15

Factors that could adversely affect our stock price include:

·fluctuations in our operating results;results and our financial condition;
·announcements of new products, partnerships or technological collaborations and announcements of the results or further actions in respect of any products, partnerships or collaborations, including termination of same;
·innovations by us or our competitors;
·governmental regulation;
·developments in patent or other proprietary rights;
·the results of technology and product development testing by us, our partners or our competitors;
·litigation;
·general stock market and economic conditions;
·number of shares available for trading (float); and
·inclusion in or dropping from stock indexes.

As of February 22, 2016,March 15, 2024, our 52-week high and low closing market priceprices for our common stockshares on the TSXV waswere CA$2.00 (US$1.607.15 and CA$0.62 (US$0.47), respectively, based1.01. In the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation has often been brought against that company. We may become involved in this type of litigation in the future. Litigation of this type may be expensive to defend and may divert our management’s attention and resources from the operation of our business

The listing of our common shares on multiple exchanges may adversely affect the liquidity and value of our common shares.

Currently, our common shares are traded on the closing exchange ratesTSXV and Nasdaq. We cannot predict the effect of listing our common shares on multiple exchanges on the respective dates.market price of our common shares, and listing on multiple exchanges may dilute the liquidity of these securities in one or more markets.

We have historically obtained, and expect to continue to obtain, additional financing primarily by way of sales of equity, which may result in significant dilution to existing shareholders.

We have not earned profits, so itsthe Company’s ability to finance operations is chiefly dependent on equity financings. Since 2012 weFunds raised over CA$43.9 million (US$38 million) inthrough equity public offerings, financing through private placements or the exercise of stock options and warrants and the conversion of convertible debt into common shares in support of the POET initiative, whichCompany’s business has resulted in significant dilution to existing shareholders.shareholder dilution. Further equity financings will also result in dilution to existing shareholders, and such dilution could be significant.

Future sales of common stock or warrants,shares, or the prospect of future sales, may depress our stock price. The exercise of share purchase options and warrants will create dilution which could adversely affect the Company’s shareholders.

Sales of a substantial number of shares of common stock or warrants,shares, or the perception that sales could occur, could adversely affect the market price of our common stock.shares. Additionally, as of February 22, 2016,March 15, 2024, there were outstanding options to purchase up to 15,298,500 shares7,918,358 of our common stock that are currently exercisable and additional outstanding options to purchase up to 10,747,000 shares of common stock that are exercisable over the next several years.shares. As of February 22, 2016,March 15, 2024, there were outstanding warrants to purchase 1,116,051 shares7,285,907 of our stock.common shares. The holders of these options and warrants have an opportunity to profit from a rise in the market price of our common stockshares with a resulting dilution in the interests of the other shareholders. The existence of these options and warrants may adversely affect the terms on which we may be able to obtain additional financing. The weighted average exercise price of issued and outstanding options is CAD$1.04 and4.82, the weighted average exercise price of warrants is CAD$0.23,1.79, which compares to the CAD$1.001.75 market price at closing on February 22, 2016.

Dilution through exercise of share options could adversely affect the Company’s shareholders.

Because the success of the Company is highly dependent upon its employees, the Company has granted to some or all of its key employees, directors and consultants options to purchase common shares as non-cash incentives. To the extent that significant numbers of such options may be granted and exercised, the interests of the other stockholders of the Company may be diluted. As of February 22, 2016, there were 26,045,500 share purchase options outstanding with a weighted average exercise price of CAD$1.04 and 1,116,051 share purchase warrants outstanding with a weighted average exercise price of CAD$0.23.March 15, 2024. If all of these securities were exercised, an additional 27,161,55115,265,764 common shares would become issued and outstanding. This represents an increase of 13.55%31.68% in the number of shares issued and outstanding and would result in significant dilution to current shareholders.shareholders

12Page 16

The risks associated with penny stock classification could affect the marketability of the Company’s common shares and shareholders could find it difficult to sell their shares.

The Company’s common shares are subject to “penny stock” rules as defined in 1934 Securities and Exchange Act Rule 3a51-1. The SEC adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Transaction costs associated with purchases and sales of penny stocks are likely to be higher than those for other securities. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system).

The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation.

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from such rules, the broker- dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the Company’s common shares in the United States and shareholders may find it more difficult to sell their shares.

The rights of our shareholders may differ from the rights typically afforded to shareholders of a U.S. corporation.

We are incorporated under the Business Corporations Act (Ontario) (the “OBCA”). The rights of holders of our common shares are governed by the laws of the Province of Ontario, including the OBCA, by the applicable laws of Canada, and by our Articles of Continuance and all amendments thereto (collectively, the “Articles”), and our by-laws (the “By-laws”). These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. The principal differences include without limitation the following:

Under the OBCA, we have a lien on any common share registered in the name of a shareholder or the shareholder’s legal representative for any debt owed by the shareholder to us. Under U.S. state law, corporations generally are not entitled to any such statutory liens in respect of debts owed by shareholders.

With regard to certain matters, we must obtain approval of our shareholders by way of at least 66 2/3% of the votes cast at a meeting of shareholders duly called for such purpose being cast in favor of the proposed matter. Such matters include without limitation: (a) the sale, lease or exchange of all or substantially all of our assets out of the ordinary course of our business; and (b) any amendments to our Articles including, but not limited to, amendments affecting our capital structure such as the creation of new classes of shares, changing any rights, privileges, restrictions or conditions in respect of our shares, or changing the number of issued or authorized shares, as well as amendments changing the minimum or maximum number of directors set forth in the Articles. Under U.S. state law, the sale, lease, exchange or other disposition of all or substantially all of the assets of a corporation generally requires approval by a majority of the outstanding shares, although in some cases approval by a higher percentage of the outstanding shares may be required. In addition, under U.S. state law the vote of a majority of the shares is generally sufficient to amend a company’s certificate of incorporation, including amendments affecting capital structure or the number of directors.

Pursuant to our By-laws, two persons present in person or represented by proxy and each entitled to vote thereat shall constitute a quorum for the transaction of business at any meeting of shareholders. Under U.S. state law, a quorum generally requires the presence in person or by proxy of a specified percentage of the shares entitled to vote at a meeting, and such percentage is generally not less than one-third of the number of shares entitled to vote.

Under rules of the Ontario Securities Commission, a meeting of shareholders must be called for consideration and approval of certain transactions between a corporation and any “related party” (as defined in such rules). A “related party” is defined to include, among other parties, directors and senior officers of a corporation, holders of more than 10% of the voting securities of a corporation, persons owning a block of securities that is otherwise sufficient to affect materially the control of the corporation, and other persons that manage or direct, to a substantial degree, the affairs or operations of the corporation. At such shareholders’ meeting, votes cast by any related party who holds common shares and has an interest in the transaction may not be counted for the purposes of determining

13

whether the minimum number of required votes have been cast in favor of the transaction. Under U.S. state law, a transaction between a corporation and one or more of its officers or directors can generally be approved either by the shareholders or a by majority of the directors who do not have an interest in the transaction.

There is no limitation imposed byNeither Canadian law nor our Articles or other charter documents onBy-laws limit the right of a non-resident to hold or vote our common shares. However,shares of the Company, other than as provided in the Investment Canada Act (the “Investment Act”), as amended by the World Trade Organization Agreement Implementation Act (the “WTOA Act”),. The Investment Act generally prohibits implementation of a direct reviewable investment by an individual, government or agency thereof, corporation, partnership, trust or joint venture that is not a “Canadian,” as defined in the Investment Act (a “non-Canadian”), unless, after review, the minister responsible for the Investment Act is satisfied that the investment is likely to be aof net benefit to Canada. An investment in ourthe common shares of the Company by a non-Canadian (other than a “WTO Investor,” as defined below) would be reviewable under the Investment Act if it were an investment to acquire direct control of the Company, and the value of ourthe assets of the Company were CA$5.0 million or more. However,more (provided that immediately prior to the implementation of the investment the Company was not controlled by WTO Investors). An investment in common shares of the Company by a WTO Investor (or by a non- Canadian other than a WTO Investor if, immediately prior to the implementation of the investment the Company was controlled by WTO Investors) would be reviewable under the Investment Act if it were an investment in our sharesto acquire direct control of the Company and the value of the assets of the Company equaled or exceeded certain threshold amounts determined on an annual basis. The threshold for a pre-closing net benefit review depends on whether the purchaser is: (a) controlled by a national of a country (other than Canada) that isperson or entity from a member of the World Trade OrganizationWTO; (b) a state-owned enterprise (SOE); or has a right of permanent residence in such(c) from a country (or byconsidered a corporation or other entity that is a “WTO Investor-controlled entity” pursuant to detailed rules set out in“Trade Agreement Investor” under the Investment Act) wouldAct. A different threshold also applies if the Canadian business carries on a cultural business. The 2024 threshold for WTO investors that are SOEs will be reviewable at a higher thresholdCA$528 million based on the book value of the Canadian business’ assets, up from CA$375512 million in assets , except2023. The 2023 thresholds for certain economic sectors with respect to whichreview for direct acquisitions of control of Canadian businesses by private sector investor WTO investors is $1.326 billion and private sector trade- agreement investors is $1.989 billion and are both based on the lower threshold would apply. “enterprise value” of the Canadian business being acquired.

Page 17

A non-Canadian, whether a national of a WTO memberInvestor or otherwise, would be deemed to acquire control of the Company for purposes of the Investment Act if he or she acquired a majority of ourthe common shares.shares of the Company. The acquisition of less than a majority, but at least one-third of our commonthe shares, would also be presumed to be an acquisition of control of the Company, unless it could be established that the Company wasis not controlled in fact by the acquirer through the ownership of votingthe shares. The United StatesIn general, an individual is a WTO Member for purposesInvestor if he or she is a “national” of a country (other than Canada) that is a member of the WTO (“WTO Member”) or has a right of permanent residence in a WTO Member. A corporation or other entity will be a “WTO Investor” if it is a “WTO Investor-controlled entity,” pursuant to detailed rules set out in the Investment Act. The U.S. is a WTO Member. Certain transactions involving our common shares would be exempt from the Investment Act, including:

·an acquisition of our common shares if the acquisition were made in connection with the person’s business as a trader or dealer in securities;
·an acquisition of control of the Company in connection with the realization of a security interest granted for a loan or other financial assistance and not for any purpose related to the provisions of the Investment Act; and
·an acquisition of control of the Company by reason of an amalgamation, merger, consolidation or corporate reorganization, following which the ultimate direct or indirect control of the Company, through the ownership of voting interests, remains unchanged. Under U.S. law, except in limited circumstances, restrictions generally are not imposed on the ability of non- residents to hold a controlling interest in a U.S. corporation.

We have adopted a Shareholders Rights Plan, which may discourage takeover offers, and limit the price investors may be willing to pay for our stock.

In 2014 our Board of Directors adopted and our shareholders ratified a Shareholder Rights Plan, the effect of which would cause substantial dilution to acquirors of more than 20% of our outstanding Common Shares, which could have the effect of delaying, deferring or preventing a change in control of our Company even if a change in control would be beneficial to our shareholders. These provisions could limit the price that certain investors might be willing to pay in the future for shares of our Common Stock.

As a “foreign private issuer”, the Company is exempt from certain sections of the Exchange Act, which results in shareholders having less complete and timely datainformation concerning the Company than if the Company were a domestic U.S. issuer.

As a “foreign private issuer,” as defined under the U.S. securities laws, we are exempt from certain sections of the Exchange Act. In particular, we are exempt from Section 14the proxy statement rules whichthat are applicable to domestic U.S. issuers. The submission ofCompany submits its proxy materials and annual meeting of shareholder information (prepared to(which are prepared in accordance with Canadian standards) onby filing a Form 6-K haswith the SEC, although those documents typically beenhave more limited information than the submissionscorresponding documents required ofto be filed by U.S. domestic issuers, andwhich results in our shareholders having less complete and timely data, including, among others, with respect to disclosure of: (i) personal and corporate relationships and age of directors and officers; (ii) material legal proceedings involving the Company, affiliates of the Company, and directors, officers promoters and control persons; (iii) the identity of principal shareholders and certain significant employees; (iv) related party transactions; (v) audit fees and change of auditors; (vi) voting policies and procedures; (vii) executive compensation; and (viii) composition of the compensation committee.Compensation Committee. In addition, due toin light of the Company’s status as a foreign private issuer, the officers, directors and principal shareholders of the Company are exempt from the short-swing insider disclosure and profit recovery provisions of Section 16 of the Exchange Act. Therefore, these officers, directors and principal shareholders are exempt from short-swing profits which apply to insiders of U.S. issuers. The foregoing exemption results in our shareholders having less data in thisthat regard than is made available by U.S. domestic issuers.

Page 18

As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the Nasdaq Capital Market (“Nasdaq”) corporate governance listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with Nasdaq’s corporate governance listing standards.

As a foreign private issuer listed on Nasdaq, we are subject to Nasdaq’s corporate governance listing standards. However, pursuant to Nasdaq rules, foreign private issuers are permitted to follow the corporate governance practices of their home country in certain instances, provided that disclosure regarding which requirements have not been complied with and confirmation regarding applicable Canadian corporate governance practices which are being followed has been provided. The Company has availed itself of the ability to follow applicable corporate governance standards of its home country in certain instances, and provided such disclosures and confirmations in applicable periodic reports filed with the SEC. Certain corporate governance practices in Canada, which is our home country, may differ significantly from Nasdaq corporate governance listing standards. Therefore, our shareholders may be afforded less protection than they otherwise would have in certain instances as a result of following such Canadian corporate governance practices.

The Company may lose its foreign private issuer status, which would then require us to comply with the Exchange Act’s domestic reporting regime and cause us to incur significant legal, accounting and other expenses.

We are a foreign private issuer, and therefore, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. The determination of foreign private issuer status is made annually on the last business day of an issuer’s most recently completed second fiscal quarter, and, accordingly, the next determination will be made with respect to us on June 30, 2023. In order to maintain our current status as a foreign private issuer, either (a) a majority of our common shares must be owned of record by persons who are not residents or citizens of the United States or (b)(i) a majority of our executive officers and a majority of our directors cannot be citizens or residents of the United States, (ii) more than 50 percent of our assets must be located outside the United States and (iii) our business must be administered principally outside the United States. If we lose our status as a foreign private issuer, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, including the requirement to prepare our financial statements in accordance with U.S. generally accepted accounting principles, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. If we lose foreign private issuer status and are unable to comply with the reporting requirements applicable to a U.S. domestic issuer by the applicable deadlines, we would not be in compliance with applicable SEC rules or the rules of Nasdaq, which could cause investors could lose confidence in our public reports and could have a material adverse effect on the trading price of our common shares.

Additionally, we are currently eligible to use the multijurisdictional disclosure system (“MJDS”), which, among other things, allows eligible Canadian issuers to make registered public offerings in the United States using a prospectus prepared and reviewed in Canada that is mainly, although not exclusively, in accordance with Canadian disclosure requirements. If the Company no longer qualifies as a foreign private issuer, it would not be eligible to use the MJDS, or other foreign issuer forms for certain securities offerings. The regulatory and compliance costs under U.S. federal securities laws as a U.S. domestic issuer may be significantly more than the costs incurred as a Canadian foreign private issuer eligible for MJDS.

If the Company is characterized as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences.

As more fully described below in ITEMItem 10.E. “Taxation” — United States Federal Income Tax Considerations — Passive Foreign Investment Company Status”, if for any taxable year our passive income, or the value of our assets that produce (or are held for the

14

production of) passive income, exceed specified levels, we may be characterized as a passive foreign investment company (“PFIC”) for U.S. federal income tax purposes. This characterization could result in adverse U.S. tax consequences to our U.S. shareholders, including gain on the disposition of our common shares being treated as ordinary income and any resulting U.S. federal income tax being increased by an interest charge. Rules similar to those applicable to dispositions generally will apply to certain “excess distributions” in respect of our common shares.

Page 19

The actual allocation of proceeds from any financing undertaken may differ from the Company’s initial or current intentions.

The Company has discretion in the use of the net proceeds from any offering of equity securities. The Company may elect to allocate proceeds differently from its initial or current intentions. The failure by the Company’s management to apply these funds effectively could have a material adverse effect on its business.

Warrants included with financings

Warrants offered with financings are not listed on any exchange. Investors may be unable to sell the warrants at the prices desired or at all. There is no existing trading market for the warrants and there can be no assurance that a liquid market will develop or be maintained for the warrants, or that an investor will be able to sell any of the warrants at a particular time (if at all). The liquidity of the trading market in the warrants, and the market price quoted for the warrants, may be adversely affected by, among other things:

changes in the overall market for the warrants;
changes in the Corporation’s financial performance or prospects;
changes or perceived changes in the Corporation’s creditworthiness;
the prospects for companies in the industry generally;
the number of holders of the warrants;
the interest of securities dealers in making a market for the warrants; and
prevailing interest rates.

ITEMItem 4. INFORMATION ON THE COMPANYInformation on the Company

A.A.History and Development of the Company.

The legal and commercial name of the Company is POET Technologies Inc. The Company was originally incorporated under the British Columbia Company Act on February 9, 1972 as Tandem Resources Ltd. On November 14, 1985, Tandem Resources Ltd. amalgamated with Stanmar Resources Ltd. and Keezic Resources Ltd., to continue as one company under the name Tandem Resources Ltd. under the British Columbia Company Act. By Articles of Continuance dated January 3, 1997, Tandem Resources Ltd. was continued under the OBCA. By Articles of Amendment dated September 26, 2006, Tandem Resources Ltd. changed its name to OPEL International Inc. By Certificate of Continuance dated January 30, 2007, OPEL International Inc. was continued under the New Brunswick Business Corporations Act. By Articles of Continuance dated November 30, 2010, OPEL International Inc. was continued under the OBCA and changed its name to OPEL Solar International Inc. By Articles of Amendment dated August 25, 2011, OPEL Solar International Inc. changed its name to OPEL Technologies Inc. By Articles of Amendment dated July 23, 2013, OPEL Technologies Inc. changed its name to POET Technologies Inc.

On May 11, 2016, in an all-stock transaction, the Company acquired all the issued and outstanding shares of DenseLight Semiconductor Pte. Ltd., a privately held Singapore company that provides optical solutions. DenseLight designs, manufactures and sells optical light source products. DenseLight was acquired for $10,500,000 of the Company’s stock. The Company has two U.S. subsidiaries, issued 1,361,115 common shares to the former shareholders of DenseLight.

Page 20

On November 8, 2019, the Company sold 100% of the issued and outstanding shares of DenseLight for $26,000,000. The Company recognized a gain on the sale of $8,707,280.

On June 22, 2016, in an all-stock transaction, the Company acquired all the issued and outstanding shares of BB Photonics Inc., a privately held US Company with a wholly owned subsidiary, BB Photonics UK Ltd. Both companies design integrated photonics solutions for the data communications market. BB Photonics and its subsidiary were acquired for consideration of $1,550,000. The acquisition was settled with the issuance of 199,609 common shares of the Company to the former shareholders of BB Photonics. The Company dissolved BB Photonics UK Ltd. on October 6, 2020.

On May 17, 2019, the Company established POET Technologies Pte. Ltd. (“PTS”), a wholly owned subsidiary in Singapore. On August 4, 2020, PTS established POET Optoelectronics Shenzhen Co., Ltd (“POET SZ”), a wholly owned subsidiary in Shenzhen, China.

On October 22, 2020, the Company signed a Joint Venture Agreement establishing a joint venture company, Super Photonics Xiamen Co., Ltd with Xiamen Sanan Integrated Circuit Co. Ltd. Super Photonics Xiamen Co., Ltd was formed on March 12, 2021.

The following is a graphic description of the Company and its subsidiaries:

OPEL Solar Inc. (“and ODIS Inc.

OPEL Solar”)Solar, Inc. (OPEL)

OPEL is a wholly-owned subsidiary of POET Technologies and is the assignee for all patents and patent applications filed by the Company prior to 2019.

ODIS Inc. (“ODIS”).

ODIS is wholly-owneda wholly owned subsidiary of OPEL Solar, which in turnInc. and is the designer of the POET Optical Interposer platform, and developer of optical engines based on the POET Optical Interposer platform.

BB Photonics Inc.

BB Photonics developed photonic integrated components for the datacom and telecom markets utilizing embedded dielectric technology that enabled the partial integration of active and passive devices into photonic integrated circuits. BB Photonics’ operation is currently dormant.

Page 21

POET Technologies Pte Ltd. (“PTS”)

PTS is a wholly owned bysubsidiary of POET Technologies Inc. Situated in Singapore, PTS designs and tests variations of the Company.

Through our subsidiary ODIS, we developPOET Optical Interposer for specific applications. PTS also develops the technology to produce a monolithic, integrated opto electronic microchip having several potential major market applications: infrared sensor arraysassembly and test methodologies for Homeland Security monitoring and imaging along with the unique combinationproduction of optical lasers,engines designed by ODIS.

POET Optoelectronics Shenzhen Co., Ltd (“POET SZ”)

POET SZ is a wholly owned subsidiary of PTS. Situated in Shenzhen, China, PTSZ validates optical engine designs produced by ODIS and electronic control circuitsworks with customers to incorporate optical engine designs into modules.

Super Photonics Xiamen Co., Ltd, (“SPX”)

SPX is a joint venture, situated in Shenzhen, China. SPX was established with Sanan IC with a sole purpose to assemble, test, package and sell cost-effective, high-performance optical engines based on POET’s proprietary Optical Interposer platform technology.

The Company operates geographically in the same microchip for potential applications in various military programsUnited States, Canada, Singapore and potentially telecom for Fiber-to-the-home. ODIS’ technology also provides the opportunity for higher speed computing capabilities.China.

Capital Expenditures

Our capital expenditures for the last three years, which principally consist of purchases of research and development equipment and instrumentation and patents are as follows:

Period Capital Expenditure  Purpose 
Fiscal 2023 $1,247,064   Instruments, equipment and patents 
Fiscal 2022 $3,074,037   Instruments, equipment and patents 
Fiscal 2021 $930,882   Instruments, equipment and patents 

Period Capital Expenditure Purpose
Fiscal 2015 $374,200  Instruments, equipment and patents
Fiscal 2014 $527,068  Instruments, equipment and patents
Fiscal 2013 $1,000,783  Instruments, equipment and patents

The Company’s registered office is located at Suite 501, 121 Richmond Street West,1107, 120 Eglinton Avenue East, Toronto, Ontario, Canada M5H 2K1M4P 1E2 and its phone number is (416) 368-9411. The Company’sCompany has operations office is located at 2550 ZankerSuite 308, 1605 N. Cedar Crest Boulevard, Allentown, PA, 18104, 21 Changi North Way, #04-06, Singapore, 498774 and Unit 02, 10th Floor, A4 Building, Kexing Science Park, No.15 Keyuan Road, San Jose, CA, 95131.Science Park Middle District, Nanshan District, Shenzhen, 518057

B.B.Business Overview.

Corporate Overview

The Company is incorporated under the laws of the Province of Ontario. The Company’s shares trade under the symbol “POET” on Nasdaq in the U.S and under the symbol “PTK” on the TSXV in Canada.

POET Technologies is a design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photonic devices onto a single chip using advanced wafer-level semiconductor manufacturing techniques. The semiconductor industry has adopted the term “Wafer-Level Chip-Scale Packaging” (or “WLCSP”) to describe similar approaches within the semiconductor industry. POET’s Optical Interposer eliminates costly components and labor-intensive assembly, alignment, and testing methods employed in conventional photonics. We believe the cost-efficient integration scheme and scalability of the POET Optical Interposer brings value to devices or systems that integrate electronics and photonics, including high-growth areas of communications and computing. The emergence of Artificial Intelligence (AI) systems over the past year has placed extraordinary demands on cloud-based AI service providers and hyperscale data centers for increases in network speeds and bandwidth. We believe that chip-scale integration is essential to developing hardware that can meet such demands and that POET is on the forefront of providing scalable solutions for current and future AI systems.

Page 22

POET targeted as the first application of the Optical Interposer the development of optical engines for optical transceivers used in internet-based data centers. Optical Engines include all the passive and active components related to the production, manipulation, and detection of light within an Optical Transceiver. Optical Transceivers plug into switches and servers within the data center and allow these network devices to send and receive data over fiber-optic cables. We chose this market because it is large in size, has established standards for device performance, and the unit volumes of devices shipped annually are exceptionally high. It is a market in which our advantages of cost, power consumption and ability to scale rapidly allow us to be competitive with other suppliers.

The rapid growth of AI software systems represents a profound opportunity for POET. We believe that the rapid growth of software services can only be sustained with hardware that meets the challenges of increasing speed and bandwidth, lower power consumption, lower cost, and the ability to scale to the volumes that will be required by data centers globally. POET meets these challenges in two ways: first, by providing to the market integrated, chip-scale Optical Engines that perform at the levels that are now being deployed in the most advanced AI clusters at speeds of 800Gbs (gigabits per second); and second, by offering what we believe is currently the only viable path to increasing the speeds and bandwidth of Optical Transceivers to 1.6Tbs (terabits per second) and 3.2Tbs in industry-standard pluggable form factors. In addition, we have used our Optical Interposer technology to develop Light Source products that address newly emerging architectures in data centers that are based on chip-to-chip data transfer using light, rather than electrons, which resolves speed, bandwidth, heat-generation and cost issues at a fundamental level. The combination of POET’s focus on leading-edge Optical Transceivers and Light Source products for next generation data center architectures essentially places POET among a small number of suppliers globally that are truly “pure play” AI hardware companies.

Research & Development

Beginning in 2017, POET began designing lasers for data communications applications and directed DenseLight Semiconductors, Pte. Ltd., a former subsidiary of the Company, to build such lasers to be compatible with the Optical Interposer platform. In 2019, the Company decided to adopt a “fab light” strategy, common among semiconductor companies, and divested its fabrication operations through the sale of DenseLight in November of that year. From 2018 - 2020, virtually all the R&D spending in the Company was dedicated to design & development of the Optical Interposer as a versatile platform technology, replete with features that enhance its utility across a variety of application spaces.

During the second half of 2021, the Company transitioned to product development by investing more than $2 million in the design & development of 100G and 200G optical engines in several configurations, including customized designs for specific customers and applications. Samples of optical engines at various stages of development were made available and delivered to customers in 2022 for initial evaluation and in 2023 for design-in and customer qualification. SPX is forecasted to produce Optical Engines in high volumes for several customers in 2024. POET’s effort in lower speed Optical Engine design and production was intended primarily as a way for POET to demonstrate the viability and market acceptance of its unique approach to integration and fabrication and to establish an initial presence in the market. However, the Company’s primary strategy is to offer Optical Engines at the highest speeds at which customers are deploying Optical Transceivers. In 2024, we expect that we will be primarily in 800G, and heavily focused on those hyperscale data centers actively implementing AI services. Consistent with this strategy, the Company has invested approximately $20 million in design, development and engineering programs related to its 400G transmit chiplets (combined in multiples of 400G to achieve 800G, 1.6T and 3.2T speeds), in 800G receive optical engines, and in light source products, and fabrication techniques.

The Company has designed, tested and sampled the current version of its 400G transmit (Tx) engine, and its 800G receive (Rx) engine with various customers. The Company intends to revise its 400G Tx product and to introduce a new version later this year. The 800G Rx has been well received, fully qualified and is expected to be incorporated in the optical transceiver modules of several customers this year. So long as the Company provides Optical Engines to optical transceiver module customers, there will always be customer centric adjustments to these products to fit their specific needs. The cost to make these adjustments will vary depending on the customer requirements.

Page 23

The Company is expected to invest an additional $11 million in 2024 in ongoing development of the 400G Tx chiplet for inclusion in 800G and 1.6T optical tranceivers. POET is also committed to the development of its own optical transceiver modules, a critical next phase in the Company’s growth plan, with investments in that program beginning this year. At the present time, the Company expects to have a functional module by 2025 with sales of modules ramping in late 2025.

Target Markets

Data Center AI Market

To support the substantial increase in bandwidth consumption, internet data center operators are increasing the scale of their internet data centers and deploying infrastructure capable of higher data transmission rates. At the present time, much of the industry is moving from 100G to 400G and higher. With the growth of AI clusters, interest in acquiring 800G capable optical transceivers has literally skyrocketed. LightCounting estimates1 that AI services will add $17 billion in revenue over the next five years to the existing nearly $5 billion in annual shipments of ethernet transceivers in 2022. As transceiver speeds have increased the cost and complexity of assembling optical modules has also increased, few module makers have the ability to achieve economies of scale with conventional, non-semiconductor-based approaches. We believe that products incorporating the Company’s unique technology will enable POET to capture a significant share of this large market, especially at the cutting edge of higher speeds, particularly as AI-driven data centers increasingly deploy 800G optical transceivers and are actively looking for 1.6T capabilities.

Light Source Markets

There are numerous established companies and start-ups addressing the need to lower power consumption and increase the efficiency of the GPUs and memory devices typically used in AI systems. To date, these bandwidth and efficiency issues have been addressed by increasing the capabilities and protocols at which electronic data network systems operate. To achieve lower power, several device makers are beginning design systems to utilize light, instead of electrons to either perform certain computations, or to manage data traveling in and out of the processor and memory chips. Using light offers significant advantages of speed and lower heat generation than comparable electronic-only devices. There are currently no reliable sources that the Company has been able to find that estimate the current or future size of this market. However, we expect that when the hardware is fully developed and the market emerges, it is bound to be very large, and could eclipse the market for optical transceivers.

1LightCounting. “July 2023 Mega Data Center Optics Market Report”, July 2023 and “LightCounting Quarterly Market Update September 2023.”

Page 24

Other Potential Photonics Markets

Other markets for POET’s integrated photonics solutions include 5G interconnect markets, such as PON and GPON, edge computing for machine-to-machine communications, and selected sensing markets, including LIDAR, Optical Coherence Tomography for medical devices, and certain consumer products, such as virtual reality systems.

Manufacturing

To address the challenge of producing devices in the large quantities that are needed by customers in the high-volume data communications industry, POET entered into an agreement in late 2020 with Xiamen Sanan Integrated Circuit Co. Ltd. (“Sanan IC”), a unique, proprietary process that addressessubsidiary of Sanan Optoelectronics Xiamen Co. Ltd. to form a joint venture to assemble, test and sell POET-designed optical engines in high volumes. Sanan is the deficienciesworld’s largest manufacturer of size, integration, power and cost efficiency associated with current opto-electronic semiconductor manufacturing technologies. The novel process can be accommodated in existing compound semiconductor fabsdevices, producing over 25 million eight-inch wafers per year across a variety of substrate types and applications. The objective of the joint venture company, which is named “Super Photonics Xiamen” (“SPX”) is to assemble, test and sell optical engines based on the POET Optical Interposer, along with minimum re-tooling, thus potentially reducing capital expenditures requireddevices procured from various suppliers, including Sanan IC, into finished products. Except for specific customers as agreed between the parties, optical engines for 100G and 200G applications will be sold exclusively world-wide by SPX. 400G optical engines will be sold by SPX in the China territory while the Company will sell 400G and 800G optical engines to adopt POET’s process technologies.customers in the United States, Europe and elsewhere outside the China territory. Volume production of optical engines designed for specific customers with high volumes is expected to ramp in mid-2024.

Our Strategy

Our vision for the Company is to become a global leader in chip-scale photonic solutions by deploying products based on our Optical Interposer technology and optical engine designs over a broad range of vertical market applications. Our Mission for the Company is to establish an industry leadership position based on the full “semiconductorization” of the photonics industry, producing validated, disruptive, IP protected products globally.

We recently refined our strategy to reflect our current thinking about how best to achieve our vision and mission for the Company:

Support Super Photonics Xiamen (SPX), a joint venture between POET and Sanan IC, as an independent company to drive growth in optical transceivers and deliver maximum cash flow to partners. POET’s designs for Optical Engines are assembled by SPX into samples that customers can test and are designed-in to modules supplied to end-users, such as network equipment companies and data center operators. POET’s shortest path to commercial success is the deployment of its Optical Engines that are designed into the optical modules of its customers. This activity provides validation for the technical feasibility, market acceptance and scalability of POET’s Optical Engines. SPX has matured to the point where it can provide design support and deliver samples and production devices to in China, where virtually all optical transceiver module manufacturers are located. As SPX builds a revenue base it becomes an asset for generating cash in the form of dividends or becomes a potential source of non-equity capital for POET to support its own growth. POET has no capital commitment requirements for the advancement of SPX to a revenue-generating entity. Prior to a future planned exit on the Shanghai Exchange, opportunities to sell a portion of POET’s equity interest in SPX are also being actively pursued.

2 PitchBook Data Inc., “Emerging Tech Research” and “Q1 and Q3 2022 Artificial Intelligence & Machine Learning Reports”, Brendan Burke, Senior Analyst.

3 “Celestial AI Raises $56 Million Series A to Disrupt the Artificial Intelligence Chipset Industry with Novel Photonic-Electronic Technology Platform”, February 4, 2022, Businesswire.

Page 25

Engage with industry leaders and incumbents. We will continue to promote the potential of the Optical Interposer and POET-designed Optical Engines to solve critical challenges with current approaches to data transfer in data center and telecom applications, especially to those hyperscale data centers implementing large-scale AI applications. We believe that the size, performance and design flexibility of POET’s chiplet approach to integration and to the rapid introduction of successive product generations is an enabling technology that will allow POET to enter markets where relatively few competitors will have the requisite technology to succeed.
Transition to making Optical Transceiver Modules for direct sales to end-users In addition to adding features to the Optical Interposer, we have added essential electronic components, such as Trans Impedance Amplifiers (TIAs) and laser drivers to the interposer platform, which improves performance and lowers the cost of module assembly. We intend to add the necessary capabilities for design and development optical transceiver modules to our existent capabilities in Optical Interposer and Optical Engine design. Being most familiar with the unique capabilities of our technology, we believe that we are in a position to rapidly extend our expertise to complete optical modules. Doing so has the advantage of avoiding a lengthy sales and qualification cycle (i.e., selling to module makers who then sell to end users) and being able to sell directly to end users, showcasing our own branded products to network equipment suppliers and data center operators..
Establish additional fabrication and sales operations for advanced, high-speed transceiver modules and packaged light source products. Internally, we refer to this our “China plus One” strategy, which is only partially dictated by the current international political climate. We are planning to develop our advanced products as modules and packaged products that we will sell directly to end-users, which will require additional fabrication, assembly, marketing and sales operations. In addition, we expect that as we approach other vertical market applications outside of optical transceivers and packaged light sources, our strategy may include the formation additional partnerships in those market segments in order to develop appropriate strategies for the fabrication of devices whose functions will be materially different from those of transceivers and with correspondingly different distribution and sales. The form of such partnerships may also be different than what was established for transceivers.
Pursue complementary strategic alliance or acquisition opportunities for inorganic growth. We intend to evaluate and selectively pursue strategic alliances or acquisition opportunities for growth and vertical integration that we believe will accelerate our penetration of specific applications or vertical markets with our technology or products.
Explore technology licensing opportunities for growth in non-target sectors. It is not possible for the Company to pursue all potential applications for the POET Optical Interposer. We will carefully consider opportunities to license our technology to others when and if appropriate.

Our Products

POET Optical Engine Products currently include the following:

● 100G LR4 Tx and Rx

● 200G FR4 Tx and Rx

● 400G/800G FR4 Rx with integrated TIA

● 400G/800G FR4 Tx with integrated Driver

● 1.6T 4xFR4 Rx with integrated TIA

● 200G/Lane Tx & Rx for 1.6T and 3.2T

Page 26

● LightBar: C-Band External Light Source

● LightBar: O-Band External Light Source

Competition

The Company currently hasphotonics market is intensely competitive and we expect experience intense competition from a number of manufacturers with alternative technologies. Many of our competitors will be larger than we are and have significantly greater financial, marketing and other resources.

In addition, several of our competitors, especially in the datacom markets, have large market capitalizations or cash reserves and are much better positioned to acquire other companies to gain new technologies or products that may displace our products. Data center equipment providers, who we expect to become our customers, and data center service providers, who are supplied by our customers, may decide to manufacture the optical subsystems that we plan to provide. We may also encounter potential customers that, because of existing relationships, are committed to the products offered by these competitors.

We believe the principal competitive factors in our target markets include the following:

use of internally manufactured components;
product breadth and functionality;
timing and pace of new product development;
breadth of customer base;
technological expertise;
reliability of products;
product pricing; and
manufacturing efficiency.

We believe that we can compete favorably with respect to the above factors based on processes, the projected performance, anticipated inherent reliability of our products, our technical expertise in photonic engine design and manufacture and cost.

Intellectual Property

We have 69 issued patents and 19 patent applications pending, including three provisional patent applications. Of the 69 issued patents, pending30 are directly related to the semiconductor Planar Opto-Electronic Technology (“POET”).Optical Interposer and include fundamental design and process patents. All 19 applications pending are Optical Interposer-related. Multiple additional applications are in various stages of preparation. The Company’s focus ispatents cover device structures, underlying technology related to the Optical Interposer, applications of the technology, and fabrication processes. We intend to continue to apply for additional patents in the future. We believe these patents provide a significant barrier to entry against competition along with company trade secrets and know-how. Currently, we are working on the design of III-V semiconductorintegrated devices, manufacturing processes, assembly and packaging processes, and products currently for data communication applications in the consumer, data center and high performance computing segments. The POET platform also enables applications in adjacent segments in military, industrial and mobility.market.

The Company is positioned as an opto-electronic product and IP Company, with an aim to leverage existing and potential relationships in establishing a POET design and manufacturing value chain, and in commercializing POET IP.

The POET platform allows the simultaneous fabrication of electronic and optical devices on a single integrated circuit, an achievement that has not been accomplished using the silicon-based technologies currently dominating the market. Key benefits of the ability to integrate electronic and optical devices are anticipated to include: (i) faster semiconductor device speeds; (ii) increased device output power; (iii) decreased need for device cooling; (iv) greater reliability; and (v) total system cost reductions. With POET’s materials system incorporating periodic table element groups III, IV and V (“Group III-V”), we expect that active optical elements and high- performance electronic elements can be packed in a single integrated circuit built around a GaAs wafer.

15

POET is being developed to be differentiated from competing semiconductor processes such as silicon, GaAs, or indium phosphide, however, by its more comprehensive set of functional capabilities and its ability to integrate them. Existing processes require the use of multiple chips, circuit boards or sub-systems being linked together by either physical snap connections or multiple cable connections that:

(i)produce the potential for multiple points of failure,
(ii)require more space, increasing the physical end product size and
(iii)require greater amounts of power with the attendant production of excess heat, thus demanding additional space for cooling and ventilation,

Unlike these processes, we anticipate that POET will be able to integrate lasers, modulators, photoreceivers and passive optics as well as high-speed, low-power electronics on one monolithically-fabricated die. This would allow POET ICs, when fully developed, to demonstrate a lower cost structure, increased power savings and increased reliability.

The fabrication of integrated circuits made of GaAs, however, is a more highly complex and precise process. Compared to the manufacturing of silicon integrated circuits, GaAs technology is less mature and more difficult to design and manufacture within specifications in large volume. In addition, the more brittle nature of GaAs wafers can result in lower manufacturing yields than with silicon wafers. During manufacturing, each wafer is processed to contain numerous integrated circuits, which may also result in lower manufacturing yields.

Adopters of our POET technology in the market will face difficulties in adapting to the larger semiconductor wafer sizes required for volume production of devices. Although GaAs has many advantages over silicon and the integration resulting from our POET technology is expected to provide advantages over the current, silicon-based, multi-circuit semiconductor model, device manufacturers may need to reconfigure how they embed semiconductors using our POET technology in their products. This could delay semiconductor manufacturers in adopting and deter adoption of the POET technology.

The Company has patents issued and patents pending for its semiconductor POET platform, which is currently being developed through ODIS. The Company has licensed the intellectual property portfolio, developed by our Founder and Chief Scientist, Dr. Geoff Taylor, at UCONN. We believe that our patent and trade secret protection on POET, together with ODIS’s specific design knowledge using POET elements, will provided us with a large, defensible barrier to outside competition.

We expect to incur additional losses and require additional financial resources to complete development. The continuation of the Company’s research and development activities and the commercialization of its products are dependent upon the Company’s ability to successfully complete its research programs, protect its intellectual property and finance its cash requirements on an ongoing basis. It is not possible to predict the outcome of future research and development activities or the financing thereof.

Research and Development Activities

The Company is conducting research and development related to expansion of the POET platform by adding processes to the POET IP portfolio. It is also engaged in developmental work related to existing POET processes for data communications applications in potential consumer, data center, high performance computing, industrial, military and mobility segments. The Company continues to develop gallium arsenide-based processes having several potential market applications, including: (i) infrared sensor arrays for defense as well as domestic monitoring and imaging applications, (ii) the unique combination of analog, mixed-signal, digital and optical functions on the same chip for potential use in high volume short reach and very short reach data communication transceivers and (iii) exploring the use of POET’s unique VCSEL technology as smart pixels for application in display applications for Augmented Reality. The Company believes that the POET process has the potential to fundamentally alter the landscape of optical data communications for a broad range of applications by offering unique integrated optical and electronic components with dramatically lower solutions cost together with increased density, reliability and lower power consumption through integration.

The Company:

1.Has successfully produced numerous distinct devices using the POET process, including on-chip, continuous-wave lasers and switching lasers with the potential for eliminating chip-to-chip metallic interconnects, complementary hetero-structure field effect transistors (HFETs), optical thyristors, and resonant cavity detectors.

2.Continues to establish Process Design Kits (“PDKs”) with an initial focus on the components essential for the design of monolithically integrated VCSEL based optical transceivers. PDKs comprise a library of design rules and parameters for the POET technology that can eventually enable POET and its partners to implement the POET fabrication process into their preferred products.

3.Is utilizing Synopsys’ and Coventor’s tools and services to help develop PDKs. PDKs will initially be used by POET and its 3rd party chip developers to create integrated opto-electronic transceiver product prototypes.

4.Is continuing to consider foundry relationships with commercial pure-play 6” foundry suppliers. In 2015, the Company signed a VCSEL Manufacturing Process Transfer agreement with Anadigics (ANAD) for early prototyping and initial development and a Manufacturing Services agreement with Wavetek (WTK) for long term manufacturing. Wavetek, which is a wholly owned subsidiary of United Microelectronics Corporation (UMC), is a pure-play semiconductor foundry based in Taiwan. In addition, the Company has signed an epitaxial wafer supply agreement with Epiworks, which is a leading provider of MOCVD wafers to the electronics and optical industry. These relationships are helping to accelerate the “Lab-to-Fab” transition of the POET technology to a 6" wafer scale. These engagements will provide the baseline process flow in a manufacturing environment and enable the demonstration of product prototypes. As Anadigics became a takeover target towards the end of the year, the Company decided to de-emphasize its engagement with Anadigics as of the end of 2015 to avoid any potential operational uncertainties.   The Company has placed its focus and priority on developing our technology with Wavetek. The realignment of all foundry activities may result in some minor delays in the Company's Q1 2017 milestones tied to device demonstration.  The Company is working closely with Wavetek to recover the schedules and complete the necessary device demonstrations on time. 

16

Industry Outlook

Social networking, cloud computing and growth in mobile computing are driving a continuous need for improvements in bandwidth and data handling capacity. This has driven and continues to drive a significant growth in data centers. Cloud data center traffic compound annual growth has been over 25%[1] compound annual growth rate (“CAGR “) and is expected to continue to grow at this rate for the next few years.

Power consumption in data centers has now become a significant issue, thus creating a need to proliferate low power computing and communications technology in data centers – to enable the conversion of power-hungry copper based communication links to fiber optics.

POET is applicable to a large portion of the opto-electronic semiconductor market as it represents an integrated comprehensive solution to increasing the performance potential of semiconductors in an economical and functional manner. The technology is particularly capable of addressing the power challenges currently faced in Data Centers. POET’s innovation potentially enables devices to manage more data at the performance of optical devices but at near the cost points of copper-based solutions. Based on the Company’s interactions with potential customers, we believe that POET may provide significant value in applications where it addresses the need for lower power consumption, solution size, and cost efficiency.

Data centers today are enduring an excruciating pain point in terms of power. Energy management costs for US data centers alone had approached US$9 billion in 2013 according to the National Resources Defense Council and are forecast to rise to $13.7 Billion by 2020. Each watt of heat that does not have to be rejected from the rack could be worth savings in outright direct energy but also in indirect energy related to cooling costs. A single copper direct attach cable consumes about 3W of power per end. Let’s take a single mega datacenter with between 10,000-100,000 servers and a rough estimate of potentially 100,000 copper links. If you can save 5W of power per copper link used in this one Data Center, this can easily translate into 0.5 million Watts of saved energy translating into significant savings in operating expenses for a single mega data center. We believe data communications, is primed for an integrated opto-electronic device and process platform that can enable low power, minimized size and component cost. This is the opportunity that POET is targeting to address, with its patented process that integrates digital, high-speed analog and optical devices on the same chip. We believe that the process can enable managing data at the speed of light and the cost of copper.

The POET platform may provide the following advantages to the data center industry:

·Up to 10X power savings improvements over existing copper technologies (especially for high speed data communication links)
·Up to 5X cost improvement over existing optical component solutions
·Performance and power of optical solutions at price points competitive to that of copper solutions, thus potentially accelerating a transition to optical communications from cumbersome copper links
·Flexible and integrated solutions that can be applied to virtually any applications that command an optical input and output for high bandwidth, including chip-to-chip communications, on-board optics and on-chip optical communications

The Company’s strategy is to complete development of its VCSEL based integrated optical platform and monetize this technology with a mix of product and licensing revenue, while continuing research towards the expansion of its IP portfolio.

The disruptive potential of POET’s technology was first recognized within the military community, and this recognition has remained strong. Applications in this market include infra-red sensor arrays and high frequency RF monolithic microwave integrated circuits.

POET is currently under development and has not yet been utilized in production environments, and there are no assurances that our development and marketing efforts will ever result in POET being utilized by any manufacturer or otherwise commercialized.

Military

POET’s platform for opto-electronic integration is designed to exploit the opto-electronic and electronic behaviors of GaAs semiconductor material. One of the benefits of this material, from a space electronics perspective, is that GaAs is significantly less susceptible to x-ray and gamma-ray total integrated dose radiation. GaAs has been a long-standing choice for high-frequency devices and circuits, though GaAs digital devices do not provide the performance that metal oxide semiconductor field effect transistor devices provide.

Important to military applications are the electronic devices that can be integrated into the POET design architecture, including both complementary heterostructure field effect transistors and complementary HBTs. These transistors will enable both analog and digital functions in POET hybrid opto-electronic devices. The technology also provides a number of key, integrable opto-electronic devices: resonant vertical cavity lasers, detectors, amplifiers and modulators for out-of-plane operation. In addition, POET innovation enables in-plane waveguide and traveling wave operation for lasers, detectors, modulators, amplifiers and directional coupler switches.

Important to the military is POET’s potential to integrate digital, radio frequency and optical technologies in a single device, which is designed to satisfy the documented high-performance capability needs for multiple space systems of all military departments and agency technology areas.

POET’s architecture, which incorporates a dense mix of active optical elements and optical waveguides together with logic and mixed signal elements, is designed to enable a wide variety of space-system components. These components, when developed, could be combined to enable a number of applications including high speed transceivers for laser communications, radio frequency transceivers, radio frequency and optical phased arrays, opto-electronic interconnects, analog-to-digital and digital-to-analog converters, uncooled visible, mid-wavelength infrared and long-wave infrared imagers, optical memory, opto-electronic and radio frequency apertures, ultra- wide-band sources and receivers, low-light-level sensors, single photon counters and optical correlators.

POET could have the ability to offer a low-cost monolithic solution to multi-spectral imaging. The compact array could provide:

(i) detection, readout and analog-to-digital conversion on a single chip; (ii) a common axis for ultraviolet, visible and infrared imaging;

(iii) wavelength scanning; and (iv) 300K operation with no cooling required. The Space Foundation has indicated that this technology

______________________

1Source: Cisco Global Cloud Index 2014

17

satisfies Space Situational Awareness (“SSA”) sensor requirements by providing required capability with significantly reduced size, weight and power. In addition, the Air Force Communications Command and Control Division (“C3”) Tech Area Plan identifies mid- and long-term space communication and C3 technology challenges that can be addressed by the photonic applications that POET technology is potentially able to provide.

Marketing Plan

Military Segment

Our initial fundamental business strategy is to continue our directed focus on the military market through licensing arrangements and by pursuing projects which meet the POET platform product design goals of the transition process, which may lead to the subsequent volume production and license revenue generation. Our intent is also to foster prime contractor involvement that will lead to either a licensing or other form of partnership relationship based on long term demand for the POET platform, and to develop that demand into a potential partner’s strategic plans for meeting government requirements. Training, supporting and energizing prime contractor sales teams will be a key ingredient to POET’s success in generating military and agency revenue.

Commercial Segment

Our commercial sales and marketing activity will be based on direct contact with target corporations by senior management or industry consultants hired by the Company. Such contact will focus on developing successful relationships within the product areas. We believe that relationship leveraging is required to first gain entrance and then acceptance of a new company with new technology. Marketing and product development activity is expected to continue throughout the POET development and transition process in order to anticipate and adapt commercially directed devices, as well as commercial applications discovered going forward, during the development phase, thus offering well-designed, well-supported, market-focused products capitalizing on the potential advantages of POET.

The release of test or prototype devices to both market segments for testing and acceptance of the POET process is important to the Company’s marketing plan. The availability of prototypes will be necessary to solicit early design wins with the potential to lead to volume production at such time as the Company can commence the POET transition.

The Company believes that the most expedient way to scale its sales efforts in both the military and commercial market segments will be to work with and through the marketing, sales and engineering teams of those firms who are respected, proven product and solution providers, already holding a significant market share within their industry.

Competition

The Company’s competitive environment encompasses current state of the art semiconductor device fabrication technologies, principally silicon photonics and Indium Phosphide technology, which have been the primary technology for developing and manufacturing integrated opto-electronic circuits utilized in the photonics markets. The Company believes that novel technological developments proprietary to it implemented on GaAs substrates provide advantages with respect to power utilization, speed and device size compared to silicon photonics technology, enabling it to provide optical communications capabilities to silicon chips which are approaching physical barriers to increasing speed and energy efficiency. Any success for POET adoption will require substantial education and marketing efforts by the Company. In addition, the incremental cost of utilizing GaAs substrates, the variations in processing steps and the limitations on wafer size and of wafer fragility will serve as hurdles to POET adoption. Adopters of our POET technology in the market will face difficulties in adapting to the larger semiconductor wafer sizes required for volume production of devices.

18

However, POET has the potential advantages of being, in some cases, (i) easier to implement in a manufacturing environment, (ii) more energy efficient, and (iii) more flexible in its potential applications. Consequently, we believe that if we are able to develop and commercialize POET, our technology should be able to compete effectively with other current technologies. As the semiconductor market is large and subject to rapid technological development, other technologies or improvements to existing technologies may emerge that could surpass the Company’s expectations for POET, in which case the Company would suffer competitive harm.

Some of our potential competitors have longer operating histories, significantly greater resources and name recognition and a larger base of customers. As a result, these competitors may have greater credibility with our potential customers. They also may be able to adopt more aggressive pricing policies and devote greater resources to the development, promotion and licensing of their technologies than we would be able to. In addition, some of our potential competitors have likely already established licensing or joint development relationships with the decision makers at our potential customers. In addition, many we perceive as potential customers have the capabilities to develop technology competitive to ours internally. These competitors may be able to leverage their existing relationships to discourage their customers from licensing or otherwise utilizing our technology. These competitors may elect not to support our technology which could complicate and impede our sales efforts. These and other competitive pressures may prevent us from competing successfully against current or future competitors, and may materially harm our business.

Our target markets are intensely competitive and characterized by rapid technological change. We cannot assure you that we will have the financial resources, technical expertise or marketing or support capabilities to compete successfully in the future. Competition is based on a variety of factors including price, performance, features, software availability, marketing, customer support, name recognition and financial strength. Further, given our contemplated reliance on semiconductor manufacturers, our competitive position is dependent on their competitive position. In addition, semiconductor manufacturers are not expected to license our architecture exclusively, and several of them also design, develop, manufacture and market semiconductor devices based on their own architectures or on other non-POET technologies.

C.Organizational Structure

The Company currently has two subsidiaries with the following corporate structure:

______________________

 (1)Page 27

Geographic Distribution of Revenue

Revenue and geographic markets in 2023, 2022 and 2021 were approximately as follows:

Region 2023  2022  2021 
Europe $191,225  $58,998  $- 
North & South America $274,552  $493,750  $209,100 

C.Organizational Structure.

The following graphically displays the organizational structure of the Company:

(1)There are 28,374,000 Class A Common Shares of OPEL Solar, Inc. issued and outstanding, all of which are held by the Company. There are no other outstanding securities of OPEL Solar, Inc. other than the Class A Common Shares.
(2)There are 5 Common Shares of ODIS Inc. issued and outstanding, held by OPEL Solar, Inc.
(3)There is 1 Ordinary share of POET Technologies Pte Ltd. issued and outstanding, held by POET Technologies Inc.
(4)There are 1,000,000 Preferred Shares and 1,050,100 Common shares of BB Photonics Inc. issued and outstanding, all of which are held by the Company. There are no other outstanding securities of BB Photonics Inc.
(5)

POET Optoelectronics Co, Ltd. is a wholly owned subsidiary of POET Technologies Pte. Ltd with a registered capital of RMB1,168,833.

(6)Super Photonics Xiamen Co., Ltd is joint venture located in Xiamen, China. The Company currently has an 76.1% interest in the joint venture with Sanan Integrated Circuit Co., Ltd, the other joint venturer, holding the remaining 23.9% interest in the joint venture.

19
D.D.Property, Plants and Equipment.

The Company’s head Canadian office is located in a 1,400-sq.400 sq. ft. leased office space in Toronto, Ontario, Canada. The Company has itsUS based operations officeare in a leased 9,043sq.3,883 sq. ft. space in San Jose, California.Allentown, Pennsylvania. Our testing operations are located in a 4,669 sq. ft leased facility in Singapore. Our product development operation is located in a 2,830 sq. ft leased facility in Shenzhen, China.

Page 28

 

The Company believes that its existing facilities are adequate to meet its needs for the foreseeable future.

ITEMItem 4A. UNRESOLVED STAFF COMMENTSUnresolved Staff Comments

Not Applicable.applicable.

ITEMItem 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTSOperating and Financial Review and Prospects

The following discussion should be read in conjunction with the audited consolidated financial statements of the Company and the related notes for the years ended December 31, 2015, 20142023, 2022 and 20132021 and the accompanying notes thereto included elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. See “Cautionary Statements Regarding Forward-Looking Statements” discussed above. Actual results could differ materially from those anticipated by forward-looking information due to factors discussed under “ITEM“Item 3.D. Risk Factors” and “ITEM“Item 4.B. Business Overview.”

A.A.Operating Results.

The information in this section should be read in conjunction with our audited consolidated financial statements for the years ended December 31, 2023, 2022 and 2021 and related notes and the information contained elsewhere in this report.

Cash and cash equivalents

Cash and cash equivalents consist of cash in current accounts of $1,249,116 (2022 - $1,981,765, 2021 - $4,216,911) and funds invested in US and Canadian Term Deposits of $1,769,953 (2022 - $7,248,080, 2021 - $10,724,864) earning interest at rates ranging from 0.20% - 0.25% and maturing in less than 90 days. The decrease was primarily due to a lack of revenue and limited equity raises during the year.

Short-term investments

The short-term investments of nil (2022 – nil, 2021 - $6,366,828); in 2021, the Company’s short term investments consisted of guaranteed investment certificates (GICs) held with one Canadian chartered bank and earn interest at rates ranging from 0.75 to 1.44%.

Selected Annual Data

The selected financial data of the Company for the years ended December 31, 2023, 2022 and 2021 was derived from the audited annual consolidated financial statements of the Company, which have been audited by Marcum LLP, independent registered public accounting firm, as described in their report which is included in this Annual Report.

The information contained in the selected financial data for the 2023, 2022 and 2021 years is qualified in its entirety by reference to the Company’s consolidated financial statements and related notes included under the heading ITEM 17. “Financial Statements” and should be read in conjunction with such financial statements and with the information appearing under the heading ITEM 5 “Operating and Financial Review and Prospects”. Except where otherwise indicated, all amounts are presented in accordance with IFRS as issued by IASB.

Page 29

The selected annual information for continuing operations for 2023, 2022 and 2021 can be further analyzed as follows:

Research and development can be analyzed as follows:

  2023  2022  2021 
          
Wages and benefits $4,298,207  $4,267,937  $3,270,528 
Subcontract fees  1,864,122   2,946,729   1,516,343 
Stock-based compensation  1,539,235   2,054,187   1,769,951 
Supplies  2,376,366   1,477,890   1,608,306 
  $10,077,930  $10,746,743  $8,165,128 

Selling, marketing and administration costs can be analyzed as follows:

Stock-based compensation $2,662,209  $2,382,417  $2,764,419 
Wages and benefits  2,649,770   2,648,862   2,643,451 
Professional fees  1,744,771   1,173,743   1,155,316 
General expenses  1,681,899   1,860,762   1,304,690 
Depreciation and amortization  1,922,140   1,293,158   1,100,522 
Rent and facility costs  134,366   157,329   87,130 
  $10,795,155  $9,516,271  $9,055,528 

Factors Affecting Our Results of Operations

Analysis of Continuing Operations

Year Ended December 31, 2023 compared to Year Ended December 31, 2022

Net loss was $20,267,365 for the year ended December 31, 2023 compared to a net loss of $21,036,690 for the same period for 2022, a decrease of $769,325 (4%). The following discusses the significant variances between the period and 2022:

Total R&D decreased by $668,813 (6%) to $10,077,930 for the year ended December 31, 2023 from $10,746,743 for the same period in 2022. For the purposes of the following analysis, non-cash stock-based compensation of $1,539,235 has been excluded and is included with the analysis of non-cash stock-based compensation below.

Depreciation and amortization increased by $628,982 (49%) to $1,922,140 for the year ended December 31, 2023 from $1,293,158 for the same period in 2022. Subsequent to the sale of DenseLight, the Company embarked on a “fab-light” strategy with a required test facility situated in Singapore and product development facility in China. The increase in depreciation and amortization was a result of assets acquired for these new facilities.

Professional fees increased by $571,028 (49%) to $1,744,771 for the year ended December 31, 2023 from $1,173,743 for the same period in 2022. During the period, the Company incurred legal fees related to certain unsuccessful financing arrangements that it was engaged in. Additionally, the Company incurred fees related to the preparation of regulatory documents to support multiple at-the-market financing programs.

Page 30

Impact of joint venture was nil for the year ended December 31, 2023 compared to a net loss of $1,465,006 for the same period in 2022. The impact of joint venture relates to the Company’s activity related to its investment in SPX. During 2023, the Company recorded a non cash gain on its contribution of IP to SPX of $1,031,807 compared to $1,746,987 in 2022. The Company recognized its share of SPX’s losses using the equity method. On a weighted average bases, the Company incurred approximately 78.9% or $(3,026,408) of the net operating loss of SPX for 2023 compared to $(3,614,211) or 83.7% in 2022. Although the Company’s equity ownership of SPX approximated 76.1% at December 31, 2023, the Company only recognized $(1,031,807) of its share of loss in SPX in 2023, compared to $(3,211,993) in 2022 because the value of its investment is carried at nil on the consolidated statements of financial position precluding further loss recognition under the standards.

General expenses and rent decreased by $201,826 (10%) to $1,816,265 for the year ended December 31, 2023 from $2,018,091 for the same period in 2022. In 2022, the Company engaged with a research and development company that does not have any revenue sources. We are developingfirm to assist with a technological process that demands significant investmentsnew shareholder outreach program at a cost of cash and other resources.$73,280. Additionally, the Company paid $30,000 to the transfer agent in annual fees to manage to various trust agreements related to debenture warrants outstanding in 2022, there were no debentures outstanding in 2023. The Company has not earned a profit since its inception. Duealso reduced the services of certain investor relations advisers in 2023.

Non-cash stock-based compensation decreased by $235,160 (5%) to $4,201,444 for the current stage ofyear ended December 31, 2023 from $4,436,604 for the process development, the Company’s most significant expenses are subcontract fees and human resources related, either directly as wages and benefits or through thesame period in 2022. The valuation of stock options is driven by a number of factors including the number of options granted, the strike price and the volatility of the Company’s stock. The stock option expense is dependent on the timing of the stock option grant and the amortization of the options as they vest. The stock options vest in accordance with the policies determined by the Board of Directors at the time of the grant consistent with the provisions of the Plan.

The Company issued warrants in USD during 2023. The issuance of those warrants created a derivative liability which is periodically remeasured and adjusted to reflect the fair value of the warrants. The Company had a non-cash adjustment of $24,865 for the year ended December 31, 2023 related to the fair value adjustment of the derivative liability.

Other (income), including interest increased by $46,670 (25%) to $234,990 for the year ended December 31, 2023 from $188,320 for the same period in 2022. The increase in other (income), including interest was a result of interest income earned from short-term investments and cash equivalents during 2023.

Year Ended December 31, 2022 compared to Year Ended December 31, 2021

Net loss for the year ended December 31, 2022 was $21,036,690 compared to a net loss of $15,669,093 for the same period in 2021, an increase of $5,367,597 (34%). The following discusses the significant variances between the period and 2021.

During the year, NRE revenue increased by $343,648 (164%) to $552,748 for the year ended December 31, 2022 from $209,100 for the same period in 2021. The Company provided services under an NRE contract to one customer in 2021. In 2022, the Company is now providing similar services to multiple customers, one of which continued to contract services from last year. The revenue relates to unique projects that are being addressed utilizing the capabilities of the POET Optical Interposer.

Total R&D increased by $2,581,615 (32%) to $10,746,743 for the year ended December 31, 2022 from $8,165,128 for the same period in 2021. For the purposes of the following analysis, non-cash stock-based compensation of $2,054,187 during the year ended December 31, 2022 has been excluded and is included with the analysis of non-cash stock-based compensation below.

R&D, excluding non-cash stock-based compensation, increased by $2,297,379 (36%) to $8,692,556 for the year ended December 31, 2022 from $6,395,177 for the same period in 2021. The increase in R&D is a result of the new stage of the Company’s development where it is transitioning from technology development to product development. As the transition occurs, qualified engineers are needed to fill roles related to new production introduction and quality control. R&D wages increased by $997,409 (30%) to $4,267,937 for the year ended December 31, 2022 from $3,270,528 for the same period in 2021. The Company has also engaged with new suppliers, through non-recurring engineering and qualification programs, to ensure that the supply of required products and services will meet the Company’s standards and will be available as needed. These programs resulted in an increase in R&D supplies and subcontract fees of $1,299,970 (42%) to $4,424,619 for the year ended December 31, 2022 from $3,124,649 for the same period in 2021.

Page 31

Interest expense was $49,738 for the year ended December 31, 2022 from $364,619 for the same period in 2021, a decrease of $314,881 (86%). The Company raised $3,729,921 in convertible debentures between April 2019 and September 2019 with two-year maturities. The Company was required to pay monthly interest on the convertible debentures. As the convertible debentures reached maturity during 2021, interest cost was reduced. All convertible debenture were either converted or matured in 2021. Interest in the year is non-cash.

Depreciation and amortization increased by $192,636 (18%) to $1,293,158 for the year ended December 31, 2022 from $1,100,522 for the same period in 2021. With the sale of DenseLight, the Company embarked on a “fab-light” strategy with a required test facility situated in Singapore and product development facility in China. The increase in depreciation and amortization was a result of assets acquired for these new facilities.

Impact of joint venture decreased by $2,910,257 (201%) to a net loss of $1,465,006 for the year ended December 31, 2022 from a net gain of $1,445,251 for the same period in 2021. The impact of joint venture relates to the Company’s activity related to its investment in SPX. During the year, the Company recognized its share of SPX’s losses using the equity method. On a weighted average basis, the Company’s share of the net operating loss was 83.7% or $3,614,211 for the year ended December 31, 2022, however the Company only recognized $3,211,993 of the net operating loss of SPX for the year ended December 31, 2022, because the investment is carried at nil (2021 - $1,445,251) on the consolidated statements of financial position. On a weighted average bases the net operating loss was 95.3% or $1,142,249 for the same period in 2021. The loss for the year ended December 31, 2022 was offset by a recognized gain of $1,746,987 related to the Company’s contribution of intellectual property to SPX in accordance with IAS 28. The Company recognized a gain of $2,587,500 during the same period in 2021.

General expenses and rent increased by $626,271 (45%) to $2,018,091 for the year ended December 31, 2022 from $1,391,820 for the same period in 2021. The increase was primarily a result of the increase in D&O insurance subsequent to the Company’s listing on Nasdaq. D&O insurance is substantially higher for US listed Companies than for Canadian listed Companies. The Company was only listed on the TSXV in 2021. Additionally, the Company’s lease for its Singapore facility was renewed in Q2 2022. The lease term is currently one year, accordingly the accounting rules relating to leases permits the Company to record rent expense. Some lease related costs in 2021 were charged to interest expense and amortization because the lease term exceeded one year. Other drivers for the increase over 2021 were the fees associated with listing on Nasdaq, costs associated with the new shareholder outreach program and costs related to the Company’s presentation at the Optical Fiber Conference. The Company did not have similar costs in 2021.

Other (income), including interest decreased by $73,511 (28%) to $188,320 for the year ended December 31, 2022 from $261,831 for the same period in 2021. During 2021, the Company received notice from the Small Business Administration of Washington, DC that its Covid-related PPP loan of $186,747 was forgiven in full. The Company did not have a similar forgiveness in the prior year. Other (income) including interest was all interest income in the year. Interest income for the year ended December 31, 2021 was $75,084.

Exchange Rate Risk

The functional currency of each of the entities included in the accompanying consolidated financial statements is the local currency where the entity is domiciled. Functional currencies include the Chinese Yuan, US, Singapore and Canadian dollar. Most transactions within the entities are conducted in functional currencies. As such, none of the entities included in the consolidated financial statements engage in hedging activities. The Company is exposed to a foreign currency risk when its subsidiaries hold current assets or current liabilities in currencies other than its functional currency. A 10% change in foreign currencies held would increase or decrease other comprehensive loss by $198,000.

Page 32

Liquidity Risk

The Company currently does not maintain credit facilities. The Company’s existing cash and cash resources are considered sufficient to fund operating and investing activities beyond one year from the issuance of these consolidated financial statements. The Company may, however, need to seek additional financing in the future.

B.Liquidity and Capital Resources.

The Company had working capital of $716,881 on December 31, 2023 compared to $5,751,101 on December 31, 2022. The Company’s statement of financial position as of December 31, 2023 reflects assets with a book value of $8,777,417 compared to $15,390,453 as of December 31, 2022. 36% of the book value at December 31, 2023 was in current assets consisting primarily of cash and cash equivalents of $3,019,069 compared to 62% of the book value as of December 31, 2022, which consisted primarily of cash and cash equivalents of $9,229,845.

During the year ended December 31, 2023, the Company had negative cash flows from operations of $(15,407,462). The Company has prepared a cash flow forecast for one year from December 31, 2023 which indicates that it does not have sufficient cash to meet its minimum expenditure commitments and therefore needs to raise additional funds to continue as a going concern. As a result, there is substantial doubt about the Company’s ability to continue as a going concern.

To address the future funding requirements, management has undertaken the following initiatives:

1.Raised CA$6,219,667 (US$4,607,161) in gross funding from a private placement on January 24, 2024.The financing included the issuance of warrants at an exercise price of CA$1.52. These warrants are currently in- the- money and will be exercisable after May 25, 2024.
2.Raised $1,607,400 in gross funding from a public offering on December 4, 2023. The financing included the issuance of warrants at an exercise price of $1.12. These warrants are currently in- the- money and holders of these warrants are encouraged to exercise them.
3.Raised $983,194 in gross proceeds from its at-the-market programs which were raised between June 30, 2023 and December 31, 2023.
4.Established a strict budgetary process with a focus on maintaining an appropriate level of corporate overheads in line with the Company’s available cash resources.

The Company’s financial statements do not include any adjustments to the assets’ carrying amount, to the expenses presented and to the reclassification of the balance sheets items that could be necessary should the Company be unable to continue its operations.

Page 33

The following is a summary of Company’s cash flows and working capital:

  2023  2022  2021 
  $  $  $ 
Net cash used in operating activities  (15,407,462)  (12,325,910)  (11,233,293)
Net cash from investing activities  (1,247,064)  3,292,791)  (7,297,710)
Net cash from financing activities  10,195,500   3,435,204   26,553,677 
Effect of exchange rate changes on cash  248,250   (114,015)  46,207 
Change in cash  (6,210,776)  (5,711,930)  8,068,881 
Opening cash  9,229,845   14,941,775   6,872,894 
Ending cash  3,019,069   9,229,845   14,941,775 

Operating Activities

During 2023, the Company recorded consolidated losses of $20,267,365 (2022 - $21,036,690, 2021 - $15,669,093).

The operating activities of the included the following non-cash items: non-cash stock-based compensation of $4,201,444 (2022 - $4,436,604, 2021 - $4,534,370), depreciation and amortization of $1,922,161 (2022 - $1,293,158, 2021 - $1,100,522), accretion of debt discount on convertible debentures and non-cash interest of $53,614 (2022 - $49,738, 2021 - $213,843). Gain on contribution of intellectual property to joint venture was $1,031,807 (2022 - $1,746,987, 2021 - $2,587,500) while the Company had a share of loss in joint venture of $1,031,807 (2022 - $3,211,993, 2021 - $1,142,249). The Company had a non-cash adjustment of $24,865 (2022 – nil, 2021 – nil) related to the fair value adjustment of the derivative liability. Other non-cash operating costs (income) was nil (2022 - $40,029, 2021 - $(172,933)).

The Company will regularly have high non-cash stock-based compensation as it uses stock options as method of attracting, retaining and motivating directors, employees and consultants of the Company and any of its subsidiaries and to closely align the personal interests of such directors, employees and consultants with those of the shareholders by providing them with the opportunity, through options, to acquire common shares in the capital of the Company while managing compensation through cash.

Subsequent to the sale of DenseLight, the Company embarked on a “fab-light” strategy with a required test facility situated in Singapore and product development facility in China. The increase in depreciation and amortization was a result of assets acquired for these new facilities.

In 2019, the Company raised $7,729,921 in convertible debentures issued at a discount. The discount on the convertible debentures was accreted over the life of the convertible debentures. The convertible debentures either matured or were converted in 2021, therefore in 2023 and 2022, non-cash cost of accretion of debt discount on convertible debentures was nil (2021 - $213,843). Non-cash interest in 2023 and 2022 related to the interest costs attributed the Company’s property leases.

The Company recognized a gain of $1,031,807 for the year ended December 31, 2023 (2022 - $1,746,987, 2021 - $2,587,500) related to its contribution of intellectual property to SPX in accordance with IAS 28. The Company only recognizes a gain on the contribution of the intellectual property equivalent to SAIC’s interest in SPX. Additionally, the Company recognizes its share of SPX’s losses using the equity method. On a weighted average basis, the Company’s share of the net operating loss was 78.9% or $3,026,408, however, the Company only recognized $1,031,807 of the net operating loss of SPX for the year ended 2023, which was equivalent to the gain in the year. No further loss is recorded because the carrying value is nil. In 2022, the Company incurred a loss of 83.7% or $3,614,211, however the Company only recognized $3,211,993 of the net operating loss of SPX for the year ended December 31, 2022 because the investment is was carried at nil (2021 - $1,445,251) on the consolidated statements of financial position.

Page 34

Consolidated negative cash flow from operations was $15,407,462 for the year ended December 31, 2023 (2022 - $12,325,910, 2021 - $11,233,293).

Investing Activities

The Company had consolidated cash flows from investing activities of $(1,247,064) for the year ended December 31, 2023 (2022 - $3,292,791, (2021 - $(7,297,710)). The Company purchased $6,366,828 of short-term investments in 2021 due to the excess cash it had on hand. These investments matured in 2022. The funds were invested in interest bearing facilities in accordance with the Company’s investment policy. No such investments were either purchased or matured in 2023. In 2023, $1,247,064 (2022 - $3,074,037, 2021 - $930,882) was used to purchase new equipment and patents.

Financing Activities

During the year ended December 31, 2023, the Company raised gross proceeds of $983,194 from the issuance of 227,673 common shares at an average price of $4.32 through an Equity Distribution Agreement, (“EDA”) with multiple agents. Pursuant to the EDA, the Company established an at-the-market (“ATM”) equity offering program whereby the Company may, at its discretion, during the term of the ATM agreement issue and sell, through the agents such number of common shares of the Company as partwould result in aggregate gross proceeds to the Company of up to $30 million. The agents were paid a commission of 3% or $29,486 of the gross proceeds raised through the ATM. The Company incurred additional financing costs including legal and filing fees of $291,226.

On December 4, 2023, the Company raised gross proceeds of $1,607,400 from the issuance of 1,786,000 units through an underwritten public offering in the United States (the “Offering”). The Offering consisted of 1,600,000 common shares of the Company and warrants to purchase up to 1,600,000 common shares of the Company at a combined public offering price of $0.90 per common share and accompanying warrant. Each warrant has an exercise price of $1.12 per common share and is exercisable for five years from the date of issuance. In addition, the Company granted the underwriter a 45-day option to purchase up to an additional 240,000 common shares and/or warrants to purchase up to an additional 240,000 common shares at the public offering price in any combination, less underwriting discounts and commissions, which the underwriter has partially exercised to purchase 186,000 additional common shares and additional warrants to purchase up to 186,000 common shares. The agents were paid a commission of 7% or $112,518 of the gross proceeds raised. The Company incurred additional financing costs including legal and filing fees of $145,089.

The fair value of the share purchase warrants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: dividend yield of 0%, risk-free interest rate of 3.54%, volatility of 75.66%, and estimated life of 5 years. The estimated fair value assigned to the warrants was $954,537.

On December 2, 2022, the Company completed a non-brokered private placement offering of 1,126,635 units at a price of $2.78 (CAD$3.81) per unit for gross proceeds of $3,184,332 (CAD$4,292,479). Each unit consists of one common share and one-half common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of $3.61 (CAD$4.95) per share until December 2, 2025. The Company paid finders’ fees aggregating to $42,090 (CAD$57,897) to four firms. The Company paid other share issue costs of $205,802 related to this private placement offering.

One director subscribed for 10,000 units of this private placement offering for gross proceeds of $27,800 (CAD$38,100).

On February 11, 2021, the Company completed a brokered private placement offering of 1,764,720 units at a price of $6.70 (CAD$8.50) per unit for gross proceeds of $11,815,595 (CAD$15,000,120). Each unit consists of one common share and one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of $9.00 (CAD$11.50) per share until February 11, 2023. At any time after June 12, 2021, the Company reserves the right to accelerate the expiry of the warrants if the Company’s average stock price exceeds $18.10 (CAD$23.00) for a period of 10 consecutive trading days. The broker was paid a cash commission of $708,667 (CAD$900,007) equating to 6% of the gross proceeds and received 1,058,832 broker warrants. Each broker warrant is exercisable into one common share of the Company at a price of $6.70 (CAD$8.50) per broker warrant until February 11, 2023. The Company incurred additional share issuance costs of $434,367 directly related to the private placement and fees to induce certain warrant holders to exercise their compensation.warrants.

Page 35

In addition to funds received from the brokered private placement, the Company received $16,118,750 from the exercise of stock options and warrants. The Company also improved its liquidity by $3,571,342 through the conversion of convertible debentures into units of the Company.

Capital Expenditures

The Company has an approved capital budget of $610,000 for the 2024 fiscal year related to research and development equipment, manufacturing equipment and patent registration. In 2023, $1,247,064 (2022 - $3,074,037, 2021 - $930,882) was either spent in cash or accrued for acquiring development and manufacturing equipment and new patents.

C.Research and Development.

Beginning in 2017, POET began designing lasers for data communications applications and directed DenseLight Semiconductors, Pte. Ltd., a former subsidiary of the Company, to build such lasers to be compatible with the Optical Interposer platform. In 2019, the Company decided to adopt a “fab light” strategy, common among semiconductor companies, and divested its fabrication operations through the sale of DenseLight in November of that year. From 2018 – 2020, virtually all the R&D spending in the Company was dedicated to design & development of the Optical Interposer as a versatile platform technology, replete with features that enhance its utility across a variety of application spaces.

During the second half of 2021, the Company transitioned to product development by investing more than $2 million in the design & development of 100G and 200G optical engines in several configurations, including customized designs for specific customers and applications. Samples of optical engines at various stages of development were made available and delivered to customers in 2022 for initial evaluation and in 2023 for design-in and customer qualification. SPX is forecasted to produce Optical Engines in high volumes for several customers in 2024. POET’s effort in lower speed Optical Engine design and production was intended primarily as a way for POET to demonstrate the viability and market acceptance of its unique approach to integration and fabrication and to establish an initial presence in the market. However, the Company’s primary strategy is to offer Optical Engines at the highest speeds at which customers are deploying Optical Transceivers. In 2024, we expect that we will be primarily in 800G, and heavily focused on those hyperscale data centers actively implementing AI services. Consistent with this strategy, the Company has invested approximately $20 million in design, development and engineering programs related to its 400G transmit chiplets (combined in multiples of 400G to achieve 800G, 1.6T and 3.2T speeds), in 800G receive optical engines, and in light source products, and fabrication techniques.

The Company has designed, tested and sampled the current version of its 400G transmit (Tx) engine, and its 800G receive (Rx) engine with various customers. The Company intends to revise its 400G Tx product and to introduce a new version later this year. The 800G Rx has been well received, fully qualified and is expected to be incorporated in the optical transceiver modules of several customers this year. So long as the Company provides Optical Engines to optical transceiver module customers, there will always be customer centric adjustments to these products to fit their specific needs. The cost to make these adjustments will vary depending on the customer requirements.

The Company is expected to invest an additional $11 million in 2024 in ongoing development of the 400G Tx chiplet for inclusion in 800G and 1.6T optical transceivers. POET is also committed to the development of its own optical transceiver modules, a critical next phase in the Company’s growth plan, with investments in that program beginning this year. At the present time, the Company expects to have a functional module by 2025 with sales of modules ramping in late 2025.

Page 36

Internally generated research costs, including the costs of developing intellectual property and maintaining patents are expensed as incurred. Internal development costs are expensed as incurred unless such costs meet the criteria for capitalization and amortization under IFRS, which to date has not occurred.

We incurred a cumulative $10,077,930, $10,746,743 and $8,165,128 of research and development expenses during the years ended December 31, 2023, 2022 and 2021 which includes non-cash stock-based compensation of $1,539,235, $2,054,187 and $1,769,951 respectively. Other expenses related to research and development expenditures in the semiconductor business include costs associated with salaries, material costs, license fees, consulting services and third-party contract manufacturing. The expenses in all years presented can be analyzed for continuing and discontinuing operations as follows:

R&D for Continuing Operations

  For the Years Ended December 31, 
  2023  2022  2021 
          
Wages and benefits $4,298,207  $4,267,937  $3,270,528 
Subcontract fees  1,864,122   2,946,729   1,516,343 
Stock-based compensation  1,539,235   2,054,187   1,769,951 
Supplies  2,376,366   1,477,890   1,608,306 
  $10,077,930  $10,746,743  $8,165,128 

D.Trend Information.

Other than as may be disclosed elsewhere in this annual report and specifically in Item 4.B. “Business Overview,” we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net revenues, income from operations, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future operating results or financial condition.

E.Critical Accounting Estimates.

 

Taxation

See ITEM 10.E. “Taxation.”

Critical Accounting Policies and Estimates

The Company prepares its audited consolidated financial statements in accordance with IFRS as issued by the IASB.IASB, which differs from U.S. GAAP. The preparation of financial statements in accordance with IFRS requires the use of certain critical accounting assumptions and estimates. These assumptions are limited by the availability of reliable comparable data and the uncertainty of predictions concerning future events. It also requires management to exercise judgment in applying the Company’s accounting policies. The Company believes that the estimates and assumptions upon which it relies are reasonable based upon information available at the time that these estimates and assumptions are made. Actual results could differ from these estimates. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed below.

Basis of presentation

These consolidated financial statements include the accounts of POET Technologies Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.

20Page 37

Foreign currency translation

 

These consolidated financial statements are presented in U.S. dollars (“USD”), which is the Company’s presentation currency.

Items included in the financial statements of each of the Company’s subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency of an entity are recognized in the statement of operations and deficit.

Assets and liabilities of entities with functional currencies other than U.S. dollars are translated into the presentation currency at the year-end rates of exchange, and the results of their operations are translated at average rates of exchange for the year. The resulting translation adjustments are included in accumulated other comprehensive loss in shareholders’ equity. Additionally, foreign exchange gains and losses related to certain intercompany loans that are permanent in nature are included in accumulated other comprehensive loss.

Financial Instruments

Financial instruments are required to be classified as one of the following: held-to-maturity; loans and receivables, fair value through profit or loss; available-for-sale or other financial liabilities.

The Company’s financial instruments includeconsist of cash and cash equivalents, short-term investments, covid-19 government support loans, contract liabilities and accounts payable and accrued liabilities. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest risk arising from these financial instruments. The Company designated itsestimates that carrying value of these instruments approximates fair value due to their short-term nature.

The following table outlines the classification of financial instruments under IFRS 9:

Financial Assets
Cash and cash equivalentsAmortized cost
Short-term investmentsAmortized cost
Accounts receivableAmortized cost
Financial Liabilities
Accounts payable and accrued liabilitiesAmortized cost
Derivative warrant liabilityFair value through profit and loss
Covid-19 government support loansAmortized cost
Contract liabilitiesAmortized cost

Debt and Debt Instruments

Convertible debentures are accounted for as a compound financial instrument with a debt component and a separate equity component. The debt component of these compound financial instruments is measured at fair value on initial recognition by discounting the stream of future interest and principal payments at the rate of interest prevailing at the date of issue for instruments of similar term and risk. The debt component is subsequently deducted from the total carrying value of the compound instrument to derive the equity component. The debt component is subsequently measured at amortized cost using the effective interest rate method. Interest expense based on the coupon rate of the debenture and the accretion of the liability component to the amount that will be payable on redemption are recognized through profit or loss as a finance cost.

Joint venture

A joint arrangement is an arrangement among two or more parties where the parties are bound by a contractual arrangement and its accounts payable and accrued liabilities as other financial liabilities.

Fair value through profit or loss financial assets are measured at fair value with gains and losses recognized in operations. Financial assets, loans and receivables and other financial liabilities are measured at amortized cost. Available-for-sale financial assets are measured at fair value with unrealized gains and losses recognized in other comprehensive loss.

Fair value of a financial instrument is the amount of consideration that would be agreed upon in an arm’s length transaction between knowledgeable, willingcontractual arrangement gives the parties who are under no compulsion to act. The fair value of a financial instrument on initial recognition is the transaction price, which is the fair valuejoint control of the consideration given or received. Subsequentarrangement. A joint venture is a form of joint arrangement where an entity is independently formed and the parties jointly have rights to initial recognition, the fair valuenet assets of the arrangement and therefore account for their interests under the equity method.

Share consolidation

On February 24, 2022, the Company filed Articles of Amendment to consolidate its common shares on a financial instrument that is quoted in active markets is basedten-for-one basis. For further clarity, for every ten (10) pre-consolidated common shares, shareholders received one (1) post-consolidated common share. On February 28, 2022 the Company’s common shares began trading on the bid price forTSXV on a post consolidation basis. The Company’s name and trading symbol remained unchanged. All references to share and per share amounts in these consolidated financial asset heldstatements and accompanying notes to the offer price for aconsolidated financial liability. When an independent price is not available, fair value is determined by using a valuation methodology which refersstatements have been retroactively restated to observable market data. Such a valuation technique includes comparisons with a similar financial instrument where an observable market price exists, discounted cash flow analysis, option pricing models and other valuation techniques commonly used by market participants. If no reliable estimate can be made,reflect the Company measures the financial instrument at cost less impairment as a last resort.ten-for-one share consolidation.

Property and equipment

Property and equipment are recorded at cost. Depreciation is calculated based on the estimated useful life of the asset using the following method and useful lives:

Machinery and equipmentStraight Line, 5 years
Leasehold improvementsStraight Line, 5 years or life of the lease, whichever is less
Office equipmentStraight Line, 3 – 5 years

 Office equipmentStraight Line, 5 yearsPage 38

 

Patents and licenses

Patents and licenses are recorded at cost and amortized on a straight linestraight-line basis over 12 years. Ongoing maintenance costs are expensed as incurred.

Stock-based Compensation

21

Stock options and warrants awarded to non-employees are accounted for using the fair value of the instrument awarded or service provided, whichever is considered more reliable. Stock options and warrants awarded to employees are accounted for using the fair value method. The fair value of such stock options and warrants granted is recognized as an expense on a proportionate basis consistent with the vesting features of each tranche of the grant. The fair value is calculated using the Black-Scholes option-pricing model with assumptions applicable at the date of grant.

Other stock-based payments

The Company accounts for other stock-based payments based on the fair value of the equity instruments issued or service provided, whichever is more reliable.

Cumulative Translation Adjustment

IFRS requires certain gains and losses such as certain exchange gains and losses arising from the translation of the financial statements of a self-sustaining foreign operation to be included in comprehensive income.

Impairment of long-lived assets

The Company’s tangible and intangible assets are reviewed for indications of impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. An assessment is made at each reporting date whether there is any indication that an asset may be impaired.

An impairment loss is recognized when the carrying amount of an asset exceeds its recoverable amount. Impairment losses are recognized in profit and loss for the year. The recoverable amount is the greater of the asset’s fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit ("CGU"(“CGU”) to which the asset belongs.

An impairment loss is reversed if there is an indication that there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. The Company did not record anNo impairment loss in 2015, 2014 or 2013.has been reported for the years ended December 31, 2023, 2022 and 2021.

Income taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred income taxes are provided on differences between the financial reporting and income tax bases of assets and liabilities and on income tax losses available to be carried forward to future years for tax purposes. Deferred income taxes are measured using the substantively enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are provided to reduce deferred incomeDeferred tax assets toare only recognized if the amount is expected to be realized.realized in the future.

Page 39

 

Other income - Government Grants

Government grants received exclusively from the Department of Defense of the United States of America and NASA, relating to research and development, are recognized as other income, net,Revenue recognition

Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognizes revenue when it transfers control over a product or service to a customer.

Sale of goods

Revenue from the sale of goods is recognized, net of discounts and customer rebates, at the point in time the transfer of control of the related products has taken place as specified in the sales contract and collectability is reasonably assured.

Service revenue

The Company provides contract services, primarily in the form of non-recurring revenue (“NRE”) where control is passed to the customer over time. The contracts generally provide agreed upon milestones for customer payment which include but are not limited to the delivery of sample products, design reports and test reports. The customer makes payment when it has approved the delivery of the projects. milestone. The Company must determine if the contract is made up of a series of independent performance obligations or a single performance obligation. Where NRE contracts contain multiple performance obligations for which a standalone transaction price can be assessed, revenue is recognized as each performance obligation is satisfied. Where NRE contracts contain a single performance obligation to be settled over time, revenue is recognized progressively based on the output method.

Other income earned on government grants in 2015 was nil (2014 - $169,832, 2013 - $342,874).

Interest income

Interest income on cash and cash equivalents classified as fair value through profit or loss is recognized as earned using the effective interest method.

Government Grants

Loans received exclusively from governmental agencies to support the Company throughout the COVID-19 pandemic qualify to be forgiven if certain conditions are met. Forgiveness of COVID-19 related loans will be recognized as other income on the consolidated statements of operations and deficit.

Wage subsidies

Wages subsidies received from the Singaporean government are netted against R&D related wages and benefits on the consolidated statements of operations and deficit.

Intangible assets

Research and development costs

Research costs are expensed in the year incurred. Development costs are also expensed in the year incurred unless the Company believes a development project meets IFRS criteria as set out in IAS 38,Intangible Assets, for deferral and amortization. IAS 38 requires all research costs be charged to expense while development costs are capitalisedcapitalized only after technical and commercial feasibility of the asset for sale or use have been established. This means that the entity must intend and be able to complete the intangible asset and either use it or sell it and be able to demonstrate how the asset will generate future economic benefits. Development costs are tested for impairment whenever events or changes indicate that its carrying amount may not be recoverable.

Page 40

In-process research and development

Under IFRS, in-process research and development (“IPR&D”) acquired in a business combination that meets the definition of an intangible asset is capitalized with amortization commencing when the asset is ready for use (i.e., when development is complete). The Company hasdoes not met the criteria set out in IAS 38, therefore no deferral has been recognized.capitalize its IPR&D.

Stock-based compensation

Stock options and warrants awarded to non-employees are accounted for using the fair value of the instrument awarded or service provided whichever is considered more reliable. Stock options and warrants awarded to employees are accounted for using the fair value method. The fair value of such stock options and warrants granted is recognized as an expense on a proportionate basis consistent with the vesting features of each tranche of the grant. The fair value is calculated using the Black-Scholes option pricing model with assumptions applicable at the date of grant.

Loss per share

Basic loss per share, net of taxes is calculated by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding during the yearperiod after giving effect to potentially dilutive financial instruments. The dilutive effect of stock options and warrants is determined using the treasury stock method.

The following new accounting policy was adopted on January 1, 2015:

Financial Instruments

IFRS 9,Financial Instruments,will replace IAS 39,Financial Instruments: Recognition and Measurement. The new standard requires entities to classify financial assets as being measured either at amortized cost or fair value depending on the business model and contractual cash flow characteristics of the asset. For financial liabilities, IFRS 9 requires an entity choosing to measure a liability at fair value to present the portion of the change in its fair value due to change in the entity’s own credit risk in the other comprehensive income rather than in the statement of profit or loss. The new standard applies to annual years beginning on or after January 1, 2015. The adoption of this policy did not impact the Company’s consolidated financial statements.

The Company has considered all other recently issued accounting pronouncements and does not believe the adopting of such pronouncements will have a material impact on its consolidated financial statements.

22

Selected Annual Data

The selected financial data of the Company for the years ended December 31, 2015, 20142023, 2022 and 20132021 was derived from the audited annual consolidated financial statements of the Company, which have been audited by Marcum LLP, independent registered public accounting firm, as described in their report which is included in this Annual Report.

The information contained in the selected financial data for the 2015, 20142023, 2022 and 20132021 years is qualified in its entirety by reference to the Company’s consolidated financial statements and related notes included under the heading ITEMItem 17. “Financial Statements” and should be read in conjunction with such financial statements and with the information appearing under the heading ITEMItem 5 “Operating and Financial Review and Prospects”. Except where otherwise indicated, all amounts are presented in accordance with IFRS as issued by IASB.

The following table relates to the operating results of the Company.

Consolidated Statements of Operations Under International Financial Reporting Standards

(US$)

  Years Ended December 31,
  2015 2014 2013
Costs and expenses            
General and administration $8,614,109  $9,677,705  $6,284,288 
Research and development  3,532,492   2,277,927   1,925,974 
Investment income, including interest  (76,431)  -   (18,371)
Loss before the following  12,070,170   11,955,632   8,191,891 
Other income  -   169,832   342,874 
Net loss  (12,070,170)  (11,785,800)  (7,849,017)
Deficit, beginning of year  (78,780,502)  (66,994,702)  (59,145,685)
Net loss  (12,070,170)  (11,785,800)  (7,849,017)
Deficit, end of year $(90,850,672) $(78,780,502) $(66,994,702)
Basic and diluted loss per share $(0.07) $(0.08) $(0.06)

23

The selected annual information for 2015, 2014 and 2013 can be further analyzed as follows:

  2015 2014 2013
Research and development expenses can be analyzed as follows:      
Wages and benefits $1,241,054  $899,758  $692,105 
Subcontract fees  1,560,819   582,943   558,073 
Stock-based compensation  552,416   641,176   565,246 
Supplies  178,203   154,050   110,550 
  $3,532,492  $2,277,927  $1,925,974 
General and administrative costs can be analyzed as follows:            
Stock-based compensation $4,265,704  $3,974,821  $3,455,907 
General expenses  1,012,340   662,672   558,560 
Professional fees  812,115   907,794   632,159 
Wages and benefits  1,306,051   1,700,600   831,950 
Management and consulting fees  665,771   595,667   581,203 
Rent  232,265   159,298   150,974 
Depreciation and amortization  319,863   236,955   73,535 
Shares issued as reduction of license fee  -   1,439,898   - 
  $8,614,109  $9,677,705  $6,284,288 

Year Ended December 31, 2015 compared to Year Ended December 31, 2014

Costs and Expenses

During the year ended December 31, 2015, the Company recorded a loss of $12,070,170 compared to a loss of $11,785,800 for the year ended December 31, 2014. Changes in major expense categories are discussed below:

SBIR Grant Income

The Company had $169,832 in SBIR grant income for the year ended December 31, 2014. During 2014 the Company decided to eliminate its use of SBIR grants in order to focus all of its resources on developing and monetizing the POET technology. The Company had no SBIR grant income for the year ended December 31, 2015.

Research and Development (“R&D”).

Non-cash stock-based compensation of $552,416 (2014 - $641,176) has been excluded from the analysis of R&D and is included with the analysis of non-cash stock-based compensation below.

During the year ended December 31, 2015, $2,980,076 was spent on R&D, of this amount, $1,560,819 was spent on subcontract services as compared to $582,943 in fiscal 2014. The subcontract fees related to work done with the Company’s VCSEL technology, epitaxy substrates and technical design kits. This development process required the use of third party consultants to both test and prove the concepts. During the year ended December 31, 2015, the Company expanded on its development roadmap which included additional proof of concept tests conducted by the Company’s then primary R&D consultant, Anadigics, Inc. The Company also engaged other R&D services providers such as Epiworks Inc., Intelligent Epitaxy Technology and Wavetek to expand the technology development. The Company has transitioned to an outsourcing model to expedite the development process. This transition is part of the Company’s ultimate objective of working with a “pure-play” foundry offering a wide range of dedicated, flexible and competitive foundry services. Additionally, in early 2015, the Company had expanded the capacity of the work being undertaken by BAE but stopped this activity in the second half of 2015 with a transition to Anadigics. BAE was the Company’s primary subcontractor in 2014, most of the subcontract fees for that year were spent on services provided by BAE.

R&D wages during the year ended December 31, 2015 increased by 38% or $341,296 over 2014. The increase in wages relate to the addition of a CTO and Program Manager along with additional over-time hours. These new employees were not with the Company in 2014. In addition, improper installation of equipment which was purchased in 2014 contributed to the team working significant over time hours to identify the cause of poor test results generated by this piece of equipment. The issues relating to the faulty installation were rectified in the first quarter of 2015. The increase is consistent with the Company’s 2015 budget.

24

Management and Consulting Fees

Management and consulting fees increased for the year ended December 31, 2015 by $70,104 over 2014. The increase was mainly due to the compensation of the Executive Co-Chairman who joined the Company in July 2014. The Company had some reduction in consulting fees due to discontinuing services that the Company felt were not adding material value.

General expenses and rent

General expenses increased by $349,668 for the year ended December 31, 2015 over 2014. The increase is primarily due to increased investor relations, travel and promotion, which collectively increased by $255,000. The Company implemented a promotion program for POET which included advertisements on Bloomberg TV and the Fox News Network. The Company also had its annual general meeting in Silicon Valley which resulted in increased logistics costs. Multiple Asian trips in securing new opportunities with potential service providers and partners increased the travel costs during the year over 2014.

Additionally, maintenance and repair costs, included in general and administrative, increased by $25,000 for the year ended December 31, 2015 over 2014. These costs resulted primarily from the improper installation of new equipment by a third party. The Company consulted with specialists in the field to assist with correcting the issues related to the faulty installation. The issues relating to the faulty installation were rectified in the first quarter of 2015. The Company also spent $17,000 on specialized software that was required to operate the equipment along with optimizing the optical elements of the POET process.

Rent expense increased by approximately $73,000 over 2014 due to the addition of the Company’s new location in Silicon Valley.

Wages and Benefits

Wages and benefits decreased by $394,549 from 2014 to 2015 as a result of the cessation of employment of the former president in September 2014 and the non-repetition of 2014 performance bonuses of $337,000 paid to the former interim CEO and former COO. The compensation to the former president included a one-time debt settlement of $100,000 which was settled in February 2014. Wages and benefits will, however, increase over the short-term with the addition of the new CEO and COO, and the transition of responsibilities between the CEO and former interim CEO. While the Company experienced decreases relating to bonuses paid to the former interim CEO and wages payable to the former president, there was a partial offsetting due to the addition of the new COO and CEO salaries.  

Professional Fees

Professional fees decreased by 11% from $907,794 in 2014 to $812,115 in 2015. Professional services in 2015 were primarily on routine operational matters as compared to 2014 when the Company incurred additional fees for the updated Pellegrino valuation report previously commissioned by it. Additionally, increased fees were incurred in 2014 for submitting a registration statement on Form 20-F in connection with the registration of its common stock under the U.S. Securities Exchange Act of 1934.

Non-Cash Stock-based Compensation

Non-cash stock-based compensation increased by $202,123 from $4,615,997 in 2014 to $4,818,120 in 2015. The Company granted 11,655,000 stock options during the year ended December 31, 2015 as compared to 6,155,000 in 2014. The number of options granted for the year ended December 31, 2015 was unusually high due to the recruitment of two new senior executive officers. The valuation of stock options is driven by a number of factors including the quantity of options granted, the strike price and the volatility of the Company’s stock. The stock option expense is dependent on the timing of the stock option grant and the amortization of the options as they vest.

The stock options vest in accordance with the policies determined by the Board of Directors from time to time consistent with the provisions of the 2015 Plan which grants discretion to the Board of Directors.

Shares issued for the reduction of license fee

For the year ended December 31, 2014, the Company had a one-time non-cash issuance of 2,000,000 common shares to the University of Connecticut valued at $1,439,898 for the reduction of certain royalty rights in exchange for an investment in the Company. The parties agreed to restructure the payment provisions of the License Agreement by reducing royalty payments to three percent (3%) of amounts received from unaffiliated third parties in respect of the exploitation of the Intellectual Property defined in the License Agreement, in consideration for 2,000,000 common shares of the Company. The Company did not have a similar expense for the year ended December 31, 2015.

Exchange Rate Risk

The Company is exposed to foreign currency risk with the Canadian dollar. The Company maintains bank accounts and cash reserves in both currencies with the majority of reserves currently in Canadian dollars which has exposure to currency fluctuations. Most of the company’s operations are transacted in US dollars. A 10% change in the Canadian dollar would increase or decrease other comprehensive loss by $1,135,639.

Year Ended December 31, 2014 compared to Year Ended December 31, 2013

The loss for the year ended December 31, 2014 increased by $3,936,783 from $7,849,017 for the year ended December 31, 2013 to $11,785,800 for the year ended December 31, 2014. The increased loss was a result of a few significant factors, the most significant of which was the one-time non-cash issuance of 2,000,000 common shares to the University of Connecticut valued at $1,439,898 for the reduction of certain royalty rights in exchange for an investment in the Company. The parties agreed to restructure the payment provisions of the License Agreement by reducing royalty payments to three percent (3%) of amounts received from unaffiliated third parties in respect of the exploitation of the Intellectual Property defined in the License Agreement, in consideration for 2,000,000 common shares of the Company.

Non-cash stock-based compensation increased by $594,844 from $4,021,153 for the year ended December 31, 2013 to $4,615,997 for the year ended December 31, 2014. Stock based compensation is calculated on the date of the stock option grant and is amortized and expensed in the year that the stock options vest. Criteria such as stock price at the grant date, and number of stock options granted will affect the value of the granted stock and in turn the stock option compensation as this amount is amortized at the stock option vest date. It is important to note that this non-cash expense is considered an integral part of the Company employing and maintaining highly qualified and competent personnel to reach its goals. For the purposes of clarity and simplicity, the Company reclassified any stock based compensation included in research and development costs to stock-based compensation.

The Company granted 6,155,000 stock options during the year in 2014 while 7,310,000 were granted in 2013.

25

The increase of $868,650 in wages and benefits is due to the addition of the COO, Stephane Gagnon ($172,000 in 2014 and $26,000 in 2013), severance package to the former CEO ($185,000 in 2014, and nil in 2013), bonuses ($475,000 in $2014 and $60,000 in 2013), and increase in director fees of $110,000 ($233,000 in 2014 and $123,000 in 2013). Having the “right people in the right places” is a key success driver of the Company. The Company is therefore committed to appropriate investments in human capital to ensure that the right people are in place to help the Company reach its strategic goals.

General expenses increased by $103,778 from $558,560 in 2013 to $662,668 in 2014. The increase was attributed to increased travel expenses, filing and regulatory fees and shareholder communications.

During the year, professional fees increased by almost 44% or $275,635 from $632,159 in 2013 to $907,794 in 2014. On January 24, 2014, the Company submitted a registration statement on Form 20-F in connection with the registration of its common stock under the U.S. Securities Exchange Act of 1934. In preparation for this filing, the Company incurred substantial legal and accounting fees. Additionally, the Company paid fees relating to the update of the Pellegrino valuation report previously commissioned by it. Legal fees for the Company continue to be a significant expense due to the regular contract reviews, patent reviews and legal costs associated with being a publicly traded Company. The Company also incurred $110,000 of recruitment fees related to the Company’s executive recruitment program.

Depreciation and amortization increased by $163,704. Depreciation and amortization was $73,535 in 2013 as compared to $237,239 in 2014. The Company added new equipment and patent registration throughout 2013 and 2014 totaling $1,528,000. The new equipment provides the Company with the opportunity to advance the POET process within the confines of its own lab and advance its timelines toward monetization. The current year is the first full year of depreciation for these new assets added in 2013 and partial depreciation for assets added in 2014.

Research and development increased by $276,023 from $1,360,728 in 2013 to $1,636,751 in 2014. The increase was primarily due to the increased wages and benefits of $207,653 resulting from the appointment of the new VP Product Development, currently the Company CTO, and annual wage increases. The CTO brings to the Company two distinct experiences: strategic product roadmap definition - addressing server and storage vertical markets; and broad integrated circuit development encompassing analog mixed signal through large digital application specific integrated circuits. The Company also added 2 new R&D employees to help support the R&D and monetizing efforts. Additionally, subcontract fees and R&D supplies increased by an aggregate $68,370. The increase in subcontract fees was primarily due to fees paid to a “3rdparty foundry” for specialty work done in replicating the fabrication process and consulting towards shrinking the PET process .

The Company has completed all its projects under SBIR grants. As a result, SBIR grant income in 2014 was $169,832 as compared to $342,874 in 2013. During 2014 the Company decided to eliminate its use of SBIR grants in order to focus all of its resources on developing and monetizing the technology.

26
B.Liquidity and Capital Resources

The Company had working capital of $14,045,498 on December 31, 2015 compared to $11,079,641 on December 31, 2014. The increase and maintenance of the higher working capital was due to the approximately $12.1 million dollars raised through the exercise of stock options and warrants during the year ended December 31, 2015.

The Company’s balance sheet as at December 31, 2015 reflects assets with a book value of $15,934,839 (2014 - $12,850,946) of which 91% (2014 - 89%) or $14,560,919 (2014 - $11,531,365) is current and consists primarily of cash totaling $14,409,996 (2014 - $11,287,864). The Company’s liquidity and unencumbered balance sheet will allow for investments in capital equipment and valuable human capital which are necessary to enable the Company to achieve its technical and operational milestones.

Between January 1, 2016 and February 22, 2016, the Company raised $1,965,327 from the exercise of 2,686,947 warrants and 628,000 stock options.

Based on current plans and cash utilization, we believe we have sufficient liquidity to support our operations and technological programs beyond the end of 2016, which include further development of the POET semiconductor process and increasing the POET intellectual property portfolio to enable us to exploit POET, through licenses and collaborative arrangements.

The Company has no debt obligations or related interest costs. The Company’s only credit facilities relate to corporate credit cards.

As of February 22, 2016, there were 1,116,051 warrants outstanding to purchase common shares at an average exercise price of CAD$0.23 expiring between June 22, 2016 and September 27, 2016. The Company anticipates that those warrants will be exercised subject to market conditions affecting the Company’s stock price. Should those warrants be exercised, there is a potential for an additional CAD$256,692 to be raised by the Company. It is important to note, that while the Company expects that warrants will be exercised, it is dependent on a number of factors that are outside of the Company’s control such as stock price and investor confidence, and no assurances can be given that any exercises will occur.

The Company is embarking on an aggressive plan of attempting to monetize POET while simultaneously improving shareholder value. The focus therefore is to remain sufficiently capitalized through lean operations.

Operating Activities

The Company’s board of directors approved the 2016 budget which continues to see commitments made to expanding and developing the POET technology platform.

The R&D process requires the use of third party consultants to both test and prove the concepts. The Company has expanded on its development roadmap which includes additional proof of concept tests conducted by the Company’s primary R&D consultant Wavetek. The Company also engaged other R&D services providers such as Epiworks Inc., and Intelligent Epitaxy Technology to expand the technology development. The Company has transitioned to an outsourcing model to expedite the development process. The transition to an outsourcing model will result in increased subcontract fees. This transition is part of the Company’s ultimate objective of working with a “pure-play” foundry offering a wide range of dedicated, flexible and competitive foundry services.

2016 operating activities will focus on:

·The continued development and expansion of the IP patent portfolio, facilitating.
·Facilitating the adoption of the POET process into opto-electronic products by providing ease of access to the platform with initiatives such as the development of the PDKs.
·Continuing the lab-fab transition through ongoing evaluation of external partners for both the epi stack growth and commercial foundry fabrication

27

Investing Activities

The Company is currently not involved in any investing activity other than the purchase of property and equipment and the registration of new patents for use in the development of its POET technology. When investing, the Company has a strict investment policy which includes investing any surplus capital only in highly liquid, highly rated financial instruments.

Financing Activities

The Company will continue to seek additional funding, primarily by way of equity offerings, to carry out its business plan and to minimize risks of its operations. The market for equity financing for companies such as us is challenging, however, and there can be no assurance that additional funding by way of equity financing will be available, or if available, on terms acceptable to the Company. The failure of the Company to obtain additional funding on a timely basis may result in the Company reducing or delaying one or more of its planned research, development and marketing programs and reducing related personnel, any of which could impair the current and future value of the business. Any additional equity financing, if secured, may result in dilution to the existing shareholders at the time of such financing. The Company may also seek additional funding from other sources, such, technology licensing, and strategic alliances, which, if obtained, may reduce the Company’s interest in its projects or products. There can be no assurance, however, that any alternative sources of funding will be available.

Capital Expenditures

The Company has an approved capital budget of $360,000 for the 2016 fiscal year related to research and development equipment and patent registration. In 2015, $374,200 was spent on acquiring development equipment and new patents. $527,068 and $1,000,783 were spent on similar capital expenditures in 2014 and 2013, respectively

28
C.Research and Development

The Company has developed a unique, proprietary process that addresses the deficiencies of size, integration, power and cost efficiency associated with current opto-electronic semiconductor manufacturing technologies. The novel process can be accommodated in existing semiconductor fabs with minimum re-tooling, thus potentially reducing capital expenditures required to adopt POET’s process technologies.

Internally generated research costs, including the costs of developing intellectual property and maintaining patents are expensed as incurred. Internal development costs are expensed as incurred unless such costs meet the criteria for deferral and amortization under IFRS, which to date has not occurred.

We incurred $3,532,492, $2,277,927 and $1,925,974 of research and development expenses in 2015, 2014 and 2013 respectively. Research and development expenditures in the semiconductor business include costs associated with salaries, material costs, license fees, consulting services and third-party contract manufacturing. The expenses in both years can be analyzed as follows:

   2015   2014   2013 
       
Wages and benefits $1,241,054  $899,758  $692,105 
Subcontract fees  1,560,819   582,943   558,073 
Stock-based compensation  552,416   641,176   565,246 
Supplies  178,203   154,050   110,550 
  $3,532,492  $2,277,927  $1,925,974 

D.Trend Information

Other than as may be disclosed elsewhere in this annual report and specifically in ITEM 4.B. “Business Overview,” we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net revenues, income from operations, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future operating results or financial condition.

E.Off-Balance Sheet Arrangements

The Company has no material off-balance sheet arrangements in place at this time.

F.Tabular Disclosures of Contractual Obligations

The following table sets forth our contractual obligations and commercial commitments as of December 31, 2015:

POET Technologies Inc.

  Payments due by period (US$)
Contractual Obligations  Total   <1 year   1-3 years   3-5 years   >5 years 
                     
Operating Lease Obligations $161,992  $133,612  $28.380  $-  $- 

G.Safe Harbor

See “Forward Looking Statements” on page 1 of this Annual Report.

ITEMItem 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEESDirectors, Senior Management and Employees

A.A.Directors and Senior Management.

The following table sets forth information regarding our Directors and Officers as ofSenior Management for the date of this Annual Report.most recent fiscal year.

29
NamePositionsAge

Date First Elected or

Appointed a

Director or Officer

Peter CopettiJean-Louis Malinge (1)(4)Executive Co-ChairmanDirector5170June 8, 2012September 5, 2017
Ajit Manocha Peter Charbonneau (1)(3)(5)Executive Co-Chairman and

Lead Independent Director

64July 7, 2014
Dr. Suresh VenkatesanChief Executive Officer and Director49June 11, 2015
Dr. Subhash DeshmukhChief Operating Officer54June 8, 2015
Kevin BarnesTreasurer and Chief Financial Officer44December 1, 2012
Stephane GagnonFormer Chief Operating Officer43November 14, 2013
Dr. Geoff TaylorFounder and Chief Scientist71April 2, 2013
John F. O’Donnell(2)(3)

Corporate Governance and Nominating Committee Chair and Director

6970February 14, 2012March 28, 2018
Dr. Suresh Venkatesan (4)

Chief Executive Officer and Chairman

Chair of Ad Hoc Strategy Committee

57June 11, 2015
Kevin BarnesVP Finance & Administration, Corporate Controller and Treasurer52December 1, 2012
Thomas R. MikaEVP & Chief Financial Officer72November 2, 2016
Vivek RajgarhiaPresident & General Manager56November 4, 2019
Chris Tsiofas (1)(2)(3)

Director

Audit and Committee Chair

56August 21, 2012
Glen Riley (2)(3)(4)

Director

Compensation Committee Chair and Director

48761August 21, 2012December 7, 2020
Todd A. DeBonis (2)Michal Lipson (3)(4)Director5153April 8, 2015October 14, 2022
David E. Lazovsky (1)Theresa Ende (2)(4)Director4467April 8, 2015October 14, 2022
Mohandas Warrior (1)Raju KankipatiDirectorSVP – Product Line Management & GM USA5545June 15, 2015May 1, 2022
Dr. Mo JinyuSVP, GM of Asia49January 1, 2022
Dr. Robert DitizioVP – Intellectual Property61December 1, 2021
Dan MeerovichVP – Product Engineering64March 2, 2020
Yong Meng (James) LeeVP & GM POET Technologies Pte. Ltd.52September 2, 2019

______________________

(1)Member of Audit Committee
(2)
(2)Member of Compensation Committee
(3)
(3)Member of Corporate Governance and Nominating Committee
(4)Member of Ad Hoc Strategy Committee
(5)Resigned from the Board on March 14, 2024

Mr. Peter Copettihas over 25 years of capital markets and management experience in key leadership roles. Since joining the company in 2012 he has been the chief architect and strategist leading the Company’s transformation in it’s Lab to Fab strategy, recently transitioning this role to the capable hands of Suresh Venkatesan, the company’s CEO, appointed in June 2015.     Historically, Mr. Copetti was personally responsible for the restructuring of both secured and unsecured debt, negotiated new equity infusion into the Company, and re-focused the Company on its original technical vision of monolithic opto-electronic integration, essentially creating today’s Company.  

Page 41

 

Mr. Ajit Manochahas over 35 years of experience in the semiconductor industry with deep knowledge of semiconductor technology and operations. He has worked in all aspects of the business including research, applied development, manufacturing, worldwide sales, to global supply chain and IT, and his most recent role has been as CEO of Global Foundries from June 2011 to January 2014. He has a wealth of experience by working in companies like AT&T, Bell Labs/Microelectronics, Philips Semiconductors (now known as NXP), Spansion, and Global Foundries. He has managed at various executive levels and successfully led very small organizations with fewer than 15 people to very large organizations with well over 25,000 people. He has also served on various boards as director and chairman. He is currently representing Global Foundries on the Semiconductor Industry Association Board and is also serving on the U.S. Presidential Committee for Advanced Manufacturing Partnership.

Dr. Deshmukh was VP Emerging Technologies and Products at Applied Materials Inc. He was also VP and General Manager of the Plasma products Business Unit as well as VP Business Development for Varian Semiconductor Equipment Associates Inc. Dr. Deshmukh holds a PhD in Chemical Sciences and has authored or co-authored over 55 technical articles. Dr. Deshmukh has been granted over 27 patents and has several patents pending.

Dr. Suresh Venkatesan as CEO. Prior to joining POET in 2015 as CEO, Dr. Venkatesan was most recentlythe Senior Vice President, Technology Development at Global FoundriesGlobalFoundries and was responsible for the company'sCompany’s Technology Research and Development. Dr. VenkatesanHe joined Global FoundriesGlobalFoundries in 2009, where he led the development and ramp up of the 28nm node and was instrumental in the technology transfer and qualification of 14nm. In addition, he was responsible for the qualification and ramp up of multiple mainstream value addedvalue-added technology nodes. Dr. Venkatesan is an industry veteran with over 22 years of experience in semiconductor technology development. Prior to joining GlobalFoundries, he held various leadership positions with Freescale Semiconductor in Austin, Texas. He holds over 25 US patents, and has co-authored over 50 technical papers. He earned a Bachelor of Technology degree in Electrical Engineering from the Indian Institute of Technology and a Master of Science and PhD degrees in Electrical Engineering from Purdue University.

Vivek Rajgarhia serves as President and General Manager. Before joining POET, Mr. Rajgarhia served as Senior Vice President & General Manager of the Lightwave Business Unit of MACOM (NASDAQ: MTSI). Mr. Rajgarhia joined MACOM through the acquisition of Optomai Inc., where he was the Co-Founder and CEO, to start MACOM’s first optical business. He was then instrumental in identifying and leading several strategic acquisitions to build an extensive portfolio of optical and photonic businesses, which formed MACOM’s Lightwave Business Unit. Mr. Rajgarhia has held several senior management positions during his 30 years in the optical communications industry. He was Director of Sales & Marketing (Asia) for Lucent Technologies’ (now Nokia) optical components, where he started Lucent’s Asia business; Vice President of Product Marketing and Business Development for OpNext (formerly Hitachi’s Fiber Optics Division), now Lumentum, where he was part of the team to spin-off the optical business from Hitachi; Director of Product Management & Marketing for JDS Uniphase (now Lumentum), and VP of Global Sales for GigOptix. Mr. Rajgarhia has been a successful entrepreneur, founding two optical companies, and has held international assignments in Hong Kong, Germany and India. He holds a Bachelor of Engineering (Electrical) degree from Stevens Institute of Technology in New Jersey.

Mr. Thomas Mika serves as EVP & CFO. Prior to joining POET, Mika served for one year as the Executive Chairman of Rennova Health, Inc., the successor company to CollabRx and its predecessor, Tegal Corporation, a semiconductor capital equipment company (NASDAQ: TGAL). On the Board of Directors of Tegal since its spin-out from Motorola in 1989, Mika assumed the roles of Chief Financial Officer in 2002, CEO in 2005 and Chairman & CEO in 2006, positions which he held until 2015. In 2015, Tegal merged with Rennova Health with Mika retaining the position of Chairman until joining POET in November 2016. In 1980, Mika co-founded IMTEC, a boutique M&A, investment and consulting firm, serving clients in the U.S., Europe and Japan over a period of 20 years, taking on the role of CEO in several ventures. Earlier in his career, Mika was a managing consultant with Cresap, McCormick & Paget and a policy analyst for the National Science Foundation. He holds a Bachelor of Science in Microbiology from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the Harvard Graduate School of Business.

Mr. Kevin Barneshas been serving as Corporate Controller and Treasurer since 2008 and briefly as Chief Financial Officer since December(2012 – 2016). Mr. Barnes holds a Master of 2012Business Administration and previously served as Controller beginning in 2008. Mr. Barnes is a member of the Institute of the Certified Management Accountants of Australia and an Accredited Chartered Secretary. Mr. Barnes served as a Corporate Controller and Business Performance Manager for EC English, one of the world’s largest language training institutes between 2006 and 2014. Mr. Barnes also servedserves as Chief Financial Officer of VVC Exploration Corporation, a minerals exploration company since 2006. From 2000 to 2006, he was a reporting manager with Duguay and Ringler Corporate Services, which specializes in financial reporting for publicly traded companies.

30Page 42

Mr. John F. O’Donnell

Dr. Mo Jinyu is a highly experienced technical and business veteran of the photonics and optoelectronics industries. Her expertise covers optical transmission system, advanced optical modulation format, tunable semiconductor lasers, DFB and FP lasers and PD/APD, optical transceiver modules and high-speed integrated packaging. Dr. Mo has more than 22 years of experience spanning several companies, including MACOM Technology Solutions, Bookham/Oclaro, Huawei, I2R in Singapore and Nexvave Photonics Technology Co., which she founded and served as Chief Technology Officer. Dr. Mo was most recently with MACOM as the Senior Director and Chief Scientist of the Lightwave business unit in Asia and site leader in Shenzhen. Dr. Mo received her PhD degree in Optical Communications from Nanyang Technological University (NTU) Singapore. She is a BA (Economics) and an LLB, has practiced law in the Citysenior member of Toronto since 1973IEEE and has been a member of IEEE’s Technical Committees for several international conferences. She has over 11 patents and more than 40 papers published in tier one journals and conferences.

Mr. Raju Kankipati brings over 20 years of experience in Optical transceivers, Optical components, Cloud data center and networks to POET. He was a Senior Director of Product Management at MACOM, focused on optical components and photonic solutions. Prior to that, Raju worked at Arista Networks as a Senior Product Manager and Engineering Manager. During this time he collaborated closely with data center customers to bring unique switching products as well as Optical transceivers to market, that helped customers deploy 40G and 100Gbps products for highly scalable and efficient networks. Raju worked as a Product Manager at Cisco prior to joining Arista. Raju started his career as an Optics Engineer at Opnext and later held various roles in sales and marketing at the Boardcompany. Raju received his MBA degree from UC Berkeley (Haas School of DirectorsBusiness) and completed his Bachelor of the Company since February of 2012. He is currently counsel to Stikeman Keeley Spiegel Pasternack LLP. His practice is primarilyEngineering in the field of corporate and securities law and, as such, he is and has been counsel to several publicly traded companies. Mr. O’Donnell is currently also Chairman of the Board of Montana Gold Mining Company Inc. (MGM: CSE).Electronics from BITS, Pilani in India.

Mr. Chris Tsiofas,, CA, CPA, earned a Bachelor’s of Commerce Degree from the University of Toronto in 1991 and has beenis a member of the Institute of Chartered Professional Accountants of Ontario since 1993.Canada and the Canadian Tax Foundation. He has been on the Board of Directors since August of 2012.2012 and has served as the Chair of the Audit Committee during his entire tenure In February 2024 he was appointed to the Board of Directors of Andrew Peller Limited (TSE:ADW) and serves as the Chair of the Audit and Pension Committees. Andrew Peller Ltd. is a leading producer and marketer of quality wines and craft beverage alcohol products in Canada. With wineries in British Columbia, Ontario, and Nova Scotia, the Company markets wines produced from grapes grown in Ontario’s Niagara Peninsula, British Columbia’s Okanagan and Similkameen Valleys, and from vineyards around the world. He is the president of MTN Chartered Professional Accountant Professional Corporation, a public accountancy firm. He sits on various private company boards. He has also served in a principal capacity in various entrepreneurial ventures resulting in successful divestitures

Mr. Jean-Louis Malinge recently retired as partner with ARCH Venture Partners, an early-stage venture capital firm with nearly $2 billion under management. Additionally, he is a board member of EGIDE SA, CAILabs and Aeponyx. EGIDE SA is a public French company which designs, manufactures and sells hermetic packages for the Toronto Chartered Accountancy firmprotection and interconnection of Myers Tsiofas Norheim LLP,several types of electronic and photonic chips. CAIlabs is a positionventure-backed French innovative start-up founded in 2013 which has developed a unique spatial multiplexing platform. Aeponyx is a venture-backed Canadian innovative start-up which develops a platform combining Silicon Nitride waveguides with planar MEMS for photonics components. From 2004 to 2013 Jean-Louis was President and CEO of Kotura, a Silicon Photonics pioneer which was acquired in 2013 by Mellanox Technologies. Prior to Kotura, Mr. Malinge was an executive with Corning Inc for 15 years. Jean-Louis hold an Executive M.B.A. from MIT Sloan School in Boston, Massachusetts. He also holds an engineering degree from the Institut National des Sciences Appliquées in Rennes, France.

Mr. Peter Charbonneau was a general partner at Skypoint Capital Corporation for almost 15 years, where he has held since 1994.

Dr. Geoff Tayloris Chief Scientist atwas jointly responsible for the Companyplacement of $100 million of capital in early-stage telecommunications and has led developmentdata communication companies Mr. Charbonneau currently serves on the board of Surgical Safety Technologies Inc. an early stage start up that uses clinically trained deep learning systems to perform advanced analytics on hospital data. He recently served on the Board of Mitel Networks Corporation, a leading global provider of cloud and on-site business communications until November 2018 when it was sold to a private equity firm. He previously served as Chairman of the POET platform since 2000, directingBoard of Trustees for the CBC Pension Board and a focused team atdirector on the ODIS subsidiaryboard of the Company. Dr. Taylor has a technical background made-up of 30 years of design and development experience in electronic and optical device physics, circuit design, opto-electronic technology, materials and applications. He is concurrently a Professor of Electrical Engineering and Photonics at the University of Connecticut, a position he has held since 1994, and is responsible for ODIS’ development efforts at the GaAs growth and fabrication facility. With over 150 papers in industry and scholarly respected journals, and dozens of patents, Dr. Taylor is widely regarded as a leading authority on GaAs solid-state physics, III-V opto-technology,Canadian Broadcasting Corporation as well as many technology and networking companies, including March Networks Corporation, TELUS Corporation, Breconridge Corporation and Dragonwave Incorporated.

Page 43

Mr. Yong Meng (James Lee) is General Manager of the Company’s Singapore subsidiary. Prior to his appointment in 2019, Mr. Lee was Vice President of Logic Technology at IMEC where he was responsible for defining the logic roadmap and developing the technology elements necessary to extend scaling with ultra-scaled FinFET, GAA devices, advanced metallization as well novel materials for emerging devices and quantum computing. Mr. Lee joined IMEC in 2015 where he was instrumental in driving collaborations with the foundries in China and was responsible for bringing in >100M euros of research partnership. Prior to IMEC, Mr. Lee had a pioneer19-year career with GLOBALFOUNDRIES where he held various technical and management positions spanning the US and Singapore focused on developing, qualifying and ramping leading edge CMOS technology in the developmentfoundry. He has over 60 patents and holds a Bachelor of monolithic integrated opto-electronic circuits. Dr. Taylor has a B.Sc from Queen’s University, and an M.A.Sc. and Ph.D.Engineering degree from the University of Toronto.Illinois at Champaign-Urbana.

Todd A. DeBonisis a veteranMr. Glen Riley has more than 30 years’ experience in leadership roles spanning both the semiconductor executive with over 27 yearsand optoelectronics industries. He most recently served as General Manager of expertisethe Filter Solutions Business Unit at Qorvo, where he was responsible for developing highly integrated RF modules used in sales, marketingflagship smartphones. Prior to the merger of RFMD and corporate development. ForTriQuint that formed Qorvo, he held multiple leadership roles at TriQuint, including Managing Director of international headquarters in Singapore, General Manager of the last decade Mr. DeBonisGaAs foundry business, and General Manager of Optoelectronics. Riley was previously the Chief Executive Officer of Opticalis, an early stage optoelectronics company focused on the development of high-density wavelength division multiplexing products. He also held prior roles as Vice President and General Manager of Global Salesthe Optoelectronic business at Agere Systems, and Strategic Development at TriQuint Semiconductor. Mr. DeBonis played an integral part in the recent mergerPresident of TriQuint with RFMD and subsequent creation of Qorvo, Inc. Mr. DeBonis previously held the position of Vice President, WorldwideAsia-Pacific Sales and Marketing at Centillium Communications. Mr. DeBonis also servedLucent Technologies Microelectronics Group. He graduated as the Vice President, Worldwide Sales for Ishoni Networks and Vice President, Sales & Marketing for the Communications Division of Infineon Technologies North America. Mr. DeBonis hasvaledictorian with a B.S. degree in Electrical Engineering from the School of Engineering at the University of Nevada.Maine and completed the General Manager Program at Harvard Business School.

David E. LazovskyMs. Theresa Ende serves as Chief Procurement Director of Arista Networks. Prior to her appointment as Chief Procurement Director in 2019, Ms. Ende served for 10 years as its Senior Director of Global Supply Chain Management. Prior to Arista, she held senior positions at JDSU Optical Division and Force10 Networks. At Cisco Systems and ROLM Telecommunications, Ms. Ende held various program management and planning management positions over a 20-year period. In 2019, she was honored as one of the “Top 100 Women of Influence” by Silicon Valley Business Journal.

Professor Michal Lipson currently serves as a Eugene Higgins Professor of Electrical Engineering and Professor of Applied Physics at Columbia University. Her research focus is on Nanophotonics and includes the investigation of novel phenomena, as well as the development of novel devices and applications. Professor Lipson pioneered critical building blocks in the field of Silicon Photonics, which today is recognized as one of the most promising directions for solving the major bottlenecks in microelectronics. She is the founderinventor of Intermolecularover 45 issued patents and served as the company’s President and Chief Executive Officer andhas co-authored more than 250 scientific publications. In recognition of her work in silicon photonics, she was elected as a member of the boardNational Academy of directorsSciences and the American Academy of Arts and Sciences. She was also awarded the NAS Comstock Prize in Physics, the MacArthur Fellowship, the Blavatnik Award, the Optical Society’s R. W. Wood Prize, the IEEE Photonics Award, and has received an honorary degree from September 2004Trinity College, University of Dublin. In 2020, she was elected the 2021 Vice President of The Optical Society and will serve as OSA President in 2023. Since 2014, every year, she has been named by Thomson Reuters as a top 1% highly cited researcher in the field of Physics.

Dr. Robert Ditizio joined POET Technologies Inc. as a consultant in 2017, assisting with the development of the Company’s Intellectual Property portfolio for the Optical Interposer platform. Dr. Ditizio was appointed Vice President in December 2021. He brings to October 2014. Mr. Lazovsky hasPOET over 20 years of IP portfolio management expertise and an in-depthexpansive knowledge of materials and semiconductor processing technology.

Prior to his work with POET Technologies, Dr. Ditizio played an instrumental role in the development of manufacturing and processing equipment for companies in the semiconductor industry, technologyincluding plasma reactors and markets. Priorcluster tool platforms for advanced etching and deposition processes in a range of engineering positions, culminating as Chief Technologist of Tegal Corporation. In addition to founding Intermolecular, equipment development, he also led the development of numerous semiconductor patterning applications including non-volatile memory etch applications, through silicon via applications, and compound semiconductor etch applications, among many others, and the development of deposition applications including CVD of polymeric films and pulsed CVD and ALD of barrier layers and complex stoichiometric films. Dr. Ditizio holds 10 patents in these areas and has published numerous technical papers. He holds BS, MS, and PhD degrees in Engineering Science from Pennsylvania State University and an MBA from the Sonoma State University.

Page 44

Mr. Lazovsky held several senior management positions at Applied Materials (NASDAQ: AMAT). From 1996 through August 2004, Mr. Lazovsky held management positions in the Metal Deposition and Thin Films Product Business Group where he was responsible for managingDan Meerovich brings to POET more than $1 billion30 years of experience in Applied Materials’ semiconductordeveloping and manufacturing equipment business. From 2003 until 2004, Mr. Lazovsky managed key strategic accounts in Business Management, where he worked closely with leading integrated circuit manufacturers. From 2002 until 2003, Mr. Lazovsky served asinnovative photonics products at MACOM, Apogee (now Broadcom), Oclaro, Multiplex (now Hisense) and JDS Uniphase. As the Technology Program Manager for the Endura 2 Platform, Applied Materials’ 300mm metal deposition platform. From 2000 until 2002. Mr. Lazovsky was based in Grenoble, France and served as Director of Product Engineering for MACOM’s Lightwave Business Management for the European region in the Metal Deposition Product Business Group. Previously, Mr. Lazovsky served as a Business Manager from 1997 to 2000 and Account Product Manager from 1995 to 1997. Mr. Lazovsky holds a B.S. in mechanical engineering from Ohio University and, as of March 31, 2014, held 41 pending or issued U.S. patents.

Mr. Mohan Warriorhas been president and chief executive officer (CEO) of Alfalight Inc. (“Alfalight”) since February 2004. Alfalight is a GaAs based high power diode laser manufacturing company with headquarters in Madison, Wisconsin. Alfalight serves military, telecom and industrial customers. Mr. Warrior established Alfalight as a leading provider of high powered laser diode solutions in both commercial and defense segments. Prior to joining Alfalight, Mr. Warrior's career included 15 years at Motorola Semiconductors (now Freescale) whereUnit, he led the test, product and assemblyprocess engineering for lasers, photodetectors, AWG waveguides, optical engines and silicon photonic PICs. Dan developed the low-cost and scalable process of laser integration onto silicon photonic integrated circuits.

Dan has set up wafer fabrication facilities, run manufacturing operations at Multiplex and Xtellus (acquired by Oclaro) and built and managed a groupChina-based manufacturing subsidiary acquired by Hisense. In addition, Dan set up and managed contract manufacturers to scale production of 3500 employees,both high performance and low-cost optical modules. Earlier in his career, Dan led the US, Scotlanddevelopment of photonic engines incorporating high speed lasers and Korea.EMLs, including the first uncooled EML module in a low cost TO platform. The company, Apogee, was later acquired by Cyoptics which was then acquired by Broadcom. Dan holds BSEE and MBA degrees from Rutgers University.

The Directors, unless otherwise noted above, have served in their respective capacities since their election and/or appointment, unless otherwise noted above, and will serve until the next Company’s annual general meeting or until a successor is duly elected, unless the office is vacated in accordance with the Articles of Continuance.

31

The Board has adopted a written Code of Business Conduct and Ethics to promote a culture of ethical business conduct and relies upon the selection of persons as directors, senior management and employees who they consider to meet the highest ethical standards. The Company’s Code of Business Ethics can be found on the Company’s web site at: www.poet-technologies.com.www.poet-technologies.com.

There are no family relationships between any of our Directors or senior management. There are no arrangements or understandings with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a Director or member of senior management, except that in connection with the entry into of a financing arrangement between the Company and IBK Capital Corporation in 2012, Mr. Copetti was appointed a Director of the Company on June 8, 2012.management.

B.B.Compensation.

Fixed Stock Option Plan

On September 21, 2007, the Directors approved a fixed 20% vesting Stock Option Plan (the “Plan”) to replace the Rolling Stock Option Plan whichthat had been in effect since May 4, 2005. The Plan was approved by the disinterested shareholders of the Company at the Shareholders’ Meeting of June 19, 2008 and accepted for filing by the TSXV. Under the Plan, the maximum number of shares (the “Maximum Number”) which may be issued pursuant to options granted under the Plan or otherwise granted cannot exceed 20% of the issued and outstanding shares. The shareholders fixed the Maximum Number at 11,930,000.1,193,000. Thereafter, the Plan has been amended by the Directors, and such amendments have been approved by the shareholders in 2009, 2011, 2013, 2014, 2015, 2016, 2018, 2020 and 2015.2021.

Omnibus Plan

On June 30, 2023, shareholders of the Company approved a fixed 20% omnibus equity incentive plan (the “Omnibus Plan”). The Maximum Number is currently 36,326,000 shares.Omnibus Plan replaces the 2021 stock option plan. The Omnibus Plan provides flexibility to the Company to grant different forms of equity-based incentive awards to directors, officers, employees and consultants. The Omnibus plan provides the Company with the choice of granting stock options, share units and deferred share units.

The purpose of the Omnibus Plan is to assist the Company in attracting, retaining and motivating directors, employees and consultants of the Company and any of its subsidiaries and to closely align the personal interests of such directors, employees and consultants with those of the shareholders by providing them with the opportunity, through options, to acquire common shares in the capital of the Company.

Page 45

 

The Omnibus Plan provides that the maximum number of common shares issuable pursuant to optionsawards granted under the Omnibus Plan and pursuant to other previously granted optionsawards is limited to the Maximum Number, currently fixed at 36,326,000.8,056,055. Any subsequent increase in the Maximum Number Reserved must be approved by shareholders of the Company and cannot, exceed 20% of the issued and outstanding shares of the Company at the time of the shareholders’ approval.increase, exceed 20% of the number of issued and outstanding shares. Awards vest in accordance with the policies determined by the Board of Directors from time to time consistent with the provisions of the Omnibus Plan which grants discretion to the Board of Directors. There is no other limit to the number of options granted to any individual, except for:

(i) 2% on a yearly basis to any one consultant and (ii) 2% on a yearly basis to any employee providing “Investor Relations Activities.”

The following paragraphs summarize some of the terms of the Omnibus Plan:

Options

An Option is an option granted by the Corporation to a Participant entitling such Participant to acquire a designated number of Shares from treasury at an exercise price set at the time of grant (the “Option Price”). Options are exercisable, subject to vesting criteria established by the Board at the time of grant as set out in the Participant’s option agreement (“Option Agreement”). Each Option shall be exercisable at such time or times and/or pursuant to the achievement of such Performance Criteria and/or other vesting conditions as the Board at the time of granting the particular Option, may determine in its sole discretion. The Board shall determine, at the time of granting the particular Option, the period during which the Option is exercisable, which shall not be more than ten (10) years from the date the Option is granted. Notwithstanding the expiration provisions hereof, if the date on which an Option Term expires falls within a Blackout Period or within nine Business Days after a Blackout Period Expiry Date, the expiration date of the Option will be the date that is ten Business Days after the Blackout Period Expiry Date. The Blackout Period must expire following the general disclosure of the undisclosed material information; provided that if an additional Blackout Period is subsequently imposed by the Corporation during the ten Business Days after the initial Blackout Period, then Blackout Period Expiry Date shall be such the tenth trading day following the end of the last imposed Blackout Period. The Omnibus Plan also permits the Board to grant an option holder, at any time, the right to deal with such Option on a cashless exercise basis, in whole or in part by notice in writing to the Corporation, where the Corporation has an arrangement with a brokerage firm that certain procedures must take place. The Omnibus Plan also permits the Board to grant an Option holder, at any time the right to deal with such Option on a net exercise mechanism, in whole or in part by notice in writing to the Corporation. The grant of an Option by the Board shall be evidenced by an Option Agreement.

Share Units

A Share Unit is an Award in the nature of a bonus for services rendered, or for future services to be rendered, and that, upon settlement, entitles the recipient Participant to acquire to receive a cash payment equal to the Market Value of a Share or at the discretion of the Corporation (or applicable Subsidiary) one Share or any combination of cash and Shares as the Corporation (or applicable Subsidiary) in its sole discretion may determine, pursuant and subject to such restrictions and conditions on vesting as the Board may determine at the time of grant, unless such Share Unit expires prior to being settled. Restrictions and conditions on vesting conditions may, without limitation, be based on the passage of time during continued employment (or other service relationship), in which case the Award is what is commonly referred to as a “Restricted Share Unit” or “RSU”, or the achievement of specified Performance Criteria, in which case the Award is what is commonly referred to as a “Performance Share Unit” or “PSU”, or both. The grant of a Share Unit by the Board shall be evidenced by a Share Unit Agreement. 22 The Board shall have sole discretion to determine if any Performance Criteria and/or other vesting conditions with respect to a Share Unit, and as contained in the Share Unit Agreement governing such Share Unit, have been met and shall communicate to a Participant as soon as reasonably practicable when any such applicable vesting conditions or Performance Criteria have been satisfied and the Share Units have vested. Notwithstanding the foregoing, if the date on which any Share Units have vested falls within a Blackout Period (as defined in the Omnibus Plan) or within nine Business Days (as defined in the Omnibus Plan) after a Blackout Period Expiry Date (as defined in the Omnibus Plan), the vesting of such Share Units will be deemed to occur on the date that is ten Business Days after the Blackout Period Expiry Date. The Blackout Period must expire following the general disclosure of the undisclosed material information; provided that if an additional Blackout Period is subsequently imposed by the Corporation during the ten Business Days after the initial Blackout Period, then Blackout Period Expiry Date shall be such the tenth trading day following the end of the last imposed Blackout Period. Subject to the vesting and other conditions and provisions in the Plan and in the Share Unit Agreement, each Share Unit awarded to a Participant shall entitle the Participant to receive on settlement, a cash payment equal to the Market Value of a Share or at the discretion of the Corporation (or applicable Subsidiary) one Share or any combination of cash and Shares as the Corporation (or applicable Subsidiary) in its sole discretion may determine, in each case less any applicable withholding taxes. Dividend Equivalents may, as determined by the Board in its sole discretion, be awarded in respect of unvested Share Units in a Participant’s Account on the same basis as cash dividends declared and paid on Shares as if the Participant was a Shareholder of record of Shares on the relevant record date. In the event that the Participant’s applicable Share Units do not vest, all Dividend Equivalents, if any, associated with such Share Units will be forfeited by the Participant and returned to the Corporation’s account.

Page 46

 

Eligibility. Options

Deferred Share Units

A deferred share unit (“DSU”) is an Award in the nature of a deferral of payment for services rendered, or for future services to be rendered, and that, upon settlement, entitles the recipient Participant to receive cash or acquire Shares, as determined by the Corporation in its sole discretion, unless such DSU expires prior to being settled. Subject to adjustments and amendments in the Plan, DSUs shall only vest, and a Participant is only entitled to redemption of a DSU, when the Participant ceases to be a director, officer or employee of the Corporation for any reason, including termination, retirement or death. The grant of a DSU by the Board shall be evidenced by a DSU Agreement. DSUs will be fully vested on the Termination Date of the applicable Participant. Notwithstanding the foregoing, if the date on which any DSUs have vested falls within a Blackout Period or within nine Business Days after a Blackout Period Expiry Date, the vesting of such DSUs will be deemed to occur on the date that is ten Business Days after the Blackout Period Expiry Date. The Blackout Period must expire following the general disclosure of the undisclosed material information; provided that if an additional Blackout Period is subsequently imposed by the Corporation during the ten Business Days after the initial Blackout Period, then Blackout Period Expiry Date shall be such the tenth trading day following the end of the last imposed Blackout Period. Subject to the vesting and other conditions and provisions in the Plan and in any DSU Agreement, each DSU awarded to a Participant the Participant to receive on settlement a cash payment equal to the Market Value of a Share, or at the discretion of the Corporation, one Share or any combination of cash and Shares as the Corporation in its sole discretion may determine. DSUs shall be redeemed and settled by the Corporation as soon as reasonably practicable following the Participant ceasing to be a director, officer or employee of the Corporation but in any event not later than December 15 of the year following the calendar year in which the Participant ceases to be any of a director, officer or employee. On redemption and settlement, the Corporation shall deliver the applicable number of Shares, or, in the sole discretion of the Corporation, cash equal to the redemption amount of such DSU specified in the applicable DSU Agreement, subject to the satisfaction of any applicable withholding tax.

Eligibility.

Awards may be granted under the Omnibus Plan to directors, employees, consultants and consultant companies of the Company and any of its subsidiaries. Stock Options may also be granted to individuals referred to as “Management Company Employees” which are employed by a company providing management services to the Company, except for services involving “Investor Relations Activities.”

Omnibus Plan Administration. Administration.

The Plan shall be administered and interpreted by the board of directors of the Corporation (the “Board”) or, if the Board of Directors is theby resolution so decides, by a committee or plan administrator subjectappointed by the Board. Subject to the adviceterms of the Plan, applicable law and recommendationsthe rules of our Compensation Committee. The plan administratorthe Exchanges, the Board (or its delegate) will have the power and authority to: (i) designate the Eligible Participants who will receive Awards (an Eligible Participant who receives an Award, a “Participant”), (ii) fix the number of Awards, if any, to be granted to each Eligible Participant and the date or dates on which such Awards shall be granted, (iii) determine the provisions and terms and conditions of each grant.any Award, including any vesting conditions or conditions based on performance of the Corporation or of an individual (“Performance Criteria”); and (iv) and make such amendments to the Plan and Awards made under the Plan as are permitted by the Plan and the rules of the Exchanges

Page 47

 

Exercise Price. Price.

The exercise price subject to an optionaward shall be determined by the Board and set forth in the option agreement, but shall be either (i) not less than the last closing price of the Company’s common shares as traded on the TSXV, unless discounted by the Board or (ii) such other price agreed by the Board and accepted by the TSXV. Except in certain circumstance,

Amendment

The Board may suspend or terminate the Company canOmnibus Plan at any time, or from time to time amend or revise the other terms of a stock option only wherethe Plan or any granted Award without the consent of the Participants provided that such suspension, termination, amendment or revision shall:

(a) not adversely alter or impair the rights of any Participant, without the consent of such Participant except as permitted by the provisions of the Omnibus Plan; and

(b) be in compliance with applicable law and with the prior TSXV acceptance is obtainedapproval, if required, of the shareholders of the Corporation, the Exchanges, or any other regulatory body having authority over the Corporation.

Subject to the terms of the Omnibus Plan, the Board may, from time to time, in its absolute discretion and wherewithout approval of the shareholders of the Corporation make the following amendments to the Omnibus Plan, unless where required by law or the requirements are met:of the Exchanges:

(i)if the amendment is in respect of an option held by an insider of the Company, but excluding amendments to extend the length of the stock option term, the Company obtains disinterested shareholder approval;
(ii)if the option exercise price is amended, at least six months have elapsed since the later of the date of commencement of the term, the date the Company’s shares commenced trading, or the date the option exercise price was last amended;
(iii)if the option price is amended to the discounted market price, the exchange hold period is applied from the date of the amendment (and for more certainty where the option price is amended to the market price, the exchange hold period will not apply); and
(iv)if the length of the stock option term is amended, any extension of the length of the term of the stock option is treated as a grant of a new option, and therefore the amended option must comply with the pricing and other requirements of the policy as if it were a newly granted option. The term of an option cannot be extended so that the effective term of the option exceeds 10 years in total. An option must be outstanding for at least one year before the Company can extend its term.

(a) any amendment to the vesting provision, if applicable, of Options or Share Units, or assignability provisions of the Awards;

32

The TSXV must accept

(b) any amendment to the expiration date of an Award that does not extend the terms of the Award past the original date of expiration of such Award;

(c) any amendment regarding the effect of termination of a proposedParticipant’s employment or engagement;

(d) any amendment beforewhich accelerates the optiondate on which any Option may be exercised under the Plan;

(e) any amendment necessary to comply with applicable law or the requirements of the Exchanges or any other regulatory body;

(f) any amendment to clarify the meaning of an existing provision of the Omnibus Plan, correct or supplement any provision of the Omnibus Plan that is inconsistent with any other provision of the Plan, correct any grammatical or typographical errors or amend the definitions in the Plan;

(g) any amendment regarding the administration of the Omnibus Plan;

(h) any amendment to add provisions permitting the grant of Awards settled otherwise than with Shares issued from treasury, or adopt a clawback provision applicable to equity compensation; and

(i) any other amendment that does not require the approval of the shareholders of the Corporation as amended. Ifoutlined in the Company cancels a stock option and within one year grants new optionsparagraph below.

Page 48

The Board shall be required to obtain disinterested shareholder approval, if required under the rules of the Exchanges, to make the following amendments:

(a) an increase in the maximum number of Shares issuable under the Plan, except in the event of an adjustment pursuant to the same individual,Omnibus Plan;

(b) except in accordance with the new options willterms of the Omnibus Plan, any amendment which reduces the exercise price of an Option or any cancellation of an Option and replacement of such Option with an Option with a lower exercise price;

(c) any amendment reduction in the price of an Option or extension of the term of an Option if the

Participant is an Insider of the Corporation at the time of the proposed amendment;

(d) any amendment which extends the expiry date of any Award, or the Restriction Period of any Share Unit beyond the original expiry date or Restriction Period;

(e) any amendment which increases the maximum number of Shares that may be subjectissuable under the Plan and any other proposed or established Share Compensation Arrangement; and;

(f) any amendment to the requirements in sections (i) to (iv) above.

Option Agreement. Options granteddefinition of Eligible Participant under the plan are evidencedPlan, provided that Shares held directly or indirectly by an option agreement that sets forthInsiders benefiting from the terms, conditions and limitations for each grant.amendments shall be excluded when obtaining such shareholder approval.

Term of the Awards. The term of each option grant shall be stated in the option agreement, provided that the term shall not exceed 10 years from the date of the grant. Prior to May 21, 2009, the term was limited to 5 years.Awards. At the meeting of the Board of Directors held on February 25, 2016, based on the report of Compensia, it was determined that in the future, stock options should generally have a term of 10 yearsyears.

Vesting Schedule.Schedule. In general, options recently granted under the Omnibus Plan vest 25% immediately and 25% every six months from the date of issue, until fully vested; provided, however, that thevested. The directors may, at their discretion, specify a different vesting period, provided that options granted to consultants performing “Investor Relations Activities” must vest in stages over 12 months with no more than 25% of the options vesting in any three monththree-month period. Prior to May 21, 2009, vesting was mandatory for all option grants.AtAt the meeting of the Board of Directors held on February 25, 2016, based on the report of Compensia, it was determined that in the future, stock options should vest 25% at the end of one year from the date of issue with the remaining 75% vesting equally on a quarterly basis over the remaining 3 years for a total vesting period of 4 years. At a meeting of the Board of Directors held on March 30, 2017, the board approved a revised one-year vesting schedule for options granted for service on the board to conform to the term for which a director is elected. Such options will vest 25% at the end of each quarter served in office.

Transfer Restrictions. OptionsAssignment

Each Award granted under the Omnibus Plan mayis personal to the Participant and shall not be transferred in any mannerassignable or transferable by the option holder other thanParticipant, whether voluntarily or by operation of law, except by will or by the laws of succession and may be exercised during the lifetime of the option holder only bydomicile of the option holder. Securities that aredeceased Participant. No Award granted hereunder shall be pledged, hypothecated, charged, transferred, assigned or otherwise encumbered or disposed of on pain of nullity.

Change of Control

In the event of a potential Change of Control (as described in the Omnibus Plan) the Board will have the power, in its sole discretion, to modify the terms of the Plan and/or the Awards to assist the Participants to tender into a take-over bid or participating in any other transaction leading to a Change of Control. For greater certainty, in the event of a take-over bid or any other transaction leading to a Change of Control, the Board shall have the power, in its sole discretion, subject to restrictions may not be transferred duringany required approval of the periodExchanges to (i) provide that any or all Awards shall thereupon terminate, provided that any such outstanding Awards that have vested shall remain exercisable until consummation of restriction.

such Change of Control, and Alteration(ii) permit Participants to conditionally exercise their vested Options, such conditional exercise to be conditional upon the take-up by such offeror of Capitalthe Shares or other securities tendered to such take-over bid in accordance with the terms of such take-over bid (or the effectiveness of such other transaction leading to a Change of Control). The Plan provides that ifIf the Corporation completes a transaction constituting a Change of Control as defined herein, occurs,and within twelve (12) months following the shares subjectChange of Control a Participant who was also an Officer or Employee of, or Consultant to, optionthe Corporation prior to the Change of Control has their position, employment or consulting agreement terminated, or the Participant is constructively dismissed, then all unvested Awards of the Participant shall immediately vest and become vestedexercisable, and may thereupon be exercised in whole or in part byremain open for exercise until the option holder. The Plan also provides for automatic adjustmentsearlier of their expiry date as set out in the number of optioned shares and/Award Agreement and the date that is twelve (12) months after such termination or the exercised price, in the event of an alteration in the share capital of the Company.dismissal.

Page 49

 

Termination of Options. Options.

In the event that the award recipient ceases employment with us or ceases to provide services to us, the options will terminate after a period of time following the termination of employment. Our Board of Directors has the authority to amend or terminate the plan subject to shareholder approval with respect to certain amendments. However, no such action may adversely affect in any material way any awards previously granted unless agreed upon by the recipient.

Officer Compensation

Total cash compensation accrued and/or paid (directly and/or indirectly) to all of our Officers during fiscal year 2023 was $2,083,669 (refer to ITEMItem 7. “Major Shareholders and Related Party Transactions” for information regarding indirect payments) to all of our Officers during fiscal year 2015 was $1,979,601.

In order to assist the Board of Directors in fulfilling its oversight responsibilities with respect to human resources matters, the Board established a Compensation Committee. The Compensation Committee reviews and makes determinations with respect to senior officer compensation on a regular basis with any discretionary compensation used only for extraordinary projects or significant milestone results that advance the Company’s growth potential. When determining Executive Officers’ compensation, the Compensation Committee receives input and guidance from the Executive Co-ChairmenChairman of the Board and the Chief Executive Officer of the Company.TheCompany. In the past, the Compensation Committee has engaged Compensiaan outside consultant to conduct a Peer Grouppeer group review that was prepared with the input of the CEO. A draft Peer Group was circulated and the CEO felt it was appropriate. Compensia has givento provide guidance to the Compensation Committee with respect to appropriate comparative terms for its incentiveexecutive compensation and stock option plan. Once this Peer Group is finalized, the second component of the engagement is a comparativegrants. The Company also utilizes peer group comparisons from subsidiary locations to assist in its salary review of 12various positions relative to the Peer Group.in those locations. The Compensation Committee will utilize theutilizes such comparative reviews to assist it in making appropriate recommendations.recommendations to the Board.

In addition to his or her fixed base salary, each officer may be eligible to receive variable pay compensation or bonus meant to motivate him or her to achieve short-termshort- term goals. Currently, the Company does not have in place established procedures for determining variable pay compensation. Stock options are a veryan important element of the variable pay compensation and do not require cash disbursement from the Company. Stock options are also generally awarded to officers, qualifying employees and consultants at the time of hire and are used as a recruitment tool to attract highly qualified and experienced executives, employees and consultants to the Company. Stock options are also granted at other times during the year. As the Company is still continuing to develop its POETOptical Interposer technology, it must conserve its limited financial resources and control costs to ensure that funds are available when needed to complete its scheduled developments. As a result, the Board of Directors has to considerCompensation Committee generally considers not only the financial situation of the Company at the time of the determination of the compensation, but also the estimated financial situation in the mid- and long-term. Also the granting of stock options aligns officers’ rewards with an increase in shareholder value over the long term. The use of stock options encourages and rewards performance by aligning an increase in each officer’s compensation with increases in the Company’s performance and in the value of the shareholders’ investments.shareholder value.

The following table sets forth all annual and long termlong-term compensation for services in all capacities to the Company for fiscal year 20152023 of the Company.

           

Options Based

Awards (1)(2)

  

Non-Equity Incentive Plan

Compensation

    

Name and Principal Position

 

Fiscal

Year

  Salary (2)  

Share-Based

Awards

(1) (2)

  

No. of

Options

  

Value of

Options

(1) (2)

  

Annual

Incentive

Plans

  

Long-term

Incentive

Plans

  

Pension

Value

  

All

other

Comp.

  

Total

Comp.

 
Dr. Suresh Venkatesan  2023  $462,000           -   100,000  $341,441   -   -   -   -  $803,441 
Thomas Mika  2023  $330,000   -   75,000  $256,081   -   -   -   -  $586,081 
Vivek Rajgarhia  2023  $325,762   -   50,000  $170,720   -   -   -   -  $496,482 
Mo Jinyu  2023  $261,667   -   50,000  $170,720   -   -   -   -  $432,387 
Raju Kankipati  2023  $240,000   -   50,000  $170,720   -   -   -   -  $410,720 
James Lee  2023  $225,750   -   50,000  $170,720   -   -   -   -  $396,470 
Dan Meerovich  2023  $211,909   -   40,000  $136,576   -   -   -   -  $348,485 
Kevin Barnes  2023  $199,740   -   40,000  $136,576   -   -   -   -  $336,316 

Robert Ditizio

  2023  $225,761   -   15,000  $51,216   -   -   -   -  $276,977 

33
        Options-Based
Awards(1)(2)
 Non-Equity Incentive Plan Compensation      
Name and Principal Position Fiscal
Year
 Salary
(2)
(US$)
 Share-
Based
Awards
(1)(2)
(US$)
 No. of
Options
 (US$) Annual
Incentive
Plans
 Long-
term
Incentive
Plans
 Pension
Value
(US$)
 All
Other
Comp.
(US$)
 Total
Comp.
(US$)
Peter Copetti
Executive Co- Chairman
  2015   391,650      200,000   188,885               580,535 
Ajit Manocha
Executive Co-Chairman
  2015   500,000      200,000   188,885               688,885 
Dr. Suresh Venkatesan(3)
Chief Executive Officer
  2015   306,378      6,357,000   5,421,577               5,727,955 
Dr. Subhash Deshmukh(4)
Chief Operating Officer
  2015   141,186      1,500,000   1,508,884               1,650,070 
Kevin Barnes
Treasurer and CFO
  2015   84,596      75,000   60,444               145,040 
Stephane Gagnon(6)
Former Chief Operating Officer
  2015   84,795                        84,795 
Daniel DeSimone(5)
Former Chief Technical Officer
  2015   160,977      540,000   348,080               509,057 

______________________

(1)The Company used the Black-Scholes model as the methodology to calculate the grant date fair value. The fair value will be recorded as an operating expense as the stock options vest based on the stock options vesting schedule from the date of grant.
(2)
(2)The exchange rate used in these calculations to convert CAD to USD is based on the average exchange rate applicable atfor the date of grant.
(3)Dr. Venkatesan was appointed as the Chief Executive Officer on June 11, 2015.
(4)Dr. Deshmukh was appointed as Chief Operation Officer on June 8, 2015
(5)Mr. DeSimone ceased his role as Chief Technical Officer on June 8, 2015.
(6)Mr. Gagnon ceased employment with the Company on June 30, 2015.year ended December 31, 2023 being 0.7408.

34Page 50

The following table sets forth information concerning all awards outstanding under a stock option plan to each of the current officers, as of December 31, 2015:2023:

    Option-based Awards Share-based Awards
First Name Last Name 

Number of

Securities

Underlying

Unexercised

Options

  

Option

Exercise

Price

 

Option

Expiration

Date

 

Value of

Unexercised

in-the-money

Options (1)

 

Number of

Shares or

Units of

Shares that

have not

Vested

 

Market or

Payout

Value of

Shares or

Units of

Shares that

have not

Vested

 

Market or

Payout

Value of

Vested

Shares or

Units of

Shares that

have not

Paid Out or

Distributed

Kevin Barnes  24,500  $2.65  CAD 13-Dec-2028 $0.00  USD N/A N/A N/A N/A N/A
Kevin Barnes  23,400  $2.80  CAD 13-Jul-2027 $0.00  USD N/A N/A N/A N/A N/A
Kevin Barnes  50,000  $3.70  CAD 15-Jan-2030 $0.00  USD N/A N/A N/A N/A N/A
Kevin Barnes  50,000  $3.80  CAD 29-May-2029 $0.00  USD N/A N/A N/A N/A N/A
Kevin Barnes  50,000  $4.00  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Kevin Barnes  2,000  $5.20  CAD 28-Mar-2028 $0.00  USD N/A N/A N/A N/A N/A
Kevin Barnes  30,000  $5.30  CAD 11-Jun-2030 $0.00  USD N/A N/A N/A N/A N/A
Kevin Barnes  40,000  $5.50  CAD 08-Aug-2033 $0.00  USD N/A N/A N/A N/A N/A
Kevin Barnes  25,000  $11.90  CAD 06-Apr-2031 $0.00  USD N/A N/A N/A N/A N/A
Mo Jinyu  100,000  $3.54  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Mo Jinyu  50,000  $5.50  CAD 08-Aug-2033 $0.00  USD N/A N/A N/A N/A N/A
Mo Jinyu  100,000  $8.10  CAD 08-Jan-2031 $0.00  USD N/A N/A N/A N/A N/A
Raju Kankipati  100,000  $3.54  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Raju Kankipati  50,000  $5.50  CAD 08-Aug-2033 $0.00  USD N/A N/A N/A N/A N/A
Raju Kankipati  100,000  $8.73  CAD 06-Apr-2032 $0.00  USD N/A N/A N/A N/A N/A
Yong Meng Lee  100,000  $3.30  CAD 04-Nov-2029 $0.00  USD N/A N/A N/A N/A N/A
Yong Meng Lee  55,000  $3.54  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Yong Meng Lee  20,000  $5.30  CAD 11-Jun-2030 $0.00  USD N/A N/A N/A N/A N/A
Yong Meng Lee  50,000  $5.50  CAD 08-Aug-2033 $0.00  USD N/A N/A N/A N/A N/A
Yong Meng Lee  25,000  $11.90  CAD 06-Apr-2031 $0.00  USD N/A N/A N/A N/A N/A
Thomas Mika  80,000  $2.80  CAD 13-Jul-2027 $0.00  USD N/A N/A N/A N/A N/A
Thomas Mika  100,000  $3.80  CAD 29-May-2029 $0.00  USD N/A N/A N/A N/A N/A
Thomas Mika  50,000  $3.85  CAD 16-Jan-2027 $0.00  USD N/A N/A N/A N/A N/A
Thomas Mika  100,000  $4.00  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Thomas Mika  95,000  $5.20  CAD 28-Mar-2028 $0.00  USD N/A N/A N/A N/A N/A
Thomas Mika  60,000  $5.30  CAD 11-Jun-2030 $0.00  USD N/A N/A N/A N/A N/A
Thomas Mika  75,000  $5.50  CAD 08-Aug-2033 $0.00  USD N/A N/A N/A N/A N/A
Thomas Mika  100,000  $6.20  CAD 02-Nov-2026 $0.00  USD N/A N/A N/A N/A N/A
Thomas Mika  45,000  $11.90  CAD 06-Apr-2031 $0.00  USD N/A N/A N/A N/A N/A
Vivek Rajgarhia  102,400  $3.30  CAD 04-Nov-2029 $0.00  USD N/A N/A N/A N/A N/A
Vivek Rajgarhia  100,000  $4.00  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Vivek Rajgarhia  115,000  $5.30  CAD 11-Jun-2030 $0.00  USD N/A N/A N/A N/A N/A
Vivek Rajgarhia  50,000  $5.50  CAD 08-Aug-2033 $0.00  USD N/A N/A N/A N/A N/A
Vivek Rajgarhia  45,000  $11.90  CAD 06-Apr-2031 $0.00  USD N/A N/A N/A N/A N/A
Suresh Venkatesan  280,000  $2.80  CAD 13-Jul-2027 $0.00  USD N/A N/A N/A N/A N/A
Suresh Venkatesan  450,000  $3.80  CAD 29-May-2029 $0.00  USD N/A N/A N/A N/A N/A
Suresh Venkatesan  200,000  $4.00  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Suresh Venkatesan  390,000  $5.20  CAD 28-Mar-2028 $0.00  USD N/A N/A N/A N/A N/A
Suresh Venkatesan  250,000  $5.30  CAD 11-Jun-2030 $0.00  USD N/A N/A N/A N/A N/A
Suresh Venkatesan  100,000  $5.50  CAD 08-Aug-2033 $0.00  USD N/A N/A N/A N/A N/A
Suresh Venkatesan  30,000  $8.60  CAD 07-Jul-2026 $0.00  USD N/A N/A N/A N/A N/A
Suresh Venkatesan  65,000  $11.90  CAD 06-Apr-2031 $0.00  USD N/A N/A N/A N/A N/A
Dan Meerovich  100,000  $2.95  CAD 17-Mar-2030 $0.00  USD N/A N/A N/A N/A N/A
Dan Meerovich  50,000  $3.54  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Dan Meerovich  40,000  $5.50  CAD 08-Aug-2033 $0.00  USD N/A N/A N/A N/A N/A
Dan Meerovich  25,000  $11.90  CAD 06-Apr-2031 $0.00  USD N/A N/A N/A N/A N/A
Robert Ditizio  100,000  $8.20  CAD 01-Dec-2031 $0.00  USD N/A N/A N/A N/A N/A
Robert Ditizio  15,000  $5.50  CAD 08-Aug-2033 $0.00  USD N/A N/A N/A N/A N/A

  Option-Based Awards Share-Based Awards

 

 

 

 

Name

 No. of Shares Underlying Unexercised Options (#) 

 

 

Option Exercise Price (CA$/share)

 

 

 

Option Expiration Date

 

 

 

Value of Unexercised In-The Money Options (1) (US$)

 

Number of

Shares or Units of Shares That Have Not Vested (#)

 

Market or Payout Value

of Share- Based Awards That Have Not Vested (US$)

Peter Copetti  2,500,000   0.235  Jun. 08, 2017  1,396,744   N/A   N/A 
   500,000   0.445  Nov. 15, 2017  203,654   N/A   N/A 
   300,000   0.49  Aug. 13, 2018  112,460   N/A   N/A 
   600,000   1.24  Aug. 12, 2019  -   N/A   N/A 
   200,000   1.54  June 12, 2020  -   N/A   N/A 
Ajit Manocha  2,000,000   1.75  July 03, 2019  -   N/A   N/A 
   100,000   1.24  Aug. 12, 2019  -   N/A   N/A 
   200,000   1.54  Jun. 12, 2020  -   N/A   N/A 
Kevin Barnes  25,000   0.23  Feb. 16, 2022  14,058   N/A   N/A 
   10,000   0.28  Mar. 17, 2020  5,263   N/A   N/A 
   100,000   0.44  Nov. 14, 2018  41,091   N/A   N/A 
   100,000   0.445  Nov. 15, 2017  40,731   N/A   N/A 
   100,000   0.49  Aug. 13, 2018  37,488   N/A   N/A 
   25,000   0.51  Sep. 28, 2021  9,011   N/A   N/A 
   50,000   0.76  Feb. 28, 2021  9,011   N/A   N/A 
   50,000   1.24  Aug. 12, 2019  -   N/A   N/A 
   50,000   1.54  June 12, 2020  -   N/A   N/A 
   25,000   1.08  Aug. 13, 2020  -   N/A   N/A 
Daniel DeSimone  200,000   1.44  Apr. 03, 2019  -   N/A   N/A 
   300,000   1.24  Aug. 12, 2019  -   N/A   N/A 
   40,000   1.54  Jun. 12, 2020  -   N/A   N/A 
   500,000   1.65  Mar. 30, 2020  -   N/A   N/A 
Dr. Suresh Venkatesan  6,357,000   1.40  June 15, 2020  -   N/A   N/A 
Dr. Subhash Deshmukh  1,500,000   1.62  Apr. 24, 2020  -   N/A   N/A 

______________________

(1)This amount is calculated based on the difference between the market value of the shares underlying the options as of December 31, 20152023, being CAD $1.01CAD$1.25 (US$0.7209)0.94), and the exercise or base price of the option. The exchange rate used in these calculations to convert CAD to USD was 0.7209,0.755, being the closing priceexchange rate at December 31, 2015.2023.

Page 51

The value vested or earned during fiscal year 20152023 of incentive plan awards granted to NEOs are as follows:

    Option-based Awards Share-based Awards

Non-equity

Incentive Plan

First Name Last Name 

Number of

Securities

Underlying

Options

Vested

  

Value

Vested

During the

Year

 

Number of

Shares or

Units of

Shares

Vested

 

Value

Vested

During the

Year

 

Compensation –

Value

Earned

During The

Year

Kevin Barnes  45,002  $37,636.48  USD N/A N/A N/A
Mo Jinyu  50,000  $32,826.62  USD N/A N/A N/A
Raju Kankipati  62,500  $32,826.62  USD N/A N/A N/A
Yong Meng Lee  50,002  $54,835.87  USD N/A N/A N/A
Thomas Mika  63,752  $47,512.94  USD N/A N/A N/A
Vivek Rajgarhia  148,749  $149,915.71  USD N/A N/A N/A
Suresh Venkatesan  185,002  $146,400.22  USD N/A N/A N/A
Dan Meerovich  43,752  $53,267.83  USD N/A N/A N/A

NEO Name(1)

Option-Based Awards – Value Vested During the Year (1)

(US$)

Share-Based Awards – Value Vested During the Year

(US$)

Non-Equity Incentive Plan Compensation – Value Earned During the Year (US$)
Ajit Manocha2,187N/AN/A
Peter Copetti60,540N/AN/A
Kevin Barnes38,850N/AN/A
Stephane Gagnon47,181N/AN/A
Daniel DeSimone18,885N/AN/A

  ______________________

(1)This amount is the dollar value that would have been realized and is computed by obtaining the difference between the market price of the underlying securities on the vesting date and the exercise or base price of the options under the option-

35

basedoption-based award. For the named executive officers’officers to have realizedrealize this value, they would have had to exercise their options and sell the shares on the day of vesting. The exchange ratesrate used in these calculations to convert CAD to USD were the rates applicableis based on the vesting dates.average exchange rate for the year ended December 31, 2023 being 0.7408.

Director Compensation

      Share- Options-Based Awards(1)(2) Non-Equity Incentive Plan Compensation      
Name and Principal
Position
 Fiscal
Year
(6)
 Salary
(2)
(US$)
 Based Awards
(1)
(US$)
 No. of
Shares
 (US$) Annual
Incentive
Plans
 Long-
term
Incentive
Plans
 Pension
Value
(US$)
 All Other
Comp.
(US$)
 Total
Comp.
(US$)
Dr. Adam Chowaniec
Former Director(5)
  2015   1,205                        1,205 
Sheldon Inwentash(4)
Former Director
  2015   19,533      100,000                  19,533 
John F. O’Donnell(3)
Director
  2015   60,118      100,000   94,442               154,560 
Todd. A. DeBonis(6)
Director
  2015   39,135      525,000   561,789               600,924 
David E. Lazovsky(6)
Director
  2015   30,135      275,000   325,683               355,818 
Chris Tsiofas
Director
  2015   66,385      300,000   283,328               349,713 
Mohan Warrior  2015   22,170      250,000   122,808               144,978 
Dr. Geoff Taylor(7)
Former Director
  2015   205,228      100,000   94,442               299,670 

During the year ended December 31, 2015, the outside, or non-management, directors were paid an annual fee of $32,000 for acting as a director, plus $1,500 per board meeting attended and $750 per committee meeting, to be paid quarterly. If independent, the Chairman of the Board is entitled to receive an additional $10,000 annually and the Committee Chairs are entitled to receive an additional $8,000 annually. Messrs. Copetti and Manocha both served as Executive Co-Chairmen in 2015. Mr. Copetti also served as interim CEO until June 11, 2015. Directors’ involvement in special assignments or services as consultant or expert will be negotiated on a case by case basis.

The following table details compensation paid/accrued for fiscal year 20152023 for each director who is not also an officer.

 ______________________

        Share-  Options Based Awards (1)(2)  Non-Equity Incentive Plan Compensation    

Name and Principal Position

 

Fiscal

Year

  Salary (2)  

Based

Awards

(1) (2)

  

No. of

Options

  

Value of

Options

(1) (2)

  

Annual

Incentive

Plans

  

Long-term

Incentive

Plans

  

Pension

Value

  

All

other

Comp.

  

Total

Comp.

 
Peter Charbonneau  2023   55,000   -   31,879  $112,678   -   -   -   -   167,678 
Chris Tsiofas  2023   40,000   -   27,722  $97,985   -   -   -   -   137,985 
Glen Riley  2023   40,000   -   27,722  $97,985   -   -   -   -   137,985 
Jean-Louis Malinge  2023   30,000   -   24,949  $88,183   -   -   -   -   118,183 
Theresa Ende  2023   30,000   -   24,949  $88,183   -   -   -   -   118,183 
Michal Lipson  2023   30,000   -   24,949  $88,183   -   -   -   -   118,183 

(1)(1)The Company used the Black-Scholes model as the methodology to calculate the grant date fair value. The fair value will be recorded as an operating expense as the stock options vest from the date of grant.
(2)The exchange rate used in these calculations to convert CAD to USD was rate of exchange applicableis based on the date of grant.
(3)The firm of Stikeman Keeley Spiegel Pasternack LLP, of which Mr. O’Donnell is counsel, billedaverage exchange rate for the sum of $107,790 for legal fees and disbursements incurred in 2015.
(4)Mr. Inwentash resigned as a director on August 13, 2015 at which time all 100,000 stock options above were cancelled. No value was assigned to the stock options. 125,000 stock options from a previous stock option grant were also cancelled.
(5)Dr. Chowaniec resigned from the Board on January 22, 2015.
(6)Messrs. DeBonis and Lazovsky were appointed to the Board on April 8, 2015.
(7)Dr. Taylor resigned as a director on August 12, 2015 but continues to serve as the Company’s chief scientist.year ended December 31, 2023 being 0.7408

Page 52

The following table sets forth information concerning all awards outstanding under the stock option plans to each of the current Directors who are not also named executive officers as of December 31, 2015:2023:

    Option-based Awards Share-based Awards
First Name Last Name 

Number of

Securities

Underlying

Unexercised

Options

  

Option

Exercise

Price

 

Option

Expiration

Date

 

Value of

Unexercised

in-the-money

Options (1)

 

Number of Shares or

Units of

Shares

that

have not

Vested

 

Market or

Payout

Value of

Shares or

Units of

Shares that

have not

Vested

 

Market or

Payout

Value of

Vested

Shares or

Units of

Shares that

have not

Paid Out or

Distributed

Peter Charbonneau  39,900  $3.30  CAD 21-Jun-2028 $0.00  USD N/A N/A N/A N/A N/A
Peter Charbonneau  40,059  $3.80  CAD 29-May-2029 $0.00  USD N/A N/A N/A N/A N/A
Peter Charbonneau  52,860  $4.00  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Peter Charbonneau  3,549  $4.20  CAD 06-Feb-2030 $0.00  USD N/A N/A N/A N/A N/A
Peter Charbonneau  15,473  $5.20  CAD 28-Mar-2028 $0.00  USD N/A N/A N/A N/A N/A
Peter Charbonneau  33,711  $5.30  CAD 11-Jun-2030 $0.00  USD N/A N/A N/A N/A N/A
Peter Charbonneau  31,879  $5.70  CAD 14-Jul-2033 $0.00  USD N/A N/A N/A N/A N/A
Peter Charbonneau  14,375  $11.90  CAD 06-Apr-2031 $0.00  USD N/A N/A N/A N/A N/A
Theresa Ende  41,368  $4.00  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Theresa Ende  24,949  $5.70  CAD 14-Jul-2033 $0.00  USD N/A N/A N/A N/A N/A
Theresa Ende  4,745  $7.16  CAD 01-Jun-2032 $0.00  USD N/A N/A N/A N/A N/A
Michal Lipson  41,368  $4.00  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Michal Lipson  24,949  $5.70  CAD 14-Jul-2033 $0.00  USD N/A N/A N/A N/A N/A
Michal Lipson  5,194  $6.59  CAD 21-Jun-2032 $0.00  USD N/A N/A N/A N/A N/A
Jean-Louis Malinge  52,500  $3.00  CAD 05-Sep-2027 $0.00  USD N/A N/A N/A N/A N/A
Jean-Louis Malinge  39,900  $3.30  CAD 21-Jun-2028 $0.00  USD N/A N/A N/A N/A N/A
Jean-Louis Malinge  36,053  $3.80  CAD 29-May-2029 $0.00  USD N/A N/A N/A N/A N/A
Jean-Louis Malinge  41,368  $4.00  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Jean-Louis Malinge  26,382  $5.30  CAD 11-Jun-2030 $0.00  USD N/A N/A N/A N/A N/A
Jean-Louis Malinge  24,949  $5.70  CAD 14-Jul-2033 $0.00  USD N/A N/A N/A N/A N/A
Jean-Louis Malinge  11,250  $11.90  CAD 06-Apr-2031 $0.00  USD N/A N/A N/A N/A N/A
Glen Riley  45,965  $4.00  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Glen Riley  22,460  $5.00  CAD 04-Dec-2030 $0.00  USD N/A N/A N/A N/A N/A
Glen Riley  27,722  $5.70  CAD 14-Jul-2033 $0.00  USD N/A N/A N/A N/A N/A
Glen Riley  11,250  $11.90  CAD 06-Apr-2031 $0.00  USD N/A N/A N/A N/A N/A
Chris Tsiofas  68,750  $2.80  CAD 13-Jul-2027 $0.00  USD N/A N/A N/A N/A N/A
Chris Tsiofas  48,767  $3.30  CAD 21-Jun-2028 $0.00  USD N/A N/A N/A N/A N/A
Chris Tsiofas  44,065  $3.80  CAD 29-May-2029 $0.00  USD N/A N/A N/A N/A N/A
Chris Tsiofas  45,965  $4.00  CAD 11-Nov-2032 $0.00  USD N/A N/A N/A N/A N/A
Chris Tsiofas  29,314  $5.30  CAD 11-Jun-2030 $0.00  USD N/A N/A N/A N/A N/A
Chris Tsiofas  27,722  $5.70  CAD 14-Jul-2033 $0.00  USD N/A N/A N/A N/A N/A
Chris Tsiofas  15,000  $8.60  CAD 07-Jul-2026 $0.00  USD N/A N/A N/A N/A N/A
Chris Tsiofas  12,500  $11.90  CAD 06-Apr-2031 $0.00  USD N/A N/A N/A N/A N/A

36

  Option-Based Awards Share-Based Awards
Name 

No. of Shares Underlying Unexercised

Options (#)

 

Option Exercise Price

(CA$/share)

 

Option Expiration

Date

 

Value of Unexercised In- The Money

Options (1) (US$)

 

Number of

Shares or Units of Shares That Have Not

Vested (#)

 

Market or

Payout Value

of Share- Based Awards That Have Not

Vested (US$)

John F. O’Donnell  150,000   0.23  16-Feb-22  84,345  N/A N/A
   12,500   0.345  19-Aug-20  5,992  N/A N/A
   500,000   0.445  15-Nov-17  203,654  N/A N/A
   300,000   0.49  13-Aug-18  112,460  N/A N/A
   300,000   1.24  12-Aug-19  0  N/A N/A
   100,000   1.54  12-Jun-20  0  N/A N/A
Chris Tsiofas  500,000   0.275  21-Aug-17  264,931  N/A N/A
   500,000   0.445  15-Nov-17  203,654  N/A N/A
   300,000   0.49  13-Aug-18  112,460  N/A N/A
   300,000   1.24  12-Aug-19  0  N/A N/A
   300,000   1.54  12-Jun-20  0  N/A N/A
Todd A. DeBonis  275,000   1.54  12-Jun-20  0  N/A N/A
   250,000   1.99  08-Apr-20  0  N/A N/A
David E. Lazovsky  250,000   1.99  08-Apr-20  0  N/A N/A
   25,000   1.54  12-Jun-20  0  N/A N/A
Mohanas Warrior  250,000   1.54  12-Jun-20  0  N/A N/A

 ______________________

(1)(1)This amount is calculated based on the difference between the market value of the shares underlying the options as of December 31, 20152023, being CAD $1.01CAD$1.25 (US$0.7209)0.94), and the exercise or base price of the option. The exchange rate used in these calculations to convert CAD to USD was 0.7209,0.755, being the closing priceexchange rate at December 31, 2015.2023.

The value vested or earned during fiscal year 20152023 of incentive plan awards granted to Directors who are not also named executive officers are as follows:

 

    Option-based Awards Share-based Awards 

Non-equity

First Name Last Name 

Number of

Securities

Underlying

Options

Vested

  

Value

Vested

During

the Year

 

Number of

Shares or

Units of

Shares

Vested

 

Value

Vested

During

the Year

 

Incentive Plan

Compensation –

Value Earned

During

The Year

Peter Charbonneau  55,585  $56,016.97  USD N/A N/A N/A
Theresa Ende  43,501  $43,838.62  USD N/A N/A N/A
Michal Lipson  43,501  $43,838.62  USD N/A N/A N/A
Jean-Louis Malinge  43,501  $43,838.62  USD N/A N/A N/A
Glen Riley  48,335  $48,710.67  USD N/A N/A N/A
Chris Tsiofas  48,335  $48,710.67  USD N/A N/A N/A

Director Name(1)

Option-Based Awards – Value Vested During the Year (1)

(US$)

Share-Based Awards – Value Vested During the Year

(US$)

Non-Equity Incentive Plan Compensation – Value Earned During the Year (US$)
Sheldon Inwentash10,935N/AN/A
John F. O’Donnell53,979N/AN/A
Dr. Geoff Taylor64,914N/AN/A
Chris Tsiofas53,979N/AN/A

  ______________________

(1)This amount is the dollar value that would have been realized and is computed by obtaining the difference between the market price of the underlying securities on the vesting date and the exercise or base price of the options under the option- based award. For the Directors to have realized this value, they would have had to exercise their options and sell the shares on the day of vesting. None of these options were exercised. The exchange rate used in these calculations to convert CAD to USD was the exchange rate applicable on the vesting date.

Termination and Change of Control Benefits

Other than disclosed belowas described in “Written Management Agreements,”their individual management agreements, the Company has no plans or arrangements in respect of remuneration received or that may be received by the Officers the Company to compensate such Officers, in the event of termination of employment (as a result of resignation, retirement, change of control) or a change of responsibilities following a change of control.

37Page 53

Pension Plan Benefits

The Company does not provide a defined benefit plan to the Officers or any of its employees.

The Company offers a defined contribution plan that is a 401k Plan but does not contribute toward such plan. The Company does not have any deferred compensation plans other than that described above.

Written Management Agreements

The Company and/or its subsidiaries have employment contracts with the following current and former Officers as follows:

Mr. Manocha entered into a memorandumindividuals were senior management of understanding (MOU) dated July 3, 2014, wherein (i) he will be paid US$41,667.67 per month (or US $500,000 per year) and he was granted 2,000,000 stock options. Mr. Manocha’s MOU was accepted. On October 1, 2015, the Company extended Mr. Manocha’s employment at the same annual rate of pay. The extension, however, divided his compensation between his compensation as an executive and his compensation has the co-chairman of the board. As of October 1, 2015, Mr. Manocha is paid annually US $375,000 as an executive and US $125,000 as co-chairman of the board.in 2023:

On June 30, 2014 Mr. Copetti entered into an Executive Employment Agreement with an effective date of February 10, 2014, wherein

(i) he will be paid CA$20,000 per month or (CA$240,000 per year) until December 31, 2014, (ii) he will be eligible for annual and special bonuses as determined by the Board of Directors; (iii) he will be reimbursed up to CA$5,000 for gym membership and medical tests; and (iv) he will receive a severance of twelve months on termination of employment by the Company, other than for cause.

Mr. Copetti’s salary was adjusted to CA$31,250 per month or (CA$375,000 per year) in October 2014. On January 1, 2015, Mr. Copetti’s employment agreement was extended on a month to month basis with an adjusted salary of CA$41,667.67 per month. On October 1, 2015, the Company extended Mr. Copetti’s employment agreement. The extended agreement divided his compensation between his compensation as an executive and his compensation has the co-chairman of the board. As of October 1, 2015, Mr. Copetti is paid, annually, CA$375,000 as an executive and US $125,000 as co-chairman of the board. The other terms of the contract remained unchanged.

Mr. Barnes has an arrangement with the Company to provide consulting services starting January 1, 2013 for a period of one year with an automatic one year renewal at a monthly rate of CA$7,000 (2016 – CA$10,000). The arrangement may be terminated by the Company without cause on six months’ notice or equivalent compensation.

Mr. DeSimone entered into Letter of Agreement dated March 28, 2014, wherein (i) he will be paid US$10,416.67 per month (or US$125,000 per year) and (ii) he was granted 200,000 stock options.

Dr. Deshmukh entered into an Executive Employment Agreement with an effective date of June 8, 2015 wherein (i) he will be paid US$250,000 (subsequently amended to US$300,000 effective January 1, 2016) per year under at-will terms of employment (ii) he will be eligible for annual and special bonuses as determined by the Board of Directors up to a maximum of US$250,000; (iii) he was granted 1,500,000 stock options vesting over 4 years; (iv) he will receive a severance of six months’ salary, if terminated during the first year of employment, plus two months’ salary additional per each full year of employment thereafter, up to a maximum of twelve months on termination of employment by the Company, other than for cause.

Dr. Venkatesan entered into an Executive Employment Agreement with an effective date of June 10, 2015 wherein (i) he will be paid US$550,000 per year under at-will terms of employment; (ii) he will be eligible for annual and special bonuses as determined by the Board of Directors; (iii) he was granted 6,357,000 stock options vesting over 4 years; (iv) he is eligible for a signing bonus of US $450,000 payable on the first anniversary of the effective date provided that the Executive Employment Agreement has not been terminated prior to that date; (v) he will receive a severance of twelve months on termination of employment by the Company, other than for cause.

NameC.Board PracticesTitle
Suresh VenkatesanCEO
Vivek RajgarhiaPresident & General Manager
Thomas MikaExecutive Vice President and CFO
Mo JinyuSVP, GM of Asia
Raju KankipatiSVP, Product Line Management & GM USA

C.Board Practices.

Our Board of Directors currently consists of eightseven (7) directors, including fourall of whom are independent, directors.except for Suresh Venkatesan, our CEO who also currently serves on the Board of Directors. Each director holds office until the next annual general meeting of the Company or until his successor is elected or appointed, unless his office is earlier vacated in accordance with the Articles of Amalgamation and all amendments thereto (the “Articles”), or with the provisions of the OBCA. The Company’s Officers are appointed to serve at the discretion of the Board, subject to the terms of the employment agreements described above.

Lead independent director

Our independent directors have selected Peter Charbonneau to serve as the lead independent director. The lead independent director’s primary role is to facilitate the functioning of the board, and to maintain and enhance the quality of our corporate governance practices. The lead independent director presides over the private sessions of our independent directors that take place following each meeting of the board and conveys the results of these meetings to the chair of the board.

The Board and committees of the Board schedule regular meetings over the course of the year.

During fiscal 2015,2023, the Board held seven17 regularly scheduled meetings, including committee meetings. ForIf for various reasons, Board members may not be able to attend a Board meeting. Allmeeting, all Board members are provided information related to each of the agenda items before each meeting, and, therefore, can provide counsel outside the confines of regularly scheduled meetings.

The Board has adopted standards for determining whether a director is independent from management. The Board reviews, consistent with the Company’s corporate governance guidelines, whether a director has any material relationship with the Company that would

38

impair the director’s independent judgment. The Board has affirmatively determined, that as of the filing of this Form 20-F, based on its standards, that Messrs.the following directors are independent: Chris Tsiofas, DeBonis, LazovskyJean-Louis Malinge, Peter Charbonneau, Glen Riley, Theresa Lan Ende and Warrior are independent.Michal Lipson.

Directors’ Service Contracts

Messrs.Venkatesan, Copetti and Manocha had entered into theAs CEO, Mr. Venkatesan has an employment contracts explained above in “Written Management Agreements.”

Dr. Taylor entered into an Agreement for Provision of Laboratory & Consulting Services to POET Technologies, dated January 29, 2014,contract with the Company pursuantwhich allows him to which he was compensated at the ratereceive a severance of $12,000 per month and later increased to $13,750 per month. The agreement covered the period from January 1, 2014 to December 31, 2014 and did not provide for benefits upontwelve months on termination of employment by the agreement. Dr. Taylor’s agreement was renewedCompany, other than for 2015 at a rate of $20,833 per month for an additional year. Dr. Taylor resigned from the board on August 12, 2015.cause. Unvested stock options will be cancelled. He will have one year to exercise vested stock options.

Page 54

 

No other director has a service contract with the Company.

Audit and Compensation Committees of the Board of Directors

We currently have four board committees; (1) an Audit Committee; (2) a Compensation Committee;Committee, (3) a Corporate Governance and& Nominating Committee, and (4) a Disclosurean Ad Hoc Strategy Committee. Committee charters if any,for the Audit, Compensation and Corporate Governance & Nominating Committees can be found at www.poet-technologies.com.on the Company’s website (poet-technologies.com). The Strategy Committee is an ad-hoc committee and therefore does not have a charter. The names of the members and a summary of the terms of the charter for each the Audit Committee and the Compensation Committee is provided below.

Audit Committee

The Audit Committee is currently comprised of three members: Chris Tsiofas (Chair), David LazovskyPeter Charbonneau and Mohandas Warrior.Jean-Louis Malinge. All three members are independent directors of the Company. Mr. Tsiofas was appointed chair of the Audit Committee on August 21, 2012. The Board has determined that Mr. Tsiofas satisfies the criteria of “audit committee financial expert” within the meaning of Item 401(h) of Regulation S-K and is independent in accordance with Rule 4200 of the NASDAQNasdaq Marketplace Rules. All members of the audit committee are financially literate, meaning they have the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Company’s financial statements.

The Audit Committee is responsible for reviewing the Company’s financial reporting procedures, internal controls and the performance of the Company’s external auditors. The Audit Committee is also responsible for reviewing the annual and quarterly financial statements and accompanying Management’s Discussion and Analysis prior to their approval by the full Board. The Audit Committee also reviews the Company’s financial controls with the auditors of the Company on an annual basis.

The Company’s independent auditor is accountable to the Board and to the Audit Committee. The Board, through the Audit Committee, has the ultimate responsibility to evaluate the performance of the independent auditor, and through the shareholders, to appoint, replace and compensate the independent auditor. Any non-audit services must be pre-approvedpre- approved by the Audit Committee.

39

Compensation Committee

The Compensation Committee is currently comprised of three members: Glen Riley (Chair), Chris Tsiofas (Chair), John O’Donnell and Todd DeBonis.Theresa Ende. Mr. TsiofasRiley was appointed chair of the Compensation Committee on NovemberOctober 14, 2014.2022. All three members are independent directors. The Board has determined that all members of the Compensation Committee are qualified as members based on the following:

Mr. Riley has more than 30 years’ experience in leadership roles spanning both the semiconductor and optoelectronics industries. He most recently served as General Manager of the Filter Solutions Business Unit at Qorvo, where he was responsible for developing highly integrated RF modules used in flagship smartphones. Prior to the merger of RFMD and TriQuint that formed Qorvo, he held multiple leadership roles at TriQuint, including Managing Director of international headquarters in Singapore, General Manager of the GaAs foundry business, and General Manager of Optoelectronics. Riley was previously the Chief Executive Officer of Opticalis, an early stage optoelectronics company focused on the development of high-density wavelength division multiplexing products. He also held prior roles as Vice President and General Manager of the Optoelectronic business at Agere Systems, and President of Asia-Pacific Sales and Marketing at Lucent Technologies Microelectronics Group. He graduated as valedictorian with a B.S. degree in Electrical Engineering from the School of Engineering at the University of Maine and completed the General Manager Program at Harvard Business School.

Page 55

Mr. Chris Tsiofas, CA, CPA, earned a Bachelor’s of Commerce Degree from the University of Toronto and Todd DeBonis are independent. Mr. O’Donnell is retained bya member of the Institute of Chartered Accountants of Canada and the Canadian Tax Foundation. He has been on the Board of Directors of the Company since August of 2012 2012 and has served as the Chair of the Audit Committee during his entire tenure. In February 2024 he was appointed to the Board of Directors of Andrew Peller Limited (TSE:ADW) and serves as the Chair of the Audit and Pension Committees. Andrew Peller Ltd. is a leading producer and marketer of quality wines and craft beverage alcohol products in Canada. With wineries in British Columbia, Ontario, and Nova Scotia, the Company markets wines produced from grapes grown in Ontario’s Niagara Peninsula, British Columbia’s Okanagan and Similkameen Valleys, and from vineyards around the world. Mr. Tsiofas is the president of MTN Chartered Professional Accountant Professional Corporation, a public accountancy firm. He sits on various private company counsel.boards. He has also served in a principal capacity in various entrepreneurial ventures resulting in successful divestitures. Tsiofas formerly served as Chairman of the Company’s Compensation Committee and has directed past engagements with the Company’s outside executive compensation consultants. Mr. Tsiofas is also the Chairman of the Audit Committee of the Board of Directors. He brings to the Compensation Committee specialized knowledge regarding the tax impact of certain compensation policies and practices on individuals and on the Company.

Ms. Lan Ende serves as Chief Procurement Director of Arista Networks. Prior to her appointment as Chief Procurement Director in 2019, Ms. Ende served for 10 years as its Senior Director of Global Supply Chain Management. Prior to Arista, she held senior positions at JDSU Optical Division and Force10 Networks. At Cisco Systems and ROLM Telecommunications, Ms. Ende held various program management and planning management positions over a 20-year period. In 2019, she was honored as one of the “Top 100 Women of Influence” by Silicon Valley Business Journal.

The Compensation Committee has extensive direct relevant experience in determining executive compensation policies and practices on behalf of the Company. In addition to being supported by outside compensation consultants on a periodic basis for peer group review, the members of the Committee are professional executives familiar with best practices associated with executive compensation, are knowledgeable about the tax implications to the Company and its executive officers of changes in the tax laws pertaining to executive compensation and have direct relevant experience with the incentives used throughout the Company’s industry to align the interests of executive management with company and shareholder interests. This gives these individuals strong insight as to the incentive structures and programs appropriate for companies of a comparable size. The seniority, experience and level of achievement of the three current members of the Compensation Committee speak to the independent judgement exercised in making decisions about the suitability of the Company’s compensation policies and practices.

The Compensation Committee discusses and makes recommendations to the Board for approval or disapproval of all compensation issues that pertain to the Company. Thesenior executives of the Company, and on issues involving employment company-wide compensation policies and practices. In general, the compensation programs of the Company are designed to reward performance and to be competitive with the compensation agreements of other comparable semiconductor companies. The Compensation Committee is responsible for evaluating the compensation of the senior management of the Company and assuring that they are compensated effectively in a manner consistent with the Company’s business, stage of development, financial condition and prospects, and the competitive environment. Specifically, the Compensation Committee is responsible for: (i) reviewing the compensation practices and policies of the Company to ensure that they are competitive and that they provide appropriate motivation for corporate performance and increased shareholder value; (ii) overseeing the administration of the Company’s compensation programs, and reviewing and approving the employees who receive compensation and the nature of the compensation provided under such programs, and ensuring that all management compensation programs are linked to meaningful and measurable performance targets; (iii) making recommendations to the Board regarding the adoption, amendment or termination of compensation programs and the approval of the adoption, amendment and termination of compensation programs of the Company, including for greater certainty, ensuring that if any equity-basedequity- based compensation plan is subject to shareholder approval, and that such approval is sought; (iv) periodically surveying the executive compensation practices of other comparable companies; (v) establishing and ensuring the satisfaction of performance goals for performance-based compensation; (vi) annually reviewing and approving the annual base salary and bonus targets for the senior executives of the Company, other than the Chief Executive Officer (the “CEO”); (vii) reviewing and approving annual corporate goals and objectives for the CEO and evaluating the CEO’s performance against such goals and objectives; (viii) annually reviewing and approving, based on the Compensation Committee’s evaluation of the CEO, the CEO’s annual base salary, the CEO’s bonus, and any stock option grants and other awards to the CEO under the Company’s compensation programs (in determining the CEO’s compensation, the Compensation Committee will consider the Company’s performance and relative shareholder return, the compensation of CEOs at other companies, and the CEO’s compensation in past years); and (ix) reviewreviewing the annual report on executive compensation required to be prepared under applicable corporate and securities legislation and regulation including the disclosure concerning members of the Compensation Committee and settling the reports required to be made by the Compensation Committee in any document required to be filed with a regulatory authority and/or distributed to shareholders.

Page 56

 

Code of Ethics

The Board has adopted a written code of business conduct and ethics. All transgressions of the code of business conduct and ethics are required to be promptly reported to the Chair of the Board or of any committee, who in turn, reports them to the Corporate Governance and Nominating Committee. The Corporate Governance and Nominating Committee is charged with investigating alleged violations of the code of business conduct and ethics. Any findings of the Corporate Governance and Nominating Committee are then reported to the full Board, which will take such action as it deems proper.appropriate. The Company’s Code of Ethics may be inspected on the Company’s website at www.poet-technologies.com(poet-technologies.com) and is filed as an Exhibit to this Annual Report.

Corporate Governance

As a foreign private issuer, we are exempt from certain requirements of the Nasdaq listing rules that are applicable to U.S. listed companies. Please see “Item 16G. Corporate Governance” for additional information.

Nasdaq’s Board Diversity Rule

Nasdaq’s Board Diversity Rule, which was approved by the SEC on August 6, 2021, is a disclosure standard designed to encourage minimum board diversity for companies and provide stakeholders with consistent, comparable disclosures concerning a company’s current board composition. The director diversity matrix required by Nasdaq Marketplace Rule 5606 is available on the Company’s website, https://poet-technologies.com, in the “Board Diversity Matrix” section under the “Investor Relations” tab.

D.D.Employees.

As of December 31, 2015 and February 22, 2016,2023, the Company had 10fifty-six (56) full-time employees and 5 consultants, including senior management; 9four (4) consultants. Sixteen (16) employees and 3three (3) consultants work at our lab facilitiesfacility either as support staff or are engaged in research and development initiatives; 1 employee and 2 consultantsfour (4) employees are employed at the Canadian office.office; twenty (28) employees are employed at our fabrication facility in Singapore; eight (8) employees are employed at our product development facility in China; one (1) consultant is located in Italy. None of the Company’s employees are covered by collective bargaining agreements.

E.E.Share Ownership.

The following table sets forth certain information regarding the beneficial ownership of our outstanding common shares for: (i) each of our Directors and Officers individually; (ii) all of our Directors and Officers as a group; and (iii) each other person known to us to own beneficially more than 5% of our common shares as of February 22, 2016.March 15, 2024. Beneficial ownership of shares is determined under rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power. The table also includes the number of shares underlying options that are exercisable within sixty (60) days of February 22, 2016. OrdinaryMarch 15, 2024. Common shares subject to these options are deemed to be outstanding for the purpose of computing the ownership percentage of the person holding these options, but are not deemed to be outstanding for the purpose of computing the ownership percentage of any other person.

Page 57

 

The shareholders listed below do not have any different voting rights from our other shareholders.

40

  Number of Shares Beneficially Owned (1) Percent of Class
Directors and Officers:        
Peter Copetti  4,085,000(2)  2.00%
Geoff Taylor  3,892,748(3)  1.91%
Ajit Manocha  2,150,000(4)  1.06%
Chris Tsiofas  1,675,000(5)  0.83%
John F. O’Donnell  1,317,500(6)  0.65%
Daniel DeSimone  760,000(7)  0.38%
Kevin Barnes  486,213(8)  0.24%
Todd DeBonis  193,750(9)  0.10%
David Lazovsky  131,250(10)  0.07%
Mohandas Warrior  62,500(11)  0.03%
Suresh Venkatesan  40,000(12)  0.02%
Subhash Deshmukh  Nil   0%
Directors and Officers Subtotal  10,475,211   5.17%
Major Shareholders:        
None that we are aware of.        

  ______________________

Number of Shares
Beneficially Owned
(1)
Percent of Class
Directors and Officers:
Chris Tsiofas64,467*
Thomas Mika138,611*
Kevin Barnes54,746*
Suresh Venkatesan158,611*
Raju Kankipati11,111*
Peter Charbonneau63,729*
Jean-Louis Malinge33,892*
Vivek Rajgarhia1,500*
Glen Riley40,129*
Michal Lipson8,196*
Directors and Officers Subtotal574,992*

Major Shareholders:
None that we are aware of.

* Less than one percent (1%).

(1)The number of shares set forth for each Director, Officer and Major Shareholder, isif any, was determined in accordance with Rule 13d-3 of the General Rules and Regulations under the Exchange Act.
(2)Includes: (i) 135,000 common shares issued and outstanding and (ii) 3,950,000 common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.
(3)Includes: (i) 977,748 common shares issued and outstanding and (ii) 2,915,000 common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.
(4)Includes: (i) zero common shares issued and outstanding and (ii) 2,150,000 common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.
(5)Includes: (i) 25,000 common shares issued and outstanding and (ii) 1,650,000 common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.
(6)Includes: (i) 30,000 common shares issued and outstanding and (ii) 1,287,500 common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.
(7)Includes: (i) zero common shares issued and outstanding and (ii) 635,000 common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.
(8)Includes: (i) 17,463 common shares issued and outstanding and (ii) 468,750 common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.
(9)Includes: (i) zero common shares issued and outstanding and (ii) 131,250 common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.
(10)Includes: (i) zero common shares issued and outstanding and (ii) 68,750 common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.
(11)Includes: (i) zero common shares issued and outstanding and (ii) 62,500 common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.
(12)Includes: (i) 40,000 common shares issued and outstanding and (ii) zero common shares that can be obtained upon the exercise of options or warrants within sixty (60) days.

See “ITEM“Item 6.B. Compensation” for the exercise prices of options.

The following table presents the options exercisable for Directors and Officers within the next 60 days:

First Name Last Name Expiry Grant Price Exercisable 
Kevin Barnes 11-Jul-2027 $2.80  CAD  1,400 
Kevin Barnes 25-Mar-2028 $5.20  CAD  2,000 
Kevin Barnes 11-Jul-2027 $2.80  CAD  10,000 
Kevin Barnes 11-Jul-2027 $2.80  CAD  12,000 
Kevin Barnes 08-Nov-2032 $4.00  CAD  15,625 
Kevin Barnes 04-Apr-2031 $11.90  CAD  17,189 
Kevin Barnes 12-Jan-2030 $3.70  CAD  20,314 
Kevin Barnes 10-Dec-2028 $2.65  CAD  24,500 
Kevin Barnes 12-Jan-2030 $3.70  CAD  25,000 
Kevin Barnes 09-Jun-2030 $5.30  CAD  26,250 
Kevin Barnes 26-May-2029 $3.80  CAD  50,000 
Peter Charbonneau 03-Feb-2030 $4.20  CAD  3,549 
Peter Charbonneau 04-Apr-2031 $11.90  CAD  14,375 
Peter Charbonneau 25-Mar-2028 $5.20  CAD  15,473 

Page 58

Peter Charbonneau 11-Jul-2033 $5.70  CAD  23,909 
Peter Charbonneau 09-Jun-2030 $5.30  CAD  33,711 
Peter Charbonneau 18-Jun-2028 $3.30  CAD  39,900 
Peter Charbonneau 26-May-2029 $3.80  CAD  40,059 
Peter Charbonneau 08-Nov-2032 $4.00  CAD  52,860 
Theresa Ende 29-May-2032 $7.16  CAD  4,745 
Theresa Ende 11-Jul-2033 $5.70  CAD  18,712 
Theresa Ende 08-Nov-2032 $4.00  CAD  41,368 
Mo Jinyu 08-Nov-2032 $3.54  CAD  31,250 
Mo Jinyu 06-Jan-2031 $8.10  CAD  75,000 
Raju Kankipati 08-Nov-2032 $3.54  CAD  31,250 
Raju Kankipati 03-Apr-2032 $8.73  CAD  43,750 
Yong Meng Lee 08-Nov-2032 $3.54  CAD  17,188 
Yong Meng Lee 04-Apr-2031 $11.90  CAD  17,189 
Yong Meng Lee 09-Jun-2030 $5.30  CAD  17,500 
Yong Meng Lee 01-Nov-2029 $3.30  CAD  100,000 
Michal Lipson 18-Jun-2032 $6.59  CAD  5,194 
Michal Lipson 11-Jul-2033 $5.70  CAD  18,712 
Michal Lipson 08-Nov-2032 $4.00  CAD  41,368 
Jean-Louis Malinge 04-Apr-2031 $11.90  CAD  11,250 
Jean-Louis Malinge 11-Jul-2033 $5.70  CAD  18,712 
Jean-Louis Malinge 09-Jun-2030 $5.30  CAD  26,382 
Jean-Louis Malinge 26-May-2029 $3.80  CAD  36,053 
Jean-Louis Malinge 18-Jun-2028 $3.30  CAD  39,900 
Jean-Louis Malinge 08-Nov-2032 $4.00  CAD  41,368 
Jean-Louis Malinge 03-Sep-2027 $3.00  CAD  52,500 
Thomas Mika 04-Apr-2031 $11.90  CAD  30,939 
Thomas Mika 08-Nov-2032 $4.00  CAD  31,250 
Thomas Mika 14-Jan-2027 $3.85  CAD  50,000 
Thomas Mika 09-Jun-2030 $5.30  CAD  52,500 
Thomas Mika 11-Jul-2027 $2.80  CAD  80,000 
Thomas Mika 25-Mar-2028 $5.20  CAD  95,000 
Thomas Mika 31-Oct-2026 $6.20  CAD  100,000 
Thomas Mika 26-May-2029 $3.80  CAD  100,000 
Vivek Rajgarhia 04-Apr-2031 $11.90  CAD  30,939 
Vivek Rajgarhia 08-Nov-2032 $4.00  CAD  31,250 
Vivek Rajgarhia 09-Jun-2030 $5.30  CAD  99,376 
Vivek Rajgarhia 01-Nov-2029 $3.30  CAD  102,400 
Glen Riley 04-Apr-2031 $11.90  CAD  11,250 
Glen Riley 11-Jul-2033 $5.70  CAD  20,792 
Glen Riley 02-Dec-2030 $5.00  CAD  22,460 
Glen Riley 08-Nov-2032 $4.00  CAD  45,965 
Chris Tsiofas 04-Apr-2031 $11.90  CAD  12,500 
Chris Tsiofas 05-Jul-2026 $8.60  CAD  15,000 
Chris Tsiofas 11-Jul-2033 $5.70  CAD  20,792 
Chris Tsiofas 09-Jun-2030 $5.30  CAD  29,314 
Chris Tsiofas 26-May-2029 $3.80  CAD  44,065 

Page 59

Chris Tsiofas 08-Nov-2032 $4.00  CAD  45,965 
Chris Tsiofas 18-Jun-2028 $3.30  CAD  48,767 
Chris Tsiofas 11-Jul-2027 $2.80  CAD  68,750 
Suresh Venkatesan 05-Jul-2026 $8.60  CAD  30,000 
Suresh Venkatesan 04-Apr-2031 $11.90  CAD  44,689 
Suresh Venkatesan 08-Nov-2032 $4.00  CAD  62,500 
Suresh Venkatesan 09-Jun-2030 $5.30  CAD  218,750 
Suresh Venkatesan 11-Jul-2027 $2.80  CAD  280,000 
Suresh Venkatesan 25-Mar-2028 $5.20  CAD  390,000 
Suresh Venkatesan 26-May-2029 $3.80  CAD  450,000 
             3,782,718 

  

Number of Warrants exercisable within 60 days

 Exercise price CA$
Glen Riley 5,000 5.00

F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation.

In 2023, the Company adopted a compensation recovery policy (the “Compensation Recovery Policy”) in compliance with Nasdaq listing standards and Rule 10D-1 of the Exchange Act, a copy of which is filed as Exhibit 97.1 to this Annual Report on Form 20-F.

We were not required to prepare an accounting restatement during the year ended December 31, 2023. As of December 31, 2023, there was no outstanding balance of erroneously awarded compensation to be recovered pursuant to the Compensation Recovery Policy.

ITEMItem 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONSMajor Shareholders and Related Party Transactions

A.A.Major Shareholders.

Holdings by Major Shareholders

Please refer to ITEMItem 6.E. “Share Ownership” for details regarding securities held by Directors, Officers and Major Shareholders.

With the exception of the participation in private placements of equity by Pinetree and Mr. Inwentash there has not been a significant change in the percentage ownership held by any major shareholders during the past three years other than through public purchases or dispositions of shares on the TSXV.

41

The Company’s major shareholders do not have any different or special voting rights.

U.S. Share Ownership

As of February 22, 2016,March 15, 2024, there were a total of 453405 holders of record of our common shares with addresses in the U.S. We believe that the number of U.S beneficial owners is substantially greater than the number of U.S record holders, because a large portion of our common shares are held of record in broker “street names.” As of February 22, 2016,March 15, 2024, U.S. holders of record held approximately 2.36%17% of our outstanding common shares.

Control of Company

The Company is a publicly owned Ontario corporation, the common shares of which are owned by Canadian residents, U.S. residents and other foreign residents. The Company is not controlled by any foreign government or other person(s) except as described in ITEM“Item 4.A. “HistoryHistory and Progress of the Company” and ITEM“Item 6.E. “ShareShare Ownership.”

Change of Control of Company Arrangements

On August 13, 2013, the Board of DirectorsNone

Page 60

B.Related Party Transactions.

No shareholder beneficially owns 5% or more of the Company approved a resolution authorizing the CompanyCompany’s common shares.

Compensation to implement a Shareholders Rights Plan (a “Rights Plan”), subject to all required approvals, including TSXV approval. The shareholders of the Company ratified the Board’s resolution at a meeting held on August 12, 2014. Authorization of a Rights Plan is intended to reflect developments in Canada with respect to shareholder rights planskey management personnel (CEO, CFO, President, GM POET Technologies Pte Ltd, VP Finance and is designed to encourage the fair treatment of shareholders in connection with any take-over bid for the Company. See ITEM 10.B. “Articles of the Corporation.”Treasurer, VP Product Line Management, SVP, GM Asia) was as follows:

  2023  2022  2021 
          
Salaries $2,044,920  $2,010,479  $1,782,297 
Share-based payments (1)  1,771,078   1,711,716   2,077,333 
             
Total $3,815,998  $3,722,195  $3,859,630 

B.(D)Related Party TransactionsShare-based payments are the fair value of options granted to key management personnel and expensed during the various years as calculated using the Black-Scholes model.

The firm of Stikeman Keeley Spiegel Pasternack LLP, of which Mr. O’Donnell is counsel, billed the sum of $104,790 for legal fees and disbursements incurred in 2015 (2014 - $174,549).

C.C.Interests of Experts and Counsel.

Not applicable.

ITEMItem 8. FINANCIAL INFORMATIONFinancial Information

A.A.Consolidated Statements and Other Financial Information.

The Company’s financial statements are stated in U.S. dollars and are prepared in accordance with IFRS as issued by the IASB.

The financial statements as required under “ITEM“Item 17. Financial Statements” are attached hereto and found immediately following the text of this Annual Report. The audit report of Marcum LLP, independent registered public accounting firm, is included herein immediately preceding the consolidated financial statements.

Legal Proceedings

The directors and the senior management of the Company do not know of any material, either active or pending, legal proceedings against them, nor is the Company involved as a plaintiff in any material proceeding or pending litigation.

The directors and the senior management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest in the Company.

42

Dividend Policy

The Company has not paid, and has no current plans to pay, dividends on its common shares. We currently intend to retain future earnings, if any, to finance the development of our business. Any future dividend policy will be determined by the Board, and will depend upon, among other factors, our earnings, if any, financial condition, capital requirements, any contractual restrictions with respect to the payment of dividends, the impact of the distribution of dividends on our financial condition, tax liabilities, and such economic and other conditions as the Board may deem relevant.

Page 61

B.B.Significant Changes.

During 2015,On February 24, 2022, the Company raised $12,076,681 fromfiled Articles of Amendment to consolidate its common shares on a ten-for-one basis. For further clarity, for every ten (10) pre-consolidated common shares, shareholders received one (1) post-consolidated common share. On February 28, 2022 the exercise of 22,413,431 warrantsCompany’s common shares began trading on the TSXV on a post consolidation basis. The Company’s name and 8,106,300 stock options.trading symbol remained unchanged. All references to share and per share amounts in these consolidated financial statements and accompanying notes to the consolidated financial statements have been retroactively restated to reflect the ten-for-one share consolidation.

Between January 1, 2016 and February 22, 2016,On March 14, 2022 the Company raised $1,965,327 fromCompany’s common shares began trading on Nasdaq under the exercise of 2,686,947 warrants and 628,000 stock options.trading symbol “POET”.

ITEMItem 9. THE OFFER AND LISTINGThe Offer and Listing

A.A.Offer and Listing Details.

The Company’s common shares began trading on the TSXV in Toronto, Ontario, Canada, on June 25, 2007. The current Stock symbol is “PTK”. The CUSIP/ISN numbers are 73044W104 / 73044W1041. The Company received new CUSIP/ISN numbers on the consolidation of the common shares on February 24, 2022. The new CUSIP/ISN numbers are 73044W302/73044W3021.

The following table lists the high and low sales price on the TSXV for the Company’s common shares for: the last six months; the last ten fiscal quarters; and the last five fiscal years.

Period Ended  High (CA$)   Low (CA$) 
Monthly        
February 22, 2016 $1.10  $0.95 
January 31, 2016 $0.98  $0.84 
December 31, 2015 $1.05  $0.80 
November 30, 2015 $0.95  $0.79 
October 31, 2015 $1.20  $0.72 
September 30, 2015 $0.99  $0.75 
         
Quarterly        
December 31, 2015 $1.20  $0.72 
September 30, 2015 $1.68  $0.62 
June 30, 2015 $2.00  $1.38 
March 31, 2015 $1.62  $1.01 
December 31, 2014 $1.61  $0.65 
September 30, 2014 $2.24  $0.90 
June 30, 2014 $2.87  $1.26 
March 31, 2014 $1.49  $0.49 
December 31, 2013 $0.60  $0.315 
         
Yearly        
December 31, 2015 $2.00  $0.62 
December 31, 2014 $2.87  $0.49 
December 31, 2013 $0.74  $0.20 
December 31, 2012 $0.74  $0.195 
December 31, 2011 $1.82  $0.26 
Period Ended 

High (CA$)

  

Low (CA$)

 
MONTHLY        
28-Feb-24  2.04   1.75 
31-Jan-24  1.79   1.18 
31-Dec-23  1.54   1.02 
30-Nov-23  3.83   1.01 
31-Oct-23  4.49   3.72 
30-Sep-23  5.50   4.17 
QUARTERLY        
28-Feb-24  2.04   1.06 
30-Nov-23  5.50   1.01 
31-Aug-23  7.75   4.84 
31-May-23  6.90   4.80 
28-Feb-23  8.31   3.60 
30-Nov-22  5.41   3.26 
31-Aug-22  7.39   4.13 
31-May-22  13.65   7.04 
28-Feb-22  11.25   7.60 
30-Nov-21  12.90   7.70 
YEARLY        
31-Dec-23  8.31   1.01 
31-Dec-22  13.65   3.26 
31-Dec-21  15.80   7.10 
31-Dec-20  7.10   2.20 
31-Dec-19  4.60   2.70 

43Page 62

B.B.Plan of Distribution.

Not Applicable.required.

C.C.Markets.

The Company’s common shares trade on (i) the TSXV in Canada under the symbol “PTK”. The Company’s common shares also trade on and (ii) Nasdaq in the OTCQX International MarketplaceUnited Stated under the symbol “POETF”“POET” (since March 14, 2022).

D.D.Selling Shareholders.

Not Applicable.required.

E.E.Dilution

Not Applicable.required.

F.F.Expenses of the Issue

Not Applicable.required.

ITEMItem 10. ADDITIONAL INFORMATIONAdditional Information

A.A.Share Capital

Not Applicable.required.

B.B.Memorandum and Articles of the CorporationAssociation.

The Company was originally formed under the British Columbia Company Act on February 9, 1972 as Tandem Resources Ltd. (“Tandem”). The Company took its current form after Tandem amalgamated with Stanmar Resources Ltd. and Keezic Resources Ltd. pursuant to Articles of Amalgamation on November 14, 1985. Tandem moved to Ontario by Articles of Continuance on January 3, 1997. Tandem changed its name to OPEL International Inc. by Articles of Amendment on September 26, 2006. OPEL International Inc. was continued under the New Brunswick Business Corporations Act on January 30, 2007, then back to Ontario by Articles of Continuance on November 30, 2010, changing its name to OPEL Solar International Inc. By Articles of Amendment on August 25, 2011, OPEL Solar International Inc. changed its name to OPEL Technologies, Inc. By Articles of Amendment on July 23, 2013, OPEL Technologies Inc. changed its name to POET Technologies Inc. Today, the Company is an Ontario corporation governed by the OBCA. The following are summaries of material provisions of our Articles of Continuance, as amended from time to time (the “Articles”), in effect as of the date of this Annual Report insofar as they relate to the material terms of our ordinarycommon shares.

Register, Entry Number and Purposes

Our Articles of Continuance became effective on November 30, 2010. Our corporation number in Ontario is 641402. The Articles of Continuance do not contain a statement of the Company’s objects and purposes, howeverpurposes. However, the Articles of Continuance provide that there are no restrictions on business that the Company may carry on or the powers the Company may exercise as permitted under the OBCA.

Page 63

 

Board of Directors

Pursuant to our By-laws and the OBCA, a director or officer who is a party to, or who is a director or officer of, or has a material interest in, any person who is a party to, a material contract or proposed material contract with the Company, shall disclose the nature and extent of his interest at the time and in the manner provided by the OBCA. Any such contract or proposed contract shall be referred to the Board or shareholders for approval even if such contract is one that in the ordinary course of the Company’s business would not require approval by the Board or shareholders, and a director interested in a contract so referred to the Board shall not vote

44

on any resolution to approve the same unless the contract or transaction: (i) relates primarily to his or her remuneration as a director of the Company or an affiliate; (ii) is for indemnity or insurance of or for the director or officer as permitted by the OBCA; or (iii) is with an affiliate.

Directors shall be paid such remuneration for their services as the Board may determine by resolution from time to time, and will be entitled to reimbursement for traveling and other expenses properly incurred by them in attending meetings of the Board or any committee thereof. Neither the Company’s Articles nor By-laws require an independent quorum for voting on director compensation. Directors are not precluded from serving the Company in any other capacity and receiving remuneration therefor. A director is not required to hold shares of the Company. There is no age limit requirement respecting the retirement or non-retirement of directors.

The directors may sign the name and on behalf of the Company, or appoint any officer or officers or any other person or persons on behalf of the Corporation either to sign on behalf of the Company, all instruments in writing and any instruments in writing so signed shall be binding upon the Company without further authorization or formality. The term “instruments in writing” includes contracts, documents, powers of attorney, deeds, mortgages, hypothecs, charges, conveyances, transfers and assignments of property (real or personal, immovable or movable), agreements, tenders, releases, receipts and discharges for the payment of money or other obligations, conveyances, transfers and assignments of shares, stocks, bonds, debentures or other securities, instruments of proxy and all paper writing.

Nothing in the Company’s By-laws limits or restricts the borrowing of money by the Company on bills of exchange or promissory notes made, drawn, accepted or endorsed by or on behalf of the Company.

Rights, Preferences and Restrictions Attaching to Common Shares

The holders of common shares are entitled to vote at all meetings of the shareholders, except meetings at which only holders of a specified class of shares are entitled to vote. Each common share carries with it the right to one vote. Subject to the rights, privileges, restrictions and conditions attaching to any other class or series of shares of the Company, the holders of the common shares are entitled to receive any dividends declared and payable by the Company on the common shares. Dividends may be paid in money or property or by issuing fully paid shares of the Company. Subject to the rights, privileges, restrictions and conditions attaching to any other class or series of shares of the Company, the holders of the common shares are entitled to receive the remaining property of the Company upon dissolution.

The holder of the Company’s one outstanding Special Voting Share is not entitled to any dividends or other distributions in respect of such share or any proceeds of liquidation or dissolution. The holder of such share is entitled to receive notice of and to attend and vote at any annual and special meetings of the shareholders and is entitled to the number of votes as is equal to the aggregate number of common shares that may be acquired upon exercise of the holder exchange rights attached to outstanding shares of Exchangeable Common Stock. The Special Voting Share is automatically redeemed by the Company, without notice, immediately once no Exchangeable Common Shares remain outstanding. The Special Voting Share was cancelled following a Board resolution on June 21, 2013.

No shares have been issued subject to call or assessment. There are no preemptivepre-emptive or conversion rights and no provisions for redemption or purchase for cancellation, surrender, or sinking or purchase funds. The common shares must be issued as fully-paid and non-assessable, and are not subject to further capital calls by the Company. The common shares are without par value. All of the common shares rank equally as to voting rights, participation in a distribution of the assets of the Company on a liquidation, dissolution or winding-up of the Company and the entitlement to dividends.

The Company does not currently have any preferred shares outstanding.

Page 64

 

Ordinary and Special Shareholders’ Meetings

The OBCA provides that the directors of a corporation shall call an annual meeting of shareholders not later than 15 months after holding the last preceding annual meeting. The OBCA also provides that, in the case of an offering corporation, the directors shall place before each annual meeting of shareholders, the financial statements required to be filed under the Ontario Securities Act and the regulation thereunder relating to the period that began immediately after the end of the last completed financial year and ended not more than six months before the annual meeting and the immediately preceding financial year, if any.

The Board has the power to call a special meeting of shareholders at any time.

Notice of the date, time and location of each meeting of shareholders must be given not less than 21 days or more than 50 days before the date of each meeting to each director, to the auditor of the Company and to each shareholder who at the close of business on the record date for notice is entered in the securities register as the holder of one or more shares carrying the right to vote at the meeting.

45

Notice of a meeting of shareholders called for any other purpose other than consideration of the minutes of an earlier meeting, financial statements, reports of the directors or auditor, setting or changing the number of directors, the election of directors and reappointment of the incumbent auditor, must state the general nature of the special business in sufficient detail to permit the shareholder to form a reasoned judgment on such business, must state the text of any special resolution to be submitted to the meeting, and must, if the special business includes considering, approving, ratifying, adopting or authorizing any document or the signing of or giving of effect to any document, have attached to it, a copy of the document or state that a copy of the document will be available for inspection by shareholders at the Company’s records office or another accessible location.

The only persons entitled to be present at a meeting of shareholders are those entitled to vote, the directors of the Company and the auditor of the Company. Any other person may be admitted only on the invitation of the chairman of the meeting or with the consent of the meeting. In circumstances where a court orders a meeting of shareholders, the court may direct how the meeting may be held, including who may attend the meeting.

Limitations on Rights to Own Securities

No share may be issued until it is fully paid.

Neither Canadian law nor our Articles or By-laws limit the right of a non-resident to hold or vote common shares of the Company, other than as provided in the Investment Canada Act (the “Investment Act”), as amended by the World Trade Organization Agreement Implementation Act (the “WTOA Act”). The Investment Act generally prohibits implementation of a direct reviewable investment by an individual, government or agency thereof, corporation, partnership, trust or joint venture that is not a “Canadian,” as defined in the Investment Act (a “non-Canadian”), unless, after review, the minister responsible for the Investment Act is satisfied that the investment is likely to be of net benefit to Canada. An investment in the common shares of the Company by a non-Canadian (other than a “WTO Investor,” as defined below) would be reviewable under the Investment Act if it were an investment to acquire direct control of the Company, and the value of the assets of the Company were CA$5.0 million or more (provided that immediately prior to the implementation of the investment the Company was not controlled by WTO Investors). An investment in common shares of the Company by a WTO Investor (or by a non-Canadiannon- Canadian other than a WTO Investor if, immediately prior to the implementation of the investment the Company was controlled by WTO Investors) would be reviewable under the Investment Act if it were an investment to acquire direct control of the Company and the value of the assets of the Company equaled or exceeded an amountcertain threshold amounts determined by the Minister of Finance (Canada) (the “Minister”) on an annual basis.

The Minister has determinedthreshold for a pre-closing net benefit review depends on whether the purchaser is: (a) controlled by a person or entity from a member of the WTO; (b) a state- owned enterprise (SOE); or (c) from a country considered a “Trade Agreement Investor” under the Investment Act. A different threshold also applies if the Canadian business carries on a cultural business. The 2024 threshold for WTO investors that are SOEs will be $528 million based on the thresholdbook value of the Canadian business’ assets, up from $512 million in 2023. The 2024 thresholds for review for direct acquisitions of control of Canadian businesses by private sector investor WTO Investors or vendors (other than Canadians) to be CA$375 million forinvestors is $1.326 billion and private sector trade- agreement investors is $1.989 billion and are both based on the year 2015. “enterprise value” of the Canadian business being acquired.

Page 65

A non-Canadian, whether a WTO Investor or otherwise, would be deemed to acquire control of the Company for purposes of the Investment Act if he or she acquired a majority of the common shares of the Company. The acquisition of less than a majority, but at least one-third of the shares, would be presumed to be an acquisition of control of the Company, unless it could be established that the Company is not controlled in fact by the acquirer through the ownership of the shares. In general, an individual is a WTO Investor if he or she is a “national” of a country (other than Canada) that is a member of the World Trade OrganizationWTO (“WTO Member”) or has a right of permanent residence in a WTO Member. A corporation or other entity will be a “WTO Investor” if it is a “WTO Investor-controlled entity,” pursuant to detailed rules set out in the Investment Act. The U.S. is a WTO Member. Certain transactions involving our common shares would be exempt from the Investment Act, including:

·an acquisition of the shares if the acquisition were made in the ordinary course of that person’s business as a trader or dealer in securities;
·
an acquisition of control of the Company in connection with the realization of a security interest granted for a loan or other financial assistance and not for any purpose related to the provisions of the Investment Act; and
·
an acquisition of control of the Company by reason of an amalgamation, merger, consolidation or corporate reorganization, following which the ultimate direct or indirect control in fact of the Company, through the ownership of voting interests, remains unchanged.

Procedures to Change the Rights of Shareholders

In order to change the rights of our shareholders with respect to certain fundamental changes as described in Section 168 of the OBCA, the Company would need to amend our Articles to effect the change. Such an amendment would require the approval of holders of two-thirds of the votes of the Company’s common shares, and any other shares carrying the right to vote at any general meeting of the shareholders of the Company, cast at a duly called special meeting. The OBCA also provides that a sale, lease or exchange of all or substantially all of the property of a corporation other than in the ordinary course of business of the corporation likewise requires the approval of the shareholders at a duly called special meeting. For such fundamental changes and sale, lease and exchange, a shareholder is entitled under the OBCA to dissent in respect of such a resolution amending the Articles and, if the resolution is adopted and the Company implements such changes, demand payment of the fair value of the shareholder’s common shares.

46

Impediments to Change of Control

ThereIn 2016, the Canadian Securities Administrators (the “CSA”) enacted amendments (the “Bid Amendments”) to the Take-Over Bid Regime. The Bid Amendments, which are no provisions of our Articles or By-laws that would have an effect of delaying, deferring or preventing a changevery significant, are contained in controlNational Instrument (NI) 62-104.

The Bid Amendments were intended to enhance the quality and integrity of the Companytake-over bid regime and that would operate onlyrebalance the current dynamics among offerors, offeree issuer boards of directors (“Offeree Boards”), and offeree issuer security holders by (i) facilitating the ability of offeree issuer security holders to make voluntary, informed and coordinated tender decisions, and (ii) providing the Offeree Board with respectadditional time and discretion when responding to a merger, acquisition or corporate restructuring involvingtake-over bid.

Specifically, the Company. On August 13, 2013, the Board of Directors of the Company approved a resolution authorizing the Company to implement a Shareholders Rights Plan (a “Rights Plan”), subject toBid Amendments require that all required approvals, including TSXV approval. The shareholders of the Company ratified the Board’s resolution at a meeting held on August 12, 2014. The approval of a Rights Plan is intended to reflect developments in Canada with respect to shareholder rights plans and is designed to encourage the fair treatment of shareholders in connection with anynon-exempt take-over bid for the Company.bids

The Rights Plan will provide the Board and the shareholders with more time to fully consider any unsolicited take-over bid for the Company without undue pressure. Furthermore, the Rights Plan will allow the Board to pursue, if appropriate, other alternatives to maximize shareholder value and to allow additional time for competing bids to emerge.

The Rights Plan was not proposed in response to, or in anticipation of, any acquisition or takeover offer and is not intended to prevent a take-over bid for the Company. Under the Rights Plan, take-over bids that meet certain requirements intended to protect the interests of all shareholders will be deemed to be “Permitted Bids”. Permitted Bids must be made by way of a takeover bid circular prepared in compliance with applicable securities laws and, among other conditions, must remain open for sixty days.

The details of the Rights Plan are summarized below.

Rights

One Right will be issued and will attach to each outstanding Common Share of the Company. A Right only becomes exercisable upon the occurrence of a Flip-In Event, which is a transaction by which a person becomes an Acquiring Person and which otherwise does not meet the requirements of a Permitted Bid. Prior to the Flip-In Event, the Rights are priced at five (5) times the Market Price of the Common Shares at the Separation Time (the “Exercise Price”). Separation Time means the close of business on the tenth Trading Day after the earlier of the first public announcement indicating that a person has become an Acquiring Person or the date of the commencement or first public announcement of an intention to commence a Take-over Bid (other than a Permitted Bid or Competitive Permitted Bid). If a Flip-In Event occurs, each Right issued under the Rights Plan thereafter will entitle all holders, other than the Acquiring Person, to purchase for the Exercise Price (5 times the Market Price) that number of Common Shares of the Company having an aggregate market value equal to twice the Exercise Price (2 times 5 times the Market Prices being 10 times the Market Price). The result of this provision is that, in the event a Flip-In Event occurs, subject to all other provisions of this agreement, each Right will constitute the right to purchase from the Company ten (10) additional Common Shares at 50% of the Market Price at the time of the Flip-In Event. This purchase could cause substantial dilution to the person or group of persons attempting to acquire control of the Company, other than by way of a Permitted Bid. The Rights expire on the termination of the Rights Plan, unless redeemed before such time.

Acquiring Person

An Acquiring Person is generally a person who becomes the beneficial owner of 20% or more of the outstanding Common Shares of the Company. Under the Rights Plan, there are various exceptions to the definition of Acquiring Person, including a person who acquires 20% or more of the outstanding Common Shares from (i) acquisitions of Common Shares by the Company (e.g. through an issuer bid), (ii) pro rata distributions of Common Shares by the Company, (iii) acquisitions of Common Shares upon exercise of Convertible Securities acquired pursuant to certain exempt transactions, (iv) an amalgamation, merger or other statutory procedure requiring shareholder approval, or (v) the issuance of Common Shares on an exempt private placement basis (subject to certain limits); and underwriters who acquire Common Shares for the purpose of a public distribution.

Beneficial Ownership

The thresholds for triggering the Rights Plan are based on the percentage of shares that are Beneficially Owned by a person or its Affiliates or Associates. This is defined in terms of legal or beneficial ownership of Common Shares. In addition, a person is deemed to be the Beneficial Owner of Common Shares in circumstances where that person or its Affiliates or Associates, as such terms are defined in the Rights Plan, and any other person acting jointly or in concert with such person, has a right to acquire Common Shares within 60 days. There are various exceptions to this definition set forth in the Rights Plan.

Permitted Bid

If a Take-over Bid is structured as a Permitted Bid, a Flip-In Event will not occur and the Rights will not become exercisable. Permitted Bids must be made by means of a Take-over Bid circular and comply with the following:

·(D)the Take-over Bid must be made to all shareholders other than the bidder;

47

·the Take-over Bid must not permit the bidder to take up any Common Shares that have been tendered pursuant to the Take- over Bid prior to the expiryreceive tenders of a period not less than 60 days after the Take-over Bid is made, and then only if at such time more than 50% of the Common Shares heldoutstanding securities of the class that are subject to the bid, excluding securities beneficially owned, or over which control or direction is exercised, by the Independent Shareholders (which term generally includes shareholders other than the bidder, its Affiliates, Associates and personsofferor or by any person acting jointly or in concert with the bidder), have been tendered pursuant to the Take-over Bid and not withdrawn;offeror (the Minimum Tender Requirement);

·the Take-over Bid must contain an irrevocable and unqualified provision that, unless it is withdrawn, Common Shares may be tendered at any time during the 60-day period referred to in the immediately preceding paragraph and that any Common Shares deposited pursuant to the Take-over Bid may be withdrawn until they have been taken up and paid for; andPage 66

(2) be extended by the offeror for an additional 10 days after the Minimum Tender Requirement has been achieved and all other terms and conditions of the bid have been complied with or waived (the 10 Day Extension Requirement); and

(3) remain open for a minimum deposit period of 105 days (the Minimum 105 Day Bid Period) unless

·(D)the Take-over Bidofferee board states in a news release a shorter deposit period for the bid of not less than 35 days, in which case all contemporaneous take-over bids must contain an irrevocable and unqualified provision that, if more than 50% of the Common Shares held by Independent Shareholders are tendered pursuant to the Takeover Bid within the 60-day period, then the bidder must make a public announcement of that fact and the Take-over Bid must then remain open for an additional 10 business days fromat least the date of such public announcement.stated shorter deposit period, or

The Rights Plan also allows(b) the issuer issues a Competing Permitted Bidnews release that it intends to be made whileeffect, pursuant to an agreement or otherwise, a Permitted Bid isspecified alternative transaction, in existence. A Competing Permitted Bid is a Take-over Bid that is made after a Permitted Bid has been made, but prior to its expiry, that satisfieswhich case all of the requirements of a Permitted Bid, except that (i) no Common Shares will be taken up or paid for until the later to occur of the date which is generally 35 days after the date the Take-over Bid is made and the 60th day after the date of the Permitted Bid that is then outstanding, and (ii) at the close of business on the date Common Shares are first taken up or paid for, more than 50% of the then outstanding Common Shares held by Independent Shareholders have been tendered in such Take-over Bid and not withdrawn. If this 50% requirement is satisfied, the applicable bidder must make a public announcement of that fact and the Take-over Bidcontemporaneous take-over bids must remain open for tendersa deposit period of Common Shares for at least ten business days after35 days.

The Bid Amendments involved fundamental changes to the datebid regime to establish a majority acceptance standard for all non-exempt take-over bids, a mandatory extension period to alleviate offeree security holder coercion concerns, and a 105 day minimum deposit period to address concerns that offeree boards did not have enough time to respond to an unsolicited take-over bid. The CSA determined not to amend National Policy 62-202 Defensive Tactics (NP 62-202) in connection with these amendments. They reminded participants in the capital markets of such public announcement.the continued applicability of NP 62-202, which means that securities regulators will be prepared to examine the actions of offeree boards in specific cases, and in light of the amended bid regime, to determine whether they are abusive of security holder rights.

The requirementsAfter canvassing several commentaries concerning the new regime, we have concluded that:

It will be much more difficult for hostile bidders as a result of target issuers having a much longer period of time to respond, concurrent with the added risk and cost to such bidders.
There is good reason to expect that, except in unusual circumstances, regulators will not permit SRPs to remain in effect after a 105 day bidding period.
A significant number of reporting issuers have not sought re-approval of their SRPs since the amendments were introduced and those that have sought to renew their SRPs have been required to amend the plans to comply with the new rules.
A large part of the traditional rationale for adopting SRPs has now been eliminated.

We believe that the amended take-over bid rules provide adequate protection against hostile bids. Having said that, it has been suggested that the new rules do not protect against creeping take-over bids for control which are exempt from the rules (such as the accumulation of 20% or more of the issuer’s shares through market transactions or the acquisition of a Permitted Bid andcontrol block through private agreements with a Competing Permitted Bid enable shareholdersfew large shareholders). These activities would however be identifiable through the early warning filing requirements. If, prior to decide whether the Take-over Bid or any Competing Permitted Bid is adequate on its own merits, without being influenced by the likelihood thatmaking a Take-over Bid will succeed. Moreover, if there is sufficient support for a Take-over Bid such that at least 50% of the Common Shares held by Independent Shareholders have been tendered to it, a shareholder who has not yet tendered to that bid will have a further 10 business days in which to decide whether to withdraw its Common Shares from a Competing Take-over Bid, if any, and whether to tender to the Take-over Bid.

Waiver and Redemption

Until the occurrence of a Flip-In Event as to which the Board has not issued a waiver, the Board, with the prior consent of the holders of Common Shares, may elect to redeem all but not less than all of the then outstanding Rights at a redemption price of $0.0001 (subject to adjustment) per Right. In addition, until the occurrence of a Flip-In Event as to which the Board has not issued a waiver, the Board may determine to waive the application of the Rights Plan to any Flip-In Event, provideddetermination that the Board will be deemedCompany ought to have waivedadopt a “strategic” SRP at an annual or special meeting of shareholders, the application ofCompany were faced with a hostile bid that we believed was not in the Rights Plan to any other Flip-In Event occurring by reason of a Take-over Bid made prior to the expiry of the Take-over Bid in respect of which the waiver is granted. The Board may also waive the application of the Rights Plan to any Flip-In Event if the Board determines that the Person became an Acquiring Person by inadvertence and without any intention to become, or knowledge that it would become, an Acquiring Person and such Person has reduced its Beneficial Ownership of Common Shares such that, at the time of the granting of a waiver, such Person is no longer an Acquiring Person. The Board will be deemed to have redeemed the Rights at the Redemption Price on the date that the Person making the Permitted Bid, Competing Permitted Bid or Takeover Bid in respect of which the Board has waived or been deemed to waive the application of the Rights Plan, has taken up and paid for the Common Shares pursuant to the applicable bid.

Termination

The Rights Plan will expire, subject to certain conditions, at the close of the Annual Meeting of Shareholdersbest interests of the Company three years afterand its shareholders, the Rights Plan is ratified bydirectors could adopt a “tactical” plan which we could take to the shareholders and every three-year anniversary thereafter and so on unless the continuationfor approval. Nevertheless, at this point in time, we are of the Rights Plan for eachopinion that such three- year period (or other period approved by the Independent Shareholders)action is approved by the Independent Shareholders of the Company.

Full Text of Rights Plan

The full text of the Rights Plan is contained in a Shareholders’ Rights Plan Agreement between the Companynot necessary and the Rights Agent, TMX Equity Transfer Services Inc., and is available onshareholders should be the Company’s website at www.poet-technologies.com.best arbiters of when “the pill must go”.

The Rights Plan will be subject to reconfirmation at every third annual meeting of shareholders subsequent to the approval date until its expiry. If the shareholders do not confirm the Rights Plan, the Rights Plan will terminate and cease to be effective at that time.

48

Stockholder Ownership Disclosure Threshold in Bylaws

Neither our Articles nor By-laws contain a provision governing the ownership threshold above which shareholder ownership must be disclosed. Pursuant to securities legislation, an Early Warning Report and an Insider Report must be filed if a shareholder obtains ownership on a partially diluted basis of 10% or greater of the Company.

Page 67

 

Special Conditions for Changes in Capital

The conditions imposed by the Company’s Articles are not more stringent than required under the OBCA.

C.C.Material Contracts.

In addition to any contracts described in “ITEM“Item 7.B. Related Party Transactions” or “ITEM“Item 4. Business Overview”, below is a summary of material contracts, other than those entered into by the Company in the ordinary course of business, to which we are or have been a party during the two years immediately preceding the date of this document. Other than contracts entered into in the ordinary course of business, we have not been a party to any other material contract within such two yeartwo-year period.

None

D.1.On May 21, 2008, the Company entered into an Agreement with BAE Systems Information And Electronic Systems Integration, Inc. (“BAE”), with a term of 15 years, whereby BAE and the Company initiated a joint development program of the Company’s POET technology, with royalties running from each to the other for licensed products sold. This Agreement was supplemented on February 25, 2015 to expand the scope of work to be performed through 2015 Exchange Controls. At present, there has not been any joint process development or transfer under this agreement, and none is anticipated in the future.

2.On April 28, 2003, the Company entered into a License Agreement with the University of Connecticut (“UCONN”), as amended on April 15, 2014 whereby UCONN granted the Company an exclusive license to the intellectual property developed under the direction of Dr. Taylor that is owned or jointly owned by UCONN for the payment of $50,000 due in the first and each subsequent year after the Company has revenue of $100,000 from the products developed pursuant to the licensed intellectual property, such amounts of consideration subject to increase by 25% every two years, up to a maximum of $1,000,000. In addition, the Company must pay annually to UCONN 3% of any sublicense revenue received for commercial, royalty bearing sublicenses of licensed intellectual property to third parties. By making a $100,000 payment to UCONN in April 2007, the license became irrevocable. As consideration for the amendment entered into on April 15, 2014, changing the royalty rate to 3%, the Company issued 2,000,000 common shares, subject to approval of the TSXV, which shall be restricted from trading until May 31, 2016.

3.On October 21, 2010, the Company entered into a Lease Agreement, as amended on March 20, 2013, with UCONN whereby the Company leases property from UCONN beginning on April 1, 2010 and extending through March 31, 2014. Monthly rent increases from $6,130 in the first three months of year one to $10,966 in year five. This Agreement was renewed on December 11, 2014 for a period of one year commencing April 1, 2015 and ending on March 31, 2016. The renewal provides for an annual rent of $158,894, discounted to $144,490 if the full amount is prepaid.

4.On February 15, 2013, the Company entered into a Service Agreement with True South Renewables, Inc. (“True South”), for a period of five years, whereby the True South will perform monitoring and maintenance services on solar trackers installed by the Company prior to the discontinuation of the solar business and divestiture of the solar assets. The Company will pay a minimum of $6,000.00 in the first year and $8,013.00 in the fifth year, in addition to hourly charges for labor and travel.

49

D.Exchange Controls

Canada has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of the Company’s securities, except as discussed in “ITEM“Item 10.E. Taxation” below.

E.E.TaxationTaxation.

The following summary discusses certain material U.S. and Canadian tax considerations related to the holding and disposition of common shares as of the hereof. Prospective purchasers of our common shares are advised to consult their own tax advisers concerning the consequences under the tax laws of the country of which they are resident or in which they are otherwise subject to tax of making an investment in our common shares.

Canadian Federal Income Tax Considerations

The Company believes the following is a brief summary of the material principal Canadian federal income tax consequences to a U.S. Holder (as defined below) of common shares of the Company who deals at arm’s length with the Company, holds the shares as capital property and who, for the purposes of the Income Tax Act (Canada) (the “Tax Act”) and the Canada — U.S. Income Tax Convention (1980) (the “Treaty”), is at all relevant times resident in the U.S., is not and is not deemed to be resident in Canada and does not use or hold and is not deemed to use or hold the shares in carrying on a business in Canada. Special rules, which are not discussed below, may apply to a U.S. Holder that is an insurer that carries on business in Canada and elsewhere. U.S. Holders are urged to consult their own tax advisors with respect to their particular circumstances.

This summary is based upon the current provisions of the Tax Act, the regulations thereunder in force at the date hereof, all specific proposals to amend such regulations and the Tax Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof and the current provisions of the Convention and the current administrative practices of the Canada Revenue Agency published in writing prior to the date hereof. This summary does not otherwise take into account or anticipate any changes in law or administrative practices whether by legislative, governmental or judicial decision or action, nor does it take into account tax laws of any province or territory of Canada or of the U.S. or of any other jurisdiction outside Canada.

For the purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of the common shares must be converted into Canadian dollars based on the relevant exchange rate applicable thereto.

This summary does not address all aspects of Canadian federal income taxation that may be relevant to any particular U.S. Holder in light of such holder’s individual circumstances. Accordingly, U.S. Holders should consult with their own tax advisors for advice with respect to their own particular circumstances.

Page 68

 

Under the Tax Act and the Treaty, a U.S. Holder of common shares will generally be subject to a 15% withholding tax on dividends paid or credited or deemed by the Tax Act to have been paid or credited on such shares. The withholding tax rate is 5% where the U.S. Holder is a corporation that beneficially owns at least 10% of the voting shares of the Company and the dividends may be exempt from such withholding in the case of some U.S. Holders such as qualifying pension funds and charities.

A U.S. Holder will generally not be subject to tax under the Tax Act on any capital gain realized on a disposition of common shares, provided that the shares do not constitute “taxable Canadian property” to the U.S. Holder at the time of disposition. Generally, common shares will not constitute taxable Canadian property to a U.S. Holder provided that such shares are listed on a designated stock exchange (which currently includes the TSXV) at the time of the disposition and, during the 60-month60- month period immediately preceding the disposition, the U.S. Holder, persons with whom the U.S. Holder does not deal at arm’s length, or the U.S. Holder together with all such persons has not owned 25% or more of the issued shares of any series or class of the Company’s capital stock. If the common shares constitute taxable Canadian property to a particular U.S. Holder, any capital gain arising on their disposition may be exempt from Canadian tax under the Convention if at the time of disposition the common shares do not derive their value principally from real property situated in Canada.

U.S. Federal Income Tax Considerations

Subject to the limitations described herein, the following discussion summarizes certain U.S. federal income tax consequences to a U.S. Holder of our common shares. A “U.S. Holder” means a holder of our common shares who is:

U.S.Holder of our common shares. A “U.S. Holder” means a holder of our common shares who is:

·an individual who is a citizen or resident of the U.S. for U.S. federal income tax purposes;
·a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in the U.S. or under the laws of the U.S. or any political subdivision thereof, or the District of Columbia;
·an estate, the income of which is subject to U.S. federal income tax regardless of its source; or

50

·a trust (i) if, in general, a court within the U.S. is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial decisions, or (ii) that has in effect a valid election under applicable U.S. Treasury Regulations to be treated as a U.S. person.

U.S. persons have the authority to control all of its substantial decisions, or (ii) that has in effect a valid election under applicable U.S. Treasury Regulations to be treated as a U.S. person.

Unless otherwise specifically indicated, this discussion does not consider the U.S. tax consequences to a person that is not a U.S. Holder (a “Non-U.S. Holder”). This discussion considers only U.S. Holders that will own our common shares as capital assets (generally, for investment) and does not purport to be a comprehensive description of all of the tax considerations that may be relevant to each U.S. Holder’s decision to purchase our common shares.

This discussion is based on current provisions of the Internal Revenue Code of 1986, as amended (the “Code”), current and proposed Treasury Regulations promulgated thereunder, and administrative and judicial decisions as of the date hereof, all of which are subject to change, possibly on a retroactive basis. This discussion does not address all aspects of U.S. federal income taxation that may be relevant to any particular U.S. Holder in light of such holder’s individual circumstances. In particular, this discussion does not address the potential application of the alternative minimum tax or the U.S. federal income tax consequences to U.S. Holders that are subject to special treatment, including U.S. Holders that:

·are broker-dealers or insurance companies;
·have elected market-to-market accounting;
·are tax-exempt organizations or retirement plans;
·are financial institutions or “financial services entities”;
·hold our common shares as part of a straddle, “hedge” or “conversion transaction” with other investments;
·acquired our common shares upon the exercise of employee stock options or otherwise as compensation;
·own directly, indirectly or by attribution at least 10% of our voting power;

·Page 69

have a functional currency that is not the U.S. Dollar;
·are grantor trusts;
·are certain former citizens or long-term residents of the U.S.; or
·are real estate trusts or regulated investment companies.

If a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds our common shares, the tax treatment of the partnership and a partner in such partnership will generally depend on the status of the partner and the activities of the partnership. Such a partner or partnership should consult its own tax advisor as to its tax consequences.

In addition, this discussion does not address any aspect of state, local or non-U.S. laws or the possible application of U.S. federal gift or estate taxes.

Each holderpotential U.S Holder of our common shares is advised to consult its own tax advisor with respect to the specific tax consequences to it of purchasing, holding or disposing of our common shares, including the applicability and effect of federal, state, local and foreign income tax and other laws to its particular circumstances.

Distributions

Subject to the discussion below under Passive“Passive Foreign Investment Company Status,,” a U.S. Holder will be required to include in gross income as ordinary dividend income the amount of any distribution paid on our common shares, including any non-U.S. taxes withheld from the amount paid, to the extent the distribution is paid out of our current or accumulated earnings and profits as determined for U.S. federal income tax purposes. Distributions in excess of such earnings and profits will be applied against and will reduce the U.S. Holder’s basis in our common shares and, to the extent in excess of such basis, will be treated as gain from the sale or exchange of our common shares. The dividend portion of such distributions generally will not qualify for the dividends received deduction available to corporations. U.S. Holders which are individuals, estates and trusts and whose income exceeds certain thresholds will be required to pay a 3.8% surtax on “net investment income” including, among other things, dividends (if any) and net gain realized from our common shares. U.S. Holders should consult with their own tax advisors regarding the application of this tax.

Subject to the discussion below under Passive“Passive Foreign Investment Company Status,,” dividends that are received by U.S. Holders that are individuals, estates or trusts will be taxedmay qualify for taxation at the rate applicable to long-term capital gains (a maximum marginal federal income tax rate of 20% for taxable years beginning after January 1, 2013)), provided that such U.S. Holders satisfy certain holding period requirements and such dividends meet the requirements of “qualified dividend income.” For this purpose, qualified dividend income generally includes dividends paid by a non-U.S. corporation may qualify if certain holding period and other requirements are met and the non-U.S. corporation is eligible for benefits of a comprehensive income tax treaty with the U.S., which benefits include an information exchange program and is determined to be satisfactory by the U.S. Secretary of the Treasury. The IRS has determined that the U.S.-CanadaU.S.- Canada Tax Treaty is satisfactory for this purpose. Dividends that fail to meet such requirements, and dividends received by corporate U.S. Holders, are taxed at ordinary income rates. No dividend received by a U.S. Holder will be a qualified dividend (i) if the U.S. Holder held the common share with respect to which the dividend was paid for less than 61 days during the 121-day period beginning on the date that is 60 days before the ex-dividend date with respect to such dividend, excluding

51

for this purpose, under the rules of Code Section 246(c), any period during which the U.S. Holder has an option to sell, is under a contractual obligation to sell, has made and not closed a short sale of, is the grantor of a deep-in-the-money or otherwise nonqualified option to buy, or has otherwise diminished its risk of loss by holding other positions with respect to, such common share (or substantially identical securities); or (ii) to the extent that the U.S. Holder is under an obligation (pursuant to a short sale or otherwise) to make related payments with respect to positions in property substantially similar or related to the common share with respect to which the dividend is paid. If we were to be a “passive foreign investment company” (as such term is defined in the Code) for any taxable year, dividends paid on our common shares in such year or in the following taxable year would not be qualified dividends. In addition, a non-corporate U.S. Holder will be able to take a qualified dividend into account in determining its deductible investment interest (which is generally limited to its net investment income) only if it elects to do so; in such case the dividend will be taxed at ordinary income rates.

Distributions of current or accumulated earnings and profits paid in foreign currency to a U.S. Holder (including any non-U.S. taxes withheld therefrom) will be includible in the income of a U.S. Holder in a U.S. Dollar amount calculated by reference to the exchange rate on the day the distribution is received. A U.S. Holder that receives a foreign currency distribution and converts the foreign currency into U.S. dollars subsequent to receipt may have foreign exchange gain or loss based on any appreciation or depreciation in the value of the foreign currency against the U.S. dollar, which€h will generally be U.S. source ordinary income or loss. A loss might not be deductible due to certain limitations.

Page 70

 

U.S. Holders will have the option of claiming the amount of any non-U.S. income taxes withheld at source either as a deduction from gross income or as a dollar-for-dollardollar-for- dollar credit against their U.S. federal income tax liability. Individuals who do not claim itemized deductions, but instead utilize the standard deduction, may not claim a deduction for the amount of the non-U.S. income taxes withheld, but such amount may be claimed as a credit against the individual’s U.S. federal income tax liability. The amount of non-

U.S.non-U.S. income taxes which may be claimed as a credit in any taxable year is subject to complex limitations and restrictions, which must be determined on an individual basis by each shareholder. These limitations include, among others, rules whichthat limit foreign tax credits allowable with respect to specific classes of income to the U.S. federal income taxes otherwise payable with respect to each such class of income. A U.S. Holder will be denied a foreign tax credit with respect to non-U.S. income tax withheld from a dividend received on the common shares if such U.S. Holder hasdoes not held the common shares for at least 16 days of the 31-daysatisfy certain holding period beginning on the date which is 15 days before the ex-dividend date with respect to such dividend, or to the extent such U.S. Holder is under an obligation to make related payments with respect to substantially similar or related property. Any days during which a U.S. Holder has substantially diminished its risk of loss on the common shares are not counted toward meeting the required 16-day holding period. requirements.

Distributions of current or accumulated earnings and profits generally will be foreign source passive income for U.S. foreign tax credit purposes.

Disposition of Common Shares

Subject to the discussion below under Passive“Passive Foreign Investment Company Status,,” upon the sale, exchange or other taxable disposition of our common shares, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder’s basis in such common shares, which is usually the cost of such shares, and the amount realized on the disposition. A U.S. Holder that uses the cash method of accounting calculates the U.S. Dollar value of the proceeds received on the sale as of the date that the sale settles, while a U.S. Holder that uses the accrual method of accounting is required to calculate the value of the proceeds of the sale as of the “trade date,” unless such U.S. Holder has elected to use the settlement date to determine its proceeds of sale. Capital gain from the sale, exchange or other disposition of common shares held more than one year is long-term capital gain, and is eligible for a reduced rate of taxation for individuals (currently a maximum marginal federal income tax rate of 20% for taxable years beginning after January 1, 2013), plus the 3.8% net investment income tax discussed above, if applicable). Gains recognized by a U.S. Holder on a sale, exchange or other disposition of common shares generally will be treated as U.S. source income for U.S. foreign tax credit purposes. A loss recognized by a U.S. Holder on the sale, exchange or other taxable disposition of common shares generally is allocated to U.S. source income. The deductibility of capital losses recognized on the sale, exchange or other taxable disposition of common shares is subject to limitations. A U.S. Holder that receives foreign currency upon disposition of common shares and converts the foreign currency into U.S. dollars subsequent to the settlement date or trade date (whichever date the taxpayer was required to use to calculate the value of the proceeds of sale) may have foreign exchange gain or loss based on any appreciation or depreciation in the value of the foreign currency against the U.S. Dollar, which will generally be U.S. source ordinary income or loss. Such loss may not be deductible due to certain limitations.

Passive Foreign Investment Company Status

We would be a passive foreign investment company (a “PFIC”) if (taking into account certain “look-through” rules with respect to the income and assets of our corporate subsidiaries in which we own 25 percent (by value) of the stock) either (i) 75 percent or more of our gross income for the taxable year was passive income or (ii) the average percentage (by value) of our total assets that are passive assets during the taxable year was at least 50 percent.

If we were a PFIC, each U.S. Holder would (unless it made one of the elections discussed below on a timely basis) be taxable on gaingains recognized from the disposition of our common shares (including gain deemed recognized if the common shares are used as security for a loan) and upon receipt of certain “excess distributions” (generally, distributions that exceed 125% of the average amount of

52

distributions in respect to such common shares received during the preceding three taxable years or, if shorter, during the U.S. Holder’s holding period prior to the distribution year) with respect to our common shares as if such income had been recognized ratably over the U.S. Holder’s holding period for the common shares. The U.S. Holder’s income for the current taxable year would include (as ordinary income) amounts allocated to the current taxable year and to any taxable year period prior to the first day of the first taxable year for which we were a PFIC. Tax would also be computed at the highest ordinary income tax rate in effect for each other taxable year period to which income is allocated, and an interest charge on the tax as so computed would also apply. Additionally, if we were a PFIC, U.S. Holders who acquire our common shares from decedents (other than nonresidentnon resident aliens) would be denied the normally available step-up in basis for such shares to fair market value at the date of death and, instead, would have a tax basis in such shares equal to the decedent’s basis, if lower.

Page 71

 

As an alternative to the tax treatment described above, a U.S. Holder could elect to treat us as a “qualified electing fund” (a “QEF”), in which case the U.S. Holder would be taxed currently, for each taxable year that we are a PFIC, on its pro rata share of our ordinary earnings and net capital gain (subject to a separate election to defer payment of taxes, which deferral is subject to an interest charge). Special rules apply if a U.S. Holder makes a QEF election after the first taxable year in its holding period in which we are a PFIC. In the event that we conclude that we will be classified as a PFIC, we will make a determination at such time as to whether we will be able to provide U.S. Holders with the information that is necessary to make a QEF election. Amounts includable in income as a result of a QEF election will be determined without regard to our prior year losses or the amount of cash distributions, if any, received from us. A U.S. Holder’s basis in its common shares will increase by any amount included in income and decrease by any amounts not included in income when distributed because such amounts were previously taxed under the QEF rules. So long as a U.S. Holder’s QEF election is in effect with respect to the entire holding period for its common shares, any gain or loss realized by such holder on the disposition of its common shares held as a capital asset ordinarily will be capital gain or loss. Such capital gain or loss ordinarily would be long-term if such U.S. Holder had held such common shares for more than one year at the time of the disposition. For non- corporate U.S. Holders, long-term capital gain is generally subject to a maximum U.S. federal income tax rate of 15% for taxable years beginning on or before December 31, 2012. The QEF election is made on a shareholder-by-shareholder basis, applies to all common shares held or subsequently acquired by an electing U.S. Holder and can be revoked only with the consent of the IRS.

As an alternative to making the QEF election, a U.S. Holder of PFIC stock which is publiclyregularly traded on a qualified exchange may in certain circumstances avoid certainthe negative effects of the tax consequences generally applicable to holders of a PFIC rules by electing to mark the stock to market and recognizing as ordinary income or loss, each taxable year that we are a PFIC, an amount equal to the difference as of the close of the taxable year between the fair market value of the PFIC stock and the U.S. Holder’s adjusted tax basis in the PFIC stock. Special rules apply if a U.S. Holder makes a mark-to-market election after the first taxable year in its holding period in which we are a PFIC. Losses would be allowed only to the extent of net mark-to-market gain previously included by the U.S. Holder under the election for prior taxable years. This election is available for so long as the Company’s common shares constitute “marketable stock,” which includes stock of a PFIC that is “regularly traded” on a “qualified exchange or other market.” Generally, a “qualified exchange or other market” includes a national market system established pursuant to Section 11A of the Exchange Act, or a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located and that has certain characteristics. A class of stock that is traded on one or more qualified exchanges or other markets is “regularly traded” on an exchange or market for any calendar year during which that class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter, subject to special rules relating to an initial public offering. It is not entirely clear whether either the OTCBBNasdaq or TSXV are qualified exchanges or other markets, or whether there will be sufficient trading volume with respect to the Company’s common shares, and accordingly, whether the common shares will be “marketable stock” for these purposes. Furthermore, there can be no assurances that the Company’s common shares will continue to trade on any of the exchanges listed above.

We believe we were not a PFIC for the year ending December 31, 20152022 and do not expect to be classified as a PFIC for the year ending December 31, 2016.2023. However, PFIC status is determined as of the end of each taxable year and is dependent on a number of factors, including the value of our passive assets, the amount and type of our gross income, and our market capitalization. Therefore, there can be no assurance that we will not becomebe classified as a PFIC for the current taxable year ending December 31, 2016 or in a future taxable year. We will notify U.S. Holders in the event we conclude that we will be treated as a PFIC for any taxable year.

Non–U.S. Holders

Except as described in “Information Reporting and Backup Withholding” below, a Non-U.S. Holder of common shares will not be subject to U.S. federal income or withholding tax on the payment of dividends on, or the proceeds from the disposition of, our common shares, unless, in the case of U.S. federal income taxes:

·such item is effectively connected with the conduct by the Non-U.S. Holder of a trade or business in the U.S. and, in the case of a resident of a country which has a treaty with the U.S., such item is attributable to a permanent establishment or, in the case of an individual, a fixed place of business, in the U.S.; or

53

·the Non-U.S. Holder is an individual who holds the common shares as a capital asset and is present in the U.S. for 183 days or more in the taxable year of the disposition of our common shares and certain other conditions are met.

Information Reporting and Backup Withholding

U.S. Holders (other than exempt recipients, such as corporations) generally are subject to information reporting requirements with respect to dividends paid on, or proceeds from the disposition of, our common shares. U.S. Holders are also generally subject to backup withholding (currently at a rate of 28%24%) on dividends paid on, or proceeds from the disposition of, our common shares unless the U.S. Holder provides IRS Form W-9 or otherwise establishes an exemption.

Non-U.S. Holders generally are not subject to information reporting or backup withholding with respect to dividends paid on, or proceeds from the disposition of, our common shares, provided that such Non-U.S. Holder provides taxpayer identification number, certifies to its foreign status, or otherwise establishes an exemption.

The amount of any backup withholding will be allowed as a credit against a U.S. or Non-U.S. Holder’s U.S. federal income tax liability and may entitle such holder to a refund, provided that certain required information is furnished to the IRS.

F.F.Dividends and Paying Agents.

Not Applicable.required.

Page 72

G.G.Statements by Experts.

The consolidated financial statements of POET Technologies Inc. as of December 31, 2015, 20142023, 2022 and 20132021 included herein, have been audited by Marcum LLP, our independent registered accounting firm for that period, 185 Asylum St, 17555 Long Wharf Drive, 8thFloor, Hartford,New Haven, CT 06103,06511, USA, as stated in their report appearing herein, and isare included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.

H.H.Documents on Display.

The Company’s documents can be viewed at its Canadian office, located at: Suite 501, 121 Richmond Street West,1107, 120 Eglinton Avenue East, Toronto, Ontario M5H 2K1,M4P 1E2, Canada. Further, we file reports under Canadian regulatory requirements on SEDAR; you may access our reports filed on SEDAR by accessing their website at www.sedar.com. The Company is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the Exchange Act), and files reports, Annual Reports and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. The Company’s reports, Annual Reports and other information can be inspected on the SEC’s website at www.sec.gov and such information can also be inspected and copies ordered at the public reference facilities maintained by the SEC at the following location: 100 F Street NE, Washington, D.C. 20549.website.

As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and currentother reports and financial statements with the SEC as frequently or as promptly as United States domestic companies whose securities are registered under the Exchange Act.

We maintain a corporate website atwww.poet-technologies.com.Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference.

I.I.Subsidiary informationInformation.

Not Applicable.applicable.

J.Annual Report to Security Holders.

If we are required to furnish an annual report to security holders on Form 6-K, we will submit such annual report in electronic format in accordance with the EDGAR Filer Manual.

ITEMItem 11. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

Short-term investments bear interest at fixed rates, and as such, are subject to interest rate risk resulting from changes in fair value from market fluctuations in interest rates. The Company does not depend on interest from its investments to fund its operations.

54

Exchange Rate Risk

The Company is exposed to foreign currency risk with the Canadian dollar. The Company maintains bank accounts and cash reserves in both currencies with the majority of reserves currently in Canadian dollars which has exposure to currency fluctuations. Most of the company’s operations are transacted in US dollars. A 10% change in the Canadian dollar would increase or decrease other comprehensive loss by $1,135,639.

The following table shows exchange rates, from CAD to USD, for the past six months:

Period High (1) Low (1) Average (2)
February 2016  0.7408   0.7140   0.7250 
January 2016  0.7228   0.6847   0.7057 
December 2015  0.7494   0.7164   0.7294 
November 2015  0.7645   0.7475   0.7533 
October 2015  0.7756   0.7529   0.7652 
September 2015  0.7611   0.7456   0.7537 
Sept. 2015 — February 22, 2016  0.7756   0.6847   0.7386 

(1)Bank of Canada monthly average rates
(2)Bank of Canada daily closing average rates

Market Risk

Market risk arises from the possibility that changes in market prices will affect the value of the financial instruments of the Company. The Company is exposed to fair value fluctuations on its cash equivalents. The Company’s other financial instruments (cash and accounts payable and accrued liabilities) are not subject to market risk, due to the short-termshort- term nature of these instruments. The Company manages market risk through its investment policy where surplus funds are only invested in a manner that will provide the optimal blend of investment returns and principal protection while meeting its daily cash flow and liquidity demands.

Interest Rate Risk

Short-term investments bear interest at fixed rates, and as such, are subject to interest rate risk resulting from changes in fair value from market fluctuations in interest rates. The Company does not depend on interest from its investments to fund its operations.

Page 73

Exchange Rate Risk

The functional currency of each of the entities included in the accompanying consolidated financial statements is the local currency where the entity is domiciled. Functional currencies include the Chinese Yuan, US, Singapore and Canadian dollar. Most transactions within the entities are conducted in functional currencies. As such, none of the entities included in the consolidated financial statements engage in hedging activities. The Company is exposed to a foreign currency risk when its subsidiaries hold current assets or current liabilities in currencies other than its functional currency. A 10% change in foreign currencies held would increase or decrease other comprehensive loss by $198,000.

The following table shows exchange rates, from CAD to USD, for the past six months:

Period High (1)  Low (1)  Average (2) 
          
February 2024  0.7471   0.7363   0.7411 
January 2024  0.7506   0.7394   0.7451 
December 2023  0.7575   0.7354   0.7460 
November 2023  0.7373   0.7218   0.7296 
October 2023  0.7362   0.7207   0.7289 
September 2023  0.7437   0.7308   0.7375 
September 2023 — February 2024  0.7575   0.7207   0.7381 

(1)Bank of Canada monthly average rates
(2)Bank of Canada daily closing average rates

The following table shows exchange rates, from SGD to USD, for the past six months:

Period High (1)  Low (1)  Average (2) 
          
February 2024  0.7479   0.7399   0.7434 
January 2024  0.7537   0.7434   0.7482 
December 2023  0.7576   0.7437   0.7510 
November 2023  0.7509   0.7306   0.7414 
October 2023  0.7338   0.7279   0.7302 
September 2023  0.7386   0.7285   0.7333 
September 2023 — February 2024  0.7576   0.7279   0.7413 

(1)Bank of Singapore monthly average rates
(2)Bank of Singapore daily closing average rates

The following table shows exchange rates, from CNY to USD, for the past six months:

Period High (1)  Low (1)  Average (2) 
          
February 2024  0.1395   0.1389   0.1390 
January 2024  0.1400   0.1390   0.1394 
December 2023  0.1408   0.1393   0.1400 
November 2023  0.1402   0.1367   0.1383 
October 2023  0.1371   0.1366   0.1368 
September 2023  0.1377   0.1361   0.1370 
September 2023 — February 2024  0.1408   0.1361   0.1384 

(1)Bank of China monthly average rates
(2)Bank of China daily closing average rates

Page 74

ITEMItem 12. Description ofOf Securities Other thanThan Equity Securities

A.A.Debt Securities.

Not Applicablerequired.

B.B.Warrants and Rights

Not Applicable.required.

C.C.Other Securities

Not Applicable.required.

D.D.American Depositary Shares.

Not Applicable.applicable.

PART II

ITEMItem 13. Defaults, Dividend Arrearages and Delinquencies

Not Applicable.applicable.

ITEMItem 14. Material Modifications to the Rights of Security Holders and Use of Proceeds

Not Applicable.applicable.

55

ITEMItem 15. Controls and Procedures

(a)Disclosure Controls and Procedures

We have performedDisclosure Controls and Procedures.

Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) under the Exchange Act as controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we carried out an evaluation of the effectiveness of our disclosure controls and procedures that are designed to ensure that the material financial and non-financial information required to be disclosed to the SEC is recorded, processed, summarized and timely reported.procedures. Based on oursuch evaluation, our management, including the CEOChief Executive Officer and CFO, hasChief Financial Officer concluded that, as of December 31, 2023, our disclosure controls and procedures (aswere not effective due to a material weakness in our internal control over financial reporting. A material weakness, as defined in Rules 13a-15(e) and 15d-15(e)the Sarbanes Oxley Act of 2002 (“SOX”), is a control deficiency, or combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report are effective. Notwithstanding the foregoing, there canannual consolidated financial statements will not be no assurance that our disclosure controls and procedures will detectprevented or uncover all failures of persons withindetected on a timely basis. The material weakness resulted from a cybersecurity event in which the Company, late in the year, received a fraudulent request to disclosepay an amount owing to a single vendor. The Company’s controls over the validity of such requests were not effective and as a result an immaterial amount was paid to an unauthorized party. Management identified the fraud and recovered the amount through its pre-existing insurance coverage. Management immediately put in place additional cyber controls to ensure that the Company’s assets are appropriately safe guarded. However, because there was not sufficient time to test those additional controls prior to year-end, the Chief Executive Officer and the Chief Financial Officer determined that a material information otherwise required to be set forth in our reports.weakness existed at December 31, 2023 (the “Cybersecurity Material Weakness”).

Page 75

 

(b)Management’s Annual Report on Internal Control over Financial Reporting

The Company’sManagement’s Annual Report on Internal Control Over Financial Reporting.

Our management, under the oversight of our Board of Directors and management are(in particular its audit committee), is responsible for establishing and maintaining adequate internal control over financial reporting.reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act and as set forth in Section 404 of SOX). The Company’s internal control system wasover financial reporting is designed to provide reasonable assurance to management and the Board of Directors regarding the reliability of financial reporting and the preparation and fair presentation of its published consolidated financial statements. Under the SOX framework, our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board. Our internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with IFRS, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.

All internal control systems,controls over financial reporting, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective may not prevent or detect misstatements and can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2015.2023. In making this assessment, it used the criteria established inInternal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that assessment and those criteria, management concluded that we did not maintain effective internal controls over financial reporting as of December 31, 2015,2023 as a result of the Cybersecurity Material Weakness.

The Cybersecurity Material Weakness did not result in a material misstatement of our consolidated financial statements for the fiscal year ended December 31, 2023 or any prior annual or interim periods nor has it resulted in any material failure to safeguard our assets, including our cash and fixed assets. However, if the Cybersecurity Material Weakness is not remediated, a material misstatement of account balances or disclosures may not be prevented, and may go undetected, which could result in a material misstatement of future annual or interim consolidated financial statements.

Following the identification of the Cybersecurity Material Weakness, management has taken steps to remediate that material weakness. Specifically, management has:

Added a procedure that requires vendors to provide on letterhead both the original bank information and the changed bank information.

Page 76

Put in place a call back procedure to contact the vendor to get verbal confirmation of the change, including confirming pertinent transactions related to prior business activity.
Upgraded email security and monitoring to more effectively identify phishing and spoofing events; and .
Initiated training programs to help staff more quickly identify spoofing and phishing events.

Although management has taken immediate remedial steps, the Cybersecurity Material Weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. Further, our independent registered accounting firm has not performed an audit of our internal control over financial reporting subsequent to December 31, 2023 and we cannot give assurances that the measures we have thus far taken to remediate the aforementioned material weakness were sufficient or that they will prevent future material weaknesses. As management continues to evaluate and work to improve our internal control over financial reporting, we may determine it necessary to take additional measures or modify the remediation measures we have taken to date.

Attestation Report of the Registered Public Accounting Firm.

Marcum LLP, the independent registered public accounting firm that audited the consolidated financial statements of the Company included in this Annual Report on Form 20-F, and has issued an attestation report on the effectiveness of the Company’s internal control over financial reporting is effective based onas of December 31, 2023.

Changes in Internal Controls Over Financial Reporting.

We have undertaken the remediation efforts described. Except for those criteria.

(c)Attestation Report of Registered Public Accounting Firm

Not applicable.

(d)Changes in Internal Controls over Financial Reporting

Thereefforts, there were no other changes in our internal control over financial reporting that occurred during the year ended December 31, 20152023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEMItem 16. [RESERVED][Reserved]

ITEMItem 16A. Audit Committee Financial Expert

Our Board of Directors has determined that Chris Tsiofas is thean audit committee financial expert. The Board has determined that Mr. Tsiofas satisfies the criteria of “audit committee financial expert” within the meaningset forth in Item 16A of Item 401(h) of regulation S-KForm 20-F and is independent in accordance with Rule 4200 of the Nasdaq Marketplace Rules.

ITEMItem 16B. Code of Ethics

In December 2007,As amended in February 2023, our Board of Directors adopted a Code of Business Conduct and Ethics (the “Code”) that applies to all our employees, including without limitation our chief executive officer, chief financial officer and principal accounting officer. Our Code may be viewed on our website atwww.poet-technologies.comand is filed as an Exhibit to this Annual Report. A copy of our Code may be obtained, without charge, upon a written request addressed to our investor relations department, 121 Richmond Street West,office at, 120 Eglinton Avenue East, Suite 201,1107, Toronto, Ontario M5H 2K1,M4P 1E2, Canada.

Page 77

 

ITEM

Item 16C. Principal Accountant Fees and Services Fees Paid to Independent Registered Public Accounting Firm

The following table sets forth, for each of the years indicated, the fees billed by our independent registered public accounting firm, Marcum LLP.

 Year Ended December 31, Year Ended December 31, 
Services Rendered 2015 2014 2023 2022 
  (in US$)    
Audit-Related Fees (1) $69,000  $59,000 
All Other Fees (2)  10,000   10,000 
Audit Fees (1) $470,455  $340,000 
Audit-Related Fees (2)  -   - 
Tax Fees (3)  16,715   14,440 
All Other Fees (4)  -   - 
Total  79,000   69,000  $487,170   354,440 

__________________________

(1)(1)Audit Fees included fees consistfor the audit of the Company’s annual consolidated financial statements, SOX 404(b) audit and professional services that would normally be providedrendered in connection with statutoryfiling of registration statements.
(2)Audit-Related Fees include fees for assurance and regulatory filings or engagements, includingrelated services that generally onlyare reasonably related to the performance of the audit and are not reported under audit fees. These fees primarily include accounting consultations regarding the accounting treatment of matters that occur in the regular course of business, implications of new accounting pronouncements, acquisitions and other accounting issues that occur from time to time.
(3)Tax Fees include fees for professional services rendered by our independent accountant can reasonably provide.
(2)Tax fees relate toregistered public accounting firm for tax compliance planning and advice.tax advice on actual or contemplated transactions.
(4)All Other Fees include fees for services rendered by our independent registered public accounting firm with respect to government incentives and other matters.

56

Our Audit Committee, in accordance with its charter, reviews and pre-approves all audit services and permitted non-audit services (including the fees and other terms) to be provided by our independent auditors. All of the services provided by Marcum LLP over the past two years were pre-approved by the Audit Committee.

Not Applicable.

ITEMItem 16D. Exemptions from the Listing Standards for Audit Committees

Not Applicable.applicable.

ITEMItem 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers

Not Applicable.applicable.

ITEMItem 16F. Change in Registrant’s Certifying AccountantsAccountant.

Not Applicable.applicable.

ITEMItem 16G. Corporate Governance

Not Applicable.A foreign private issuer that follows home country practices in lieu of certain provisions of the Nasdaq rules must disclose the ways in which its corporate governance practices differ from those followed by U.S. domestic companies. As required by Nasdaq Rule 5615(a)(3), the Company discloses on its website, www.poet-technologies.com, each requirement of the Nasdaq rules that it does not follow and describes the home country practice it follows in lieu of such requirements.

ITEMItem 16H. Mine Safety Disclosure

Not applicable.

Page 78

 

Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not Applicable.applicable.

Item 16J. Insider Trading Policies

The Company has adopted an Insider Trading Policy governing the purchase, sale and other dispositions of the Company’s securities by directors, senior management and employees that is reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and all applicable listing standards. A copy of the policy is filed as Exhibit 11.2 hereto.

Item 16K. Cybersecurity

We believe cybersecurity is key to the Company achieving its strategic goals and objectives. Based on the nature of our business and the industry in which we operate, we are faced with a variety of cybersecurity threats including phishing emails, ransomware attacks, malicious attachments, social engineering attacks and denial of service attacks, among others. Our customers, suppliers, subcontractors and partners face similar cybersecurity threats, and a cybersecurity incident impacting us or any of these entities could materially adversely affect our operations, performance and results of operations.

Our information security organization has implemented a governance structure and processes to assess, identify, manage and report cybersecurity risks. We engage third-party service providers to conduct evaluations of our security controls, including testing both the design and operational effectiveness of security controls.

In the event of an incident, we intend to follow our incident management procedures, which outline the steps to be followed from incident detection to mitigation, recovery and notification, including notifying functional areas (e.g., legal, compliance and internal audit), as well as senior leadership and the Board, as appropriate.

On a regular basis, the Company analyzes its internet-based services to identify vulnerabilities and assesses the protection and the detection capabilities. The cybersecurity compliance status of assets is centrally evaluated across the Company’s global sites and business and operational functions. Results are shared within the Company’s relevant business units and across global functions. The Company implements corrective measures and improvement actions in response to these processes, as appropriate. Data classification and protection tools are in place, such as the implementation of a specific process and technology aimed at detecting and responding to abnormal data flows.

Cybersecurity risks and threats, including as a result of any previous cybersecurity incidents, have not materially impacted and are not reasonably expected to materially impact us or our operations to date. However, we recognize the ever-evolving cyber risk landscape and cannot provide any assurances that we will not be subject to a material cybersecurity incident in the future.

Governance

The Board of Directors and our Audit Committee oversee management’s processes for identifying and mitigating risks, including cybersecurity risks, to help align our risk exposure with our strategic objectives. Senior leadership have developed a process to regularly brief the Audit Committee and Board of Directors on our cybersecurity and information security policies and procedures, and the Board of Directors will be apprised of cybersecurity incidents deemed to have a potential material impact on the Company.

We use an outsourced IT firm, to manage our overall information security strategy, policy, cyber threat detection and response, cyber architecture and processes for the security of our network and intellectual property. Various technologies and techniques are used to monitor and manage cybersecurity risks. Policies and processes are regularly updated.

Page 79

 

PART III

ITEMItem 17. Financial Statements

The Company’s consolidated financial statements are stated in U.S. dollars and are prepared in accordance with IFRS.IFRS as issued by the International Accounting Standards Board.

The consolidated financial statements required under ITEMItem 17 are attached hereto and found immediately following the text of this Annual Report and are incorporated by reference herein. The audit report of Marcum LLP, independent registered public accounting firm, is included herein immediately preceding the audited consolidated financial statements.

a.Audited Financial Statements— for the years ended December 31, 2015, 20142023, 2022 and 20132021 and as of December 31, 2015, 20142023, 2022 and 20132021

ITEMItem 18. Financial Statements

The Company has elected to provide financial statements pursuant to ITEMItem 17.

ITEM

Item 19. Exhibits

1.11.1Certificate and Articles of Continuance* (1)
1.21.2Amended and Restated Bylaws** (2)
1.34.1Asset Purchase Agreement with Tracker Acquisition, Inc.,Articles of Amendment, dated December 17, 2012*February 24, 2022 (8)
2.04.2Agreement with BAE Systems Information And Electronic Systems Integration, Inc., dated May 21, 2008*Description of Securities (6)
4.14.3License Agreement with the University of Connecticut, dated April 28, 2003, as amended April 15, 2014* (1)
4.34.4Lease Agreement with the University of Connecticut, dated December 11, 2014.**
4.5Agency Agreement with IBK Capital Corp., dated February 14, 2013*
4.6Credit Agreement with TCA Global Credit Master Fund, LP, dated March 30, 2012*
4.7Memorandum of Understanding with Ajit Manocha, dated July 3, 2014**
4.8Letter of Agreement with Daniel DeSimone, dated March 28, 2014**
4.9Executive Employment Agreement with Peter Copetti, dated June 30, 2014**
4.10Shareholder Rights Plan Agreement between the Company and TMX Equity Transfer Services, Inc.**(2)
4.44.11Consulting Agreement with Dr. Geoff Taylor, dated January 12, 2015**
4.12Employment Agreement with Stephane Gagnon, dated November 5, 2013*
4.13Employment Agreement with Suresh Venkatesan, dated June 10, 2015 ***(3)
4.54.14Employment Agreement with Subhash Deshmukh,Vivek Rajgarhia, dated June 8, 2015 ***November 4, 2019 (6)

574.6Employment Agreement with Thomas Mika, dated November 2, 2016 (4)

4.74.152014Definitive agreement with San’an Integrated Circuit Co., Ltd dated October 21, 2020 (7)
4.8Sale and Purchase Agreement for DenseLight Semiconductors PTE, LTD, dated April 27, 2016 (4)
4.9Sale and Purchase Agreement for BB Photonics Inc. dated May 16, 2016 (4)
4.102021 Stock Option Plan** (8)
4.114.16Form of Option Agreement*Agreement(1)
4.124.17Form of Warrant for Purchase of Common Shares* (1)
4.134.18Stock Specimen Certificate* (1)
4.158.1Share Sale Agreement for DenseLight Semiconductors PTE, Ltd dated August 20, 2019 (6)
4.16Omnibus Incentive Plan (10)
4.18Underwriting Agreement with Maxim Group LLC (10)
4.20Form of Warrant Certificate, December 4, 2023 (10)
4.22Securities Trading Policy (10)
4.23Equity Distribution Agreement Dated June 29, 2023 (10)
4.24Equity Distribution Agreement Dated September 1, 2023 (10)
4.27Warrant indenture with TSX Trust Company, dated February 11, 2021 (7)
4.28Engagement letter with Cormark Securities Inc, dated January 25, 2021 (7)
4.29Upsize letter with Cormark Securities Inc, dated January 26, 2021 (7)
4.30Form of Subscription for Units of Private Placement, dated February 11, 2021 (7)
4.31Form of Subscription for Units of Private Placement, dated December 2, 2022 (9)
4.32Form of Warrant Certificate, dated December 2, 2022 (9)
8.1List of Subsidiaries: See ITEM 4.C.Subsidiaries (10)
11.111.1Code of Business Conduct and Ethics** (7)
12.112.1Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)*** under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (10)
12.212.2Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)*** under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (10)
13.113.1Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*** (10)
13.213.2Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*** (10)
23.1Consent of Marcum LLP, independent registered accounting firm (10)
97.1POET Technologies Inc. Clawback Policy (10)
101. INS(*)Inline XBRL Instance Document (10)
101.SCH(*)Inline XBRL Taxonomy Extension Schema Linkbase Document (10)
101. AL(*)Inline XBRL Taxonomy Extension Calculation Linkbase Document (10)
101.DEF(*)Inline XBRL Taxonomy Extension Definition Linkbase Document (10)
101.LAB(*)Inline XBRL Taxonomy Extension Label Linkbase Document (10)
101.PRE(*)Inline XBRL Taxonomy Extension Presentation Linkbase Document (10)
104(*)Cover Page Interactive Data File (embedded within Inline XBRL document) (10)

_____________________

*(1) Filed as an exhibit to the Company’s registration statement under the Securities and Exchange Act on Form 20-F/A20-F on May 15, 2014 and incorporated herein by reference.

**(2) Filed as an exhibit to the Company’s annual Form 20-F on April 13, 2015 and incorporated herein by reference.

***(3) Filed herewith.as an exhibit to the Company’s annual Form 20-F on March 18, 2016 and incorporated herein by reference.

WHERE TO FIND ADDITIONAL INFORMATION(4) Filed as an exhibit to the Company’s annual Form 20-F on April 18, 2017 and incorporated herein by reference.

(5) Filed as an exhibit to the Company’s annual Form 20-F on April 30, 2019 and incorporated herein by reference

(6) Filed as an exhibit to the Company’s annual Form 20-F on April 29, 2020 and incorporated herein by reference.

(7) Filed as an exhibit to the Company’s annual Form 20-F on April 9, 2021 and incorporated herein by reference

(8) Filed as an exhibit to the Company’s annual Form 20-F on April 26, 2022 and incorporated herein by reference

(9) Filed as an exhibit to the Company’s annual Form 20-F on March 31, 2023 and incorporated herein by reference

(10) Filed as an exhibit to this Form 20-F.

(*) In accordance with Rule 402 of Regulation S-T, the information in these exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Page 80

 

SIGNATURES

The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.

POET TECHNOLOGIES INC.
/s/ Suresh Venkatesan
Suresh Venkatesan
Chief Executive Officer

Date: March 28, 2024

Page 81

We file reports and other information with the Securities and Exchange Commission located at 100 F Street NE, Washington, D.C. 20549;Commission; you may obtain copies of our filings with the SEC by accessing their website located at www.sec.gov. Further, we file reports under Canadian regulatory requirements on SEDAR; you may access our reports filed on SEDAR by accessing their website at www.sedar.com.

MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL INFORMATION

The accompanying consolidated financial statements of the Company and other financial information contained in this Annual Report are the responsibility of management. The consolidated financial statements have been prepared in conformity with IFRS, using management’s best estimates and judgments, where appropriate. In the opinion of management, these consolidated financial statements reflect fairly the financial position and the results of operations and cash flows of the Company within reasonable limits of materiality. The financial information contained elsewhere in this Annual Report has been reviewed to ensure consistency with that in the consolidated financial statements.

To assist management in discharging these responsibilities, the Company maintains a system of procedures and internal control which is designed to provide reasonable assurance that its assets are safeguarded against loss from unauthorized use or disposition, that transactions are executed in accordance with management’s authorization and that the financial records form a reliable base for the preparation of accurate and reliable financial information.

The Board of Directors ensuresendeavors to ensure that management fulfills its responsibilities for the financial reporting and internal control. The Board of Directors exercises this responsibility through its independent Audit Committee comprising a majority of unrelated and outside directors. The Audit Committee meets periodically with management and annually with the external auditors to review audit recommendations and any matters that the auditors believe should be brought to the attention of the Board of Directors. The Audit Committee also reviews the consolidated financial statements and recommends to the Board of Directors that the statements be approved for issuance to the shareholders.

The consolidated financial statements for the years ended December 31, 2015, 20142023, 2022 and 20132021 have been audited by Marcum LLP, independent registered public accounting firm, which has full and unrestricted access to the Audit Committee. Marcum’s report on the consolidated financial statements is presented herein.

58Page 82

SIGNATURES

 

The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

POET TECHNOLOGIES INC.
/s/ Suresh Venkatesan
CEO
Date: March 17, 2016

59

 

INDEPENDENT AUDITORS’ REPORT

To the Audit Committee of the

Shareholders and Board of Directors and Shareholdersof

ofPOET Technologies Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated statements of financial statementsposition of POET Technologies Inc., which comprise the consolidated statements (the “Company”) as of financial position as at December 31, 2015, 20142023, 2022 and 2013, and2021, the related consolidated statements of operations and deficit, comprehensive loss, changes in shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2015, 20142023, and 2013, andthe related notes comprising a summary of significant accounting policies and other explanatory information.

Management's responsibility for(collectively referred to as the consolidated financial statements

Management is responsible for“financial statements”). In our opinion, the preparation and fair presentation of these consolidated financial statements present fairly, in accordanceall material respects, the financial position of the Company as of December 31, 2023, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.Board.

 

Auditors’ responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our auditsalso have audited, in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States). ("PCAOB"), the Company's internal control over financial reporting as of December 31, 2023, based on the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013 and our report dated March 15, 2024, expressed an adverse opinion on the effectiveness of the Company’s internal control over financial reporting because of the existence of a material weakness.

Explanatory Paragraph – Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has a incurred significant losses over the past few years and needs to raise additional funds to meet its future obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission, Ontario Securities Commission and the PCAOB.

Page 1

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we comply with ethical requirements and plan and perform the auditaudits to obtain reasonable assurance about whether the consolidated financial statements are free fromof material misstatement.

An audit involvesmisstatement, whether due to error or fraud. Our audits included performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment ofassess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, or error. In making those risk assessments, we consider internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design auditperforming procedures that are appropriaterespond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An auditfinancial statements. Our audits also includesincluded evaluating the appropriateness of accounting policiesprinciples used and the reasonableness of accountingsignificant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a reasonable basis for our opinion.

Critical Audit Matters

Critical audit opinion.matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

/s/ Marcum LLP

Marcum llp

We have served as the Company’s auditor since 2009, such date takes into account the acquisition of a portion of UHY LLP by Marcum LLP in April 2010.

Hartford, CT

March 15, 2024

PCAOB ID 688

 

Opinion

Page 2

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

ON INTERNAL CONTROL OVER FINANCIAL REPORTING

To the Shareholders and Board of Directors of

POET Technologies Inc.

Adverse Opinion on Internal Control Over Financial Reporting

We have audited POET Technologies Inc.’s (the “Company”) internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weakness described in the following paragraph on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

A material weakness is a control deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in “Management’s Annual Report on Internal Control Over Financial Reporting”. The Company’s controls responsible for verification of changes to payment instructions from the Company’s vendors was not effective.

This material weakness was considered in determining the nature, timing and extent of audit tests applied in our audit of the fiscal December 31, 2023 consolidated financial statements, present fairly,and this report does not affect our report dated March 15, 2024 on those financial statements.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated statements of financial position as of December 31, 2023, 2022 and 2021 and the related consolidated statements of operations and deficit, comprehensive loss, changes in shareholders’ equity, and cash flows and the related notes for each of the three years in the period ended December 31, 2023 of the Company and our report dated March 15, 2024 expressed an unqualified opinion, which includes an explanatory paragraph regarding the Company’s ability to continue as a going concern, on those financial statements.

Page 3

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying “Management Annual Report on Internal Control Over Financial Reporting”. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission, the Ontario Securities Commission, and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects,respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the consolidatedrisk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial positionreporting is a process designed to provide reasonable assurance regarding the reliability of POET Technologies Inc. as at December 31, 2015, 2014financial reporting and 2013, and its consolidatedthe preparation of financial performance and its consolidated cash flowsstatements for the years ended December 31, 2015, 2014 and 2013external purposes in accordance with IFRS.generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that degree of compliance with the policies or procedures may deteriorate.

/s/ Marcum LLP

Marcum llp

Hartford, CT

March 15, 2024

Page 4

 

/s/ Marcum LLP

Hartford, CT

March 17, 2016

 

POET TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Expressed in US Dollars)

December 31, 2015  2014  2013 
Assets            
Current            
Cash and cash equivalents
 $14,409,996  $11,287,864  $3,260,967 
Prepaids and other current assets  150,923   243,501   267,012 
Marketable securities  -   -   397 
   14,560,919   11,531,365   3,528,376 
Property and equipment (Note 4)  947,107   1,058,860   903,792 
Patents and licenses (Note 5)  426,813   260,721   125,676 
  $15,934,839  $12,850,946  $4,557,844 
Liabilities            
             
Current            
Accounts payable and accrued liabilities (Note 6) $515,421  $451,724  $256,027 
             
Shareholders' Equity            
Share capital (Note 7(b))  81,027,171   61,688,953   42,911,455 
Warrants (Note 8)  2,013,747   6,458,659   8,135,590 
Contributed surplus (Note 9)  25,618,159   23,616,664   20,261,067 
Accumulated other comprehensive loss  (2,388,987)  (584,552)  (11,593)
Deficit  (90,850,672)  (78,780,502)  (66,994,702)
   15,419,418   12,399,222   4,301,817 
  $15,934,839  $12,850,946  $4,557,844 
December 31, 2023  2022  2021 
Assets
Current         
Cash and cash equivalents (Note 2) $3,019,069  $9,229,845  $14,941,775 
Short-term investments (Note 2)  -   -   6,366,828  
Accounts receivable (Notes 3)  -   62,842   - 
Prepaids and other current assets (Note 4)  150,676   275,507   480,523 
             
Total current assets  3,169,745   9,568,194   21,789,126 
Investment in joint venture (Note 5)  -   -   1,445,251 
Property and equipment (Note 6)  4,623,228   5,070,507   3,064,234 
Patents and licenses (Note 7)  502,055   510,705   528,476 
Right of use asset (Note 8)  482,389   241,047   326,890 
             
Total assets $8,777,417  $15,390,453  $27,153,977 
             
Liabilities
 
Current            
Accounts payable and accrued liabilities (Note 9) $2,301,457  $3,362,430  $1,791,222 
Covid-19 government support loans (Note 23)  30,200   29,520   31,660 
Lease liability (Note 8)  204,939   150,951   101,074 
Contract liabilities (Note 3)  -   274,192   - 
             
Total current liabilities  2,536,596   3,817,093   1,923,956 
             
Non-current lease liability (Note 8)  307,141   128,312   258,274 
Derivative warrant liability (Note 10 and 11(b))  1,002,264   -   - 
             
Total liabilities  3,846,001   3,945,405   2,182,230 
             
Shareholders’ Equity
 
Share capital (Note 11(b))  165,705,423   151,206,539   147,729,846 
Warrants and compensation options (Note 12)  670,115   5,905,642   5,328,455 
Contributed surplus (Note 13)  55,447,961   51,016,808   46,954,333 
Accumulated other comprehensive loss  (2,601,058)  (2,660,281)  (2,053,917)
Deficit  (214,291,025)  (194,023,660)  (172,986,970)
             
Total equity  4,931,416   11,445,048   24,971,747 
             
Total equity and liabilities $8,777,417  $15,390,453  $27,153,977 

Commitments and contingencies (Note 11)15)

On behalf of the Board of Directors

/s/ Suresh Venkatesan/s/ Chris Tsiofas
DirectorDirectorDirector

The accompanying notes are an integral part of these consolidated financial statements.

2Page 5

POET TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND DEFICIT

(Expressed in US Dollars)

For the Years Ended December 31, 2015  2014  2013 
Costs and expenses            
General and administration (Note 16)
 $8,614,109  $9,677,705  $6,284,288 
Research and development (Note 16)  3,532,492   2,277,927   1,925,974 
Investment income, including interest  (76,431)  -   (18,371)
Loss before the following  12,070,170   11,955,632   8,191,891 
Other income (Note 2)  -   169,832   342,874 
Net loss  (12,070,170)  (11,785,800)  (7,849,017)
Deficit, beginning of year
  (78,780,502)  (66,994,702)  (59,145,685)
Net loss  (12,070,170)  (11,785,800)  (7,849,017)
Deficit, end of year $(90,850,672) $(78,780,502) $(66,994,702)
Basic and diluted loss per share (Note 10) $(0.07) $(0.08) 

$

(0.06)

For the Years Ended December 31, 2023  2022  2021 
          
Revenue (Note 21) $465,777  $552,748  $209,100 
             
Operating expenses            
Selling, marketing and administration (Note 20)  10,795,155   9,516,271   9,055,528 
Research and development (Note 20)  10,077,930   10,746,743   8,165,128 
             
Operating expenses  20,873,085   20,263,014   17,220,656 
             
Operating loss before the following  (20,407,308)  (19,710,266)  (17,011,556)
Interest expense (Notes 8)  (70,182)  (49,738)  (364,619)
Other income, including interest  234,990   188,320   75,084 
Forgiveness of Covid-19 government support loans (Note 23)  -   -   186,747 
Gain on contribution of intellectual property to joint venture (Note 5)  1,031,807   1,746,987   2,587,500 
Share of loss in joint venture (Note 5)  (1,031,807)  (3,211,993)  (1,142,249)
Fair value adjustment to derivative warrant liability (Note 10 and 11(b))  (24,865)  -   - 
             
Net loss  (20,267,365)  (21,036,690)  (15,669,093)
             
Deficit, beginning of year  (194,023,660)  (172,986,970)  (157,317,877)
             
Net loss  (20,267,365)  (21,036,690)  (15,669,093)
             
Deficit, end of year $(214,291,025) $(194,023,660) $(172,986,970)
             
Basic and diluted net loss per share (Note 14) $(0.51) $(0.57) $(0.45)

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Expressed in US Dollars)

For the Years Ended December 31, 2015  2014  2013  2023  2022  2021 
         
Net loss $(12,070,170) $(11,785,800) $(7,849,017) $(20,267,365) $(21,036,690) $(15,669,093)
Other comprehensive loss - net of income taxes Exchange differences on translating foreign operations  (1,804,435)  (572,959)  (255,422)
            
Other comprehensive (loss) - net of income taxes Items that may in the future be reclassified to profit (loss):            
Exchange differences on translating foreign operations  59,223   (606,364)  (70,705)
            
Comprehensive loss $(13,874,605) $(12,358,759) $(8,104,439) $(20,208,142) $(21,643,054) $(15,739,798)

The accompanying notes are an integral part of these consolidated financial statements.

3Page 6

POET TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS'SHAREHOLDERS’ EQUITY

(Expressed in US Dollars)

For the Years Ended December 31, 2015  2014  2013  2023  2022  2021 
Share Capital                        
Beginning balance $61,688,953  $42,911,455  $40,225,401  $151,206,539  $147,729,846 $114,586,260 
Funds from the exercise of stock options  668,259   418,845   3,124,392 
Fair value of stock options exercised  587,035   374,129   2,699,042 
Funds from the exercise of warrants and compensation warrants  9,373,245   8,404,265   37,111   7,767,067   284,437   12,994,358 
Fair value of warrants and compensation warrants exercised  4,444,912   3,545,406   23,387   4,418,783   79,547   5,351,586 
Warrant exercise incentive  -   (31,712)  - 
Funds from the exercise of stock options  2,703,436   1,481,716   152,502 
Fair value assigned to stock options exercised  2,816,625   1,261,156   121,368 
Funds from private placements  -   4,546,000   7,189,200 
Fair value of warrants and compensation warrants issued  -   (1,869,231)  (4,308,292)
Conversion of convertible debentures  -   -   3,571,342 
Fair value of warrants issued on conversion of convertible debentures  -   -   (1,229,305)
Funds from common shares issued through ATM Financing  983,194   -   - 
Funds from common shares issued on public or private offerings  1,607,400   3,184,332   11,815,595 
Share issue costs  -   -   (529,222)  (578,317)  (247,892)  (1,143,034)
Common shares issued for reduction of license fee  -   1,439,898   - 
Common shares issued to settle accounts payable  -   40,029   13,814 
Fair value of warrants issued on public or private offering  (954,537)  (656,734)  (3,766,007)
Fair value of broker warrant issued as share issue costs  -   -   (288,197)
                        
December 31,  81,027,171   61,688,953   42,911,455   165,705,423   151,206,539   147,729,846 
                        
Special Voting Share            
Equity Component of convertible debentures            
Beginning balance  -   -   100   -   -   565,121 
Cancellation of special voting share  -   -   (100)
Fair value of equity component of convertible debentures  -   -   (565,121)
            
December 31,  -   -   -   -   -   - 
                        
Warrants            
Warrants and Compensation Options            
Beginning balance  6,458,659   8,135,590   3,850,685   5,905,642   5,328,455   5,557,002 
Fair value of warrants and compensation warrants issued  -   1,869,231   4,308,292 
Fair value of warrants and compensation warrants exercised  (4,444,912)  (3,545,406)  (23,387)  (4,418,783)  (79,547)  (5,351,586)
Fair value of expired warrants  -   (756)  - 
Fair value of expired warrants and compensation options  (816,744)  -   (160,470)
Fair value of warrants issued on the exercise of convertible debentures  -   -   1,229,305 
Fair value of warrants issued on private placement  -   656,734   3,766,007 
Fair value of broker warrants issued as share issue costs  -   -   288,197 
                        
December 31,  2,013,747   6,458,659   8,135,590   670,115   5,905,642   5,328,455 
                        
Contributed Surplus                        
Beginning balance  23,616,664   20,261,067   16,361,282   51,016,808   46,954,333   44,407,679 
Stock-based compensation  4,818,120   4,615,997   4,021,153   4,201,444   4,436,604   4,534,370 
Fair value of stock options exercised  (2,816,625)  (1,261,156)  (121,368)  (587,035)  (374,129)  (2,699,042)
Fair value of expired warrants  -   756   - 
Fair value of expired warrants and compensation options  816,744   -   160,470 
Fair value effect of conversion of convertible debentures  -   -   550,856 
                        
December 31,  25,618,159   23,616,664   20,261,067   55,447,961   51,016,808   46,954,333 
                        
Accumulated Other Comprehensive Income            
Accumulated Other Comprehensive Loss            
Beginning balance  (584,552)  (11,593)  243,829   (2,660,281)  (2,053,917)  (1,983,212)
Other comprehensive loss attributable to common shareholders - translation adjustment  (1,804,435)  (572,959)  (255,422)
Other comprehensive (loss) attributable to common shareholders - translation adjustment  59,223   (606,364)  (70,705)
                        
December 31,  (2,388,987)  (584,552)  (11,593)  (2,601,058)  (2,660,281)  (2,053,917)
                        
Deficit                        
Beginning balance  (78,780,502)  (66,994,702)  (59,145,685)  (194,023,660)  (172,986,970)  (157,317,877)
Net loss  (12,070,170)  (11,785,800)  (7,849,017)  (20,267,365)  (21,036,690)  (15,669,093)
                        
December 31,  (90,850,672)  (78,780,502)  (66,994,702)  (214,291,025)  (194,023,660)  (172,986,970)
                        
Total shareholders' equity $15,419,418  $12,399,222  $4,301,817 
Total Shareholders’ Equity $4,931,416  $11,445,048$  24,971,747 

The accompanying notes are an integral part of these consolidated financial statements.

4Page 7

POET TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Expressed in US Dollars)

For the Years Ended December 31, 2015  2014  2013 
CASH (USED IN) PROVIDED BY:
            
OPERATING ACTIVITIES            
Net loss $(12,070,170) $(11,785,800) $(7,849,017)
Adjustments for:            
Depreciation of property and equipment (Note 4)
  276,139   210,717   60,738 
Amortization of patents and licenses (Note 5)  43,722   26,238   12,797 
Product warranty reserve  -   -   (25,999)
Stock-based compensation (Note 9)  4,818,120   4,615,997   4,021,153 
Shares issued for reduction of license fee (Note 7(b))  -   1,439,898   - 
Net change in non-cash working capital accounts:  (6,932,189)  (5,492,950)  (3,780,328)
Accounts receivable  -   -   96,749 
Prepaid and other current assets  92,578   23,908   (163,726)
Accounts payable and accrued liabilities  63,697   195,697   24,124 
Cash flows from operating activities  (6,775,914)  (5,273,345)  (3,823,181)
INVESTING ACTIVITIES            
Purchase of property and equipment (Note 4)  (164,386)  (365,785)  (882,860)
Purchase of patents and licenses (Note 5)  (209,814)  (161,283)  (62,923)
Cash flow from investing activities  (374,200)  (527,068)  (945,783)
FINANCING ACTIVITIES            
Issue of common shares for cash, net of issue costs  12,076,681   14,400,269   6,849,591 
Cash flow from financing activities  12,076,681   14,400,269   6,849,591 
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH
            
EQUIVALENTS  (1,804,435)  (572,959)  (255,422)
NET CHANGE IN CASH AND CASH EQUIVALENTS
  3,122,132   8,026,897   1,825,205 
CASH AND CASH EQUIVALENTS, beginning of year  11,287,864   3,260,967   1,435,762 
CASH AND CASH EQUIVALENTS, end of year $14,409,996  $11,287,864  $3,260,967 
For the Years Ended December 31, 2023  2022  2021 
          
CASH AND CASH EQUIVALENTS (USED IN) PROVIDED BY:         
          
OPERATING ACTIVITIES            
Net loss $(20,267,365) $(21,036,690) $(15,669,093)
Adjustments for:            
Depreciation of property and equipment (Note 6)  1,653,798   1,054,264   840,366 
Amortization of patents and licenses (Note 7)  87,761   80,246   69,560 
Amortization of right of use asset (Note 8)  180,602   158,648   190,596 
Fair value adjustment to derivative warrant liability (Note 10)  24,865   -   - 
Accretion of debt discount on convertible debentures and non-cash interest (Notes 8)  53,614   49,738   213,843 
Stock-based compensation (Note 13)  4,201,444   4,436,604   4,534,370 
Non-cash settled operating costs (Notes 6 and 11)  -   40,029   13,814 
Gain on contribution of intellectual property to joint venture (Note 5)  (1,031,807)  (1,746,987)  (2,587,500)
Share of loss in joint venture (Note 5)  1,031,807   3,211,993   1,142,249 
Forgiveness of covid-19 government support loans (Note 23)  -   -   (186,747)
             
Total adjustments to reconcile profit (loss)  (14,065,281)  (13,752,155)  (11,438,542)
Net change in non-cash working capital accounts:            
Accounts receivable  62,000   (61,099)  - 
Prepaid and other current assets  126,936   (356,199)  134,926 
Accounts payable and accrued liabilities  (1,256,925)  1,596,690   70,323 
Contract liabilities  (274,192)  246,853   - 
             
Cash flows from operating activities  (15,407,462)  (12,325,910)  (11,233,293)
             
INVESTING ACTIVITIES            
Maturity (purchase) of short-term investments (Note 2)  -   6,366,828   (6,366,828)
Purchase of property and equipment (Note 6)  (1,167,953)  (3,011,562)  (771,523)
Purchase of patents and licenses (Note 7)  (79,111)  (62,475)  (159,359)
             
Cash flows from investing activities  (1,247,064)  3,292,791   (7,297,710)
             
FINANCING ACTIVITIES            
Issue of common shares for cash, net of issue costs (Note 11)  10,447,603   3,639,722   26,791,311 
Payment of lease liability (Note 8)  (252,103)  (204,518)  (237,634)
             
Cash flows from financing activities  10,195,500   3,435,204   26,553,677 
             
Effect of exchange rate on cash  248,250   (114,015)  46,207 
             
Net change in cash and cash equivalents  (6,210,776)  (5,711,930)  8,068,881 
Cash and cash equivalents, beginning of year  9,229,845   14,941,775   6,872,894 
             
Cash and cash equivalents, end of year $3,019,069  $9,229,845  $14,941,775 

The accompanying notes are an integral part of these consolidated financial statements.

5Page 8

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

1.DESCRIPTION OF BUSINESS

1.DESCRIPTION OF BUSINESS

POET Technologies Inc. is incorporated in the Province of Ontario. POET Technologies Inc. (andand its subsidiaries ODIS Inc. ("ODIS"(the “Company”) design and Opel Solar Inc., both operating indevelop the US, collectively,POET Optical Interposer and Photonic Integrated Circuits for the "Company") is the developer of the planar opto-electronic technology (“POET”) platform semiconductor process IP for monolithic fabrication of integrated circuit devices containing both electronicdata center and optical elements on a single die.tele-communications markets. The Company'sCompany’s head office is located at 121 Richmond Street West,120 Eglinton Avenue East, Suite 501,1107, Toronto, Ontario, Canada M5H 2K1.M4P 1E2. These audited consolidated financial statements of the Company were approved by the Board of Directors of the Company on March XXX, 2016.15, 2024.

These financial statements have been prepared on the going concern basis which assumes that the Company will have sufficient cash to pay its debts, as and when they become payable, for a period of at least 12 months from the date the financial report was authorised for issue.

As of December 31, 2023, the Company has accumulated losses of $(214,291,025) and working capital of $633,149. During the year ended December 31, 2023, the Company had negative cash flows from operations of $(15,407,462). The Company has prepared a cash flow forecast for one year from December 31, 2023 which indicates that it does not have sufficient cash to meet its minimum expenditure commitments and therefore needs to raise additional funds to continue as a going concern. As a result, there is substantial doubt about the Company’s ability to continue as a going concern.

To address the future funding requirements, management has undertaken the following initiatives:

2.1.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESRaised CA$6,219,667 (US$4,607,161) in gross funding from a private placement on January 24, 2024.The financing included the issuance of warrants at an exercise price of CA$1.52. These warrants are currently in- the- money and will be exercisable after May 25, 2024.
2.Raised $1,607,400 in gross funding from a public offering on December 4, 2023. The financing included the issuance of warrants at an exercise price of $1.12. These warrants are currently in- the- money and holders of these warrants are encouraged to exercise them.
3.Established a strict budgetary process with a focus on maintaining an appropriate level of corporate overheads in line with the Company’s available cash resources.

The Company’s financial statements do not include any adjustments to the assets’ carrying amount, to the expenses presented and to the reclassification of the balance sheets items that could be necessary should the Company be unable to continue its operations.

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

These consolidated financial statements of the Company and its subsidiaries were prepared in accordance with International Financial Reporting Standards ("IFRS"(“IFRS”), as issued by the International Accounting Standards Board ("IASB"(“IASB”).

The preparation of financial statements in accordance with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed below:

Basis of presentation

These consolidated financial statements include the accounts of POET Technologies Inc. and its subsidiaries.subsidiaries; ODIS Inc. (“ODIS”), Opel Solar Inc. (“OPEL”), BB Photonics Inc. (“BB Photonics”), POET Technologies Pte Ltd. (“PTS”) and POET Optoelectronics Shenzhen Co., Ltd (“POET Shenzhen”). All intercompany balances and transactions have been eliminated on consolidation.

Page 9

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Business combinations

Acquisitions of businesses are accounted for using the acquisition method. The acquisition cost is measured at the acquisition date at the fair value of the consideration transferred, including all contingent consideration.

Subsequent changes in contingent consideration are accounted for through the consolidated statements of operations and deficit and consolidated statements of comprehensive loss in accordance with the applicable standards.

Goodwill arising on acquisition is initially measured at cost, being the difference between the fair value of the consideration transferred including the recognized amount of any non-controlling interest in the acquiree and the net recognized amount (generally fair value) of the identifiable assets and liabilities assumed at the acquisition date. If the net of the amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer’s previously held interest in the acquiree (if any), the excess is recognized immediately in the consolidated statements of operations and deficit as a bargain purchase gain.

Acquisition-related costs, other than those that are associated with the issue of debt or equity securities that the Company incurs in connection with a business combination, are expensed as incurred.

Foreign currency translation

These consolidated financial statements are presented in U.S. dollars ("USD"(“USD”), which is the Company'sCompany’s presentation currency.

Items included in the financial statements of each of the Company'sCompany’s subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"“functional currency”). Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency of an entity are recognized in the statement of operations and deficit.

Assets and liabilities of entities with functional currencies other than U.S. dollars are translated into the presentation currency at the year end rates of exchange, and the results of their operations are translated at average rates of exchange for the year. The resulting translation adjustments are included in accumulated other comprehensive loss in shareholders'shareholders’ equity. Additionally, foreign exchange gains and losses related to certain intercompany loans that are permanent in nature are included in accumulated other comprehensive loss. Elements of equity are translated at historical rates.

6

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Financial Instruments

Financial instruments

Financial assets held with an objective to hold assets in order to collect contractual cash flows which arise on specified dates that are requiredsolely principal and interest are measured at amortised cost using the effective interest method. Debt investments held with an objective to be classifiedhold both assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest as onewell as selling the asset on the basis of the following: held-to-maturity; loans and receivables, fair value through profit or loss; available-for-sale orare measured at FVTOCI. All other financial liabilities.

The Company's financial instruments include cashassets are classified and cash equivalents, accounts payable and accrued liabilities. The Company designated its cash and cash equivalents asmeasured at fair value through profit or loss and its accounts payable and accrued(“FVTPL”). Financial liabilities are classified as other financial liabilities.

Fair value through profiteither FVTPL or loss financial assets are measured at fair value with gains and losses recognized in operations. Financial assets, loans and receivables and other financial liabilities, are measured at amortized cost. Available-for-sale financial assetsand the portion of the change in fair value that relates to the Company’s credit risk is presented in other comprehensive income (loss). Instruments classified as FVTPL are measured at fair value with unrealized gains and losses recognized in net income (loss). Other financial liabilities are subsequently measured at amortised cost using the effective interest method.

Page 10

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other comprehensive loss.than financial assets and financial liabilities classified as FVTPL, are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in consolidated net income (loss).

Fair valueDerecognition

Financial assets

The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. Any interest in transferred financial assets that is created or retained by the Company is recognized as a separate asset or liability.

Financial liabilities

A financial liability is derecognized from the balance sheet when it is extinguished, that is, when the obligation specified in the contract is either discharged, cancelled or expires. Where there has been an exchange between an existing borrower and lender of debt instruments with substantially different terms, or there has been a substantial modification of the terms of an existing financial liability, this transaction is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. A gain or loss from extinguishment of the original financial liability is recognized in profit or loss.

The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities.

The following table outlines the classification of financial instruments under IFRS 9:

SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS

Financial Assets
Cash and cash equivalentsAmortized cost
Short-term investmentsAmortized cost
Accounts receivableAmortized cost
Financial Liabilities
Accounts payable and accrued liabilitiesAmortized cost
Contract liabilitiesAmortized cost
Covid-19 government support loansAmortized cost
Derivative warrant liabilityFair value through profit and loss (FVTPL)

Convertible debentures are accounted for as a compound financial instrument with a debt component and a separate equity component. The debt component of these compound financial instruments is the amount of consideration that would be agreed upon in an arm’s length transaction between knowledgeable, willing parties who are under no compulsion to act. Themeasured at fair value of a financial instrument on initial recognition by discounting the stream of future interest and principal payments at the rate of interest prevailing at the date of issue for instruments of similar term and risk. The debt component is subsequently deducted from the transaction price, which is the fairtotal carrying value of the consideration given or received. Subsequentcompound instrument to initial recognition,derive the fair value of a financial instrument thatequity component. The debt component is quoted in active markets issubsequently measured at amortized cost using the effective interest rate method. Interest expense based on the bid price for a financial asset heldcoupon rate of the debenture and the offer price for a financial liability. When an independent price is not available, fair value is determined by using a valuation methodologyaccretion of the liability component to the amount that refers to observable market data. Such a valuation technique includes comparisons with a similar financial instrument where an observable market price exists, discounted cash flow analysis, option pricing models and other valuation techniques commonly used by market participants. If no reliable estimate canwill be made, the Company measures the financial instrument at cost less impairmentpayable on redemption are recognized through profit or loss as a last resort.finance cost.

Page 11

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Cash and cash equivalents

Cash and cash equivalents consist of cash in current accounts of $1,249,116 (2022 - $1,981,765, 2021 - $4,216,911) and funds invested in US and Canadian Term Deposits of $1,769,953 (2022 - $7,248,080, 2021 - $10,724,864) earning interest at rates ranging from 0.20% - 0.25% and maturing in less than 90 days.

Short-term investments

The short-term investments of nil (2022 - nil, 2021 - $6,366,828) consist of guaranteed investment certificates (GICs) held with one Canadian chartered bank and earn interest at rates ranging from 0.75 to 1.44%.

Property and equipment

Property and equipment are recorded at cost. Depreciation is calculated based on the estimated useful life of the asset using the following method and useful lives:

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED LIFE

Machinery and equipmentStraight Line, 5 years
Leasehold improvementsStraight Line, 5 years or life of the lease, whichever is less
Office equipmentStraight Line, 3 - 5 years

Patents and licenses

Patents and licenses are recorded at cost and amortized on a straight line basis over 12 years. Ongoing maintenance costs are expensed as incurred.

7

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Impairment of long-lived assets

The Company’s tangible and intangible assets are reviewed for indications of impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. An assessment is made at each reporting date whether there is any indication that an asset may be impaired.

An impairment loss is recognized when the carrying amount of an asset exceeds its recoverable amount. Impairment losses are recognized in profit and loss for the year. The recoverable amount is the greater of the asset’s fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit ("CGU"(“CGU”) to which the asset belongs.

An impairment loss is reversed if there is an indication that there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. The Company did not record anNo impairment loss has been reported for the years ended December 31, 2023, 2022 and 2021.

Page 12

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in 2015, 2014 or 2013.US Dollars)

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Income taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred income taxes are provided on differences between the financial reporting and income tax bases of assets and liabilities and on income tax losses available to be carried forward to future years for tax purposes. Deferred income taxes are measured using the substantively enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are provided to reduce deferred incomeDeferred tax assets toare only recognized if the amount is expected to be realized.realized in the future.

Other income - Government GrantsRevenue recognition

Government grants received exclusively from the Department of Defense of the United States of America and NASA, relating to research and development, are recognized as other income, net,Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognizes revenue when it transfers control over a product or service to a customer.

Sale of goods

Revenue from the sale of goods is recognized, net of discounts and customer rebates, at the point in time the transfer of control of the related products has taken place as specified in the sales contract and collectability is reasonably assured.

Service revenue

The Company provides contract services, primarily in the form of non-recurring revenue (“NRE”) where control is passed to the customer over time. The contracts generally provide agreed upon milestones for customer payment which include but are not limited to the delivery of sample products, design reports and test reports. The customer makes payment when it has approved the delivery of the projects. milestone. The Company must determine if the contract is made up of a series of independent performance obligations or a single performance obligation. Where NRE contracts contain multiple performance obligations for which a standalone transaction price can be assessed, revenue is recognized as each performance obligation is satisfied. Where NRE contracts contain a single performance obligation to be settled over time, revenue is recognized progressively based on the output method.

Other income earned on government grants in 2015 was nil (2014 - $169,832, 2013 - $342,874).

Interest income

Interest income on cash and cash equivalents classified as fair value through profit or loss is recognized as earned using the effective interest method.

Wage subsidies

Wages subsidies received from the Singaporean government are netted against R&D related wages and benefits on the consolidated statements of operations and deficit.

Government Grants

Loans received exclusively from governmental agencies to support the Company throughout the COVID-19 pandemic qualify to be forgiven if certain conditions are met. Forgiveness of COVID-19 related loans will be recognized as other income on the consolidated statements of operations and deficit.

8Page 13

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

2.2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Intangible assets

Research and development costs

Research costs are expensed in the year incurred. Development costs are also expensed in the year incurred unless the Company believes a development project meets IFRS criteria as set out in IAS 38,Intangible Assets, for deferral and amortization. IAS 38 requires all reseachresearch costs be charged to expense while development costs are capitalised only after technical and commercial feasibility of the asset for sale or use have been established. This means that the entity must intend and be able to complete the intangible asset and either use it or sell it and be able to demonstrate how the asset will generate future economic benefits. Development costs are tested for impairment whenever events or changes indicate that its carrying amount may not be recoverable.

In-Process Research and Development

Under IFRS, in-process research and development (“IPR&D”) acquired in a business combination that meets the definition of an intangible asset is capitalized with amortization commencing when the asset is ready for use (i.e., when development is complete). The Company hasdoes not met the the criteria set out in IAS 38, therefore no deferral has been recognized.capitalize its IPR&D.

Stock-based compensation

Stock options and warrants awarded to non employees are accounted formeasured using the fair value of the instrument awardedgoods or service provided whicheverservices received unless that fair value cannot be estimated reliably, in which case measurement is considered more reliable.based on the fair value of the stock options. Stock options and warrants awarded to employees are accounted for using the fair value method. The fair value of such stock options and warrants granted is recognized as an expense on a proportionate basis consistent with the vesting features of each tranche of the grant. The fair value is calculated using the Black-Scholes option pricing model with assumptions applicable at the date of grant.

Loss per share

Basic loss per share, net of taxes is calculated by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding during the yearperiod after giving effect to potentially dilutive financial instruments. The dilutive effect of stock options and warrants is determined using the treasury stock method.

Joint Venture

A joint arrangement is an arrangement among two or more parties where the parties are bound by a contractual arrangement and the contractual arrangement gives the parties joint control of the arrangement. A joint venture is a form of joint arrangement where an entity is independently formed and the parties jointly have rights to the net assets of the arrangement and therefore account for their interests under the equity method. The following new accounting policy was adoptedCompany has a joint venture in China and uses the equity method to account for its share of the joint venture’s operations.

Share Consolidation

On February 24, 2022, the Company filed Articles of Amendment to consolidate its common shares on January 1, 2015: Financial instruments

IFRS 9,Financial Instruments,replaces IAS 39, Financial Instruments: Recognition and Measurement. The

new standard requires entities to classify financial assets as being measured either at amortized cost or fair value dependinga ten-for-one basis. For further clarity, for every ten (10) pre-consolidated common shares, shareholders received one (1) post-consolidated common share. On February 28, 2022 the Company’s common shares began trading on the business modelTSX Venture Exchange on a post consolidation basis. The Company’s name and contractual cash flow characteristics of the asset. For financial liabilities, IFRS 9 requires an entity choosingtrading symbol remained unchanged. All references to measure a liability at fair value to present the portion of the changeshare and per share amounts in its fair value due to change in the entity’s own credit risk in the other comprehensive income rather than in the statement of profit or loss. The adoption of this policy did not impact the Company'sthese consolidated financial statements.

3.RECENT ACCOUNTING PRONOUNCEMENTS

The following is a summary of recent accounting pronouncements that may affectstatements and accompanying notes to the Company.

IFRS 15, Revenue from Contracts with Customers ("IFRS 15"). The IASB issued IFRS 15, which is effective for annual years beginning on or after January 1, 2017. The standard contains a single model that applies to contracts with customers and two approaches to recognizing revenue: at a point in time and over time. The model features a contract-based five-step analysis of transactions to determine whether, how much and when revenue is recognized. New estimates and judgmental thresholdsconsolidated financial statements have been introduced, which may affectretroactively restated to reflect the amount and/or timing of revenue recognized. The Company is in the process of assessing the impact of this standard on its consolidated financial statements.ten-for-one share consolidation.

9Page 14

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

3.ACCOUNTS RECEIVABLE AND CONTRACT LIABILITIES

4.PROPERTY AND EQUIPMENT

  Construction in
progress
  Leashold
improvements
  Machinery and
equipment
  Office
equipment
  Total 
Cost                    
Balance, January 1, 2013 $-  $-  $27,500  $2,335  $29,835 
Additions (1)      -   931,449   6,411   937,860 
Balance, December 31, 2013  -   -   958,949   8,746   967,695 
Additions  3,152   -   314,973   47,660   365,785 
Balance, December 31, 2014  3,152   -   1,273,922   56,406   1,333,480 
Additions  7,024   5,896   126,181   25,285   164,386 
Reclassification  (10,176)  10,176   -   -   - 
Balance,December 31, 2015  -   16,072   1,400,103   81,691   1,497,866 
Accumulated Depreciation                    
Balance, January 1, 2013      -   2,750   415   3,165 
Depreciation for the year      -   59,250   1,488   60,738 
Balance, December 31, 2013  -   -   62,000   1,903   63,903 
Depreciation for the year  -   -   203,008   7,709   210,717 
Balance, December 31, 2014  -   -   265,008   9,612   274,620 
Depreciation for the year  -   3,104   258,190   14,845   276,139 
Balance, December 31, 2015  -   3,104   523,198   24,457   550,759 
Carrying Amounts                    
At December 31, 2013 $-  $-  $896,949  $6,843  $903,792 
At December 31, 2014 $3,152  $-  $1,008,914  $46,794  $1,058,860 
At December 31, 2015 $-  $12,968  $876,905  $57,234  $947,107 

Revenue Contract Balances

(1)Included in 2013 additions is $55,000 in deposits that were paid in 2012 and included in prepaids and other current assets.

5.PATENTS AND LICENSES

SCHEDULE OF REVENUE CONTRACT BALANCES

Cost    
Balance, January 1, 2013 $103,229 
Additions  62,923 
Balance, December 31, 2013  166,152 
Additions  161,283 
Balance, December 31, 2014  327,435 
Additions  209,814 
Balance, December 31, 2015  537,249 
Accumulated Depreciation    
Balance, January 1, 2013  27,679 
Amortization  12,797 
Balance, December 31, 2013  40,476 
Amortization  26,238 
Balance, December 31, 2014  66,714 
Amortization  43,722 
Balance, December 31, 2015  110,436 
Carrying Amounts    
At December 31, 2013 $125,676 
At December 31, 2014 $260,721 
At December 31, 2015 $426,813 
  Contract 
  Receivables  Liabilities 
Opening balance, January 1, 2022 $-  $- 
Customer deposits  -   (779,870)
Changes due to payment, fulfillment of performance obligations or        
revenues recognized  62,842   489,906 
Effect of changes in foreign exchange rates  -   15,772 
         
Balance, December 31, 2022 $62,842  $(274,192)
Changes due to payment, fulfillment of performance obligations or revenues recognized  (62,842)  271,069 
Effect of changes in foreign exchange rates  -   3,123 
         
Balance, December 31, 2023 $-  $- 

4.PREPAIDS AND OTHER CURRENT ASSETS

The following table reflects the details of prepaids and other current assets at December 31:

SCHEDULE OF PRREPAIDS AND OTHER CURRENT ASSETS

  2023  2022  2021 
Sales tax recoverable and other current assets $57,200  $128,321  $141,568 
Deposits on equipment  -   -   288,287 
Prepaid expenses  93,476   147,186   50,668 
             
Prepaids and other current assets $150,676  $275,507  $480,523 

5.JOINT VENTURE

On October 20, 2020, the Company signed a Joint Venture Agreement (“JVA”) establishing a joint venture, Super Photonics Xiamen Co., Ltd (“SPX”) in Xiamen China, with Xiamen Sanan Integrated Circuit Co. Ltd. (“Sanan IC”) whose purpose is to design, develop, manufacture and sell 100G, 200G and 400G optical engines based on POET’s proprietary Optical Interposer platform technology. SPX was registered on March 12, 2021. SPX will be subsequently capitalized through a combination of committed cash, capital equipment and intellectual property from Sanan IC and intellectual property and know-how from the Company.

The Company’s contribution of intellectual property to SPX was independently valued at $22,500,000 at the time of its contribution. During the year ended December 31, 2023, the Company recognized a gain of $1,031,807 (2022 - $1,746,987, 2021 - $2,587,500) related to its contribution of intellectual property to SPX in accordance with IAS 28. The Company only recognized a gain on the contribution of the intellectual property equivalent to the Sanan IC’s interest in SPX, the unrecognized gain of $17,133,706 (2022 - $18,159,632, 2021 - $19,912,500) will be applied against the investment and periodically realized as the Company’s ownership interest in SPX is reduced. As at December 31, 2023, Sanan IC’s and the Company’s ownership interests were approximately 23.9% and 76.1% respectively (2022 - 19.3% and 80.7%, 2021 - 11.5% and 88.5%).

SPX was determined to be a joint venture as both Sanan IC and POET exercise joint control over SPX. All relevant activity of SPX require unanimous consent.

10Page 15

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

5.JOINT VENTURE (Continued)

The Company’s investment in joint venture during the year can be summarized as follows:

SCHEDULE OF INVESTMENT IN JOINT VENTURE

Balance, January 1, 2021$-
Contribution of intellectual property22,500,000
Unrecognized gain on contribution of intellectual property(19,912,500)
Share of loss in joint venture for the year ended December 31, 2021(1,142,249)
Investment balance, December 31, 20211,445,251
Recognized gain on contribution of intellectual property1,746,987
Share of loss in joint venture for the year ended December 31, 2022(3,211,993)
Effect of changes in foreign exchange rates19,755
Investment balance, December 31, 2022-
Recognized gain on contribution of intellectual property1,031,807
Share of loss in joint venture for the year ended December 31, 2023(1,031,807)
Effect of changes in foreign exchange rates-
Investment balance, December 31, 2023$-

Summarized financial information of the joint venture is as follows:

SCHEDULE OF FINANCIAL INFORMATION OF JOINT VENTURE

December 31, 2023  2022  2021 
          
Current assets $1,758,587  $1,951,654  $2,287,252 
Intangible assets  16,155,786   18,708,065   22,500,000 
Liabilities  (149,306)  (180,897)  (44,683)
Owners Equity  (17,765,067)  (20,478,822)  (24,742,569)
             
Net loss $3,830,962  $4,319,857  $1,212,417 

The Company recognizes its share of SPX’s profits or losses using the equity method. On a weighted average basis, the Company’s share of the net operating loss was 78.9% or $(3,026,408), however the Company recognized $(1,031,807) of the net operating loss of SPX for the year ended December 31, 2023 (2022 - 83.7% or $(3,211,993), 2021 - $95.3% or $(1,142,249)). In accordance with IAS 28, the Company can only account for a loss to the extent that it carries a net investment in the joint venture on the statement of financial position. The Company’s current share of the operating loss is a result of the high value of the Company’s initial contribution. The Company’s share of the loss will reduce as Sanan IC periodically contributes cash and other assets to SPX.

6.PROPERTY AND EQUIPMENT

SCHEDULE OF PROPERTY AND EQUIPMENT

  Equipment not ready for use  Leasehold improvements  Machinery and equipment  Office equipment  Total 
                
Cost                    
Balance, January 1, 2021 $227,147  $71,928  $3,994,657 $128,185  $4,421,917 
Additions,net of returns  (128,575)  -   842,877   57,221   771,523 
Reclassification  (96,334)  47,393   48,941   -   - 
Effect of changes in foreign exchange rates  (2,238)  (2,206)  (56,455)  (2,137)  (63,036)
                     
Balance,December 31, 2021  -   117,115   4,830,020   183,269   5,130,404 
Additions, net of returns (1)  1,902,713   -   1,087,414   21,435   3,011,562 
Reclassification  (141,702)  -   162,917   (21,215)  - 
Effect of changes in foreign exchange rates  54,898   6,544   11,270   (5,587)  67,125 
                     
Balance, December 31, 2022  1,815,909   123,659   6,091,621   177,902   8,209,091 
Property and equipment at cost, beginning  1,815,909   123,659   6,091,621   177,902   8,209,091 
Additions  206,018   -   949,551   12,384   1,167,953 
Additions, net of returns  206,018   -   949,551   12,384   1,167,953 
Reclassification  (2,013,090)  -   2,013,090   -   - 
Effect of changes in foreign exchange rates  (8,837)  597   41,246   5,560   38,566 
                     
Balance, December 31, 2023  -   124,256   9,095,508   195,846   9,415,610 
Property and equipment at cost, ending  -   124,256   9,095,508   195,846   9,415,610 

Page 16

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

6.PROPERTY AND EQUIPMENT (Continued)

  Equipment not ready for use  Leasehold improvements  Machinery and equipment  Office equipment  Total 
                
Accumulated Depreciation                    
Balance, January 1, 2021  -   10,777   1,146,014   79,372   1,236,163 
Depreciation for the year  -   18,891   794,834   26,641   840,366 
Effect of changes in foreign exchange rates  -   (142)  (10,122)  (95)  (10,359)
                     
Balance, December 31, 2021  -   29,526   1,930,726   105,918   2,066,170 
Depreciation for the year  -   24,079   1,000,085   30,100   1,054,264 
Effect of changes in foreign exchange rates  -   2,529   27,727   (12,106)  18,150 
                     
Balance, December 31, 2022  -   56,134   2,958,538   123,912   3,138,584 
Property and equipment, accumulated depreciation, beginning  -   56,134   2,958,538   123,912   3,138,584 
Depreciation for the year  -   24,684   1,600,981   28,133   1,653,798 
                    
Balance, December 31, 2023  -   80,818   4,559,519   152,045   4,792,382 
Property and equipment, accumulated depreciation, ending  -   80,818   4,559,519   152,045   4,792,382 
                     
Carrying Amounts                    
At December 31, 2021 $-  $87,589$  2,899,294 $77,351  $3,064,234 
At December 31, 2022 $1,815,909  $67,525$  3,133,083 $53,990  $5,070,507 
At December 31, 2023 $-  $43,438$  4,535,989 $43,801  $4,623,228 
Property and equipment, carrying amounts $-  $43,438$  4,535,989 $43,801  $4,623,228 

 6.(1)

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

During 2022, the Company returned $196,490 in equipment to a vendor. The equipment was not needed as the Company had alternatives. The equipment was returned without penalty to the Company.

December 31, 2015  2014  2013 
Trade payable $337,564  $79,406  $94,824 
Payroll related liabilities  104,788   113,338   89,243 
Accrued liabilities  73,069   258,980   71,960 
  $515,421  $451,724  $256,027 

7.PATENTS AND LICENSES

SCHEDULE OF PATENTS AND LICENSES

     
Cost    
Balance, January 1, 2021 $837,102 
Additions  159,359 
     
Balance, December 31, 2021  996,461 
Additions  62,475 
     
Balance, December 31, 2022  1,058,936 
Patents and licenses, cost, beginning  1,058,936 
Additions  79,111 
     
Balance, December 31, 2023  1,138,047 
Patents and licenses, cost, ending  1,138,047 
     
Accumulated Amortization    
Balance, January 1, 2021  398,425 
Amortization  69,560 
     
Balance, December 31, 2021  467,985 
Amortization  80,246 
     
Balance, December 31, 2022  548,231 
Patents and licenses, accumulated amortization, beginning  548,231 
Amortization  87,761 
     
Balance, December 31, 2023  635,992 
Patents and licenses, accumulated amortization, ending  635,992 
     
Carrying Amounts    
     
At December 31, 2021 $528,476 
At December 31, 2022 $510,705 
At December 31, 2023 $502,055 
Patents and licenses, carrying amounts $502,055 

Page 17

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

8.RIGHT OF USE ASSET AND LEASE LIABILITY

The Company recognizes a lease liability and right of use asset relating to its commercial leases. The lease liability is measured at the present value of the remaining lease payments, discounted using the Company’s incremental borrowing rate of 12%.

SCHEDULE OF RIGHT OF USE ASSET AND LEASE LIABILITY

Right of use asset Building 
Cost    
Balance, January 1, 2021 $653,232 
Effect of changes in foreign exchange rates  (4,122)
Balance, December 31, 2021  649,110 
Lease modification  81,542 
Balance, December 31, 2022  730,652 
Right of use asset, cost, beginning  730,652 
Addition  420,806 
Balance, December 31, 2023  1,151,458 
Right of use asset, cost, ending  1,151,458 
     
Accumulated Amortization    
Balance, January 1, 2021  132,546 
Amortization  190,596 
Effect of changes in foreign exchange rates  (922)
Balance, December 31, 2021  322,220 
Amortization  158,648 
Effect of changes in foreign exchange rates  8,737 
Balance, December 31, 2022  489,605 
Right of use asset, accumulated amortization, beginning  489,605 
Amortization  180,602 
Effect of changes in foreign exchange rates  (1,138)
Balance, December 31, 2023  669,069 
Balance, December 31, 2023  669,069 

Carrying Amounts    
At December 31, 2021 $326,890 
At December 31, 2022 $241,047 
At December 31, 2023 $482,389 
Carrying Amounts $482,389 

Page 18

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

8.RIGHT OF USE ASSET AND LEASE LIABILITY (Continued)

Lease liability
Balance, January 1, 2021 $531,997 
Interest expense  67,675 
Lease payments  (237,634)
Effect of changes in foreign exchange rates  (2,690)
Balance, December 31, 2021  359,348 
Interest expense  49,738 
Lease modification  81,542 
Lease payments  (204,518)
Effect of changes in foreign exchange rates  (6,847)
Balance, December 31, 2022  279,263 
Lease liability, beginning  279,263 
Interest expense  53,613 
Lease modification  - 
Additions  424,021 
Lease payments  (252,103)
Effect of changes in foreign exchange rates  7,286 
Balance, December 31, 2023 $512,080 
Lease liability, ending $512,080 

9.ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at December 31 was as follows:

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

  2023  2022  2021 
          
Trade payables $1,370,658  $2,723,531  $987,498 
Payroll related liabilities  563,588   452,751   521,692 
Accrued liabilities  367,211   186,148   282,032 
             
 Total accounts payable and accrued liabilities $2,301,457  $3,362,430  $1,791,222 

10.DERIVATIVE WARRANT LIABILITY

On December 4, 2023, the Company raised gross proceeds of $1,607,400 from the issuance of 1,786,000 units through an underwritten public offering in the United States (the “Offering”). The Offering consisted of 1,786,000 common shares of the Company and warrants to purchase up to 1,786,000 warrants. The warrants are exercisable into common shares of the Company at a price of $1.12 until December 4, 2028.

Because the functional currency of the entity issuing the warrant is Canadian dollars but the warrants are exercisable in United States dollars, the Company may receive a variable amount in Canadian dollars when the warrants are exercised as the foriegn exchange may vary over the warrant exercise period. The variability in potential future cashflows resulted in a derivative warrant liability which will be periodically remeasured with any gains or losses charged to the consolidated statements of operations and deficit.

The fair value of the share purchase warrants was estimated on the date of issuance using the Black-Scholes option pricing model with the following weighted average assumptions: dividend yield of 0%, risk-free interest rate of 3.54%, volatility of 75.66%, and estimated life of 5 years. The estimated fair value assigned to the warrants and recognized as a derivative liability on the date of issuance was $954,537. The derivative liability was remeasured on December 31, 2023. The remeasurement resulted in a loss of $24,865.

Page 19

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

10.DERIVATIVE WARRANT LIABILITY (continued)

The following table presents the details of the derivative warrant liability:

SCHEDULE OF DERIVATIVE WARRANT LIABILITY

  

December 31,

2023

  December 4,
2023
 
Stock price ($CA) $1.25  $1.22 
Exercise price ($CA) $1.52  $1.52 
Expected life in years  5.00   5.00 
Volatility  75.66%  75.66%
Dividend yield  0%  0%
Risk free interest rate  3.54%  3.54%
Fair value of derivative warrant liability $1,002,264  $954,537 

 

11.SHARE CAPITAL

 

7.

(a)

SHARE CAPITAL

AUTHORIZED

(a)AUTHORIZED

Unlimited number of common shares

One special voting share

(b)COMMON SHARES ISSUED

SCHEDULE OF COMMON SHARES ISSUED

  Number of
Shares
  Amount 
Balance, January 1, 2013
  117,528,615  $40,225,401 
Shares issued on the exercise of stock options  607,500   152,502 
Fair value of stock options exercised  -   121,368 
Shares issued on private placement  14,400,000   7,189,200 
Fair value of warrants and compensation warrants issued  -   (4,308,292)
Share issue costs  -   (529,222)
Shares issued on the exercise of warrants and compensation warrants  140,000   37,111 
Fair value of warrants exercised  -   23,387 
Balance, December 31, 2013
  132,676,115   42,911,455 
Shares issued on the exercise of stock options  4,824,950   1,481,716 
Fair value of stock options exercised  -   1,261,156 
Shares issued on private placements  7,692,307   4,546,000 
Fair value of warrants and compensation warrants issued  -   (1,869,231)
Shares issued on the exercise of warrants and  compensation warrants  19,384,712   8,404,265 
Fair value of warrants and compensation warrants exercised  -   3,545,406 
Warrant exercise incentive  -   (31,712)
Shares issued for reduction of license fee  2,000,000   1,439,898 
Balance, December 31, 2014  166,578,084   61,688,953 
Shares issued on the exercise of stock options  8,106,300   2,703,436 
Fair value of stock options exercised  -   2,816,625 
Shares issued on the exercise of warrants and compensation warrants  22,413,431   9,373,245 
Fair value of warrants exercised  -   4,444,912 
Balance, December 31, 2015  197,097,815  $81,027,171 
  Number of Shares  Amount 
Balance, January 1, 2021  29,461,811  $114,586,260 
Funds from the exercise of stock options  1,001,519   3,124,392 
Fair value of stock options exercised  -   2,699,042 
Issued on the conversion of convertible debentures (Note 10)  1,119,750   3,571,342 
Fair value of warrants issued upon conversion of convertible debentures  -   (1,229,305)
Funds from the exercise of warrants  3,144,750   12,994,358 
Fair value of warrants exercised  -   5,351,586 
Funds from Common shares issued on private placement  1,764,720   11,815,595 
Fair value of warrants issued on private placement  -   (3,766,007)
Share issue costs  -   (1,143,034)
Fair value of broker warrants issued as share issue costs  -   (288,197)
Shares issued to settle accounts payable  1,678   13,814 
Balance, December 31, 2021  36,494,228   147,729,846 
Funds from Common shares issued on private placement  1,126,635   3,184,332 
Fair value of warrants issued on private placement  -   (656,734)
Share issue costs  -   (247,892)
Shares issued to settle accounts payable  5,422   40,029 
Funds from the exercise of stock options  143,437   418,845 
Fair value of stock options exercised  -   374,129 
Funds from the exercise of warrants and compensation warrants  72,500   284,437 
Fair value of warrants and compensation warrants exercised  -   79,547 
Adjustment for 10 for 1 share consolidation  (272)  - 
Balance, December 31, 2022  37,841,950   151,206,539 
Funds from common shares issued through ATM financing  227,673   983,194 
Funds from Common shares issued on private placement  1,786,000   1,607,400 
Fair value of warrants issued on private placement  -   (954,537)
Share issue costs  -   (578,317)
Funds from the exercise of stock options  268,356   668,259 
Fair value of stock options exercised  -   587,035 
Funds from the exercise of warrants and compensation warrants  2,364,066   7,767,067 
Fair value of warrants and compensation warrants exercised  -   4,418,783 
Balance, December 31, 2023  42,488,045  $165,705,423 

Page 20

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

11.SHARE CAPITAL (Continued)

2021

On February 14, 2013,11, 2021, the Company completed a brokered private placement financing for gross proceeds aggregating $7,189,200 ($7,200,000 CAD). The Company issued 14,400,000offering of 1,764,720 units at a price of $0.499 ($0.50 CAD)$6.70 (CAD$8.50) per unit.unit for gross proceeds of $11,815,595 (CAD$15,000,120). Each unit consists of one common share and one common share purchase warrant. Each whole warrant entitles the holder to purchase one additional common share of the Company at a price of $0.748 ($0.75 CAD)$9.00 (CAD$11.50) per share until February 11, 2023. At any time after June 12, 2021, the Company reserves the right to accelerate the expiry of the warrants if the Company’s average stock price exceeds $18.10 (CAD$23.00) for a period of two years.10 consecutive trading days. The agentsbroker was paid a cash commission of $708,667 (CAD$900,007) equating to 6% of the gross proceeds and received cash commissions in105,883 broker warrants. Each broker warrant is exercisable into one common share of the aggregateCompany at a price of $503,244 ($504,000 CAD)$6.70 (CAD$8.50) per broker warrant until February 11, 2023. The Company incurred additional share issuance costs of $434,367 directly related to the private placement and 1,440,000 compensationwarrant exercises.

The fair value of the share purchase warrants in connectionand broker warrants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: dividend yield of 0%, risk-free interest rate of 0.19%, volatility of 75.26%, and estimated life of 2 years. The estimated fair value assigned to the warrants and broker warrants was $3,766,007 and $288,197, respectively.

2022

In 2020, the Company engaged with a firm to assist with its shareholder communications strategy. The terms of the agreement require the Company to issue common shares at certain pre-determined dates in satisfaction of past services rendered. During the year ended December 31, 2022, the Company settled $40,029 (2021 - $13,814) in accounts payable related to services rendered in 2022 under this agreement by issuing 5,422 (2021 - 1,678) common shares at a price of $7.38 (CAD$9.38) (2021 - $8.20 (CAD$10.10)) per share to the firm.

On December 2, 2022, the Company completed a non-brokered private placement. placement offering of 1,126,635 units at a price of $2.78 (CAD$3.81) per unit for gross proceeds of $3,184,332 (CAD$4,292,479). Each compensationunit consists of one common share and one half common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at $0.499 ($0.50 CAD)a price of $3.61 (CAD$4.95) per share for a period of three years. Additionaluntil December 2, 2025. The Company paid finders’ fees aggregating to $42,090 (CAD$57,897) to four firms. The Company paid other share issue costs amountedof $205,802 related to $25,978 ($26,017 CAD).this private placement offering.

11

POET TECHNOLOGIES INC.One director subscribed for 10,000 units of this private placement offering for gross proceeds of $27,800 (CAD$38,100).

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

7.SHARE CAPITAL (Continued)

The fair value of the share purchase warrants and compensation warrants was estimated using the Black-scholes option pricing model with the following assumptions: dividend yield of 0%, interest rate of 1.16% and 1.24%, volatility of 121% and 111.35% and estimated life of 2 and 3 years. The estimated fair value assigned to the warrants and compensation warrants was $3,825,178 ($3,844,400 CAD) and $483,114 ($483,840 CAD) respectively.

On February 13, 2014, the Company completed a $4,546,000 ($5,000,000 CAD) private placement financing. The financing consisted of 7,692,307 units at a price of $0.59 ($0.65 CAD) per unit. Each unit comprised one common share and one common share purchase warrant. One warrant allows the holder to acquire one additional common share of the Company at an exercise price of $0.91 ($1.00 CAD) per share for a year of 2 years, expiring on February 12, 2016. No commission was payable with respect to this financing.

The fair value of thebroker warrants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: dividend yield of 0%0%, risk-free interest rate of 1.017%3.48%, volatility of 92.22%69.93%, and estimated life of 2 years.3 years. The estimated fair value assigned to the warrants was $1,869,231 ($2,076,923 CAD)$656,734.

2023

During the year ended December 31, 2023, the Company raised gross proceeds of $983,194 from the issuance of 227,673 common shares through an Equity Distribution Agreement, (“EDA”) with multiple agents. Pursuant to the EDA, the Company established an at-the-market (“ATM”) equity offering program whereby the Company may, at its discretion, during the term of the ATM agreement issue and sell, through the agents such number of common shares of the Company as would result in aggregate gross proceeds to the Company of up to US$30 million. The agents were paid a commission of 3% or $29,486 of the gross proceeds raised through the ATM. The Company incurred additional financing costs including legal and filing fees of $291,226.

Page 21

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

11.SHARE CAPITAL (Continued)

On December 4, 2023, the Company raised gross proceeds of $1,607,400 from the issuance of 1,786,000 units through an underwritten public offering in the United States (the “Offering”). The Offering consisted of 1,600,000 common shares of the Company and warrants to purchase up to 1,600,000 common shares of the Company at a combined public offering price of US$0.90 per common share and accompanying warrant. Each warrant has an exercise price of US$1.12 per common share and is exercisable for five years from the date of issuance. In addition, the Company granted the underwriter a 45 day option to purchase up to an additional 240,000 common shares and/or warrants to purchase up to an additional 240,000 common shares at the public offering price in any combination, less underwriting discounts and commissions, which the underwriter has partially exercised to purchase 186,000 additional common shares and additional warrants to purchase up to 186,000 common shares. The agents were paid a commission of 7% or $112,518 of the gross proceeds raised. The Company incurred additional financing costs including legal and filing fees of $145,089.

The fair value of the share purchase warrants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: dividend yield of 0%, risk-free interest rate of 3.54%, volatility of 75.66%, and estimated life of 5 years. The estimated fair value assigned to the warrants was $954,537 (Note 10).

Share Consolidation

On February 24, 2022, the Company filed Articles of Amendment to consolidate its common shares on a ten-for-one basis. For further clarity, for every ten (10) pre-consolidated common shares, shareholders received one (1) post-consolidated common share. On February 28, 2022, the Company’s common shares began trading on the TSX Venture Exchange on a post consolidation basis. The Company’s name and trading symbol remained unchanged. All references to share and per share amounts in these consolidated financial statements and accompanying notes to the consolidated financial statements have been retroactively restated to reflect the ten-for-one share consolidation.

12.WARRANTS AND COMPENSATION OPTIONS

 

During 2014, the Company paid $31,712 ($35,000 CAD) as incentives for the exercise of warrants.

(c)SPECIAL VOTING SHARE

On June 5, 2007, one (1) special voting share was issued in conjunction with a Support and Trust Agreement entered into amongst POET Technologies Inc, OPEL Solar Inc ("OSI"). and Equity Transfer & Trust Company. The special voting share was returned to treasury and cancelled on June 21, 2013.

8.WARRANTS

The following table reflects the continuity of warrants:warrants and compensation options:

SCHEDULE OF WARRANTS AND COMPENSATION OPTIONS

  Average Exercise Price  Number of Warrants  Historical Fair value 
Balance, January 1, 2013
 $0.33   26,778,569  $3,850,685 
Warrants issued  0.75   14,400,000   3,825,178 
Compensation warrants issued  0.50   1,440,000   483,114 
Exercised  0.17   (140,000)  (23,387)
Balance, December 31, 2013  0.48   42,478,569   8,135,590 
Warrants issued  0.91   7,692,307   1,869,231 
Expired  0.29   (3,500)  (756)
Exercised  0.43   (19,384,712)  (3,545,406)
Balance, December 31, 2014  0.61   30,782,664   6,458,659 
Warrants and compensation warrants exercised  0.42   (22,413,431)  (4,444,912)
Balance, December 31, 2015 $0.79   8,369,233  $2,013,747 
  Historical
Average Exercise
Price
  Number of
Warrants/ Compensation options
  Historical
Fair value
 
Balance, January 1, 2021 $3.90   3,269,050 $5,557,002 
Fair value of warrant issued on private placement (Note 11)  9.00   1,764,720   3,766,007 
Fair value of broker warrants issued on private placement  6.70   105,883   288,197 
Fair value of warrants issued on conversion of            
convertible debentures  3.80   1,119,750   1,229,305 
Historical fair value assigned to warrants exercised  3.90   (3,144,750)  (5,351,586)
Fair value of expired warrants  3.90   (93,300)  (160,470)
Balance, December 31, 2021  7.10   3,021,353   5,328,455 
Fair value of warrant issued on private placement  1.17   563,318   656,734 
Historical fair value assigned to warrants exercised  3.90   (72,500)  (79,547)
Balance, December 31, 2022  6.15   3,512,171   5,905,642 
Historical fair value assigned to warrants exercised  3.27   (2,364,066)  (4,418,783)
Fair value of expired warrants  4.50   (584,787)  (816,744)
Fair value of warrant issued on public offering  -   1,786,000   - 
Balance, December 31, 2023 $1.77   2,349,318 $670,115 

12Page 22

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

8.WARRANTS (Continued)

13.STOCK OPTIONS AND CONTRIBUTED SURPLUS

As at December 31, 2015 the following warrants were outstanding:

  Number of
Warrants
  Historical
Fair Value ($)
  Historical
Exercise
Price ($)
  Expiry Date
Warrants  6,734,577   1,636,402   0.91  February 12, 2016
Compensation warrants  515,355   172,899   0.50  February 14, 2016
Compensation warrants  38,040   6,659   0.22  June 22, 2016
Compensation warrants  11,250   2,006   0.22  July 31, 2016
Compensation warrants  33,111   5,998   0.22  September 7, 2016
Compensation warrants  536,900   98,681   0.22  September 13, 2016
Compensation warrants  500,000   91,102   0.22  September 27, 2016
   8,369,233   2,013,747   0.79   

These warrants were issued in Canadian dollars and are exercisable at prices ranging from $0.23 CAD and $1.00 CAD.

9.STOCK OPTIONS AND CONTRIBUTED SURPLUS

Stock Options

On June 12, 2015,30, 2023, shareholders of the Company approved amendments toa fixed 20% omnibus equity incentive plan (the “Omnibus Plan”). The Omnibus Plan replaces the Company's fixed 20%2021 stock option plan (as amended, referredplan. The Omnibus Plan provides flexibility to as the "2015 Plan"). Under the 2015 Plan, the board of directors may grant options to acquire common shares of the Company to qualifiedgrant different forms of equity-based incentive awards to directors, officers, employees and consultants. The 2015Omnibus plan provides the Company with the choice of granting stock options (“Options”), share units (“Share Units”) and deferred share units (“DSUs”). The Omnibus Plan provides that the maximum number of common shares issuable pursuant to optionsawards granted under the 2015Omnibus Plan and pursuant to other previously granted optionsawards is limited to 36,326,0008,056,055 (the “Number Reserved”). Any subsequent increase in the Number Reserved must be approved by shareholders of the Company and cannot, at the time of the increase, exceed 20%20% of the number of issued and outstanding shares. The stock optionsAwards vest in accordance with the policies determined by the Board of Directors from time to time consistent with the provisions of the 2015Omnibus Plan which grants discretion to the Board of Directors.

Stock option transactions and the number of stock options outstanding were as follows:

SCHEDULE OF STOCK OPTIONS OUTSTANDING

 Number of
Options
  Weighted average
Exercise
Price
  Number of
Options
 Historical Weighted Average Exercise Price 
Balance, January 1, 2013  17,602,750  $0.35 
Balance, January 1, 2021  5,114,449  $3.30 
Expired/cancelled  (572,500)  0.53   (166,438)  3.40 
Exercised  (607,500)  0.25   (1,001,519)  3.00 
Granted  7,310,000   0.46   1,013,125   8.50 
Balance, December 31, 2013  23,732,750   0.38 
Balance, December 31, 2021  4,959,617   4.40 
Expired/cancelled  (825,000)  1.01   (117,438)  6.02 
Exercised  (4,824,950)  0.31   (143,437)  2.85 
Granted  6,155,000   1.26   2,043,083   3.32 
Balance, December 31, 2014  24,237,800   0.61 
Balance, December 31, 2022  6,741,825   4.10 
Expired/cancelled  (1,068,000)  1.13   (182,750)  4.66 
Exercised  (8,106,300)  0.43   (268,356)  2.49 
Granted (1)  11,655,000   1.19 
Balance, December 31, 2015  26,718,500  $0.89 
Granted  1,002,170   4.11 
Balance, December 31, 2023  7,292,889  $3.92 

(1)   Of the 11,655,000 options granted during the year, 187,000 options granted at $0.65 per share have been granted conditional on TSX Venture Exchange and shareholder approval of an increase to the Company's stock option plan at the Company's 2016 annual general meeting.

13

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

9.STOCK OPTIONS AND CONTRIBUTED SURPLUS (Continued)

During the year the Company granted 11,655,000 (2014 - 6,155,000, 2013 - 7,310,000) stock options to officers, employees and consultants of the Company to purchase common shares at an average price of $1.19 (2014 - $1.26, 2013 - $0.46) per share.

During the year,ended December 31, 2023, the Company recorded stock-based compensation of $4,818,120 (2014$4,201,444 (2022 - $4,615,997, 2013$4,436,604, 2021 -

$4,021,153)4,534,370) relating to stock options that vested during the year.

The stock options granted were valued using the Black-Scholes option pricing model using the following assumptions:

SCHEDULE OF STOCK OPTIONS ASSUMPTIONS

  2015  2014  2013 
Weighted average exercise price
 $1.19  $1.26  $0.46 
Weighted average risk-free interest rate  0.98%  1.58%  1.75%
Weighted average dividend yield  0%  0%  0%
Weighted average volatility  102.7%  102%  113%
Weighted average estimated life  5 years   5 years   5 years 
Weighted average share price $1.19  $1.26  $0.46 
             
Share price on the various grant dates were:  2015   2014   2013 
First grant $1.31  $1.31  $0.53 
Second grant  1.59   1.10   0.50 
Third grant  1.33   1.64   0.44 
Fourth grant  1.14   1.13   0.46 
Fifth grant  1.13   -   0.47 
Sixth grant  1.25   -   0.42 
Seventh grant  1.19   -   0.43 
Eight grant  0.83   -   - 
Ninth grant  0.72   -   - 
Tenth grant  0.63   -   - 
Eleventh grant  0.74   -   - 
Twelfth grant  0.62   -   - 
Thirteenth grant  0.65   -   - 
  2023  2022  2021 
Weighted average exercise price $4.11  $3.32  $8.50 
Weighted average risk-free interest rate  2.88% - 3.48%   1.80% - 3.48%   0.80% - 1.48% 
Weighted average dividend yield  0%  0%  0%
Weighted average volatility  82.17% - 82.45%  83.51%  90.68%
Weighted average estimated life  10 years   10 years   10 years 
Weighted average share price $4.11  $3.32  $8.50 
Share price on the various grant dates:  $4.05 - $4.63   $2.72 - $6.71   $6.20 - $9.50 
Weighted average fair value $3.42  $2.70  $7.50 

Page 23

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

13.STOCK OPTIONS AND CONTRIBUTED SURPLUS (Continued)

The underlying expected volatility was determined by reference to the Company'sCompany’s historical share price movements, its dividend policy and dividend yield and past experience relating to the expected life of granted stock options.

The weighted average remaining contractual life and weighted average exercise price of options outstanding and of options exercisable as at December 31, 20152023 are as follows:

SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE AND WEIGHTED AVERAGE EXERCISE PRICE OF OPTIONS

Options Outstanding Options Exercisable 
Exercise
Range
 Number
Outstanding
  Historical Weighted Average Exercise
Price
  Weighted
Average Remaining Contractual Life (years)
  Number
Exercisable
  Historical Weighted Average Exercise
Price
 
$0.83 - $1.97  7,000  $1.97   4.59   7,000  $1.97 
$1.98 - $2.80  1,851,073  $2.45   6.17   1,328,577  $2.36 
$2.81 - $9.02  5,434,816  $4.44   7.21   3,373,128  $4.38 
   7,292,889  $3.92   6.95   4,708,705  $3.81 

14.LOSS PER SHARE

SCHEDULE OF INCOME (LOSS) PER SHARE

 

Options Outstanding Options Exercisable 
Exercise Range Number Outstanding  Weighted Average Exercise Price  Weighted Average Remaining Contractual Life (years)  Number Exercisable  Average Weighted Exercise Price 
$0.11 - $0.25  2,860,000  $0.23   2.03   2,860,000  $0.23 
$0.28 - $0.31  532,500  $0.28   1.92   532,500  $0.28 
$0.34 - $0.37  65,000  $0.33   4.64   65,000  $0.33 
$0.38 - $0.86  7,219,000  $0.46   2.44   7,119,000  $0.46 
$0.87 - $1.64  16,042,000  $1.19   4.19   4,332,500  $1.21 
   26,718,500  $0.89   3.44   14,909,000  $0.63 
             
  2023  2022  2021 
Numerator            
Net loss $(20,267,365) $(21,036,690) $(15,669,093)
Denominator            
Weighted average number of common shares outstanding  40,099,752   36,739,857   34,545,752 
Weighted average number of common shares outstanding - diluted  40,099,752   36,739,857   34,545,752 
Basic and diluted loss per share $(0.51) $(0.57) $(0.45)

14

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

9.

STOCK OPTIONS AND CONTRIBUTED SURPLUS (Continued)

Contributed Surplus

The following table reflects the continuity of contributed surplus:

  Amount
Balance, January 1, 2013  16,361,282 
Stock-based compensation  4,021,153 
Fair value of stock options exercised  (121,368)
Balance, December 31, 2013  20,261,067 
Stock-based compensation  4,615,997 
Fair value of stock options exercised  (1,261,156)
Fair value of expired warrants  756 
Balance, December 31, 2014  23,616,664 
Stock-based compensation  4,818,120 
Fair value of stock options exercised  (2,816,625)
Balance, December 31, 2015 $25,618,159 

10.LOSS PER SHARE

December 31,  2015   2014   2013 
Numerator            
Net loss $(12,070,170) $(11,785,800) $(7,849,017)
Denominator            
Weighted average number of            
common shares outstanding  185,091,882   156,488,296   130,743,149 
Weighted average number of common            
shares outstanding - diluted  185,091,882   156,488,296   130,743,149 
Basic and diluted loss per share $(0.07) $(0.08) $(0.06)

The effect of common share purchase options, warrants, compensation warrants and shares to be issued on the net loss in 2015, 20142023, 2022 and 20132021 is not reflected as they are anti-dilutive.

15.COMMITMENTS AND CONTINGENCIES

 

11.COMMITMENTS AND CONTINGENCIES

The Company has two operating leases for developmenton four facilities; head office located in Toronto, Canada, design and testing operations expiringlocated in Allentown, Pennsylvania (formerly in San Jose, California) and operating facilities located in Singapore and China. The Company’s design and testing operations was initiated on April 1, 2021 and expires on September 30, 2025. The lease on the Company’s operating facilities in Singapore terminated on May 31, 2023. The lease was renewed on June 1, 2023 and expires on March 31, 20162027. The lease on the Company’s operating facilities in China was initiated in November 19, 2021 and Januaryexpired on November 18, 2023. The lease on the operating facility in China was renewed for another three year term, expiring on November 18, 2026. As of December 31, 2017 and one operating lease for its2023, the Company’s head office space expiring March 31, 2016.was on a month to month lease term.

Rent expense under these leases was $204,987 for the year ended December 31, 2015 (2014 - $153,398, 2013 - $118,068).

Remaining minimum annual rentallease payments to the lease expiration dates are as follows:

SCHEDULE OF REMAINING ANNUAL RENTAL PAYMENTS LEASE

December 31, 2016 $133,612 
January 1, 2017 through 2019  28,380 
  $161,992 
     
2024 $281,048 
2025 and beyond  390,873 
Remaining minimum annual rental payments $671,921 

15Page 24

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

16.RELATED PARTY TRANSACTIONS

12.RELATED PARTY TRANSACTIONS

Compensation to key management personnel were as follows:

SCHEDULE OF COMPENSATION TO KEY MANAGEMENT PERSONNEL

December 31, 2015 2014 2013
         
 2023  2022 2021 
             
Salaries $1,979,601  $1,363,417  $867,231  $2,044,920  $2,010,479  $1,782,297 
Share-based payments(1)  3,283,361   1,167,245   1,481,517   1,771,078   1,711,716   2,077,333 
                        
Total $5,262,962  $2,530,662  $2,348,748  $3,815,998  $3,722,195  $3,859,630 

(1)Share-based payments are the fair value of options granted to key management personnel and expensed during the various years as calculated using the Black-Scholes model.

(1)    Share-based payments are the fair value of options granted to key management personnel and expensed during the year as calculated using the Black-Scholes model.

During the year ended December 31, 2014, the Company settled $100,000 that was advanced to the former CEO of the Company. The amount was non interest bearing and short-term in nature. The Company settled the amount due from the former CEO in return for a reduction in his compensation and certain other entitlements.

In 2014, the former CEO of the Company received a severance package of $185,000 to be paid over one year. The full amount of the severance package was accounted for in 2014.

The Company paid or accrued $104,790 in fees and disbursements for the year ended December 31, 2015 (2014 - $174,549, 2013 - $91,316) to a law firm, of which a director is counsel, for legal services rendered to the Company.

All transactions with related parties have occurred in the normal course of operations and are measured at the exchange amounts, which are the amounts of consideration established and agreed to by the related parties.

13.SEGMENT INFORMATION

17.SEGMENT INFORMATION

The Company and its subsidiary operatessubsidiaries operate in a single segment; the design, manufacture and sale of semi-conductor products and services for military and industrialcommercial applications. The Company’s operating and reporting segment reflects the management reporting structure of the organization and the manner in which the chief operating decision maker regularly assesses information for decision making purposes, including the allocation of resources. A summary of the Company's operating segmentCompany’s operations is below:

OPEL, ODIS, Inc. (“ODIS”)POET Shenzhen and PTS

Odis is

OPEL, ODIS, POET Shenzhen and PTS are the developerdesigners and developers of the POET Optical Interposer platform semiconductor process IP for monolithic fabrication of integrated circuit devices containing both electronic and optical elementsengines based on a single die.the POET Optical Interposer platform.

BB Photonics

BB Photonics developed photonic integrated components for the datacom and telecom markets utilizing embedded dielectric technology that enabled the partial integration of active and passive devices into photonic integrated circuits. BB Photonics’ operation is currently dormant.

On a consolidated basis, the Company operates geographically in Singapore, China (collectively “Asia”), the United States and Canada. Geographical information is as follows:

  2015
As of December 31, US Canada Consolidated
Current assets $3,055,947 $11,504,972 $14,560,919
Property and equipment  924,443   22,664   947,107 
Patents and licenses  426,813   -   426,813 
Total Assets $4,407,203  $11,527,636  $15,934,839 

SCHEDULE OF GEOGRAPHICAL INFORMATION

             
2023 
As of December 31, Asia  US  Canada  Consolidated 
Current assets $326,926  $149,227  $2,693,592  $3,169,745 
Property and equipment  4,089,653   533,575   -   4,623,228 
Patents and licenses  -   502,055   -   502,055 
Right of use asset  379,462   102,927   -   482,389 
                 
Total Assets $4,796,041  $1,287,784  $2,693,592  $8,777,417 

16Page 25

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

17.13.SEGMENT INFORMATION (Continued)

Year Ended December 31, Asia  US  Canada  Consolidated 
Revenue $465,777  $-  $-  $465,777 
                 
Selling, marketing and administration  (2,753,484)  (6,226,291)  (1,815,380)  (10,795,155)
Research and development  (6,249,120)  (3,662,418)  (166,392)  (10,077,930)
Gain on contribution of intellectual property to joint venture  1,031,807   -   -   1,031,807 
Interest expense  (27,906)  (42,276)  -   (70,182)
Loss on fair value of derivative warrant liability  -   -   (24,865)  (24,865)
Other income, including interest  -   -   234,990   234,990 
Share of loss in joint venture  (1,031,807)  -   -   (1,031,807)
                 
Net loss $(8,564,733) $(9,930,985) $(1,771,647) $(20,267,365)

  2015
   US   Canada   Consolidated 
For the year ended December 31,     ��      
General and administration $6,622,514  $1,991,595  $8,614,109 
Research and development  3,532,492   -   3,532,492 
Investment income  -   (76,431)  (76,431)
Net Loss $10,155,006  $1,915,164  $12,070,170 
             
  2014
As of December 31,  US   Canada   Consolidated 
Current assets $3,106,274  $8,425,091  $11,531,365 
Property and equipment  1,054,636   4,224   1,058,860 
Patents and licenses  260,721   -   260,721 
Total Assets $4,421,631  $8,429,315  $12,850,946 
             
             
  US   Canada   Consolidated 
For the year ended December 31,            
General and administration $5,827,262  $3,850,443  $9,677,705 
Research and development  2,277,927   -   2,277,927 
Other income  (169,832)  -   (169,832)
Net Loss $7,935,357  $3,850,443  $11,785,800 
             
  2013
As of December 31,  US   Canada   Consolidated 
Current assets $640,538  $2,887,838  $3,528,376 
Property and equipment  903,792   -   903,792 
Patents and licenses  125,676   -   125,676 
 $1,670,006  $2,887,838  $4,557,844 
             
  US   Canada   Consolidated 
For the year ended December 31,            
General and administration $2,922,008  $3,362,280  $6,284,288 
Research and development  1,925,974   -   1,925,974 
Investment income  (18,371)  -   (18,371)
Other income  (342,874)  -   (342,874)
 $4,486,737  $3,362,280  $7,849,017
             
2022 
As of December 31, Asia  US  Canada  Consolidated 
Current assets $664,658  $133,501  $8,770,035  $9,568,194 
Investment in joint venture  -   -   -   - 
Property and equipment  4,496,734   573,773   -   5,070,507 
Patents and licenses  -   510,705   -   510,705 
Right of use asset  55,775   185,272   -   241,047 
                 
Total Assets $5,217,167  $1,403,251  $8,770,035  $15,390,453 

The Year Ended December 31, Asia  US  Canada  Consolidated 
Revenue $552,748  $-  $-  $552,748 
                 
Selling, marketing and administration  (2,121,596)  (5,885,970)  (1,508,705)  (9,516,271)
Research and development  (6,344,016)  (4,205,177)  (197,550)  (10,746,743)
Gain on contribution of intellectual property to joint venture  1,746,987   -   -   1,746,987 
Interest expense  (17,701)  (32,037)  -   (49,738)
Forgiveness of Covid-19 government support loans  -   -   -   - 
Other income, including interest  -   -   188,320   188,320 
Share of loss in joint venture  (3,211,993)  -   -   (3,211,993)
                 
Net loss $(9,395,571) $(10,123,184) $(1,517,935) $(21,036,690)

As of December 31,  Asia   US   Canada   Consolidated 
2021 
             
As of December 31,  Asia   US   Canada   Consolidated 
Current assets $537,647  $291,772  $20,959,707  $21,789,126 
Investment in joint venture  1,445,251   -   -   1,445,251 
Property and equipment  2,787,273   276,961   -   3,064,234 
Patents and licenses  -   528,476   -   528,476 
Right of use asset  150,134   176,756   -   326,890 
                 
Total Assets $4,920,305  $1,273,965  $20,959,707  $27,153,977 

Note: Certain 2013 and 2014 amounts have been reclassified to conform with the current year's presentation.

17Page 26

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

17.SEGMENT INFORMATION (Continued)

The Year Ended December 31, Asia  US  Canada  Consolidated 
Revenue $209,100  $-  $-  $209,100 
                 
Selling, marketing and administration $(1,563,829) $(5,460,917) $(2,030,784) $(9,055,530)
Research and development  (4,849,553)  (2,679,452)  (636,123)  (8,165,128)
Forgiveness of Covid-19 government support loans  -   186,747   -   186,747 
Interest expense  (35,043)  (32,632)  (296,944)  (364,619)
Gain on contribution of intellectual to joint venture  2,587,500   -   -   2,587,500 
Other income, including interest  -   -   75,084   75,084 
Share of loss in joint venture  (1,142,249)  -   -   (1,142,249)
                 
Net loss $(4,794,074) $(7,986,254) $(2,888,767) $(15,669,095)

18.FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

 

14.FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company'sCompany’s financial instruments consist of cash and cash equivalents, short-term investments, covid-19 government support loans, derivative warrant liability and accounts payable and accrued liabilities. Unless otherwise noted, it is management'smanagement’s opinion that the Company is not exposed to significant interest or credit risksrisk arising from these financial instruments. The Company estimates that the faircarrying value of these instruments approximates fair value due to their short term nature.

The Company has classified financial assets and (liabilities) as follows:follows at December 31:

SCHEDULE OF CLASSIFIED FINANCIAL ASSETS AND LIABILITIES

  2023  2022  2021 
          
Financial assets, measured at amortized cost:            
Cash and cash equivalents $3,019,069  $9,229,845  $14,941,775 
Short-term investments $-  $-  $6,366,828 
Accounts receivable, measured at amortized cost:            
Accounts receivable $-  $62,842  $- 
Other liabilities, measured at amortized cost:            
Accounts payable and accrued liabilities $(2,301,457) $(3,362,430) $(1,791,222)
Covid-19 government support loans $(30,200) $(29,520) $(31,660)
Contract liabilities $-  $(274,192) $- 
Fair value through profit or loss (FVTPL):            
Derivative warrant liability $(1,002,264) $-  $- 

December 31, 2015 2014 2013
Fair value through profit or loss, measured at fair value:            
Cash $14,409,996  $11,287,864  $3,260,967 
Other liabilities, measured at amortized cost:            
Accounts payable and accrued liabilities $(515,421) $(451,724) $(256,027)

Financial instruments recorded at fair value on the balance sheet are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - valuation based on quoted prices (unadjusted) observed in active markets for identical assets or liabilities.

Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability either directly or indirectly.

Level 3 - valuation techniques based on inputs for the asset or liability that are not based on observable market data.

Cash and cash equivalents were determined using level 1 inputs.

Exchange Rate Risk

The functional currency of each of the entities included in the accompanying consolidated financial statements is the local currency where the entity is domiciled. Functional currencies include the Chinese Yuan, US, Singapore and Canadian dollar. Most transactions within the entities are conducted in functional currencies. As such, none of the entities included in the consolidated financial statements engage in hedging activities. The Company is exposed to a foreign currency risk with the Canadian dollar.when its subsidiaries hold current assets or current liabilities in currencies other than its functional currency. A 10%10% change in the Canadian dollarforeign currencies held would increase or decrease other comprehensive loss by $1,135,639.$198,000.

Liquidity Risk

 

The Company currently does not maintain credit facilities. The Company'sCompany’s existing cash and cash resources are not considered sufficient to fund operating and investing activities through 2016.beyond one year from the date of these consolidated financial statements. The Company may, however, need to seek additional financing in the future.

18Page 27

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

19.CAPITAL MANAGEMENT

15.CAPITAL MANAGEMENT

 

In the management of capital, the Company includes shareholders'shareholders’ equity (excluding accumulated other comprehensive incomecompehensive loss and deficit) and cash. The components of capital on December 31, 20152023 were:

SCHEDULE OF COMPONENTS OF CAPITAL

Cash and cash equivalents $3,019,069 
Shareholders’ equity $221,823,499 

Cash and cash equivalents$14,409,996
Shareholders' equity$108,659,077

The Company'sCompany’s objective in managing capital is to ensure that financial flexibility is present to increase shareholder value through growth and responding to changes in economic and/or market conditions; to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business and to safeguard the Company’s ability to obtain financing should the need arise.

In maintaining its capital, the Company has a strict investment policy which includes investing its surplus capital only in highly liquid, highly rated financial instruments.

The Company reviews its capital management approach on an ongoing basis. There were no changes in the Company’s approach to capital management during the year.

16.EXPENSES

20.EXPENSES

Research and development costs can be analysed as follows:

SCHEDULE OF EXPENSES BY NATURE

  2023  2022  2021 
          
Wages and benefits $4,298,207  $4,267,937  $3,270,528 
Subcontract fees  1,864,122   2,946,729   1,516,343 
Stock-based compensation  1,539,235   2,054,187   1,769,951 
Supplies  2,376,366   1,477,890   1,608,306 
             
Research and development costs $10,077,930  $10,746,743  $8,165,128 

For the Year Ended December 31, 2015 2014 2013
Wages and benefits $1,241,054  $899,758  $692,105 
Subcontract fees  1,560,819   582,943   558,073 
Stock-based compensation  552,416   641,176   565,246 
Supplies  178,203   154,050   110,550 
  $3,532,492  $2,277,927  $1,925,974 
General and administrative costs can be analysed as follows:            
Stock-based compensation $4,265,704  $3,974,821  $3,455,907 
General expenses  1,012,340   662,672   558,560 
Professional fees  812,115   907,794   632,159 
Wages and benefits  1,306,051   1,700,600   831,950 
Management and consulting fees  665,771   595,667   581,203 
Rent  232,265   159,298   150,974 
Depreciation and amortization  319,863   236,955   73,535 
Shares issued as reduction of license fee (Note 18)  -   1,439,898   - 
  $8,614,109  $9,677,705  $6,284,288 

Selling, marketing and administration costs can be analysed as follows:

Stock-based compensation $2,662,209  $2,382,417  $2,764,419 
Wages and benefits  2,649,770   2,648,862   2,643,451 
Professional fees  1,744,771   1,173,743   1,155,316 
General expenses  1,681,899   1,860,762   1,304,690 
Depreciation and amortization  1,922,140   1,293,158   1,100,522 
Rent and facility costs  134,366   157,329   87,130 
             
Selling, marketing and administration costs $10,795,155  $9,516,271  $9,055,528 

21.REVENUE

Disaggregated Revenues

The Company disaggregates revenue by timing of revenue recognition, that is, at a point in time and revenue over time. During the year ended December 31, 2023, the Company recognized $465,777 (2022 - $552,748, 2021 - $209,100) from non-recurring engineering services. The revenue is recognized over time.

19Page 28

POET TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

 

22.INCOME TAXES

17.INCOME TAXES

The following table reconciles the expected income tax recovery at the Canadian statutory income tax rate of 26.5%26.5% for 2015 (20142023 (2022 - 26.5%26.5%, 20132021 - 26.5%26.5%) to the amounts recognized in operations.

SCHEDULE OF INCOME TAX RECOVERY

For the Year Ended December 31, 2023  2022  2021 
          
Net loss before taxes $(20,267,365) $(21,036,690) $(15,669,093)
             
Expected current income tax recovery  5,370,852   5,574,723   4,152,310 

For the Year Ended December 31,  2015   2014   2013 
Net loss $12,070,170  $11,785,800 7,849,017 
Expected income tax recovery  3,198,595   3,123,200   2,566,600 
Changes from:            
             
Amounts not deductible for tax purposes  (1,276,802)  (1,604,700)  (1,052,000)
Other non-deductible items  (2,700)  (6,100)  (18,400)
Deductible share issuance costs  56,000   100,000   99,000 
Effect of prior years' loss adjustment  -   171,600   - 
Unrecognized tax losses  (2,854,093)  (2,347,300)  (1,422,513)
Foreign tax differential  879,000   563,300   (172,687)
             
Income tax recovery recognized $-  $-  $- 

Adjustments to income tax recovery:

For the Year Ended December 31, 2023  2022  2021 
          
Amounts not deductible for tax purposes $(1,113,000) $(1,177,000) $(1,201,600)
Other non-deductible items  (69,000)  (66,000)  (111,000)
 Other deductible items  191,000   161,000   157,000 
Non-taxable gain (loss)  -   (388,000)  383,000 
Non-taxable loan forgiveness  -   -   49,000 
Deferred R&D expenses, net  (459,000)  (627,000)  - 
Foreign tax differential  (905,538)  (828,000)  (508,000)
Unrecognized tax recovered (losses)  (3,015,314)  (2,649,723)  (2,920,710)
             
Income tax recovery recognized $-  $-  $- 

The following table reflects future income tax assets at December 31:

SCHEDULE OF FUTURE INCOME TAX ASSETS

  2023  2022  2021 
          
Resource assets $1,024,271  $1,024,271  $1,024,271 
Gross unamortized share issue costs  810,000   1,081,250   1,114,604 
Capitalized S.174 expenses  5,900,000   2,368,000   - 
Canadian non-capital losses  22,585,000   21,955,000   21,404,000 
Canadian capital losses  5,300,000   5,156,000   5,565,125 
US non-capital losses  95,300,000   93,000,000   86,073,000 
Singapore non-capital losses  19,300,000   13,800,000   9,180,000 
             
Unused income tax losses  150,219,271   138,384,521   124,361,000 
Unrecognized deferred tax assets  (150,219,271)  (138,384,521)  (124,361,000)
             
Deferred income tax assets recognized $-  $-  $- 

Page 29

   2015   2014   2013 
Resource assets $1,024,271  $1,024,271  $1,024,271 
Gross unamortized share issue costs  328,119   544,278   884,000 
Canadian non-capital losses  9,451,357   7,544,985   3,931,000 
Canadian capital losses  -   -   2,950,943 
US non-capital losses  58,742,322   52,682,069   48,797,000 
   69,546,069   61,795,603   57,587,214 
Unrecognized deferred tax assets  (69,546,069)  (61,795,603)  (57,587,214)
Future income tax assets recognized $-  $-  $- 

POET TECHNOLOGIES INC.

Note: 2013 future tax assets have been adjustedNOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

23.COVID-19 GOVERNMENT SUPPORT LOANS

In March 2020, the United States Congress passed the Paycheck Protection Program (“PPP”), authorizing loans to reflectsmall businesses for use in paying employees that they continue to employ throughout the gross valueCOVID-19 pandemic and for rent, utilities and interest on mortgages. Loans obtained through the PPP are eligible to be forgiven as long as the proceeds are used for qualifying purposes and certain other conditions are met. On May 3, 2020, the Company received a loan in the amount of $186,747 through the PPP. During the year, the Company received notice from the Small Business Administration of Washington, DC that the PPP loan was forgiven in full. The forgiven loan was reclassified to the consolidated statements of operations and deficit and recognized as income for the year ended December 31, 2021.

On April 9, 2020, the Canadian government launched the Canada Emergency Business Account (“CEBA”) which is intended to support businesses during COVID-19 by providing interest free financing of up to $30,200 (CA$40,000) until December 31, 2023. If 75% of the assets.

18.REDUCTION OF LICENSE FEE

In 2014loan is repaid by December 31, 2023 (extended to January 18, 2024), the Universityloan recipient will be eligible for a loan forgiveness of Connecticut agreed to convert certain royalty rights intothe remaining 25% of the amount loaned. On April 15, 2020, the Company received a significant investmentloan in the Company.amount of $30,200 through the CEBA. If the loan has not been repaid by January 18, 2024, the outstanding amount will be automatically extended for an additional two years at 5% interest per annum payable monthly and maturing on December 31, 2025. The parties agreed to restructure the payment provisionsCompany repaid 75% of the License Agreement by reducing royalty payments to three percent (3%amount borrowed on January 15, 2024.

24.SUBSEQUENT EVENTS

On January 24, 2024, the Company raised gross proceeds of CA$6,219,667 (US$4,607,161) from the issuance of amounts received from unaffiliated third parties in respect5,098,088 units through a private placement financing facility (the “Offering”) at an offering price CA$1.22 (US$0.90). Each unit consisted of one common share of the exploitation of the Intellectual Property defined in the License Agreement, in consideration for 2,000,000Company and one common share purchase warrant to purchase up to 5,098,088 common shares for a period of the Company. The common shares were valued at $1,439,898 (CAD

$1,580,000). The market value of shares was determined using the quoted market price of the Company's stock on the TSX.V onfive (5) years from the date of closing at a price of CA$1.52 (US$1.12) per share. The Company paid finder’s fees of CA$43,829 (US$32,466) to certain parties that were instrumental of introducing some of the agreement between the Company and the University of Connecticut.

19.SUBSEQUENT EVENT

Subsequentsubscribers to the year end,Company.

Directors, management and employees acquired 459,522 units of the company received $1,965,327 from the exerciseoffering for gross proceeds of 2,686,947 warrants and 628,000 stock options.CA$560,617 (US$415,272).

Page 20

Page 30